1 00:00:05,880 --> 00:00:09,240 >>I WOULD LIKE TO WELCOME THE 2 00:00:09,240 --> 00:00:11,080 MEMBERS OF THE COMMITTEE, THE 3 00:00:11,080 --> 00:00:15,600 NCI STAFF, AND GUESTS. I WOULD 4 00:00:15,600 --> 00:00:18,560 LIKE TO REMIND YOU AS COMMITTEE 5 00:00:18,560 --> 00:00:20,440 MEMBERS YOU MUST ABSENT 6 00:00:20,440 --> 00:00:22,200 YOURSELVES DURING SPECIFIC 7 00:00:22,200 --> 00:00:23,760 DISCUSSIONS WHEREVER YOU FEEL 8 00:00:23,760 --> 00:00:25,120 YOUR PARTICIPATION AND 9 00:00:25,120 --> 00:00:26,960 DELIBERATIONS ARE OF PARTICULAR 10 00:00:26,960 --> 00:00:28,880 PRODUCT, PROGRAM OR OTHER 11 00:00:28,880 --> 00:00:30,400 SPECIFIC MATTER WOULD CONSTITUTE 12 00:00:30,400 --> 00:00:32,520 A CONFLICT OF INTEREST OR CREATE 13 00:00:32,520 --> 00:00:35,480 THE APPEARANCE OF ONE. WE ARE 14 00:00:35,480 --> 00:00:37,080 ALWAYS THE BEST JUDGE OF WHETHER 15 00:00:37,080 --> 00:00:38,960 WE ARE IN CONFLICT. SO I 16 00:00:38,960 --> 00:00:40,760 ENCOURAGE YOU. IT IS INCUMBENT 17 00:00:40,760 --> 00:00:43,400 UPON YOU TO ADVISE THE EXECUTIVE 18 00:00:43,400 --> 00:00:48,040 SECRETARY, DR. LODEK LOPACZYNSKI 19 00:00:48,040 --> 00:00:49,560 AND ABSTAIN FROM ANY DISCUSSION 20 00:00:49,560 --> 00:00:51,040 OR ACTION REGARDING THAT MATTER. 21 00:00:51,040 --> 00:00:53,760 IN KEEPING WITH CURRENT 22 00:00:53,760 --> 00:00:54,560 POLICIES, CONFLICT OF INTEREST 23 00:00:54,560 --> 00:01:01,040 BASED ON FINANCIAL HOLDINGS OF 24 00:01:01,040 --> 00:01:02,000 SPECIAL GOVERNMENT EMPLOYEES 25 00:01:02,000 --> 00:01:05,000 WHICH CATEGORIES ALL MEMBERS, WE 26 00:01:05,000 --> 00:01:06,560 MUST DEPEND UPON YOU TO 27 00:01:06,560 --> 00:01:08,000 VOLUNTARILY ABSENT YOURSELVES 28 00:01:08,000 --> 00:01:10,080 DURING DISCUSSIONS OF MATTERS 29 00:01:10,080 --> 00:01:11,760 THAT COULD IMPACT THE STATUS OF 30 00:01:11,760 --> 00:01:13,440 THOSE HOLDINGS. WE TRUST YOUR 31 00:01:13,440 --> 00:01:15,720 JUDGMENT IN THESE INSTANCES. 32 00:01:15,720 --> 00:01:17,480 MEMBERS OF THE PUBLIC WHO MAY 33 00:01:17,480 --> 00:01:20,880 WISH TO EXPRESS VIEWS REGARDING 34 00:01:20,880 --> 00:01:24,720 ITEMS DISCUSSED DURING TODAY'S 35 00:01:24,720 --> 00:01:26,440 MEETING MAY DO SO IN WRITING TO 36 00:01:26,440 --> 00:01:28,040 DR. LOPACZYNSKI, EXECUTIVE 37 00:01:28,040 --> 00:01:28,800 SECRETARY OF THE COMMITTEE 38 00:01:28,800 --> 00:01:31,800 WITHIN TEN DAYS AFTER THE 39 00:01:31,800 --> 00:01:33,360 MEETINGING. ANY WRITTEN STATEMES 40 00:01:33,360 --> 00:01:34,800 BY MEMBERS OF THE PUBLIC WILL 41 00:01:34,800 --> 00:01:36,760 RECEIVE CAREFUL CONSIDERATION. 42 00:01:36,760 --> 00:01:38,480 BY LAW, A QUORUM OF COMMITTEE 43 00:01:38,480 --> 00:01:40,360 MEMBERS IS REQUIRED FOR EACH 44 00:01:40,360 --> 00:01:43,000 INSTANCE IN WHICH A VOTE OCCURS 45 00:01:43,000 --> 00:01:45,000 DURING TODAY'S MEETING A MINIMUM 46 00:01:45,000 --> 00:01:50,120 OF 7 APPOINTED MEMBERS MUST BE 47 00:01:50,120 --> 00:01:51,480 PRESENT TO VOICE THEIR VOTES. 48 00:01:51,480 --> 00:01:54,440 SINCE WE CANNOT PREDICT TIME OR 49 00:01:54,440 --> 00:01:55,600 OCCURRENCE OF ANY MOTION, YOUR 50 00:01:55,600 --> 00:01:56,920 PRESENCE IS A MUST FOR ALL 51 00:01:56,920 --> 00:02:01,720 SEGMENTS OF THE MEETING. DO WE 52 00:02:01,720 --> 00:02:04,760 HAVE A QUORUM? 53 00:02:04,760 --> 00:02:06,800 >>LET ME DOUBLE CHECK WITH JOY. 54 00:02:06,800 --> 00:02:07,880 >>YES. 55 00:02:07,880 --> 00:02:08,800 >>WE ARE GOOD. 56 00:02:08,800 --> 00:02:12,040 >>SO WE DO HAVE SEVEN MEMBERS. 57 00:02:12,040 --> 00:02:17,240 >>PERFECT. WITH THAT, DO I HAVE 58 00:02:17,240 --> 00:02:19,280 A MOTION TO APPROVE MINUTES FROM 59 00:02:19,280 --> 00:02:21,280 THE LAST FNLAC MEETING ON JUNE 60 00:02:21,280 --> 00:02:31,840 27, 2022? MOTION TO APPROVE? DID 61 00:02:33,320 --> 00:02:33,720 SOMEONE RAISE -- 62 00:02:33,720 --> 00:02:34,640 >>MOTION. 63 00:02:34,640 --> 00:02:37,960 >>OKAY. SECRET OKAY. SECOND? 64 00:02:37,960 --> 00:02:39,120 >>I'LL SECOND. 65 00:02:39,120 --> 00:02:41,840 >>ANY DISCUSSION? ALL THOSE IN 66 00:02:41,840 --> 00:02:49,960 FAVOR? AYE. ANYONE OPPOSED? OR 67 00:02:49,960 --> 00:02:53,680 ABSTENTIONS? THANK YOU. JUST TO 68 00:02:53,680 --> 00:02:55,240 DRAW YOUR ATTENTION TO THE 69 00:02:55,240 --> 00:02:57,160 FUTURE MEETING DATES YOU CAN SEE 70 00:02:57,160 --> 00:02:59,280 THE DATES LISTED ON YOUR AGENDA, 71 00:02:59,280 --> 00:03:00,880 THERE WILL BE A VIRTUAL MEETING 72 00:03:00,880 --> 00:03:04,760 OUR NEXT MEETING WILL BE 73 00:03:04,760 --> 00:03:06,240 VIRTUAL, ON FEBRUARY 27, MARK 74 00:03:06,240 --> 00:03:09,000 YOUR CALENDARS ACCORDINGLY. WE 75 00:03:09,000 --> 00:03:16,360 WILL ACTUALLY HOPEFULLY BE LIVE 76 00:03:16,360 --> 00:03:18,600 IN PERSON NEXT JULY 10 THROUGH 77 00:03:18,600 --> 00:03:20,120 11, HOPEFULLY THAT WILL HAPPEN, 78 00:03:20,120 --> 00:03:22,120 BE NICE TO SEE PEOPLE IN PERSON. 79 00:03:22,120 --> 00:03:27,640 OUR FIRST ITEM OF TODAY, IS THE 80 00:03:27,640 --> 00:03:29,520 NCI PRINCIPLE DEPUTY DIRECTORS 81 00:03:29,520 --> 00:03:32,400 REPORT BY DR. DOUG LOWY. 82 00:03:32,400 --> 00:03:33,960 >>THANK YOU SO MUCH. GOOD 83 00:03:33,960 --> 00:03:35,200 MORNING, EVERYONE. THANK YOU, 84 00:03:35,200 --> 00:03:41,160 VERY MUCH FOR JOINING AND IT IS 85 00:03:41,160 --> 00:03:45,840 A PLEASURE TO TALK WITH YOU ONCE 86 00:03:45,840 --> 00:03:47,200 AGAIN PERHAPS FOR THE LAST TIME 87 00:03:47,200 --> 00:03:49,520 AS DEPUTY DIRECTOR. I'M HOPING 88 00:03:49,520 --> 00:03:52,960 THAT WHEN WE MEET IN FEBRUARY, 89 00:03:52,960 --> 00:03:55,840 THAT DR. BERTAGNOLLI WILL NOT 90 00:03:55,840 --> 00:03:59,600 ONLY HAVE BEEN AT THE HELP FOR A 91 00:03:59,600 --> 00:04:01,640 SUBSTANTIAL TIME PERIOD BUT SHE 92 00:04:01,640 --> 00:04:04,040 WILL FEEL MUCH BETTER THAN SHE 93 00:04:04,040 --> 00:04:06,160 IS TODAY. IF I COULD HAVE THE 94 00:04:06,160 --> 00:04:09,200 NEXT SLIDE PLEASE. I'M GOING TO 95 00:04:09,200 --> 00:04:17,080 COVER A FEW ISSUES TODAY. FIRST 96 00:04:17,080 --> 00:04:18,720 I WANT TO WELCOME THE FIVE NEW 97 00:04:18,720 --> 00:04:21,360 MEMBERS OF THE FNLAC COMMITTEE. 98 00:04:21,360 --> 00:04:29,000 MARY HENDRIX, RODNEY HO CAROL 99 00:04:29,000 --> 00:04:31,640 BOLT AND ANGELA GRONENBORN. I 100 00:04:31,640 --> 00:04:33,000 WANT TO POINT OUT FOR ANGELA, 101 00:04:33,000 --> 00:04:36,320 THIS IS HER SECOND TIME AROUND 102 00:04:36,320 --> 00:04:40,080 AFTER A PERIOD NOT BEING A 103 00:04:40,080 --> 00:04:42,880 MEMBER OF THE FNLAC. AND 104 00:04:42,880 --> 00:04:44,400 AFANTASTIC MADABHUSHI. IT IS A 105 00:04:44,400 --> 00:04:45,880 SPECIAL PLEASURE TO WELCOME 106 00:04:45,880 --> 00:04:49,120 ANGELA BACK ONCE AGAIN. I'M 107 00:04:49,120 --> 00:04:52,200 GOING TO COVER FOUR DIFFERENT 108 00:04:52,200 --> 00:04:57,240 ISSUES, ONE IS ABOUT NCI NEWS 109 00:04:57,240 --> 00:05:02,160 THEN A FEW RESEARCH ADVANCES 110 00:05:02,160 --> 00:05:04,400 CANCER MOON SHOT THEN ENDING 111 00:05:04,400 --> 00:05:08,440 WITH BUNCH OF UPDATES ANNUAL 112 00:05:08,440 --> 00:05:11,880 PLAN BUDGET PAROLE FOR FY 24 AND 113 00:05:11,880 --> 00:05:14,880 ALTHOUGH FY 23 IS ONLY 12 DAYS 114 00:05:14,880 --> 00:05:16,680 OLD, THIS IS ONE OF THE FEW 115 00:05:16,680 --> 00:05:21,320 THINGS THAT THE NCI DOES LONG IN 116 00:05:21,320 --> 00:05:24,920 ADVANCE. NEXT SLIDE PLEASE. AS 117 00:05:24,920 --> 00:05:30,240 I ASSUME ALL OF YOU KNOW, MONICA 118 00:05:30,240 --> 00:05:32,440 BERTAGNOLLI STARTED A WEEK AGO 119 00:05:32,440 --> 00:05:38,920 AS THE NCI DIRECTOR AND SHE IS A 120 00:05:38,920 --> 00:05:41,480 POSITIVE FORCE, HAS HIT THE 121 00:05:41,480 --> 00:05:44,920 GROUND RUNNING. SHE IS NOT HERE 122 00:05:44,920 --> 00:05:46,640 DOWN IN BETHESDA TODAY BECAUSE 123 00:05:46,640 --> 00:05:49,080 SHE'S NOT FEELING THAT WELL BUT 124 00:05:49,080 --> 00:05:53,160 NEVERTHELESS SHE IS GOING TO SAY 125 00:05:53,160 --> 00:05:54,640 A FEW WORDS TO YOU AFTER MY 126 00:05:54,640 --> 00:05:56,480 PRESENTATION. SHE AND I ARE 127 00:05:56,480 --> 00:05:59,880 GOING TO TAKE YOUR QUESTIONS 128 00:05:59,880 --> 00:06:02,320 AFTERWARDS. SHE AND I HAVE 129 00:06:02,320 --> 00:06:03,200 AGREED IF THEY ARE EASY 130 00:06:03,200 --> 00:06:04,760 QUESTIONS I WILL ANSWER THEM AND 131 00:06:04,760 --> 00:06:06,800 IF THEY ARE DIFFICULT QUESTIONS 132 00:06:06,800 --> 00:06:13,360 SHE WILL ANSWER THEM. NEXT SLIDE 133 00:06:13,360 --> 00:06:16,800 PLEASE. SO I WANT TO UPDATE YOU 134 00:06:16,800 --> 00:06:21,200 ON THE RECOMPETITION. REQUEST 135 00:06:21,200 --> 00:06:24,480 FOR PROPOSALS WAS RELEASED THE 136 00:06:24,480 --> 00:06:26,240 END OF JUNE AND THE CURRENT 137 00:06:26,240 --> 00:06:30,600 PROPOSAL DUE DATE IS MID 138 00:06:30,600 --> 00:06:34,360 FEBRUARY. WE ARE PLANNING FOR A 139 00:06:34,360 --> 00:06:36,040 PRE-PROPOSAL CONFERENCE SOMETIME 140 00:06:36,040 --> 00:06:38,160 IN THE NEXT COUPLE OF MONTHS. WE 141 00:06:38,160 --> 00:06:40,800 ARE ALSO DEVELOPING PLANS FOR IN 142 00:06:40,800 --> 00:06:46,280 PERSON TOUR OF THE NCI FREDERICK 143 00:06:46,280 --> 00:06:51,840 SPACE AT FORT DEE TRI DEITRICK.E 144 00:06:51,840 --> 00:06:54,480 AWARD DATE IS SOMETIME IN 2024. 145 00:06:54,480 --> 00:06:57,800 BECAUSE THE TIME LINE IS 146 00:06:57,800 --> 00:06:59,440 SUBSTANTIAL. WE ARE MAKING EVERY 147 00:06:59,440 --> 00:07:04,560 EFFORTS FOR THIS TO BE AN OPEN 148 00:07:04,560 --> 00:07:08,640 COMPETITION FOR THE FREDERICK 149 00:07:08,640 --> 00:07:15,320 CANCER RESEARCH FACILITY. NEXT 150 00:07:15,320 --> 00:07:19,960 WEEK IS GOING TO BE THE FOURTH 151 00:07:19,960 --> 00:07:24,440 RAS INITIATIVE SYMPOSIUM. IT IS 152 00:07:24,440 --> 00:07:27,000 A THREE DAY MEETING, THE LAST 153 00:07:27,000 --> 00:07:29,200 RAS SYMPOSIUM WHICH WAS 154 00:07:29,200 --> 00:07:33,120 ESSENTIALLY TWO YEARS AGO WAS A 155 00:07:33,120 --> 00:07:35,320 VIRTUAL MEETING. IT WAS ATTENDED 156 00:07:35,320 --> 00:07:39,160 BY MORE THAN 1500 PEOPLE NOT 157 00:07:39,160 --> 00:07:41,800 JUST IN THE UNITED STATES BUT IN 158 00:07:41,800 --> 00:07:46,160 MANY OTHER COUNTRIES AS WELL. 159 00:07:46,160 --> 00:07:51,200 THE RAS INITIATIVE IS COMING UP 160 00:07:51,200 --> 00:07:56,720 FOR REREVIEW. YOU ALL AT FNLAC 161 00:07:56,720 --> 00:07:58,800 WILL BE DISCUSSING THE OUTCOME 162 00:07:58,800 --> 00:08:03,360 OF THAT REVIEW WHEN YOU MEET IN 163 00:08:03,360 --> 00:08:06,240 FEBRUARY. THE RAS SYMPOSIUM WILL 164 00:08:06,240 --> 00:08:08,720 BE IN PERSON AND MONICA IS GOING 165 00:08:08,720 --> 00:08:11,960 TO BE OPENING THE MEETING THIS 166 00:08:11,960 --> 00:08:14,000 COMING MONDA MONDAY. IT SHOULD A 167 00:08:14,000 --> 00:08:16,960 VERY EXCITING MEETING. IT ALSO 168 00:08:16,960 --> 00:08:20,760 WILL BE AVAILABLE VIRTUALLY FOR 169 00:08:20,760 --> 00:08:22,640 THOSE WHO CAN'T COME BUT WHO 170 00:08:22,640 --> 00:08:31,880 MIGHT WANT TO PARTICIPATE. YOU 171 00:08:31,880 --> 00:08:34,080 HEARD FROM RICH VOLKERS A COUPLE 172 00:08:34,080 --> 00:08:37,080 OF MEETINGS AGO ABOUT THE FNLCR 173 00:08:37,080 --> 00:08:39,840 AWARENESS CAMPAIGN. THERE IS 174 00:08:39,840 --> 00:08:43,240 GOING TO BE A NEW VIDEO MARKING 175 00:08:43,240 --> 00:08:45,320 TEN YEARS OF THE FREDERICK 176 00:08:45,320 --> 00:08:47,120 NATIONAL LABORATORY. THERE ALSO 177 00:08:47,120 --> 00:08:51,160 IS GOING TO BE A CANCER CURRENTS 178 00:08:51,160 --> 00:08:55,920 BLOG AT THE NCI WEBSITE NEXT 179 00:08:55,920 --> 00:08:58,000 MONTH. ALSO A SURVEY OF 180 00:08:58,000 --> 00:09:00,640 EXTRAMURAL RESEARCHERS TO FIND 181 00:09:00,640 --> 00:09:03,440 OUT HOW WELL KEPT IS THE SECRET 182 00:09:03,440 --> 00:09:06,200 OF THE FREDERICK NATIONAL 183 00:09:06,200 --> 00:09:07,760 LABORATORY. HOPEFULLY AT LEAST 184 00:09:07,760 --> 00:09:12,360 SOME OF THEM WILL HAVE HEARD 185 00:09:12,360 --> 00:09:13,800 ABOUT IT. THERE ARE GOING TO BE 186 00:09:13,800 --> 00:09:15,920 SOME PRESENTATIONS TODAY TALKING 187 00:09:15,920 --> 00:09:16,800 ABOUT SOME OF THE ACTIVITIES 188 00:09:16,800 --> 00:09:21,000 GOING ON AT FREDERICK NATIONAL 189 00:09:21,000 --> 00:09:25,960 LABORATORY. A COUPLE OF WEEKS 190 00:09:25,960 --> 00:09:29,000 AGO MONICA WAS INVOLVED IN 191 00:09:29,000 --> 00:09:33,960 ORGANIZING A MEETING BEFORE SHE 192 00:09:33,960 --> 00:09:35,840 BECAME NCI DIRECTOR OF A WHITE 193 00:09:35,840 --> 00:09:39,600 HOUSE FORUM ON CHILDHOOD CANCER. 194 00:09:39,600 --> 00:09:46,520 IT WAS WIDELY ATTENDED A SERIES 195 00:09:46,520 --> 00:09:48,520 OF PANEL DISCUSSIONS AND IT WAS 196 00:09:48,520 --> 00:09:53,280 A HIGHLY INFORMATIVE MEETING AND 197 00:09:53,280 --> 00:09:54,520 DISCUSSING A LOT ABOUT THE SATE 198 00:09:54,520 --> 00:09:59,600 OF THE ART OF CHILDHOOD CANCER 199 00:09:59,600 --> 00:10:00,680 RESEARCH AROUND IMPLEMENTATION. 200 00:10:00,680 --> 00:10:03,240 A NUMBER OF SPECIFIC ISSUES FOR 201 00:10:03,240 --> 00:10:05,760 THE WAY FORWARD. GREG RIEMAN WHO 202 00:10:05,760 --> 00:10:09,720 HAS BEEN AT THE FDA FOR A LONG 203 00:10:09,720 --> 00:10:14,320 TIME FOCUS ON CANCER RESEARCH 204 00:10:14,320 --> 00:10:18,280 ISSUES AND FDA APPROVALS IS 205 00:10:18,280 --> 00:10:20,760 GOING TO BE THE SCIENTIFIC 206 00:10:20,760 --> 00:10:23,240 DIRECTOR OF THE NCI CHILDHOOD 207 00:10:23,240 --> 00:10:24,480 CANCER DATA INITIATIVE. HE WAS 208 00:10:24,480 --> 00:10:28,200 ONE OF THE PEOPLE AND STEVEN 209 00:10:28,200 --> 00:10:29,760 CHANNICK HEAD OF INTRAMURAL 210 00:10:29,760 --> 00:10:31,760 DIVISION OF CANCER EPIPEOPLOLOGY 211 00:10:31,760 --> 00:10:34,920 AND GENETICS WAS ON THE A 212 00:10:34,920 --> 00:10:43,520 DIFFERENT PANEL. JUST A FEW 213 00:10:43,520 --> 00:10:46,000 UPDATES MANY ARE AWARE OF THE 214 00:10:46,000 --> 00:10:50,840 ENORMOUS ADVANCES MADE FOR 215 00:10:50,840 --> 00:10:53,720 BREAST CANCER WITH HER 2 BUT 216 00:10:53,720 --> 00:10:55,280 COUPLE OF MONTHS AGO THE FDA 217 00:10:55,280 --> 00:11:01,400 GAVE ACCELERATED APPROVAL FOR A 218 00:11:01,400 --> 00:11:07,120 HER 2 INHIBITOR VERSION, 219 00:11:07,120 --> 00:11:09,600 TRASTUZIMAB DEROTECAN. THIS IS 220 00:11:09,600 --> 00:11:13,880 FOR PATIENTS WHO HAVE ABNORMAL 221 00:11:13,880 --> 00:11:16,240 HER 2 EXPRESSION IN THEIR LUNG 222 00:11:16,240 --> 00:11:17,760 CANCER. IT IS FIRST TIME 223 00:11:17,760 --> 00:11:20,440 PATIENTS WITH HR 2 MUTANT LUNG 224 00:11:20,440 --> 00:11:21,880 CANCER HAVE FDA APPROVED 225 00:11:21,880 --> 00:11:25,000 TARGETED THERAPY OPTION. THIS 226 00:11:25,000 --> 00:11:30,360 ADDS TO THE LONG LIST OF 227 00:11:30,360 --> 00:11:31,520 THERAPEUTIC OPTIONS FOR PEOPLE 228 00:11:31,520 --> 00:11:36,240 WITH LUNG CANCER WHICH HAS 229 00:11:36,240 --> 00:11:38,040 CONTRIBUTED SUBSTANTIALLY TO 230 00:11:38,040 --> 00:11:40,800 DECREASE MORTALITY RATES IN LUNG 231 00:11:40,800 --> 00:11:42,760 CANCER BEYOND INCREASE IN 232 00:11:42,760 --> 00:11:44,400 MORTALITY RATES AS A RESULT OF 233 00:11:44,400 --> 00:11:49,800 SMOKING CESSATION BY ITSELF. 234 00:11:49,800 --> 00:11:53,760 THIS IS SOMETHING THAT MIGHT BE 235 00:11:53,760 --> 00:11:57,680 USEFUL FOR PATIENTS WITH 236 00:11:57,680 --> 00:12:02,640 GLIOMAS. DEPENDENCE ON DE NOVO 237 00:12:02,640 --> 00:12:05,520 NUCLEOTIDE SYNTHESIS AND A DRUG 238 00:12:05,520 --> 00:12:10,360 THAT MAY BE ABLE TO EXPLOIT THIS 239 00:12:10,360 --> 00:12:13,360 VULNERABILITY. THERE'S GOING TO 240 00:12:13,360 --> 00:12:16,240 BE A CLINICAL TRIAL SPONSORED BY 241 00:12:16,240 --> 00:12:21,120 THE GLIAL BLASTOMA THERAPEUTICS 242 00:12:21,120 --> 00:12:24,440 NETWORK. IF YOU WANT MORE 243 00:12:24,440 --> 00:12:25,840 INFORMATION THE PAPER, THE 244 00:12:25,840 --> 00:12:29,280 CITATION IS LISTED AT THE BOTTOM 245 00:12:29,280 --> 00:12:30,200 OF THIS SLIDE. NEXT SLIDE 246 00:12:30,200 --> 00:12:35,560 PLEASE. THIS SLIDE IN MANY WAYS 247 00:12:35,560 --> 00:12:38,960 MULTIPLE MYELOMA IS THE POSTER 248 00:12:38,960 --> 00:12:41,760 CHILD FOR THE NUMBER OF NEW 249 00:12:41,760 --> 00:12:42,960 THERAPEUTIC OPTIONS WHICH HAS 250 00:12:42,960 --> 00:12:47,920 BEEN CORRELATED WITH AN ENORMOUS 251 00:12:47,920 --> 00:12:49,520 INCREASE IN SURVIVAL RATE OF 252 00:12:49,520 --> 00:12:53,200 PATIENTS WITH MULTIPLE MYELOMA. 253 00:12:53,200 --> 00:12:57,120 BUT HERE IS YET ANOTHER 254 00:12:57,120 --> 00:13:00,360 POTENTIAL ADVANCE OF 255 00:13:00,360 --> 00:13:05,560 IMMUNOTHERAPEUTIC DRUG 256 00:13:05,560 --> 00:13:08,160 TECLISAVAW B, IN PEOPLE WITH 257 00:13:08,160 --> 00:13:09,600 MYELOMA THAT THAT HAVE NOT 258 00:13:09,600 --> 00:13:10,640 RESPONDED TO OTHER TREATMENTS 259 00:13:10,640 --> 00:13:12,520 AND NEARLY TWO-THIRDS OF 260 00:13:12,520 --> 00:13:16,960 PARTICIPANTS HAD A PARTIAL 261 00:13:16,960 --> 00:13:19,080 RESPONSE. THIS IS SOMETHING THAT 262 00:13:19,080 --> 00:13:21,400 MAYBE ADDED TO THE ALREADY 263 00:13:21,400 --> 00:13:23,040 SUBSTANTIAL ARMAMENTARIUM FOR 264 00:13:23,040 --> 00:13:24,400 THE TREATMENT OF MULTIPLE 265 00:13:24,400 --> 00:13:29,240 MYELOMA. NEXT SLIDE PLEASE. I 266 00:13:29,240 --> 00:13:33,480 NOW WANT TO SAY A COUPLE OF 267 00:13:33,480 --> 00:13:37,320 SLIDES ABOUT HEALTH DISPARITIES. 268 00:13:37,320 --> 00:13:39,720 WE TALKED A LOT IN THE PAST 269 00:13:39,720 --> 00:13:42,120 ABOUT HEALTH DISPARITIES TRYING 270 00:13:42,120 --> 00:13:46,160 TO OVERCOME THEM WITH A LOT OF 271 00:13:46,160 --> 00:13:47,520 DIRECT PATIENT ENGAGEMENT 272 00:13:47,520 --> 00:13:50,760 COMMUNITY ENGAGEMENT, THE 273 00:13:50,760 --> 00:13:52,360 IMPORTANCE FOR CLINICAL TRIALS 274 00:13:52,360 --> 00:13:56,520 IN THOSE AREAS BUT I WANT HERE 275 00:13:56,520 --> 00:13:59,120 TO TALK ABOUT POTENTIAL 276 00:13:59,120 --> 00:14:00,440 IMPORTANCE OF TECHNOLOGY 277 00:14:00,440 --> 00:14:02,680 DEVELOPMENT AND HEALTH 278 00:14:02,680 --> 00:14:03,600 DISPARITIES AND IT IS 279 00:14:03,600 --> 00:14:04,800 PARTICULARLY RELEVANT FOR THE 280 00:14:04,800 --> 00:14:06,880 FREDERICK NATIONAL LABORATORY 281 00:14:06,880 --> 00:14:11,240 WHICH IS SO HEAVILY ORIENTED 282 00:14:11,240 --> 00:14:12,560 TOWARDS TECHNOLOGY DEVELOPMENT. 283 00:14:12,560 --> 00:14:16,360 IN THE UPPER LEFT RECTANGLE, 284 00:14:16,360 --> 00:14:19,600 WHAT I HAVE SHOWN HERE IS THE 285 00:14:19,600 --> 00:14:21,160 TECHNOLOGY CAN DECREASE 286 00:14:21,160 --> 00:14:22,240 DISPARITIES, INCREASE 287 00:14:22,240 --> 00:14:26,680 DISPARITIES OR BE NEUTRAL. ON 288 00:14:26,680 --> 00:14:28,800 THE BOTTOM LEFT RECTANGLE DON'T 289 00:14:28,800 --> 00:14:32,040 WAIT UNTIL THE END TO CONSIDER 290 00:14:32,040 --> 00:14:35,040 THE POSSIBLE IMPACT ON 291 00:14:35,040 --> 00:14:38,160 DISPARITIES. INSTEAD AS SHOWN IN 292 00:14:38,160 --> 00:14:40,640 THE UPPER RIGHT RECTANGLE TO 293 00:14:40,640 --> 00:14:42,960 INCREASE THE LIKELIHOOD OF 294 00:14:42,960 --> 00:14:44,960 TECHNOLOGICAL DEVELOPMENT, 295 00:14:44,960 --> 00:14:46,840 DECREASING DISPARITIES THINK 296 00:14:46,840 --> 00:14:49,360 ABOUT DISPARITIES FROM THE 297 00:14:49,360 --> 00:14:52,520 BEGINNING OF THE PROCESS. MORE 298 00:14:52,520 --> 00:14:56,000 DIRECT APPROACH COULD BE TO 299 00:14:56,000 --> 00:14:59,760 DEVELOP TECHNOLOGY WHOSE GOAL 300 00:14:59,760 --> 00:15:05,200 INCLUDES REDUCING DISPARITIES. 301 00:15:05,200 --> 00:15:06,840 LAST MONTH I GAVE THE KEYNOTE 302 00:15:06,840 --> 00:15:10,320 ADDRESS AT THE AACR CONFERENCE 303 00:15:10,320 --> 00:15:12,000 ON THE SCIENCE OF CANCER HEALTH 304 00:15:12,000 --> 00:15:14,080 DISPARITIES IN RACIAL ETHNIC 305 00:15:14,080 --> 00:15:16,520 MINORITIES IN MEDICALLY 306 00:15:16,520 --> 00:15:17,960 UNDERSERVED. THESE WERE SOME 307 00:15:17,960 --> 00:15:20,360 TAKE HOME MESSAGES. FIRST WE 308 00:15:20,360 --> 00:15:23,000 HAVE MADE SOME PROGRESS. OVER 309 00:15:23,000 --> 00:15:25,520 THE LAST 20 YEARS MORTALITY 310 00:15:25,520 --> 00:15:28,280 RATES FROM CANCER HAVE GONE DOWN 311 00:15:28,280 --> 00:15:30,320 VIRTUALLY EVERY RACIAL AND 312 00:15:30,320 --> 00:15:32,880 ETHNIC GROUP WITH THE NOTABLE 313 00:15:32,880 --> 00:15:34,400 EXCEPTION OF AMERICAN INDIANS 314 00:15:34,400 --> 00:15:37,040 AND ALASKA NATIVES. BUT THERE'S 315 00:15:37,040 --> 00:15:40,240 STILL A LONG WAY TO GO TO 316 00:15:40,240 --> 00:15:42,040 ADDRESS THIS MULTI-FACETED 317 00:15:42,040 --> 00:15:43,840 PROBLEM. SECOND POINT WAS WE 318 00:15:43,840 --> 00:15:46,600 MUST BE INCLUSIVE IN OUR 319 00:15:46,600 --> 00:15:50,200 RESEARCH AND ALSO IN THE CANCER 320 00:15:50,200 --> 00:15:52,720 RESEARCH WORK FORCE. THIRD, WE 321 00:15:52,720 --> 00:15:55,840 ALL POTENTIALLY HAVE A ROLE TO 322 00:15:55,840 --> 00:15:57,920 PLAY WHETHER FOCUSED ON THE 323 00:15:57,920 --> 00:16:00,080 UNITED STATES OR LOW AND MIDDLE 324 00:16:00,080 --> 00:16:02,680 INCOME COUNTRIES WHICH ALSO HAVE 325 00:16:02,680 --> 00:16:06,600 ENORMOUS CANCER DISPARITIES. OUR 326 00:16:06,600 --> 00:16:08,920 RULES CAN SPAN A WIDE RANGE OF 327 00:16:08,920 --> 00:16:10,280 RESEARCH FROM TECHNOLOGY 328 00:16:10,280 --> 00:16:12,760 DEVELOPMENT AIMED AT REDUCING 329 00:16:12,760 --> 00:16:14,760 DISPARITIES TO RESEARCH ITSELF 330 00:16:14,760 --> 00:16:17,040 ON THE AFFECTED POPULATIONS. 331 00:16:17,040 --> 00:16:20,800 NEXT SLIDE. I NOW AM GOING TO 332 00:16:20,800 --> 00:16:25,080 TALK ABOUT THE CANCER MOON SHOT 333 00:16:25,080 --> 00:16:28,720 AND AS PRESIDENT BIDEN HAS SAID, 334 00:16:28,720 --> 00:16:32,280 ENDING CANCER FOR AS WE KNOW IT 335 00:16:32,280 --> 00:16:35,280 FOR ALL. NEXT SLIDE. LAST 336 00:16:35,280 --> 00:16:39,080 SEPTEMBER EXACTLY A MONTH AGO, 337 00:16:39,080 --> 00:16:42,240 THE PRESIDENT ANNOUNCED THAT 338 00:16:42,240 --> 00:16:44,080 BEATING CANCER IS SOMETHING WE 339 00:16:44,080 --> 00:16:46,440 CAN DO TOGETHER AND THAT IS WHY 340 00:16:46,440 --> 00:16:48,360 I'M HERE TODAY, WAS EXACTLY A 341 00:16:48,360 --> 00:16:50,920 MONTH AGO ON THE 60TH 342 00:16:50,920 --> 00:16:53,000 ANNIVERSARY OF PRESIDENT 343 00:16:53,000 --> 00:16:58,280 KENNEDY'S MOON SHOT ADDRESS. HE 344 00:16:58,280 --> 00:17:02,120 TALKED ABOUT A NUMBER OF NCI 345 00:17:02,120 --> 00:17:03,800 INITIATIVES BUT EVEN MORE 346 00:17:03,800 --> 00:17:06,160 IMPORTANT, DURING HIS SPEECH HE 347 00:17:06,160 --> 00:17:11,480 INTRODUCED MONICA WHO WAS IN THE 348 00:17:11,480 --> 00:17:12,440 ODD YENS. AND TALKED ABOUT WE 349 00:17:12,440 --> 00:17:14,320 CAN USHER IN THE SAME 350 00:17:14,320 --> 00:17:15,680 UNWILLINGNESS TO POSTPONE THE 351 00:17:15,680 --> 00:17:19,080 SAME NATIONAL PURPOSE TO END 352 00:17:19,080 --> 00:17:27,600 CANCER AS WE KNOW IT. THREE OF 353 00:17:27,600 --> 00:17:29,480 THE PROGRAMS PRESIDENT BIDEN 354 00:17:29,480 --> 00:17:32,400 MENTIONED WERE CANCER MOON SHOT 355 00:17:32,400 --> 00:17:36,800 SCHOLARS PROGRAM, OUR TELEHEALTH 356 00:17:36,800 --> 00:17:38,520 PROGRAM WHERE WE REASONABLY 357 00:17:38,520 --> 00:17:41,480 GIVEN NUMBER OF AWARDS AND 358 00:17:41,480 --> 00:17:43,280 MULTI-CANCER DETECTION TEST. YOU 359 00:17:43,280 --> 00:17:45,560 CAN FIND OUT MORE ABOUT THESE 360 00:17:45,560 --> 00:17:49,240 AREAS THAT THE NCI WEBSITE UNDER 361 00:17:49,240 --> 00:17:55,800 ABOUT THE CANCER MOON SHOT SHOTE 362 00:17:55,800 --> 00:17:58,320 OF THE REALLY KEY FEATURES AS I 363 00:17:58,320 --> 00:18:00,040 HAVE DISCUSSED PREVIOUSLY IS 364 00:18:00,040 --> 00:18:02,560 INCREASING ENROLLMENT OF 365 00:18:02,560 --> 00:18:05,880 UNDER-REPRESENTED GROUPS TO NCI 366 00:18:05,880 --> 00:18:07,920 CLINICAL TRIALS. THE GOAL IS TO 367 00:18:07,920 --> 00:18:12,320 MIMIC THE AT RISK POPULATION FOR 368 00:18:12,320 --> 00:18:14,560 THE SPECIFIC CANCER STUDY 369 00:18:14,560 --> 00:18:20,600 INCLUDING PEOPLE WITH 370 00:18:20,600 --> 00:18:21,560 MULTICO-MORBIDITIES UP TO NOW 371 00:18:21,560 --> 00:18:25,440 GENERALLY INCLUDED IN THE 372 00:18:25,440 --> 00:18:27,240 CLINICAL TRIALS. WE NEED A 373 00:18:27,240 --> 00:18:29,440 GREATER INVESTMENT FOR 374 00:18:29,440 --> 00:18:32,080 INCREASING COMMUNITY ENGAGEMENT. 375 00:18:32,080 --> 00:18:34,240 WE HAVE SEVERAL PROGRAMS ON 376 00:18:34,240 --> 00:18:37,360 THAT. AS I MENTIONED EARLIER, 377 00:18:37,360 --> 00:18:39,160 MORE DIVERSITY AMONG HEALTHCARE 378 00:18:39,160 --> 00:18:42,840 PROVIDERS. AND NCI IS SUPPORTING 379 00:18:42,840 --> 00:18:44,840 THIS DEVELOPMENT AS WELL. THE 380 00:18:44,840 --> 00:18:47,320 NEXT SLIDE TELLS YOU ABOUT SOME 381 00:18:47,320 --> 00:18:49,640 OF THE PROGRESS THAT WE HAVE 382 00:18:49,640 --> 00:18:55,640 MADE AS A RESULT OF LONG TERM 383 00:18:55,640 --> 00:18:59,440 COMMITMENT THAT IN 2000 ONLY 384 00:18:59,440 --> 00:19:03,440 ABOUT 14% OF THE ENROLLMENT IN 385 00:19:03,440 --> 00:19:06,120 CLINICAL TRIALS WERE AMONG 386 00:19:06,120 --> 00:19:10,040 MINORITIES. WHEREAS AS A RESULT 387 00:19:10,040 --> 00:19:14,480 OF CONCERTED EFFORT BY MCKASKILL 388 00:19:14,480 --> 00:19:18,120 STEVENS AND OTHERS, A CRUEL TO 389 00:19:18,120 --> 00:19:19,040 CLINICAL TRIALS THROUGH NCI 390 00:19:19,040 --> 00:19:21,240 COMMUNITY ONCOLOGY RESEARCH 391 00:19:21,240 --> 00:19:22,960 PROGRAM AND THE NATIONAL 392 00:19:22,960 --> 00:19:26,800 CLINICAL TRIALS NETWORK IT HAS 393 00:19:26,800 --> 00:19:30,760 GONE UP TO 25% IN RECENT THREE 394 00:19:30,760 --> 00:19:33,760 YEAR PERIOD. DURING THE PANDEMIC 395 00:19:33,760 --> 00:19:36,280 THE INCREASE ACTUALLY HAS EVEN 396 00:19:36,280 --> 00:19:39,760 BEEN HIGHER WITH CLOSER TO 30% 397 00:19:39,760 --> 00:19:42,680 ENROLLMENT IN 20 AND 21. NEXT 398 00:19:42,680 --> 00:19:48,720 SLIDE. NEXT MONTH WE ARE 399 00:19:48,720 --> 00:19:49,960 TALKING ABOUT THE IMPORTANCE NOT 400 00:19:49,960 --> 00:19:52,720 JUST OF INCREASING DIVERSITY 401 00:19:52,720 --> 00:19:55,280 EQUITY INCLUSION IN LATE PHASE 402 00:19:55,280 --> 00:19:56,760 TRIALS BUT ALSO EARLY PHASE 403 00:19:56,760 --> 00:20:00,480 TRIALS. . SO NEXT MONTH ON 404 00:20:00,480 --> 00:20:02,800 NOVEMBER 16TH GOING TO BE A 405 00:20:02,800 --> 00:20:06,840 MEETING TO DISCUSS THIS ISSUE 406 00:20:06,840 --> 00:20:09,480 WITH EARLY PHASE TRIALS. ANYONE 407 00:20:09,480 --> 00:20:10,640 WHO WOULD LIKE TO PARTICIPATE IS 408 00:20:10,640 --> 00:20:14,600 GOING TO BE A VIRTUAL MEETING. 409 00:20:14,600 --> 00:20:20,520 PLEASE FEEL FREE TO DO SO. MY 410 00:20:20,520 --> 00:20:22,680 LAST TOPIC IS TO TALK ABOUT THE 411 00:20:22,680 --> 00:20:25,360 ANNUAL PLAN AND BUDGET PROPOSAL 412 00:20:25,360 --> 00:20:30,960 FOR FY 24. WE USUALLY ARE A YEAR 413 00:20:30,960 --> 00:20:34,920 AHEAD OF WHERE THE BUDGET IS. 414 00:20:34,920 --> 00:20:37,800 THE PLAN CAME OUT LAST MONTH AS 415 00:20:37,800 --> 00:20:43,920 WE WERE ENDING FY 22. WE USUALLY 416 00:20:43,920 --> 00:20:48,120 HIGHLIGHT A FEW AREAS, THEY ARE 417 00:20:48,120 --> 00:20:50,040 NOT COMPREHENSIVE, NOT INTENDED 418 00:20:50,040 --> 00:20:51,920 TO BE -- THIS IS WHAT WE ARE -- 419 00:20:51,920 --> 00:20:55,120 WHAT WE ARE PRIORITIZING. IT IS 420 00:20:55,120 --> 00:20:57,560 REALLY THIS IS WHAT WE THINK ARE 421 00:20:57,560 --> 00:20:59,920 SOME INTERESTING AREAS TO 422 00:20:59,920 --> 00:21:02,360 DISCUSS. THE NEXT SLIDE SHOWS 423 00:21:02,360 --> 00:21:05,240 YOU THE FOUR AREAS THAT WERE 424 00:21:05,240 --> 00:21:09,400 HIGHLIGHTED, ASYMPTOMATIC 425 00:21:09,400 --> 00:21:10,960 MULTI-CANCER DETECTION, CELL 426 00:21:10,960 --> 00:21:13,080 THERAPY TO TREAT CANCER 427 00:21:13,080 --> 00:21:16,440 PERSISTENT POVERTY AND CANCER. 428 00:21:16,440 --> 00:21:20,440 UNDRUGABLE CANCER TARGETS. WE 429 00:21:20,440 --> 00:21:22,960 BELIEVE AS TIME GOES ON THE 430 00:21:22,960 --> 00:21:25,960 NUMBER OF UNDRUGGABLE CANCER 431 00:21:25,960 --> 00:21:29,640 TARGETS HAVE REALLY DIMINISHED 432 00:21:29,640 --> 00:21:32,720 SUBSTANTIALLY. I THINK DIRECTLY 433 00:21:32,720 --> 00:21:34,640 TARGETING TUMOR SUPPRESSER 434 00:21:34,640 --> 00:21:37,240 PROTEINS, REMAINS A CHALLENGE. 435 00:21:37,240 --> 00:21:39,440 BUT IN MANY OTHER WAYS THE 436 00:21:39,440 --> 00:21:43,120 POSITIVE FACTORS THAT CONTRIBUTE 437 00:21:43,120 --> 00:21:46,320 TO INDUCTION AND MAINTENANCE OF 438 00:21:46,320 --> 00:21:47,800 CANCER REALLY MORE AND MORE OF 439 00:21:47,800 --> 00:21:51,560 THEM ARE COMING UNDER OUR SWAY 440 00:21:51,560 --> 00:21:55,320 IN TERMS OF BEING CANDIDATE 441 00:21:55,320 --> 00:21:57,640 INTERVENTIONS. SOME OF THAT WILL 442 00:21:57,640 --> 00:22:00,840 BE DISCUSSED NEXT WEEK ON THE 443 00:22:00,840 --> 00:22:05,040 FIRST DAY OF THE RAS SYMPOSIUM 444 00:22:05,040 --> 00:22:10,320 BUT AS IT RELATES TO RAS. THIS 445 00:22:10,320 --> 00:22:13,720 TALKS ABOUT THE PROPOSAL FROM 446 00:22:13,720 --> 00:22:19,320 THE NCI FOR INCREASING THE 447 00:22:19,320 --> 00:22:24,840 CANCER BUDGET BETWEEN 2023 AND 448 00:22:24,840 --> 00:22:31,960 2024. I WANT YOU TO THINK ABOUT 449 00:22:31,960 --> 00:22:33,880 THIS AS FIRST INCREASING THE 450 00:22:33,880 --> 00:22:35,200 BASE BUDGET BECAUSE IT IS 451 00:22:35,200 --> 00:22:36,920 ABSOLUTELY CRITICAL, THERE WERE 452 00:22:36,920 --> 00:22:39,080 SO MANY DIFFERENT ASPECTS THAT 453 00:22:39,080 --> 00:22:40,120 ARE SUPPORTED WITH THE BASE 454 00:22:40,120 --> 00:22:41,440 BUDGET. FOR EXAMPLE, THE 455 00:22:41,440 --> 00:22:43,960 FREDERICK NATIONAL LABORATORY 456 00:22:43,960 --> 00:22:48,760 FOR CANCER RESEARCH. THE SPORE 457 00:22:48,760 --> 00:22:51,240 PROGRAMS, THE INVESTIGATOR 458 00:22:51,240 --> 00:22:52,720 INITIATED RESEARCH. THERE'S SO 459 00:22:52,720 --> 00:22:54,480 MANY DIFFERENT AREAS THAT ARE 460 00:22:54,480 --> 00:22:58,120 COVERED BY THE BASE BUDGE BUDGEN 461 00:22:58,120 --> 00:23:00,200 ADDITION, TRYING TO SUPPORT AND 462 00:23:00,200 --> 00:23:03,480 MAKE FEASIBLE THE ASPIRATIONAL 463 00:23:03,480 --> 00:23:06,200 GOALS OF THE BIDEN 464 00:23:06,200 --> 00:23:08,520 ADMINISTRATION TO END CANCER AS 465 00:23:08,520 --> 00:23:15,360 WE KNOW IT FOR ALL. FOR MY LAST 466 00:23:15,360 --> 00:23:17,720 SLIDE, THIS IS A SLIDE THAT I 467 00:23:17,720 --> 00:23:21,920 SHOWED LAST TIME JUST TO REMIND 468 00:23:21,920 --> 00:23:27,840 EVERYONE WE STARTED FY 23, 12 469 00:23:27,840 --> 00:23:30,160 DAYS AGO. WE ARE CURRENTLY IN A 470 00:23:30,160 --> 00:23:32,320 CONTINUING RESOLUTION. WE HOPE 471 00:23:32,320 --> 00:23:36,080 THAT WE MIGHT GET A FULL YEAR 472 00:23:36,080 --> 00:23:38,640 APPROPRIATION BEFORE CHRISTMAS 473 00:23:38,640 --> 00:23:40,720 AS AN EARLY CHRISTMAS GIFT. WE 474 00:23:40,720 --> 00:23:43,320 LOOK FORWARD TO THE 475 00:23:43,320 --> 00:23:45,080 APPROPRIATION ACTUALLY BEING 476 00:23:45,080 --> 00:23:47,160 SUBSTANTIALLY HIGHER THAN EVEN 477 00:23:47,160 --> 00:23:50,840 THE FY 22 APPROPRIATION. THE 478 00:23:50,840 --> 00:23:53,800 SENATE CAME IN WITH THEIR MARK 479 00:23:53,800 --> 00:23:59,000 BEING MORE THAN $400 MILLION. 480 00:23:59,000 --> 00:24:02,880 OVER 2022: THE HOUSE WHICH WAS 481 00:24:02,880 --> 00:24:09,800 A PARTIAL MARK WAS FOR A BIT 482 00:24:09,800 --> 00:24:11,360 UNDER 300 MILLION AND WE NEED TO 483 00:24:11,360 --> 00:24:13,240 SEE WHAT WILL HAPPEN. NCI WILL 484 00:24:13,240 --> 00:24:15,800 MAKE A SUFFICIENT USE OF 485 00:24:15,800 --> 00:24:18,840 RESOURCES AS WE CAN. REGARDLESS 486 00:24:18,840 --> 00:24:22,960 OF WHAT THE FINAL FULL YEAR 487 00:24:22,960 --> 00:24:26,120 APPROPRIATION MAY BE. SO IF I 488 00:24:26,120 --> 00:24:27,880 COULD HAVE THE LAST SLIDE, IT IS 489 00:24:27,880 --> 00:24:31,200 MY PLEASURE TO INTRODUCE DR. 490 00:24:31,200 --> 00:24:34,320 MONICA BERTAGNOLLI. NCI 491 00:24:34,320 --> 00:24:36,600 DIRECTOR, TO SAY A FEW WORDS, 492 00:24:36,600 --> 00:24:41,600 THEN WE WILL TAKE QUESTIONS AND 493 00:24:41,600 --> 00:24:45,440 COMMENTS AFTER MONICA COMPLETES 494 00:24:45,440 --> 00:24:46,280 HER REMARKS. 495 00:24:46,280 --> 00:24:49,160 >>THANK YOU SO MUCH. FIRST 496 00:24:49,160 --> 00:24:52,880 THING FIRST. I DON'T HAVE COVID. 497 00:24:52,880 --> 00:24:54,760 RUN OF THE MILL COLD, WHO KNEW 498 00:24:54,760 --> 00:24:58,040 THOSE THINGS STILL HAPPEN BUT I 499 00:24:58,040 --> 00:24:59,880 HAVE BEEN TESTED FIVE TIMES. I 500 00:24:59,880 --> 00:25:02,960 DON'T HAVE COVID. BUT THE DAYS 501 00:25:02,960 --> 00:25:05,400 WHEN IT WAS ACCEPTABLE TO BE 502 00:25:05,400 --> 00:25:06,800 SNEEZING AND COUGHING A BIT IN A 503 00:25:06,800 --> 00:25:07,920 ROOM WITH YOUR COLLEAGUES ARE 504 00:25:07,920 --> 00:25:14,880 LONG GONE. SO I STAYED HOME. TO 505 00:25:14,880 --> 00:25:16,400 BE POLITE TO EVERYONE. THANK YOU 506 00:25:16,400 --> 00:25:18,720 DOUG FOR YOUR CONSIDERATION. I'M 507 00:25:18,720 --> 00:25:20,800 JUST FINE. SECOND DOUG HIT QUOTE 508 00:25:20,800 --> 00:25:21,920 I HIT THE GROUND RUNNING, 509 00:25:21,920 --> 00:25:23,280 UNQUOTE. LET ME TELL YOU WHY I 510 00:25:23,280 --> 00:25:26,920 WAS ABLE TO HIT THE GROUND WITH 511 00:25:26,920 --> 00:25:29,240 AT LEAST SOME SOLID GROUND UNDER 512 00:25:29,240 --> 00:25:33,120 MY FEET, THAT WAS DUE TO DOUG 513 00:25:33,120 --> 00:25:38,040 AND JIM AND DINA AND ANN. I'M 514 00:25:38,040 --> 00:25:40,240 JUST GIVING YOU THE TOP LIST 515 00:25:40,240 --> 00:25:42,800 HERE WHO WERE SO GENEROUS TO ME 516 00:25:42,800 --> 00:25:44,880 IN THE DAYS THAT I WAS TRYING TO 517 00:25:44,880 --> 00:25:51,680 PREP TO TAKE THE REIGNS. I OWE 518 00:25:51,680 --> 00:25:54,160 THEM A TREMENDOUS AMOUNT HELPING 519 00:25:54,160 --> 00:25:56,520 ME GET UP TO SPEED. THAT'S WHY 520 00:25:56,520 --> 00:25:58,040 I HAVE ANY STABILITY RIGHT NOW, 521 00:25:58,040 --> 00:25:59,320 GRATEFUL TO HAVE THEIR CONTINUED 522 00:25:59,320 --> 00:26:01,160 HELP. THANK YOU TO DOUG FINALLY. 523 00:26:01,160 --> 00:26:04,320 THIS IS THE THIRD TIME HE HAS 524 00:26:04,320 --> 00:26:08,400 TAKEN OVER AND IT HAS BEEN CLEAR 525 00:26:08,400 --> 00:26:11,200 THAT EVERYONE WENT WITHOUT A 526 00:26:11,200 --> 00:26:13,880 HITCH. NCI JUST KEPT MOVING 527 00:26:13,880 --> 00:26:17,760 THROUGH ITS MISSION WITHOUT A 528 00:26:17,760 --> 00:26:19,800 SINGLE LOSS OF FORWARD MOMENTUM 529 00:26:19,800 --> 00:26:20,680 OR STABILITY THROUGH DOUG'S 530 00:26:20,680 --> 00:26:22,280 LEADERSHIP. SO HUE SO MUCH, DOUG 531 00:26:22,280 --> 00:26:30,040 FOR THAT. FIRST OF ALL, I AM 532 00:26:30,040 --> 00:26:34,160 REALLY ONE OF THE THINGS I AM 533 00:26:34,160 --> 00:26:36,960 ALMOST MOST EXCITED FRANKLY, 534 00:26:36,960 --> 00:26:38,400 ABOUT THIS POSITION IS THE 535 00:26:38,400 --> 00:26:39,680 OPPORTUNITY TO WORK WITH 536 00:26:39,680 --> 00:26:44,720 FREDERICK NATIONAL LABS. I AM 537 00:26:44,720 --> 00:26:46,000 FAMILIAR WITH FEDERALLY FUNDED 538 00:26:46,000 --> 00:26:47,240 RESEARCH AND DEVELOPMENT 539 00:26:47,240 --> 00:26:50,240 CENTERS, I HAVE SPENT THE LAST 540 00:26:50,240 --> 00:26:52,080 SEVEN PLUS YEARS WORKING VERY 541 00:26:52,080 --> 00:26:54,440 CLOSELY WITH MIDER CORPORATION 542 00:26:54,440 --> 00:26:56,680 ON THEIR ACTIVITIES, FUNDED BY 543 00:26:56,680 --> 00:26:58,680 HEALTH AND HUMAN SERVICES BY 544 00:26:58,680 --> 00:27:00,760 OTHER PARTS OF HEALTH AND HUMAN 545 00:27:00,760 --> 00:27:02,480 SERVICES AND BY DEPARTMENT OF 546 00:27:02,480 --> 00:27:08,040 DEFENSE. I HAVE BEEN A 547 00:27:08,040 --> 00:27:09,520 COLLABORATOR IN MANY ACTIVITIES. 548 00:27:09,520 --> 00:27:12,160 THE MOST SIGNIFICANT RELATED TO 549 00:27:12,160 --> 00:27:15,800 CANCER INVOLVING THE FDA. SO I'M 550 00:27:15,800 --> 00:27:17,920 VERY FAMILIAR WITH THE FFRDC 551 00:27:17,920 --> 00:27:23,280 MECHANISM AND I'M A HUGE FAN. I 552 00:27:23,280 --> 00:27:26,520 UNDERSTAND CLEARLY IT BRINGS 553 00:27:26,520 --> 00:27:29,920 ESSENTIAL THING TO NCI. THAT IS 554 00:27:29,920 --> 00:27:31,400 INFRASTRUCTURE SUPPORT FOR 555 00:27:31,400 --> 00:27:33,480 INTRAMURAL INVESTIGATORS. 556 00:27:33,480 --> 00:27:34,920 ABSOLUTELY CRUCIAL AND WOULD BE 557 00:27:34,920 --> 00:27:35,640 DIFFICULT TO ACHIEVE IN OTHER 558 00:27:35,640 --> 00:27:42,760 WAYS. ON TOP OF THAT IMPORTANT 559 00:27:42,760 --> 00:27:46,920 SERVICE PROVIDES FLEXIBILITY AND 560 00:27:46,920 --> 00:27:48,880 THE BRING IN EXPERTISE WHEREVER 561 00:27:48,880 --> 00:27:53,040 THAT MIGHT BE. TO UNDERTAKE 562 00:27:53,040 --> 00:28:00,120 SPECIAL PROJECTS THAT HAVE HAVE 563 00:28:00,120 --> 00:28:01,680 VERY HIGHLY DEFINED SCOPE AND 564 00:28:01,680 --> 00:28:03,360 LIMITED DURATION TO ACHIEVE 565 00:28:03,360 --> 00:28:06,200 GOALS THAT THEN CAN BE 566 00:28:06,200 --> 00:28:09,960 DISSEMINATED TO THE ENTIRE WORLD 567 00:28:09,960 --> 00:28:12,600 TO BENEFIT OF THOSE WHO ARE 568 00:28:12,600 --> 00:28:14,960 TACKLING PROBLEMS. THE FFRDC 569 00:28:14,960 --> 00:28:16,960 MECHANISM IS A FLEXIBLE 570 00:28:16,960 --> 00:28:19,840 INCREDIBLY COLLABORATIVE WAY TO 571 00:28:19,840 --> 00:28:22,760 ACHIEVE THAT IS I HAVE FOUND 572 00:28:22,760 --> 00:28:28,240 UNPARALLELED. VERY GRATEFUL FOR 573 00:28:28,240 --> 00:28:30,840 THIS ORGANIZATION. AND 574 00:28:30,840 --> 00:28:32,040 ASSOCIATION WITH NCI AND NIH. 575 00:28:32,040 --> 00:28:38,520 THE FINAL THING TO SAY IS IRAM 576 00:28:38,520 --> 00:28:40,080 HERE TO LISTEN, STILL LEARNING 577 00:28:40,080 --> 00:28:41,680 STILL HAVE A LOT TO LEARN ABOUT 578 00:28:41,680 --> 00:28:44,520 INDIVIDUALLY WHAT FREDERICK 579 00:28:44,520 --> 00:28:48,160 HISTORY IS, WHAT IT IS DOING, 580 00:28:48,160 --> 00:28:50,040 PRIORITIES. MOST IMPORTANT WHICH 581 00:28:50,040 --> 00:28:52,480 IS WHAT WE NEED FROM YOU. 582 00:28:52,480 --> 00:28:57,000 CRITICAL FEEDBACK ON WHAT WE CAN 583 00:28:57,000 --> 00:28:59,080 DO BETTER. DON'T PULL PUNCHES. 584 00:28:59,080 --> 00:29:01,640 WE NEED TO KNOW WHAT ARE 585 00:29:01,640 --> 00:29:03,840 OPPORTUNITIES MISSED, WHAT ARE 586 00:29:03,840 --> 00:29:06,440 -- WHAT HAS GONE WELL, WHAT IS 587 00:29:06,440 --> 00:29:08,560 NOT BEEN GREAT AND WHAT ARE IN 588 00:29:08,560 --> 00:29:09,680 PARTICULAR WHAT ARE 589 00:29:09,680 --> 00:29:11,800 OPPORTUNITIES SO THAT WE USE THE 590 00:29:11,800 --> 00:29:13,080 RESOURCES DEVOTED TO FREDERICK 591 00:29:13,080 --> 00:29:18,600 THE BEST WAY POSSIBLE. THAT IS 592 00:29:18,600 --> 00:29:20,400 IT. I'M HERE TO LEARN AND 593 00:29:20,400 --> 00:29:22,600 GRATEFUL FOR YOUR ADVICE AND 594 00:29:22,600 --> 00:29:23,880 PARTICIPATION IN THIS IMPORTANT 595 00:29:23,880 --> 00:29:24,880 ADVISORY COMMITTEE FOR 596 00:29:24,880 --> 00:29:29,960 FREDERICK. THANKS GUESS WE WILL 597 00:29:29,960 --> 00:29:36,360 TAKE QUESTIONS NOW. ANYONE. 598 00:29:36,360 --> 00:29:38,400 >>I TOO HAVE A COLD AND BEEN 599 00:29:38,400 --> 00:29:39,480 TESTED, WE ARE IN THE SAME 600 00:29:39,480 --> 00:29:44,400 PLACE. WHEN YOU SNEEZE AND COUGH 601 00:29:44,400 --> 00:29:45,480 EVERYONE LOOKS AT YOU AND YOU 602 00:29:45,480 --> 00:29:46,960 HAVE TO SHOW YOUR TEST RESULTS. 603 00:29:46,960 --> 00:29:51,400 IT IS CRAZY. I AM EXCITED FOR 604 00:29:51,400 --> 00:29:55,360 YOUR LEADERSHIP. SURE EVERYONE 605 00:29:55,360 --> 00:29:59,560 IS AWARE SHE IS FIRST NAIL NCI 606 00:29:59,560 --> 00:30:02,080 DIRECTOR WE HAVE HAD, 607 00:30:02,080 --> 00:30:06,200 CONTRIBUTES TO DIVERSITY AND 608 00:30:06,200 --> 00:30:08,560 FOCUS ON THOSE ISSUES. EXCITED 609 00:30:08,560 --> 00:30:12,240 FOR YOUR LEADERSHIP. I THINK YOU 610 00:30:12,240 --> 00:30:18,960 WILL FIND FREDERICK IS I DON'T 611 00:30:18,960 --> 00:30:20,200 WANT TO SAY IT IS A DIAMOND IN 612 00:30:20,200 --> 00:30:22,080 THE ROUGH BECAUSE MANY WAYS IT 613 00:30:22,080 --> 00:30:22,560 IS A INDICTMENT BUT THE 614 00:30:22,560 --> 00:30:26,280 CHALLENGE IS GETTING THE WORD 615 00:30:26,280 --> 00:30:28,480 OUT OUT SO EVERYBODY KNOWS, THE 616 00:30:28,480 --> 00:30:29,760 CAPABILITIES AND WHAT FREDERICK 617 00:30:29,760 --> 00:30:31,760 CAN DO FOR THEM OR WHAT THINGS 618 00:30:31,760 --> 00:30:36,080 THEY OFFER. PLEASE, WHO ELSE ON 619 00:30:36,080 --> 00:30:38,960 THE COMMITTEE WOULD LIKE TO ASK 620 00:30:38,960 --> 00:30:49,480 A QUESTION OR COMMENT. Z YES. 621 00:30:53,520 --> 00:30:54,520 THERE WE GO. 622 00:30:54,520 --> 00:31:02,360 >>THERE WAS MENTION TRYING TO 623 00:31:02,360 --> 00:31:04,880 EXTEND RANKS OF TARGETS 624 00:31:04,880 --> 00:31:06,240 MANIPULATED, UNDRUGGABLE 625 00:31:06,240 --> 00:31:07,160 TARGETS, IF YOU WILL. I HATE 626 00:31:07,160 --> 00:31:13,120 THAT TERM. BUT JUST THINGS WE 627 00:31:13,120 --> 00:31:16,560 HAVE DRUGGED. WHAT IS THE VISION 628 00:31:16,560 --> 00:31:18,840 HOW TO DO THAT IN PRACTICE TO 629 00:31:18,840 --> 00:31:26,880 ADVANCE THAT MISSION? POSSIBLE 630 00:31:26,880 --> 00:31:29,000 DA, I'LL START AND MAYBE JIM 631 00:31:29,000 --> 00:31:29,920 DOROSHOW WOULD LIKE TO COMMENT 632 00:31:29,920 --> 00:31:35,760 AS WELL. ONE OF THE PROPOSALS 633 00:31:35,760 --> 00:31:40,680 WE HAVE MADE FOR THE CANCER MOON 634 00:31:40,680 --> 00:31:46,320 SHOT TO INCREASE PIPELINE OF NEW 635 00:31:46,320 --> 00:31:48,200 DRUGS. WE SEE OCCURRING IN AT 636 00:31:48,200 --> 00:31:53,760 LEAST TWO DIFFERENT WAYS, ONE IS 637 00:31:53,760 --> 00:31:56,360 THROUGH ONE THROUGH THE NEXT 638 00:31:56,360 --> 00:31:57,680 PROGRAM DISCUSSED HERE AND IS 639 00:31:57,680 --> 00:32:00,480 RUN THROUGH THE FREDERICK 640 00:32:00,480 --> 00:32:03,400 NATIONAL LAB BUT THE OTHER CAN 641 00:32:03,400 --> 00:32:04,720 BE THROUGH INVESTIGATOR 642 00:32:04,720 --> 00:32:09,640 INITIATED RESEARCH OF OTHER 643 00:32:09,640 --> 00:32:13,120 KINDS JIM, DO YOU WANT TO 644 00:32:13,120 --> 00:32:13,680 COMMENT? 645 00:32:13,680 --> 00:32:15,280 >>YOU WHERE MUTED. 646 00:32:15,280 --> 00:32:19,280 >>IF I CAN UNMUTE. OKAY. IT 647 00:32:19,280 --> 00:32:20,840 IS A GREAT QUESTION. I WANT TO 648 00:32:20,840 --> 00:32:24,640 REITERATE WHAT DOUG SAID BECAUSE 649 00:32:24,640 --> 00:32:27,040 ONE OF THE THINGS WE FIND IS 650 00:32:27,040 --> 00:32:28,920 THAT THOUGH WE GET LOTS OF 651 00:32:28,920 --> 00:32:30,200 APPLICATIONS WE WOULD LIKE MANY 652 00:32:30,200 --> 00:32:31,560 MORE APPLICATIONS FOR THE NEXT 653 00:32:31,560 --> 00:32:33,440 PROGRAM, WE HAVE A GREAT TEAM 654 00:32:33,440 --> 00:32:37,520 THAT HAS JUST BEEN REVIEWED, 655 00:32:37,520 --> 00:32:38,920 PRODUCTIVITY THE LAST FIVE SIX 656 00:32:38,920 --> 00:32:44,320 YEARS IS GREAT. WE HAVE A VERY 657 00:32:44,320 --> 00:32:45,160 OUTSTANDING WAY TO SUPPORT 658 00:32:45,160 --> 00:32:46,040 OUTSTANDING INVESTIGATORS. 659 00:32:46,040 --> 00:32:48,080 ESPECIALLY THE TRANSITION FROM 660 00:32:48,080 --> 00:32:49,560 RO1 SPONSORED RESEARCH WHICH 661 00:32:49,560 --> 00:32:51,160 NEEDS TO INCREASE BUT THEN TO 662 00:32:51,160 --> 00:32:52,200 KINDS OF THINGS HARD TO DO AT 663 00:32:52,200 --> 00:32:56,000 UNIVERSITY. TO MAKE THOSE 664 00:32:56,000 --> 00:32:57,320 FACILITIES AND RESOURCES 665 00:32:57,320 --> 00:32:58,280 AVAILABLE TO INVESTIGATORS SO 666 00:32:58,280 --> 00:32:59,840 THEY CAN MOVE ON TO THE 667 00:32:59,840 --> 00:33:05,200 COMMERCIAL SPHERE. WE HAVE A 668 00:33:05,200 --> 00:33:06,320 GENEROUS BUDGET BUT NOT ENOUGH 669 00:33:06,320 --> 00:33:08,120 TO SUPPORT THE RANGE OF PROJECTS 670 00:33:08,120 --> 00:33:09,360 THAT WE LIKE TO MOVE FORWARD. SO 671 00:33:09,360 --> 00:33:12,240 WE ARE HOPEFUL THAT THOSE 672 00:33:12,240 --> 00:33:15,880 RESOURCES WOULD BE FORTHCOMING 673 00:33:15,880 --> 00:33:19,840 IF THE MOON SHOT IS FUNDED. 674 00:33:19,840 --> 00:33:24,440 >>BEFORE MONICA SAYS WHAT SHE 675 00:33:24,440 --> 00:33:26,880 THINKS, IT IS NOT AT ALL THAT WE 676 00:33:26,880 --> 00:33:28,760 THINK ABOUT WORKING 677 00:33:28,760 --> 00:33:32,240 INDEPENDENTLY OF BIOTECH AND 678 00:33:32,240 --> 00:33:34,480 PHARMACEUTICAL INDUSTRY BUT THAT 679 00:33:34,480 --> 00:33:35,840 IT HAS BEEN DEMONSTRATED OVER 680 00:33:35,840 --> 00:33:40,240 THE LAST FEW YEARS, THAT 681 00:33:40,240 --> 00:33:42,240 INVESTIGATORS HAVE AN IMPORTANT 682 00:33:42,240 --> 00:33:46,640 ROLE TO PLAY WHEN IT COMES TO 683 00:33:46,640 --> 00:33:49,200 TRANSLATIONAL RESEARCH. MONICA. 684 00:33:49,200 --> 00:33:53,280 >>I GUESS THE ONLY COMMENT TO 685 00:33:53,280 --> 00:33:58,360 THROW HERE ONE OF THE THINGS NCI 686 00:33:58,360 --> 00:34:01,240 CORE TO EVERYTHING NCI DOES IS 687 00:34:01,240 --> 00:34:04,320 ROBUST BASIC SCIENCE INITIATIVE 688 00:34:04,320 --> 00:34:09,480 THAT IS FOCUSED ON DEVELOPING 689 00:34:09,480 --> 00:34:11,920 CLINICAL TREATMENTS AND 690 00:34:11,920 --> 00:34:14,120 PREVENTION APPROACH. WHEN YOU 691 00:34:14,120 --> 00:34:17,240 SAY UNDRUGGABLE, WHAT DOES THAT 692 00:34:17,240 --> 00:34:19,440 MEAN? WE NEED TO DOUBLE DOWN ON 693 00:34:19,440 --> 00:34:22,000 CORE ACTIVITY IS UNDERSTANDING 694 00:34:22,000 --> 00:34:24,040 WHAT CANCER MEANS. UNDERSTANDING 695 00:34:24,040 --> 00:34:28,320 DIVERSITY ACROSS POPULATIONS AND 696 00:34:28,320 --> 00:34:30,640 WAYS TO CIRCUMVENT THAT, THAT'S 697 00:34:30,640 --> 00:34:32,000 BETTER THAN SAYING SOMETHING IS 698 00:34:32,000 --> 00:34:33,320 UNDRUGGABLE BUT IT IS A BUZZ 699 00:34:33,320 --> 00:34:37,680 WORD THAT WE HAVE TO SOMEHOW 700 00:34:37,680 --> 00:34:39,240 DEAL WITH, SO I THINK WITHIN 701 00:34:39,240 --> 00:34:40,640 THIS PART OF THE MOON SHOT, IT 702 00:34:40,640 --> 00:34:44,680 WILL BE A WAY OF EXPRESSING 703 00:34:44,680 --> 00:34:48,760 SIGNALING VERY CLEARLY, THAT YOU 704 00:34:48,760 --> 00:34:51,120 CAN'T EVER GIVE UP ON BASIC 705 00:34:51,120 --> 00:34:53,880 DISCOVERY RESEARCH TO UNDERSTAND 706 00:34:53,880 --> 00:34:57,760 BIOLOGY AND ACHIEVE THERAPEU 707 00:34:57,760 --> 00:34:58,120 THERAPEUTICS. 708 00:34:58,120 --> 00:35:01,880 >>TOTALLY AGREE. I WOULD JUST 709 00:35:01,880 --> 00:35:05,920 SAY THERE IS CERTAINLY A BIAS 710 00:35:05,920 --> 00:35:11,640 AGAINST NON-TRADITIONAL TARGETS 711 00:35:11,640 --> 00:35:13,200 IN PHARMA MAKES SENSE BECAUSE 712 00:35:13,200 --> 00:35:14,520 THEY ARE LOOKING TO GET TO A 713 00:35:14,520 --> 00:35:16,080 DRUG QUICKLY. I THINK ACADEMIC 714 00:35:16,080 --> 00:35:18,480 RESEARCH HAS A VERY IMPORTANT 715 00:35:18,480 --> 00:35:20,080 ROLE TO PLAY IN EXPANDING THE 716 00:35:20,080 --> 00:35:22,760 UNIVERSE OF TARGETS, TIPPET OF 717 00:35:22,760 --> 00:35:26,280 TARGETS HOW TO TARGET, BUT THAT 718 00:35:26,280 --> 00:35:28,600 REQUIRES REVIEWERS AND GRANT 719 00:35:28,600 --> 00:35:31,720 MECHANISMS THAT WILL GO OUT ON A 720 00:35:31,720 --> 00:35:34,160 LIMB TO TAKE THE RISK TO SEE HOW 721 00:35:34,160 --> 00:35:35,800 CAN WE TARGET SOMETHING NOVEL 722 00:35:35,800 --> 00:35:37,040 THAT HASN'T BEEN TARGETED 723 00:35:37,040 --> 00:35:39,400 PREVIOUSLY. 724 00:35:39,400 --> 00:35:41,720 >>WE HAVE A BUNCH OF QUESTIONS, 725 00:35:41,720 --> 00:35:47,680 START WITH DANIEL. YOU ARE 726 00:35:47,680 --> 00:35:48,760 MUTED. 727 00:35:48,760 --> 00:35:51,080 >>CAN YOU HEAR ME NOW? 728 00:35:51,080 --> 00:35:54,440 >>YES. 729 00:35:54,440 --> 00:35:56,920 >>ONCOLOGIST, I SPECIALIZE IN 730 00:35:56,920 --> 00:35:59,360 OVARIAN CANCER AND I'M DELIGHTED 731 00:35:59,360 --> 00:36:07,560 THAT MONICA AS A SURGEON SIGN 732 00:36:07,560 --> 00:36:09,040 TICES YOU HAVE AN INCREDIBLE 733 00:36:09,040 --> 00:36:12,440 CAREER, MY CONCERNS ARE TWOFOLD, 734 00:36:12,440 --> 00:36:14,800 ONE THE LACK OF DIMINISHING ROLE 735 00:36:14,800 --> 00:36:18,200 OF THE SURGEON SCIENTIST. 736 00:36:18,200 --> 00:36:22,600 WONDERING IF THERE IS ANYTHING 737 00:36:22,600 --> 00:36:23,600 RELATED SPECIFICALLY TO THAT 738 00:36:23,600 --> 00:36:25,720 GROUP OF PEOPLE WHO PLAY A VERY 739 00:36:25,720 --> 00:36:28,560 UNIQUE ROLE IN TRANSLATING 740 00:36:28,560 --> 00:36:30,240 REALLY FUNDAMENTAL BASIC 741 00:36:30,240 --> 00:36:33,960 FINDINGS TO THE CLINIC IS MY 742 00:36:33,960 --> 00:36:35,080 FIRST QUESTION. SECOND QUESTION 743 00:36:35,080 --> 00:36:39,400 HAS TO DO WITH DIVERSITY. 744 00:36:39,400 --> 00:36:41,600 >>SURGEON SCIENTIST, IT IS 745 00:36:41,600 --> 00:36:43,280 CLEAR WHAT THE ISSUE IS THERE, I 746 00:36:43,280 --> 00:36:46,600 WILL JUST SAY IT. SURGEONS MAKE 747 00:36:46,600 --> 00:36:50,440 -- ARE MUCH, MUCH MORE EFFECTIVE 748 00:36:50,440 --> 00:36:51,480 WITHIN THEIR ACADEMIC 749 00:36:51,480 --> 00:36:54,880 INSTITUTIONS. WITHIN THE 750 00:36:54,880 --> 00:36:56,680 OPERATING ROOM THAN WHEN IN THE 751 00:36:56,680 --> 00:36:58,440 RESEARCH LABORATORY. WHEN THEY 752 00:36:58,440 --> 00:37:00,960 ARE IN THE OPERATING ROOM THEY 753 00:37:00,960 --> 00:37:05,160 MAKE TEN TIMES THE MONEY, WHEN 754 00:37:05,160 --> 00:37:07,320 THEY ARE IN THE RESEARCH LAB. IT 755 00:37:07,320 --> 00:37:08,320 IS AN ECONOMICKISH SHAH SHOE AND 756 00:37:08,320 --> 00:37:13,880 HAS BEEN FOR THE LAST 40 YEARS. 757 00:37:13,880 --> 00:37:16,800 CERTAINLY MY ENTIRE CAREER. THE 758 00:37:16,800 --> 00:37:19,600 WAY WE GET SURGEON SCIENTISTS 759 00:37:19,600 --> 00:37:20,520 BECAUSE THERE ARE PLENTY THAT 760 00:37:20,520 --> 00:37:22,200 COME OUT OF TRAINING PROGRAMS, 761 00:37:22,200 --> 00:37:24,640 COME OUT WITH Ph.D.s, COME 762 00:37:24,640 --> 00:37:27,240 OUT WITH EXCELLENT CREDENTIALS. 763 00:37:27,240 --> 00:37:30,400 IS TO FIND A WAY TO GET THEM 764 00:37:30,400 --> 00:37:32,960 FUNDED. GET THEM FUNDED BY NIH 765 00:37:32,960 --> 00:37:36,040 GRANTS. BECAUSE THAT IS THE ONLY 766 00:37:36,040 --> 00:37:38,600 THING THAT BUYS THEM THEIR 767 00:37:38,600 --> 00:37:40,720 ABILITY TO DO WORK IN OUR 768 00:37:40,720 --> 00:37:42,840 CURRENT ACADEMIC CENTERS. AND 769 00:37:42,840 --> 00:37:44,800 BUYS THEIR TIME AWAY FRANKLY 770 00:37:44,800 --> 00:37:46,080 FROM BEING IN THE OPERATING ROOM 771 00:37:46,080 --> 00:37:50,040 ALL THE TIME. I THINK ANY 772 00:37:50,040 --> 00:37:51,600 PROGRAMS THAT SUPPORT HIGH 773 00:37:51,600 --> 00:37:52,520 QUALITY INDIVIDUALS TO BE ABLE 774 00:37:52,520 --> 00:37:54,240 TO ACHIEVE THAT FUNDING IS GOING 775 00:37:54,240 --> 00:37:55,840 TO BE THE ONLY WAY TO SOLVE THIS 776 00:37:55,840 --> 00:37:59,600 PROBLEM. 777 00:37:59,600 --> 00:38:05,560 >>THIS IS DOUG. LET ME SAY THAT 778 00:38:05,560 --> 00:38:08,920 ONE OF THE NEW PROGRAMS WE HAVE 779 00:38:08,920 --> 00:38:14,080 IS THE K AWARDS SPECIFICALLY FOR 780 00:38:14,080 --> 00:38:16,400 SURGEONS AND TRAINING WHICH NOW 781 00:38:16,400 --> 00:38:19,800 ARE PERMITTING 50% TIME RATHER 782 00:38:19,800 --> 00:38:24,040 THAN THE 75% AS THE MINIMUM 783 00:38:24,040 --> 00:38:27,400 AMOUNT. THE FIRST CLASS SEEM TO 784 00:38:27,400 --> 00:38:28,560 BE A TERRIFIC GROUP OF PEOPLE 785 00:38:28,560 --> 00:38:32,080 AND LOOKING FORWARD TO ANOTHER 786 00:38:32,080 --> 00:38:39,040 CLASS IN THE COMING YEAR. I WAS 787 00:38:39,040 --> 00:38:42,120 TALKING YESTERDAY WITH MARTHA 788 00:38:42,120 --> 00:38:44,240 ZEIGLER FROM THE INTRAMURAL 789 00:38:44,240 --> 00:38:45,560 PROGRAM WHO IS A SURGEON AND 790 00:38:45,560 --> 00:38:51,600 SHE'S DOING SOME ANALYSES OF 791 00:38:51,600 --> 00:38:53,040 SURGEONS AND ONE OF THE THINGS 792 00:38:53,040 --> 00:38:59,640 SHE POINTED OUT IS IN THE RECENT 793 00:38:59,640 --> 00:39:01,640 PAST OF THE SURGEONS WHO HAVE 794 00:39:01,640 --> 00:39:04,280 RO1 AWARDS FROM NCI, THREE 795 00:39:04,280 --> 00:39:11,880 QUARTERS OF THEM ARE FOR BASIC 796 00:39:11,880 --> 00:39:13,000 RESEARCH, GETTING BACK TO THE 797 00:39:13,000 --> 00:39:14,240 ISSUE MONICA YOU WERE TALKING 798 00:39:14,240 --> 00:39:15,920 ABOUT BUT THE OVERALL PROPORTION 799 00:39:15,920 --> 00:39:22,400 OF SURGEONS INVOLVED IN GETTING 800 00:39:22,400 --> 00:39:24,040 NCI AWARDS HAS GONE UP A BIT 801 00:39:24,040 --> 00:39:26,320 OVER THE LAST FEW YEARS. IN 802 00:39:26,320 --> 00:39:28,440 CONTRAST TO PHYSICIAN SCIENTISTS 803 00:39:28,440 --> 00:39:32,480 IN GENERAL. 804 00:39:32,480 --> 00:39:34,320 >>IF I CAN MAKE ONE COMMENT, 805 00:39:34,320 --> 00:39:36,440 THIS WAS AMONG CANCER CENTER 806 00:39:36,440 --> 00:39:39,560 DIRECTORS, NOT PERTINENT TO 807 00:39:39,560 --> 00:39:41,120 FREDERICK BUT THE CANCER CENTERS 808 00:39:41,120 --> 00:39:43,840 BRANCH AND NCI DESIGNATION IS 809 00:39:43,840 --> 00:39:45,720 THAT IF PROTECTED TIME COULD BE 810 00:39:45,720 --> 00:39:47,920 PART OF INSTITUTIONAL 811 00:39:47,920 --> 00:39:50,800 COMMITMENTS SUCH THAT 812 00:39:50,800 --> 00:39:51,920 INSTITUTIONS WOULD HELP TO 813 00:39:51,920 --> 00:39:54,280 SUPPORT PROTECTED TIME. IN 814 00:39:54,280 --> 00:39:56,160 CANCER CENTERS GET CREDIT FOR 815 00:39:56,160 --> 00:39:58,560 THAT, THAT MIGHT INCENTIVIZE A 816 00:39:58,560 --> 00:40:01,840 LITTLE BIT MORE PROTECTED TIME. 817 00:40:01,840 --> 00:40:03,280 BECAUSE THERE IS SUCH A 818 00:40:03,280 --> 00:40:04,000 FINANCIAL CRUNCH THESE 819 00:40:04,000 --> 00:40:07,720 INSTITUTIONS HAVE. 820 00:40:07,720 --> 00:40:09,440 >>I CAN TO MAKE A PLUG RELATED 821 00:40:09,440 --> 00:40:12,520 TO DIVERSITY AND HEALTH 822 00:40:12,520 --> 00:40:14,840 DISPARITIES THAT THE GREATEST 823 00:40:14,840 --> 00:40:16,440 DISPARITY SIGN IN GAIN LO 824 00:40:16,440 --> 00:40:18,040 DODGECAL CANCER IS AMONG BLACK 825 00:40:18,040 --> 00:40:20,920 WOMEN DIAGNOSED WITH ENDOMETRIAL 826 00:40:20,920 --> 00:40:22,920 CANCER. AND THE INCIDENCE IS 827 00:40:22,920 --> 00:40:26,040 RISING A RAPIDLY. THE MORTALITY 828 00:40:26,040 --> 00:40:29,520 IS ALSO ASTOUNDING. I HOPE THAT 829 00:40:29,520 --> 00:40:32,920 WE CAN FIND WAYS TO BRIDGE OUR 830 00:40:32,920 --> 00:40:37,280 BASIC FINDINGS AGGRESSIVE 831 00:40:37,280 --> 00:40:41,360 MOLECULAR TYPES WITH WHAT WE ARE 832 00:40:41,360 --> 00:40:43,280 SEEING CLINICALLY 833 00:40:43,280 --> 00:40:45,440 >>I PRESENTED SOMETHING ABOUT 834 00:40:45,440 --> 00:40:49,960 THE NON-ENDOMETRIAL CANCER LAST 835 00:40:49,960 --> 00:40:51,720 TIME WHERE THE STATISTICS ARE 836 00:40:51,720 --> 00:40:56,800 JUST STAGGERING FOR MORTALITY 837 00:40:56,800 --> 00:41:00,520 RATE ESPECIALLY AMONG AFRICAN 838 00:41:00,520 --> 00:41:03,640 AMERICAN WOMEN, BUT NOW ALSO 839 00:41:03,640 --> 00:41:04,960 AMONG HISPANIC WOMEN. WE ARE 840 00:41:04,960 --> 00:41:07,840 PLANNING TO HAVE A WORKSHOP IN 841 00:41:07,840 --> 00:41:10,560 THE FIRST QUARTER OF NEXT YEAR. 842 00:41:10,560 --> 00:41:14,280 TO DEAL WITH THIS. THIS ALREADY 843 00:41:14,280 --> 00:41:18,600 WAS A MOON SHOT ACTIVITY FROM 844 00:41:18,600 --> 00:41:22,440 MOON SHOT 1.0. BUT IT IS CLEAR 845 00:41:22,440 --> 00:41:24,680 WE NEED TO PUT MORE EFFORT INTO 846 00:41:24,680 --> 00:41:27,120 THIS AREA. 847 00:41:27,120 --> 00:41:37,680 >>SO WE HAVE FOUR MINUTES LEFT. 848 00:41:42,000 --> 00:41:42,200 ALRY SOB? 849 00:41:42,200 --> 00:41:43,960 >>COUPLE OF THINGS. I IT IS T 850 00:41:43,960 --> 00:41:45,240 A DIAMOND IN THE ROUGH BUT A 851 00:41:45,240 --> 00:41:46,760 HIDDEN DIAMOND. DR. JOHNSON AND 852 00:41:46,760 --> 00:41:49,840 I TALKED HOW THE ADVISORY BOARD 853 00:41:49,840 --> 00:41:51,240 CAN HELP ELEVATE OR DEVELOP 854 00:41:51,240 --> 00:41:55,000 STRATEGY OR TACTICAL PLANS THAT 855 00:41:55,000 --> 00:41:56,800 WILL HELP THAT HIDDEN DIAMOND 856 00:41:56,800 --> 00:42:01,560 BECOME A VISIBLE DIAMOND. THE 857 00:42:01,560 --> 00:42:03,840 SECOND THING IS I WAS INTRIGUED 858 00:42:03,840 --> 00:42:06,720 THAT ONE OF THE BUDGETS 859 00:42:06,720 --> 00:42:08,800 PRIORITIES WAS CELL THERAPY FOR 860 00:42:08,800 --> 00:42:10,160 TREATMENT OF CANCER. THAT IS MY 861 00:42:10,160 --> 00:42:14,760 JAM. I WANTED TO KNOW WHERE I 862 00:42:14,760 --> 00:42:15,680 COULD FIND OUT MORE DETAILS ON 863 00:42:15,680 --> 00:42:19,720 THAT. 864 00:42:19,720 --> 00:42:24,960 >>LET JIM DOROSHOW RESPOND TO 865 00:42:24,960 --> 00:42:25,640 THAT 866 00:42:25,640 --> 00:42:28,720 >>MY APOLOGIES IN MY OFFICE 867 00:42:28,720 --> 00:42:30,080 BUILDING 31. DOING CONSTRUCTION 868 00:42:30,080 --> 00:42:32,080 BOTH ABOVE AND BELOW ME SO I 869 00:42:32,080 --> 00:42:34,320 MISSED PART OF THE FIRST PART OF 870 00:42:34,320 --> 00:42:35,560 YOUR QUESTION BECAUSE SOME 871 00:42:35,560 --> 00:42:36,680 INCREDIBLE NOISE I HAVE NO IDEA 872 00:42:36,680 --> 00:42:38,560 WHAT IT WAS, I HOPE THE ROOF -- 873 00:42:38,560 --> 00:42:40,280 CEILING IS OKAY. CAN I ASK YOU 874 00:42:40,280 --> 00:42:41,240 REPEAT THE FIRST PART OF YOUR 875 00:42:41,240 --> 00:42:43,600 QUESTION? 876 00:42:43,600 --> 00:42:45,400 >>THE ONLY THING RELEVANT TO 877 00:42:45,400 --> 00:42:48,480 YOU IS IN ONE OF THE BUDGET 878 00:42:48,480 --> 00:42:51,200 PRIORITIES FOR UPCOMING FISCAL 879 00:42:51,200 --> 00:42:52,720 YEAR WAS CELL THERAPY FOR 880 00:42:52,720 --> 00:42:53,720 TREATMENT OF CANCER. INTO FIND 881 00:42:53,720 --> 00:42:54,840 OUT WHERE I COULD GET MORE 882 00:42:54,840 --> 00:42:57,440 INFORMATION ON THAT INITIATIVE 883 00:42:57,440 --> 00:42:59,640 AND WHAT IT INVOLVES. 884 00:42:59,640 --> 00:43:01,480 >>THE FIRST PART IS A NEW RFA 885 00:43:01,480 --> 00:43:06,080 THAT WAS RECENTLY RELEASED. 886 00:43:06,080 --> 00:43:07,800 CALLED CAN CAN ACT. TO SET UP A 887 00:43:07,800 --> 00:43:09,200 NETWORK OF CELL THERAPY CENTERS 888 00:43:09,200 --> 00:43:12,200 THAT WILL DO BOTH PILOT STUDIES, 889 00:43:12,200 --> 00:43:16,640 AT THEIR OWN INSTITUTION BUT IT 890 00:43:16,640 --> 00:43:18,360 IS INTIMATELY CONNECTED WITH OUR 891 00:43:18,360 --> 00:43:19,920 RECENTLY EXPANDED LABS IN 892 00:43:19,920 --> 00:43:24,400 FREDERICK. GMP PRODUCTION 893 00:43:24,400 --> 00:43:27,720 FACILITIES SO THE IDEA IS THAT 894 00:43:27,720 --> 00:43:29,640 PILOT STUDIES DONE SINGLE 895 00:43:29,640 --> 00:43:30,520 INSTITUTION BUT WHEN THERE IS 896 00:43:30,520 --> 00:43:33,800 REQUIREMENT FOR LARGER STUDIES 897 00:43:33,800 --> 00:43:34,840 MULTI-INSTITUTIONAL TRIALS, WILL 898 00:43:34,840 --> 00:43:36,600 PRODUCE THE GMP QUALITY MATERIAL 899 00:43:36,600 --> 00:43:39,760 IN FREDERICK. THEN DO ALL THE 900 00:43:39,760 --> 00:43:41,680 REGULATORY FOR THOSE STUDIES, 901 00:43:41,680 --> 00:43:43,960 HOLD INDs AND HELP 902 00:43:43,960 --> 00:43:45,440 INSTITUTIONS WORK TOGETHER FOR 903 00:43:45,440 --> 00:43:46,480 MULTI-INSTITUTIONAL CELL THERAPY 904 00:43:46,480 --> 00:43:46,720 TRIALS. 905 00:43:46,720 --> 00:43:50,040 >>THANK YOU SO MUCH, JIM. I 906 00:43:50,040 --> 00:43:52,040 WILL KEEP MY PIES OUT FOR THAT 907 00:43:52,040 --> 00:43:52,200 RFA. 908 00:43:52,200 --> 00:43:59,240 >>DO YOU HAVE A QUESTION? 909 00:43:59,240 --> 00:44:01,480 >>DR. MADABHUSHI EMORY 910 00:44:01,480 --> 00:44:03,720 UNIVERSITY. CONGRATULATIONS FOR 911 00:44:03,720 --> 00:44:05,840 MONICA. MY GROUP FOCUS ON 912 00:44:05,840 --> 00:44:07,240 ARTIFICIAL INTELLIGENCE AND 913 00:44:07,240 --> 00:44:11,480 USING AI FROM IMAGING DATA TO 914 00:44:11,480 --> 00:44:13,000 PREDICT TREATMENT RESPONSE I 915 00:44:13,000 --> 00:44:14,560 HAVE BEEN AT A NUMBER OF NCI 916 00:44:14,560 --> 00:44:16,360 WORKSHOPS AND MEETINGS AND I 917 00:44:16,360 --> 00:44:22,160 THINK DOUG WAS AT A MEETING AS 918 00:44:22,160 --> 00:44:24,360 WELL, FOCUSING ON AI AND CANCER 919 00:44:24,360 --> 00:44:26,360 DISPARITIES. DONNA SINGER AND I 920 00:44:26,360 --> 00:44:28,360 WERE AT A MEETING SAN DIEGO THAT 921 00:44:28,360 --> 00:44:30,000 FOCUSED ON AI AND IMMUNOLOGY 922 00:44:30,000 --> 00:44:34,320 THAT HAD A CANCER FOCUS AS WELL 923 00:44:34,320 --> 00:44:35,240 ONE QUESTION THAT KEEPS COMING 924 00:44:35,240 --> 00:44:37,680 UP IS ACCESS TO DATA SETS, 925 00:44:37,680 --> 00:44:38,240 PARTICULARLY COMPLETE HAD 926 00:44:38,240 --> 00:44:43,640 CLINICAL TRIALS. THE IS A 927 00:44:43,640 --> 00:44:44,880 STRUGGLE FOR FOLKS INTERESTED IN 928 00:44:44,880 --> 00:44:46,760 AI AND COMPUTATIONAL ANALYTICS 929 00:44:46,760 --> 00:44:50,320 TO REALLY BE ABLE TO ACCESS DATA 930 00:44:50,320 --> 00:44:51,680 SETS PARTICULARLY SCANS AND 931 00:44:51,680 --> 00:44:53,200 PATHOLOGY IMAGES NOT TISSUE 932 00:44:53,200 --> 00:44:55,640 BLOCKS WHICH IS PATHOLOGY IMAGE 933 00:44:55,640 --> 00:45:04,000 FROM COMPLETED CLINICAL TRIALS, 934 00:45:04,000 --> 00:45:04,720 THAT INCLUDES COOPERATIVE 935 00:45:04,720 --> 00:45:06,680 GROUPS. WHAT STRATEGIES ARE IN 936 00:45:06,680 --> 00:45:08,800 PLACE TO ADDRESS THE ISSUES, 937 00:45:08,800 --> 00:45:10,440 THAT IS HUGE UNTAPPED POTENTIAL 938 00:45:10,440 --> 00:45:11,680 THERE. WHICH SHOULD BE MADE 939 00:45:11,680 --> 00:45:21,920 AVAILABLE. 940 00:45:24,920 --> 00:45:26,120 >>THIS IS AS FAR AS I'M 941 00:45:26,120 --> 00:45:27,440 CONCERNED ONE OF MY HIGHEST 942 00:45:27,440 --> 00:45:28,720 PRIORITIES IS TO FIGURE OUT HOW 943 00:45:28,720 --> 00:45:32,520 WE CAN DO BETTER WITH THIS. AS A 944 00:45:32,520 --> 00:45:38,200 FORMER COOPERATIVE GROUP CHAIR 945 00:45:38,200 --> 00:45:40,000 WHO WOULD FORMAT AND SUBMITTED 946 00:45:40,000 --> 00:45:48,480 EVERY ONE OF OUR LARGE TRIAL TO 947 00:45:48,480 --> 00:45:50,720 ARCHIVE AND PUBLICLY ACCESSIBLE 948 00:45:50,720 --> 00:45:58,080 DATABASES. ALSO SAW ISSUES WITH 949 00:45:58,080 --> 00:45:59,080 BEING ABLE TO STORE AND 950 00:45:59,080 --> 00:46:00,640 INTEGRATE IMAGES TO THOSE 951 00:46:00,640 --> 00:46:01,520 COLLECTIONS SO THEY CAN BE 952 00:46:01,520 --> 00:46:02,560 ADEQUATELY USED BY PEOPLE LIKE 953 00:46:02,560 --> 00:46:10,480 YOU. THIS IS A CRITICAL STEP TO 954 00:46:10,480 --> 00:46:12,360 TAKE. WE HAVE LOTS OF DATA SETS 955 00:46:12,360 --> 00:46:13,920 AND LOTS OF DATA COLLECTED. WE 956 00:46:13,920 --> 00:46:15,920 ARE NOT USING IT OPTIMALLY. VERY 957 00:46:15,920 --> 00:46:17,160 CLEARLY. SO I DON'T HAVE AN 958 00:46:17,160 --> 00:46:20,280 ANSWER FOR YOU RIGHT NOW. I CAN 959 00:46:20,280 --> 00:46:22,040 JUST TELL YOU WHAT YOU HAVE 960 00:46:22,040 --> 00:46:24,240 ARTICULATED I HAVE HEARD FROM SO 961 00:46:24,240 --> 00:46:29,520 MANY DIFFERENT AVENUES WE HAVE 962 00:46:29,520 --> 00:46:30,600 TO SIT DOWN AND FIGURE HOW TO 963 00:46:30,600 --> 00:46:33,040 TAKE THIS ON. I MADE A JOKE I 964 00:46:33,040 --> 00:46:34,240 THINK EARLIER IN THE WEEK WHEN I 965 00:46:34,240 --> 00:46:37,320 SAY WE JUST NEED A MATCH MAKER 966 00:46:37,320 --> 00:46:41,960 YOU WERE WHERE IS DATA WHO NEEDS 967 00:46:41,960 --> 00:46:43,320 IT HOW WE GET IT TO THEM BECAUSE 968 00:46:43,320 --> 00:46:45,200 WE CAN DO BETTER. DON'T HAVE AN 969 00:46:45,200 --> 00:46:46,200 ANSWER YET BUT IT IS HIGH 970 00:46:46,200 --> 00:46:47,200 PRIORITY TO FIGURE OUT WHAT WE 971 00:46:47,200 --> 00:46:55,600 DO. 972 00:46:55,600 --> 00:46:57,520 >>OKAY. NEED TO MOVE ON. DOUG, 973 00:46:57,520 --> 00:47:08,040 I TURN IT BACK OVER TO YOU. 974 00:47:11,000 --> 00:47:16,400 >>WE WANT TO THANK CAT BOLLARD 975 00:47:16,400 --> 00:47:18,280 AND LINCOLN STEIN FOR HAVING 976 00:47:18,280 --> 00:47:19,960 BEEN IMPORTANT AND ACTIVE 977 00:47:19,960 --> 00:47:21,400 MEMBERS OF THE FREDERICK 978 00:47:21,400 --> 00:47:27,000 NATIONAL LABORATORY ADVISORY 979 00:47:27,000 --> 00:47:29,360 COMMITTEE. I HAVE TO WARN BOTH 980 00:47:29,360 --> 00:47:34,040 OF YOU THAT WE KNOW WHERE YOU 981 00:47:34,040 --> 00:47:37,480 LIVE. WE WILL FIND OTHER 982 00:47:37,480 --> 00:47:40,680 APPLICATIONS AND OTHER ENDEAVORS 983 00:47:40,680 --> 00:47:42,600 BECAUSE THE TWO OF YOU ARE MUCH 984 00:47:42,600 --> 00:47:45,440 TOO GOOD TO MAKE THIS ADIEU, SO 985 00:47:45,440 --> 00:47:47,600 THIS IS AN AU REVOIR. THANKS SO 986 00:47:47,600 --> 00:47:50,680 MUCH. 987 00:47:50,680 --> 00:47:54,600 >>THANKS DOUG. IT DOES WORRY ME 988 00:47:54,600 --> 00:47:54,960 BUT THANK YOU. 989 00:47:54,960 --> 00:48:05,280 >>THANK YOU, FOR YOUR SERVICE. 990 00:48:05,280 --> 00:48:06,560 >>SCOTT, YOU ARE MUTED I 991 00:48:06,560 --> 00:48:09,680 BELIEVE. 992 00:48:09,680 --> 00:48:11,360 OPERATOR: I WANT TO 993 00:48:11,360 --> 00:48:16,120 CONGRATULATE. THANK YOU FOR 994 00:48:16,120 --> 00:48:17,800 YOUR SERVICE. 995 00:48:17,800 --> 00:48:19,720 >>GET US BACK ON SCHEDULE. MY 996 00:48:19,720 --> 00:48:24,720 PLEASURE, WE WILL HEAR FROM DR. 997 00:48:24,720 --> 00:48:26,600 DWIGHT NISSLEY TO TALK ABOUT 998 00:48:26,600 --> 00:48:37,160 CRYOEM TRAINING. GOOD MORNING. 999 00:48:39,320 --> 00:48:40,400 >>I LEAD THE CANCER RESEARCH 1000 00:48:40,400 --> 00:48:41,760 TECHNOLOGY PROGRAM HERE AT THE 1001 00:48:41,760 --> 00:48:42,920 FREDERICK NATIONAL LABORATORY 1002 00:48:42,920 --> 00:48:44,920 WHICH INCLUDES THE NATIONAL 1003 00:48:44,920 --> 00:48:48,320 CRYOEM FACILITY. I WILL TELL YOU 1004 00:48:48,320 --> 00:48:49,360 ABOUT THE TRAINING PROGRAM WE 1005 00:48:49,360 --> 00:48:56,320 HELD RECENTLY. SO WE STOOD UP 1006 00:48:56,320 --> 00:48:58,680 THE NATIONAL CRYOEM FACILITY IN 1007 00:48:58,680 --> 00:49:02,280 2017. WITH THE IDEA OF PROVIDING 1008 00:49:02,280 --> 00:49:04,360 A RESOURCE TO THE COMMUNITY, TO 1009 00:49:04,360 --> 00:49:07,840 THE NATION TO COLLECT HIGH 1010 00:49:07,840 --> 00:49:12,640 QUALITY CRYOEM DATA. WE ALSO 1011 00:49:12,640 --> 00:49:15,320 COUPLE OF YEARS AGO SET UP 1012 00:49:15,320 --> 00:49:16,400 TECHNOLOGY COMPONENT WHICH IS 1013 00:49:16,400 --> 00:49:20,480 MEANT TO EXPLORE NEW APPROACH 1014 00:49:20,480 --> 00:49:23,440 AND FEED INTO THE NSEF FOR THE 1015 00:49:23,440 --> 00:49:24,440 BENEFIT OF NATIONAL CANCER 1016 00:49:24,440 --> 00:49:28,120 RESEARCH COMMUNITY. EARLY ON WE 1017 00:49:28,120 --> 00:49:30,000 IDENTIFIED THREE COMMUNITIES WE 1018 00:49:30,000 --> 00:49:32,160 THOUGHT WERE IMPORTANT TO TRY TO 1019 00:49:32,160 --> 00:49:34,040 SERVE THROUGH THESE EFFORTS. 1020 00:49:34,040 --> 00:49:37,680 THE FIRST ONE WAS PEOPLE WITH 1021 00:49:37,680 --> 00:49:40,120 EXPERIENCE IN CRYOEM NEED ACCESS 1022 00:49:40,120 --> 00:49:41,440 TO HIGH INSTRUMENTATION WHICH 1023 00:49:41,440 --> 00:49:43,600 CAN BE EXPENSIVE AND SOME OF THE 1024 00:49:43,600 --> 00:49:49,120 EXPERTISE TO RUN IT. THE SECOND 1025 00:49:49,120 --> 00:49:50,960 COMMUNITY WE THOUGHT ENGAGE IN 1026 00:49:50,960 --> 00:49:53,000 TIME THOSE EXPERIENCE STRUCTURAL 1027 00:49:53,000 --> 00:49:54,760 BIOLOGY INCLUDING 1028 00:49:54,760 --> 00:49:57,040 CRYSTALLOGRAPHERS NMR PEOPLE, 1029 00:49:57,040 --> 00:49:58,160 UNDERSTANDING BIOCHEMISTRY BUT 1030 00:49:58,160 --> 00:50:00,360 NEEDED TRAINING OR ACCESS TO 1031 00:50:00,360 --> 00:50:01,400 SAMPLE PREPARATION AN DATA 1032 00:50:01,400 --> 00:50:07,880 COLLECTION. THE THIRD WE WANTED 1033 00:50:07,880 --> 00:50:10,000 TO ENGAGE LONG TERM BIOLOGIST 1034 00:50:10,000 --> 00:50:11,120 INTERESTED IN BIOMEDICAL 1035 00:50:11,120 --> 00:50:14,440 PROBLEMS THAT BENEFIT FROM A 1036 00:50:14,440 --> 00:50:16,000 STRUCTURAL BIOLOGY APPROACH. 1037 00:50:16,000 --> 00:50:17,320 PROBABLY NEED MORE INTERACTION 1038 00:50:17,320 --> 00:50:24,720 OR TRAINING. THE FIRST COMMUNITY 1039 00:50:24,720 --> 00:50:26,400 WE SET UP THE COLLECTION 1040 00:50:26,400 --> 00:50:32,040 FACILITY. THIS IS METRICS THIS 1041 00:50:32,040 --> 00:50:32,960 IS THE LAST FIEFS YEARS FOR THE 1042 00:50:32,960 --> 00:50:34,800 COLLECTION FACILITY, VOIDED 1043 00:50:34,800 --> 00:50:35,920 SUPPORT OR COLLECTED DATA FROM 1044 00:50:35,920 --> 00:50:38,120 50 INSTITUTION AND NOW MORE THAN 1045 00:50:38,120 --> 00:50:40,800 125 INVESTIGATORS. COMING UP ON 1046 00:50:40,800 --> 00:50:45,880 900 IMAGING SESSIONS, AND THIS 1047 00:50:45,880 --> 00:50:47,840 STARTED TO RESULT IN 1048 00:50:47,840 --> 00:50:49,400 PUBLICATIONS WITH CURRENTLY 1049 00:50:49,400 --> 00:50:52,560 PROBABLY 30 PUBLICATIONS COMING 1050 00:50:52,560 --> 00:50:58,720 OUT PER YEAR THAT ACTINOLEK OUR 1051 00:50:58,720 --> 00:51:01,120 COLLECTION -- ACKNOWLEDGE OUR 1052 00:51:01,120 --> 00:51:04,040 COLLECTION. THEY BOTH HAVE TIME 1053 00:51:04,040 --> 00:51:06,360 K 3 CAMERA DETECTOR. WITH AN 1054 00:51:06,360 --> 00:51:09,840 ENERGY FILTER. WE CURRENTLY 1055 00:51:09,840 --> 00:51:12,280 COLLECT FOR TWO DAY SESSION TO 1056 00:51:12,280 --> 00:51:14,480 GET ABOUT SIX TO 7,000 IMAGES 1057 00:51:14,480 --> 00:51:19,200 WHICH IS SUFFICIENT FOR A GOOD 1058 00:51:19,200 --> 00:51:22,080 STRUCTURE IF A GOOD SAMPLE, WE 1059 00:51:22,080 --> 00:51:23,680 ADDED FRINGE FREE IMAGING WHICH 1060 00:51:23,680 --> 00:51:25,480 INCREASES THE AMOUNT OF DATA 1061 00:51:25,480 --> 00:51:30,920 THAT CAN BE ACQUIRED DURING 1062 00:51:30,920 --> 00:51:32,080 COLLECTION SESSION AND UPDATED 1063 00:51:32,080 --> 00:51:33,120 THE WORK FLOW IN SOME OF THE 1064 00:51:33,120 --> 00:51:36,720 WARE WE USE TO COLLECT DATA. 1065 00:51:36,720 --> 00:51:40,880 MOVERRING TO THE SECOND SET OF 1066 00:51:40,880 --> 00:51:41,560 BIOLOGISTS WE THOUGHT WOULD 1067 00:51:41,560 --> 00:51:47,760 PROVIDE RESOURCES TO, THOSE 1068 00:51:47,760 --> 00:51:50,360 EXPERIENCE WITH BIOCHEMISTRY AND 1069 00:51:50,360 --> 00:51:52,280 STRUCTURAL BIOLOGY. PART OF WHAT 1070 00:51:52,280 --> 00:51:54,480 WE SET UP NOW, LONG TERM WOULD 1071 00:51:54,480 --> 00:51:58,080 LIKE TO ACTUALLY START PROVIDING 1072 00:51:58,080 --> 00:52:00,880 THIS AS SERVICE ONCE WE VALIDATE 1073 00:52:00,880 --> 00:52:06,800 THIS PLATFORM, AUTOMATED GRID 1074 00:52:06,800 --> 00:52:08,560 PREPARATION, MAKING SAMPLES CAN 1075 00:52:08,560 --> 00:52:16,240 BE CHALLENGING AND TAKES 1076 00:52:16,240 --> 00:52:18,800 PRACTICE IN THE ART. THE SYSTEM 1077 00:52:18,800 --> 00:52:21,760 WE REQUIRED AND INVOLVED IS IN 1078 00:52:21,760 --> 00:52:23,560 VITROJET. WE HOPE IT GIVES MORE 1079 00:52:23,560 --> 00:52:25,440 CONTROL OVER SAMPLES AND 1080 00:52:25,440 --> 00:52:26,240 REPRODUCIBILITY, WE ARE 1081 00:52:26,240 --> 00:52:28,440 VALIDATING THAT RIGHT NOW AND 1082 00:52:28,440 --> 00:52:32,560 EVENTUALLY PROVIDE ACCESS TO 1083 00:52:32,560 --> 00:52:33,880 USER TO THIS SAMPLE PREPARATION 1084 00:52:33,880 --> 00:52:37,480 APPROACH. IN THE TECHNOLOGY 1085 00:52:37,480 --> 00:52:44,480 DEVELOPMENT COMPONENT, WE LOOK 1086 00:52:44,480 --> 00:52:47,440 FOR NEWER PLATFORMS MORE 1087 00:52:47,440 --> 00:52:48,360 ACCESSIBLE IN TERMS OF COST AND 1088 00:52:48,360 --> 00:52:51,920 MIGHT BE APPLICABLE FOR 1089 00:52:51,920 --> 00:52:52,960 UNIVERSITIES AND OTHER 1090 00:52:52,960 --> 00:52:55,360 INSTITUTIONS THESE INCLUDE THE 1091 00:52:55,360 --> 00:52:56,320 CRYOARM 200 THAT WE HAVE HERE. 1092 00:52:56,320 --> 00:53:00,640 THESE ARE LOWER ENERGY ELECTRON 1093 00:53:00,640 --> 00:53:02,240 MICROSCOPES, PAIRED WITH VARIOUS 1094 00:53:02,240 --> 00:53:04,880 CAMERAS. WE ARE TRYING TO PUSH 1095 00:53:04,880 --> 00:53:10,160 RESOLUTION LIMITS AND AGAIN IN 1096 00:53:10,160 --> 00:53:13,680 LOWER COST PLATFORM AND TAKE ON 1097 00:53:13,680 --> 00:53:15,240 CHALLENGING SAMPLES. THE GROUP 1098 00:53:15,240 --> 00:53:21,720 MADE PROGRESS IN THESE AREAS. 1099 00:53:21,720 --> 00:53:22,960 THE THIRD COMMUNITY WE WANT TO 1100 00:53:22,960 --> 00:53:28,080 ENGAGE LONG TERM AND FOCUS OF 1101 00:53:28,080 --> 00:53:30,600 TRAINING IS PEOPLE THAT HAVE NO 1102 00:53:30,600 --> 00:53:33,200 EXPERIENCE IN CRYOEM AND NEED 1103 00:53:33,200 --> 00:53:35,040 TRAINING IN ALLS SECRETARIES OF 1104 00:53:35,040 --> 00:53:36,480 THE UP PER WORK FLOW. THE 1105 00:53:36,480 --> 00:53:37,360 TRAINING SESSION WE SET UP WAS 1106 00:53:37,360 --> 00:53:42,640 MEANT TO TARGET THIS GROUP OR 1107 00:53:42,640 --> 00:53:44,520 BRING THIS INTO THE FOLD. WE 1108 00:53:44,520 --> 00:53:46,880 HELD THE CRYOEM TRAINING PROGRAM 1109 00:53:46,880 --> 00:53:49,120 A MONTH AGO AT THE ATRF IN 1110 00:53:49,120 --> 00:53:53,280 FREDERICK. IT WAS A ONE WEEK 1111 00:53:53,280 --> 00:53:57,200 PROGRAM MORNING FEATURED LECT 1112 00:53:57,200 --> 00:53:58,200 LECTURES AND AFTERNOON FEATURED 1113 00:53:58,200 --> 00:53:59,360 HANDS ON PRACTICAL EXPERIENCES 1114 00:53:59,360 --> 00:54:03,840 IN THE LABS. YANNA AND THOMAS 1115 00:54:03,840 --> 00:54:05,640 EDWARDS WERE THE TECHNICAL 1116 00:54:05,640 --> 00:54:09,240 SCIENTIFIC LEADS HERE AT THE 1117 00:54:09,240 --> 00:54:11,480 NSEF, DESIGNED AND IMPLEMENTED 1118 00:54:11,480 --> 00:54:12,480 THE PROGRAM. THERE WERE PEOPLE 1119 00:54:12,480 --> 00:54:15,560 THAT HELPED OUT INCLUDING OUR 1120 00:54:15,560 --> 00:54:20,720 CHIEF SCIENCE OFFICER, 1121 00:54:20,720 --> 00:54:22,560 PARTNERSHIP DEVELOPMENT OFFICE, 1122 00:54:22,560 --> 00:54:24,960 GARY ROBINSON, OFFICE OF 1123 00:54:24,960 --> 00:54:27,120 SCIENTIFIC OPERATIONS AND PATTY 1124 00:54:27,120 --> 00:54:28,000 MARTINEZ FROM THE CANCER 1125 00:54:28,000 --> 00:54:32,440 RESEARCH TECHNOLOGY PROGRAM. WE 1126 00:54:32,440 --> 00:54:34,560 DECIDED FOR THE FIRST YEAR TO 1127 00:54:34,560 --> 00:54:36,040 KEEP SOMEWHAT LIMITED IN SIZE. 1128 00:54:36,040 --> 00:54:38,920 WE WANTED 12 ATTENDEES AT THE 1129 00:54:38,920 --> 00:54:42,040 WORKSHOP. WE HAT MORE THAN 60 1130 00:54:42,040 --> 00:54:43,280 APPROXIMATE APPLICANTS, THEY 1131 00:54:43,280 --> 00:54:44,640 SUBMIT AD CV, A LETTER OF 1132 00:54:44,640 --> 00:54:45,720 INTEREST, LETTERS OF 1133 00:54:45,720 --> 00:54:47,600 RECOMMENDATIONS, WE FORMED A 1134 00:54:47,600 --> 00:54:49,320 TEAM HERE OF BOTH FREDERICK 1135 00:54:49,320 --> 00:54:50,320 NATIONAL LAB AND GOVERNMENT 1136 00:54:50,320 --> 00:54:51,920 PERSONNEL THAT REVIEWED AND 1137 00:54:51,920 --> 00:54:57,120 SELECTED THE APPLICANTS. WE GOT 1138 00:54:57,120 --> 00:55:03,000 GOOD GEOGRAPHICAL REPRESENTATION 1139 00:55:03,000 --> 00:55:04,840 AND TRIED TO MAKE SURE WE WERE 1140 00:55:04,840 --> 00:55:06,960 GETTING PEOPLE THAT MAY NOT HAVE 1141 00:55:06,960 --> 00:55:11,560 ACCESS TO SOME OF THE TRAINING 1142 00:55:11,560 --> 00:55:13,280 OPPORTUNITIES AVAILABLE ELSE 1143 00:55:13,280 --> 00:55:15,680 WHERE ACCESS TO THE RAINING 1144 00:55:15,680 --> 00:55:16,520 PROGRAM HERE. WE HAD EIGHT 1145 00:55:16,520 --> 00:55:19,640 SPEAKER THE OUTSIDE, SEVERAL 1146 00:55:19,640 --> 00:55:23,360 FROM SEVERAL THAT WERE PART OF 1147 00:55:23,360 --> 00:55:24,520 THE WEEK LONG TRAINING SESSION. 1148 00:55:24,520 --> 00:55:33,880 THIS IS THE AGENDA WE HAD A TALK 1149 00:55:33,880 --> 00:55:35,160 FROM CYNTHIA WOULDBURG FROM 1150 00:55:35,160 --> 00:55:37,240 HOPKINSMENT TALKED HER USE OF 1151 00:55:37,240 --> 00:55:40,600 CRYOEM LOOKING AT NUCLEOSOME, 1152 00:55:40,600 --> 00:55:43,840 HISTONE STRUCTURE, REGULATION OF 1153 00:55:43,840 --> 00:55:47,440 TRANSCRIPTION. WENT OVER 1154 00:55:47,440 --> 00:55:50,640 NEGATIVE STAINING PRECURSOR TO 1155 00:55:50,640 --> 00:55:53,640 CRYOEM STUDIES AND THOMAS 1156 00:55:53,640 --> 00:55:54,840 EDWARDS TALKED GRID PREPARATION. 1157 00:55:54,840 --> 00:55:56,080 IN THE AFTERNOON THERE'S HANDS 1158 00:55:56,080 --> 00:55:59,360 ON TRAINING FOR GRID PREPARATION 1159 00:55:59,360 --> 00:56:02,600 AND SAMPLE PREP. ON DAY TWO, 1160 00:56:02,600 --> 00:56:04,160 LOOK AT USING THESE AUTOMATED 1161 00:56:04,160 --> 00:56:07,440 PLATFORMS INCLUDING THE VITROJET 1162 00:56:07,440 --> 00:56:09,240 FOR SAMPLE PREPARATION, AGAIN 1163 00:56:09,240 --> 00:56:12,240 TRY TO STANDARDIZE AND MAKE 1164 00:56:12,240 --> 00:56:13,600 AMPLE PREPARATION MORE 1165 00:56:13,600 --> 00:56:14,800 ACCESSIBLE TO PEOPLE NOT QUITE 1166 00:56:14,800 --> 00:56:19,160 AS EXPERIENCED. DAY 3 WAS A 1167 00:56:19,160 --> 00:56:21,960 COURSE ELECTRON MICROSCOPY. WE 1168 00:56:21,960 --> 00:56:24,000 HEARD FROMNALLY, ALUMNUS OF 1169 00:56:24,000 --> 00:56:28,080 FREDERICK NATIONAL LAB, ALL THE 1170 00:56:28,080 --> 00:56:29,320 PLATFORMS THERMAL ISSUE 1171 00:56:29,320 --> 00:56:31,120 PROVIDING RIGHT NOW, MATT 1172 00:56:31,120 --> 00:56:35,400 HUTCHINSON TALKED DATA STORA ST. 1173 00:56:35,400 --> 00:56:37,320 DAY FOUR TO US CANNED ON THEORY 1174 00:56:37,320 --> 00:56:41,680 BEHIND ACQUIRING IMAGES IN 1175 00:56:41,680 --> 00:56:44,440 CRYOEM PLATFORMS AND APPROACH 1176 00:56:44,440 --> 00:56:50,000 PICKING AND CATEGORIZING THINGS 1177 00:56:50,000 --> 00:56:51,800 TO 2D CLASSIFICATION THEN BE 1178 00:56:51,800 --> 00:56:55,440 USED FOR MODEL BUILDING. AND 1179 00:56:55,440 --> 00:56:57,800 DAY FIVE FEATURED OUTSIDE 1180 00:56:57,800 --> 00:56:59,360 SPEAKERS AND EXPERTS ON MODEL 1181 00:56:59,360 --> 00:57:00,960 BUILDING. IN THE MORNING IT WAS 1182 00:57:00,960 --> 00:57:03,160 LECTURE IN THEORY, IN THE 1183 00:57:03,160 --> 00:57:04,320 AFTERNOON IT WAS HAND ON 1184 00:57:04,320 --> 00:57:05,800 EXPERIENCE BUILDING MODELS, WITH 1185 00:57:05,800 --> 00:57:07,920 SOME OF THE DATA SETS THAT 1186 00:57:07,920 --> 00:57:14,160 BEFORE COLLECTED HERE. THIS TOOK 1187 00:57:14,160 --> 00:57:16,920 WORK OBVIOUSLY. THOMAS EDWARDS 1188 00:57:16,920 --> 00:57:18,800 AND TEAM AT THE COLLECTION 1189 00:57:18,800 --> 00:57:20,400 FACILITY, DESIGNED AND 1190 00:57:20,400 --> 00:57:21,720 IMPLEMENTED AND SUPPORTED A LOT 1191 00:57:21,720 --> 00:57:25,920 OF THE COURSE. AND YANNA AND HER 1192 00:57:25,920 --> 00:57:27,240 TEAM WERE INVOLVED IN THE 1193 00:57:27,240 --> 00:57:32,520 LECTURES AS PARTS OF THE COURSE 1194 00:57:32,520 --> 00:57:34,680 OVERALL, STUDENTS OR ATTENDEES, 1195 00:57:34,680 --> 00:57:37,640 THEY APPRECIATED THE COURSE, 1196 00:57:37,640 --> 00:57:38,840 THEY FELT THAT THERE WAS HANDS 1197 00:57:38,840 --> 00:57:41,040 ON EXPERIENCE AND FELT IT WAS 1198 00:57:41,040 --> 00:57:42,600 VALUABLE TO THE FEEDBACK WAS 1199 00:57:42,600 --> 00:57:49,320 QUITE POSITIVE. THIS IS A PHOTO 1200 00:57:49,320 --> 00:57:50,800 OF THE ATTENDEES. WE LIKE TO 1201 00:57:50,800 --> 00:57:52,560 THINK OF THIS AS CAN EXAMPLE HOW 1202 00:57:52,560 --> 00:57:57,000 WE USE THE NATIONAL LAB TO 1203 00:57:57,000 --> 00:57:59,240 NUCLEATE OR ENABLE RESEARCH 1204 00:57:59,240 --> 00:58:00,840 COMMUNITY AND WE LOOK FORWARD TO 1205 00:58:00,840 --> 00:58:04,000 DOING THESE TYPE OF COURSES IN 1206 00:58:04,000 --> 00:58:05,320 THE FUTURE. WITH THAT I WILL 1207 00:58:05,320 --> 00:58:06,080 STOP AND TAKE QUESTIONS YOU 1208 00:58:06,080 --> 00:58:16,560 MIGHT HAVE. ANY QUESTIONS? 1209 00:58:17,400 --> 00:58:18,760 SOUNDS LIKE A VERY SUCCESSFUL 1210 00:58:18,760 --> 00:58:22,480 TRAINING PROGRAM. JOHN. 1211 00:58:22,480 --> 00:58:25,600 >>THIS IS GREAT. KUDOS FOR 1212 00:58:25,600 --> 00:58:29,040 BRINGING THE TECHNOLOGY UP AND 1213 00:58:29,040 --> 00:58:31,560 STARTING TO TRAIN THE COMMUNITY. 1214 00:58:31,560 --> 00:58:35,000 THE PATH WITH BOTH NMR AND X-RAY 1215 00:58:35,000 --> 00:58:36,360 CRYSTALLOGRAPHY OVER THE YEARS 1216 00:58:36,360 --> 00:58:38,280 IS THEY EVOLVE FROM HIGHLY 1217 00:58:38,280 --> 00:58:39,520 TECHNICAL TO TOOLS MOST HAD 1218 00:58:39,520 --> 00:58:42,600 ACCESS TO. THAT WAS TO SOME 1219 00:58:42,600 --> 00:58:45,680 EXTENT FACILITATED BY REGIONAL 1220 00:58:45,680 --> 00:58:48,440 CENTERS PROVIDING ACCESS. IS 1221 00:58:48,440 --> 00:58:49,360 THERE ANY -- I DON'T KNOW IF 1222 00:58:49,360 --> 00:58:51,000 THIS IS THE PURVIEW OF FNLAC BUT 1223 00:58:51,000 --> 00:58:53,160 IS THERE ANY VIEW OF A MODEL 1224 00:58:53,160 --> 00:58:54,920 LIKE THAT, GOING FORWARD FOR 1225 00:58:54,920 --> 00:59:02,680 CRYOEM? THERE IS AN NIH FUND 1226 00:59:02,680 --> 00:59:05,640 THROUGH NIGMS AND THREE REGIONAL 1227 00:59:05,640 --> 00:59:08,080 CENTERS WITH MANY CRYOEM 1228 00:59:08,080 --> 00:59:09,360 MICROSCOPE PLATFORMS THOSE ARE 1229 00:59:09,360 --> 00:59:16,080 UP AND RUNNING NOW. THE NCI SET 1230 00:59:16,080 --> 00:59:17,200 THIS UP FIVE YEARS AGO WITH A 1231 00:59:17,200 --> 00:59:22,680 BIT OF FOCUS ON CANCER RELATED 1232 00:59:22,680 --> 00:59:25,120 TOPICS WHERE NIGMS ARE OPEN TO 1233 00:59:25,120 --> 00:59:26,760 ALL BIOLOGY. THAT MODEL IS IN 1234 00:59:26,760 --> 00:59:30,600 PLACE AND PART OF THE LONG TERM 1235 00:59:30,600 --> 00:59:35,360 SOLUTION PROVIDING ACCESS TO THE 1236 00:59:35,360 --> 00:59:35,840 ENTIRE COUNTRY. 1237 00:59:35,840 --> 00:59:40,880 >>THANK YOU, ROB. RAVI. 1238 00:59:40,880 --> 00:59:44,320 >>THANK YOU FOR SHARING THOSE 1239 00:59:44,320 --> 00:59:45,640 RESOURCES AND ALSO TRAINING, IT 1240 00:59:45,640 --> 00:59:50,880 IS VERY IMPORTANT. I WORK ON 1241 00:59:50,880 --> 00:59:54,400 DIFFERENT PROJECTS WITH ACADEMIC 1242 00:59:54,400 --> 01:00:02,600 AND TRANSLATE THEIR PRODUCTS SO 1243 01:00:02,600 --> 01:00:04,840 PASSIONATE ABOUT HAVING THAT 1244 01:00:04,840 --> 01:00:06,200 ACCESS ACADEMIC ENTREPRENEURIAL 1245 01:00:06,200 --> 01:00:09,880 TO BE ABLE TO ADDRESS KEY 1246 01:00:09,880 --> 01:00:11,680 QUESTIONS THEY MAY BE EXPERT, 1247 01:00:11,680 --> 01:00:14,960 NOT EXPERT OF BUT ACCESSIBLE TO 1248 01:00:14,960 --> 01:00:17,480 THESE TWO AND HAVING HIGH END 1249 01:00:17,480 --> 01:00:20,400 MODEL, HIGHLY IMPORTANT TO DRIVE 1250 01:00:20,400 --> 01:00:25,560 INNOVATIONS. THINGS THAT ARE 1251 01:00:25,560 --> 01:00:29,080 CHALLENGING TO ANALYZE DRUG 1252 01:00:29,080 --> 01:00:33,520 TARGETS CELL THERAPY, MEMBRANE 1253 01:00:33,520 --> 01:00:37,960 BOUND MOLECULES. THAT IS THE 1254 01:00:37,960 --> 01:00:39,200 DRIVING OF RESOLUTION, THE 1255 01:00:39,200 --> 01:00:43,160 DRIVING OF QUALITY OF WORK AND 1256 01:00:43,160 --> 01:00:45,680 REPRODUCIBILITY,S OR THAT GLAD 1257 01:00:45,680 --> 01:00:50,000 TO SEE THAT PUT TO USE IN 1258 01:00:50,000 --> 01:00:56,600 FREDERICK FACILITY. TRAINING TO 1259 01:00:56,600 --> 01:00:57,680 MAKE OUTREACH PRODUCTIVE 1260 01:00:57,680 --> 01:01:00,440 STRATEGIES. SO THESE ARE 1261 01:01:00,440 --> 01:01:04,080 OPPORTUNITIES WE MUST SEE TO 1262 01:01:04,080 --> 01:01:05,200 REACH OUT TO THOSE SCIENTISTS 1263 01:01:05,200 --> 01:01:11,120 WITH LIMITED RESOURCES HAVING 1264 01:01:11,120 --> 01:01:12,320 THE GEOGRAPHIC CONSIDERATIONS 1265 01:01:12,320 --> 01:01:16,400 FOR TRAINING IS IDEAL, THAT IS 1266 01:01:16,400 --> 01:01:21,200 GOOD, ANYTHING WE CAN DO TO 1267 01:01:21,200 --> 01:01:26,480 PROMOTE LET US KNOW. I'M STILL 1268 01:01:26,480 --> 01:01:30,760 LEARNING HOW THAT OPERATES. TO 1269 01:01:30,760 --> 01:01:31,520 HELP YOU ANY CONNECTIONS WE CAN 1270 01:01:31,520 --> 01:01:38,440 DO. DR. LOWY, YOU HAD A 1271 01:01:38,440 --> 01:01:38,720 QUESTION? 1272 01:01:38,720 --> 01:01:45,400 >>I WANTED TO RESPOND TO JOHN'S 1273 01:01:45,400 --> 01:01:47,880 EXCELLENT QUESTION. WHEN HAROLD 1274 01:01:47,880 --> 01:01:52,160 VARMUS WAS THE NCI DIRECTOR, HE 1275 01:01:52,160 --> 01:01:57,800 ACTUALLY WANTED TO HAVE SOME 1276 01:01:57,800 --> 01:02:03,760 NETWORK ORGANIZED BY THE NIH. 1277 01:02:03,760 --> 01:02:07,360 BUT THAT EFFORT DIDN'T RESONATE 1278 01:02:07,360 --> 01:02:10,680 WITH THE REST OF THE NIH. WHEN I 1279 01:02:10,680 --> 01:02:16,920 BECAME ACTING DIRECTOR IN 2015, 1280 01:02:16,920 --> 01:02:19,240 ONE QUESTION I ASKED FRANCIS 1281 01:02:19,240 --> 01:02:22,440 COLLINS WAS WHAT TO DO ABOUT 1282 01:02:22,440 --> 01:02:27,200 THIS ISSUE. HE SAID DOUG, IF I 1283 01:02:27,200 --> 01:02:30,080 WANT TO DO CRYOEM SET IT UP AT 1284 01:02:30,080 --> 01:02:34,560 FREDERICK. DON'T WAIT FOR THE 1285 01:02:34,560 --> 01:02:40,400 REST OF THE NIH TO COME ALONG. 1286 01:02:40,400 --> 01:02:41,320 THAT IS WHAT WE DID. 1287 01:02:41,320 --> 01:02:50,000 >>VERY GOOD. VERY GOOD FOR 1288 01:02:50,000 --> 01:02:51,440 SIGHT. ANYTHING ELSE? WE WILL 1289 01:02:51,440 --> 01:02:53,080 LEARN ABOUT PATIENT DERIVED 1290 01:02:53,080 --> 01:02:56,680 MODELS REPOSITORY BY DR.S 1291 01:02:56,680 --> 01:02:57,480 DOROSHOW AND EVRARD. 1292 01:02:57,480 --> 01:02:59,800 >>THANKS, CANDICE AND THANKS, 1293 01:02:59,800 --> 01:03:00,560 EVERYONE FOR THE OPPORTUNITY TO 1294 01:03:00,560 --> 01:03:02,760 GIVE THIS UPDATE TO THE FNLAC 1295 01:03:02,760 --> 01:03:05,280 ABOUT THE WHAT WE CALL THE PDMR. 1296 01:03:05,280 --> 01:03:06,440 SOME OF YOU HAVE HEARD ABOUT 1297 01:03:06,440 --> 01:03:08,080 THIS FACILITY IN THE PAST. I 1298 01:03:08,080 --> 01:03:09,720 THINK YOU WILL FIND SOME NEW 1299 01:03:09,720 --> 01:03:11,400 THINGS THAT WE HAVE BEEN DOING 1300 01:03:11,400 --> 01:03:12,760 AND IT WILL BE GOOD TO GIVE YOU 1301 01:03:12,760 --> 01:03:17,520 A STATUS UPDATE OF A PROJECT 1302 01:03:17,520 --> 01:03:18,960 NEAR AND DEAR TO MY HEART AND I 1303 01:03:18,960 --> 01:03:21,560 HAVE A CHANCE TO SHARE THIS 1304 01:03:21,560 --> 01:03:22,920 PRESENTATION WITH MY CLOSE 1305 01:03:22,920 --> 01:03:25,400 COLLEAGUE DR. EVRARD WHO MANAGE 1306 01:03:25,400 --> 01:03:28,120 IT IS FA SIT IN FREDERICK FOR 1307 01:03:28,120 --> 01:03:32,840 THE NCI. THE OUTLINE IS FIRST 1308 01:03:32,840 --> 01:03:33,920 TALK MODEL DEVELOPMENT AND 1309 01:03:33,920 --> 01:03:35,040 DISTRIBUTION SO YOU GET A SENSE 1310 01:03:35,040 --> 01:03:38,360 OF HOW BIG IS THIS, WHAT IS 1311 01:03:38,360 --> 01:03:39,800 AVAILABLE TO THE EXTRAMURAL 1312 01:03:39,800 --> 01:03:40,760 COMMUNITY, WHO IS TAKING 1313 01:03:40,760 --> 01:03:43,160 ADVANTAGE OF IT. I WILL GIVE 1314 01:03:43,160 --> 01:03:44,000 YON VIGNETTE OF MECHANISM OF 1315 01:03:44,000 --> 01:03:47,840 ACTION STUDY THAT WE HAVE TAKEN 1316 01:03:47,840 --> 01:03:49,920 USING THESE MODELS AND THEN 1317 01:03:49,920 --> 01:03:53,880 YVONNE WILL SHARE WITH YOU 1318 01:03:53,880 --> 01:03:55,920 RECENT MODELING DATA THAT CAME 1319 01:03:55,920 --> 01:03:57,840 OUT OF THE QUESTION HOW BEST DO 1320 01:03:57,840 --> 01:03:59,920 YOU REPORT XENOGRAPH TO 1321 01:03:59,920 --> 01:04:04,440 THERAPEUTIC DATA? ALL OF YOU IF 1322 01:04:04,440 --> 01:04:05,040 YOU HAVE BEEN IN THIS BUSINESS 1323 01:04:05,040 --> 01:04:06,600 FOR PERIOD OF TIME UNDERSTAND 1324 01:04:06,600 --> 01:04:09,920 THE INCREDIBLE LACK OF STANDA 1325 01:04:09,920 --> 01:04:14,200 STANDARDIZATION FOR XENOGRAPHING 1326 01:04:14,200 --> 01:04:15,760 THE PRE-CLINICAL CLINICAL IN 1327 01:04:15,760 --> 01:04:18,120 XENOGRAPHS SO PDMR IN 1328 01:04:18,120 --> 01:04:22,280 CONJUNCTION WITH PDX NET WHICH 1329 01:04:22,280 --> 01:04:25,360 IS ORIGINAL MOON SHOT PROJECT 1330 01:04:25,360 --> 01:04:27,160 WHICH HAS AFFILIATES PRODUCING 1331 01:04:27,160 --> 01:04:30,800 MODELS AND EXPERIMENTS,ING TO 1332 01:04:30,800 --> 01:04:33,080 WITH US BROADLY HAVE DONE THIS 1333 01:04:33,080 --> 01:04:34,160 PROJECT TO BRING TOGETHER LOTS 1334 01:04:34,160 --> 01:04:37,560 OF DATA TO TRY TO UNDERSTAND 1335 01:04:37,560 --> 01:04:39,240 DEVELOP A TOOL THAT WILL BE 1336 01:04:39,240 --> 01:04:41,440 AVAILABLE TO THE GENERAL 1337 01:04:41,440 --> 01:04:46,880 COMMUNITY. HELP STANDARDIZE AND 1338 01:04:46,880 --> 01:04:47,760 HELP UNDERSTAND IF YOU HAVE A 1339 01:04:47,760 --> 01:04:48,960 TREATMENT DOES IT WORK AND HOW 1340 01:04:48,960 --> 01:04:51,920 DO YOU BEST REPORT THOSE DATA. 1341 01:04:51,920 --> 01:04:54,560 YVONNE WILL MAKE THAT 1342 01:04:54,560 --> 01:04:58,960 PRESENTATION. WHAT IS THE PDMR 1343 01:04:58,960 --> 01:05:01,360 AND WHY DID IT START? WE WERE 1344 01:05:01,360 --> 01:05:02,960 INTERESTED IN DEVELOPING A 1345 01:05:02,960 --> 01:05:04,320 REPOSITORY FOR THESE MODELS TO 1346 01:05:04,320 --> 01:05:06,760 HELP ACADEMIC DISCOVERY EFFORTS 1347 01:05:06,760 --> 01:05:08,520 AND ALSO TO FACILITATE PUBLIC 1348 01:05:08,520 --> 01:05:13,040 PRIVATE PARTNERSHIPS. WE 1349 01:05:13,040 --> 01:05:14,920 DEVELOPED ANNOTATED SET OF 1350 01:05:14,920 --> 01:05:16,960 PASSAGE MODELS COMPREHENSIVE 1351 01:05:16,960 --> 01:05:18,240 MOLECULAR CHARACTERIZATION AND 1352 01:05:18,240 --> 01:05:25,160 SIGNIFICANT QUALITY CONTROL. OUR 1353 01:05:25,160 --> 01:05:27,520 GOAL TO COMPLIMENT EXISTING PDM 1354 01:05:27,520 --> 01:05:29,040 INSTITUTIONS AND FOCUS ON 1355 01:05:29,040 --> 01:05:31,880 UNDER-REPRESENTED MODELS RARE 1356 01:05:31,880 --> 01:05:33,800 CANCER, AND TO TRY TO PUSH THE 1357 01:05:33,800 --> 01:05:38,000 ENVELOPE IN TERMS OF DEVELOPING 1358 01:05:38,000 --> 01:05:39,680 MODELS FROM THE APPROPRIATE 1359 01:05:39,680 --> 01:05:41,800 UNDERSERVED MINORITIES. BOTTOM 1360 01:05:41,800 --> 01:05:46,200 LINE FOR THIS EFFORT WAS TO 1361 01:05:46,200 --> 01:05:47,840 PROVIDE MODELS AT MODEST COST SO 1362 01:05:47,840 --> 01:05:49,200 NO SINGLE INVESTIGATOR EVEN IF 1363 01:05:49,200 --> 01:05:52,680 THAT PERSON HAS ONE R21 GRANT OR 1364 01:05:52,680 --> 01:05:55,680 ONE RO1 WILL NOT BE ABLE THE 1365 01:05:55,680 --> 01:05:56,960 AFFORD MULTIPLE MODELS TO 1366 01:05:56,960 --> 01:05:58,240 FACILITATE EXPERIMENTS AND 1367 01:05:58,240 --> 01:05:59,920 PROVIDE ALL ASSOCIATED DATA WITH 1368 01:05:59,920 --> 01:06:01,400 MODELS WITH CLINICAL HISTORY 1369 01:06:01,400 --> 01:06:04,160 PRIOR TREATMENT, HISTOLOGY, 1370 01:06:04,160 --> 01:06:05,600 EXOSOME SEQUENCING RNA 1371 01:06:05,600 --> 01:06:06,840 SEQUENCING AND THE SOPs THAT 1372 01:06:06,840 --> 01:06:08,720 WERE USED TO PRODUCE THIS DATA 1373 01:06:08,720 --> 01:06:10,840 ON A PUBLIC WEBSITE. AND IN 1374 01:06:10,840 --> 01:06:12,920 FACT THAT WEBSITE REFERENCED 1375 01:06:12,920 --> 01:06:14,440 HERE ONE CAN GET THAT DATA 1376 01:06:14,440 --> 01:06:17,200 WITHOUT BUYING ANY OF THE 1377 01:06:17,200 --> 01:06:18,120 MODELS. FOR ANY KIND OF 1378 01:06:18,120 --> 01:06:22,240 INFORMATION YOU WOULD LIKE TO 1379 01:06:22,240 --> 01:06:24,800 REVIEW. SO I WILL TALK ABOUT THE 1380 01:06:24,800 --> 01:06:27,480 DISTRIBUTION AND MODEL 1381 01:06:27,480 --> 01:06:28,800 DEVELOPMENT FIRST PART OF MY 1382 01:06:28,800 --> 01:06:30,520 TALK. HERE GIVES YOU AN IDEA WE 1383 01:06:30,520 --> 01:06:31,840 HAVE TAKEN THE LAST SEVERAL 1384 01:06:31,840 --> 01:06:36,520 YEARS CLOSE TO 4,000 SPECIMENS. 1385 01:06:36,520 --> 01:06:37,640 COLLECTED AT INSTITUTIONS ACROSS 1386 01:06:37,640 --> 01:06:38,440 THE UNITED STATES, YOU WILL SEE 1387 01:06:38,440 --> 01:06:42,080 A LIST OF THOSE INSTITUTIONS. 1388 01:06:42,080 --> 01:06:44,080 AND SPECIAL INDEPENDENT MEDIA. 1389 01:06:44,080 --> 01:06:47,600 NEXT DAY IMPLANTATION AND NSG 1390 01:06:47,600 --> 01:06:49,920 MICE. OVERALL OUR TAKE RATE FOR 1391 01:06:49,920 --> 01:06:52,240 ACCESSIBLE SPECIMENS IS 30% BUT 1392 01:06:52,240 --> 01:06:53,480 WHAT YOU CAN SEE IS VARIABILITY 1393 01:06:53,480 --> 01:06:55,560 THAT IS CONSISTENT WITH THE 1394 01:06:55,560 --> 01:06:59,640 GENERAL -- THIS IS A LARGE 1395 01:06:59,640 --> 01:07:01,120 EFFORT IF YOU LOOK ACROSS 1396 01:07:01,120 --> 01:07:02,680 INDIVIDUAL PUBLICATIONS THIS IS 1397 01:07:02,680 --> 01:07:05,480 CONSISTENT WITH WHAT YOU FIND, 1398 01:07:05,480 --> 01:07:06,840 WE HAVE A HIGH TAKE RATE FOR 1399 01:07:06,840 --> 01:07:09,160 HEAD AND NECK CANCER, HIGH TAKE 1400 01:07:09,160 --> 01:07:12,600 RATE FOR MALIGNANT MELANOMAS. GI 1401 01:07:12,600 --> 01:07:15,560 CANCER PANCREAS AND COLON, AS 1402 01:07:15,560 --> 01:07:18,560 EVERYONE KNOWS WELL ARE FAIRLY 1403 01:07:18,560 --> 01:07:22,200 EASY TO ESTABLISH BUT WHAT IS 1404 01:07:22,200 --> 01:07:23,720 PERHAPS LESS WELL APPRECIATED IS 1405 01:07:23,720 --> 01:07:25,520 HOW DIFFICULT IT IS TO GET 1406 01:07:25,520 --> 01:07:27,000 MODELS FROM NEUROENDOCRINE 1407 01:07:27,000 --> 01:07:32,880 TUMORS TO GROW. MOST MODEL IT IS 1408 01:07:32,880 --> 01:07:34,360 BREAST CANCER THAT WE HAVE ARE 1409 01:07:34,360 --> 01:07:35,680 PATIENTS WITH TRIPLE NEGATIVE 1410 01:07:35,680 --> 01:07:37,320 BREAST CANCER. VERY DIFFICULT 1411 01:07:37,320 --> 01:07:39,480 UNDERTAKING TO GET HORMONE 1412 01:07:39,480 --> 01:07:42,520 RESPONSE TUMORS TO GROW IN SG 1413 01:07:42,520 --> 01:07:48,880 MICE. WE CAME TO REALIZATION 1414 01:07:48,880 --> 01:07:52,080 LATE. BUT TWO, THREE YEARS AGO, 1415 01:07:52,080 --> 01:07:55,080 I CAN'T TELL YOU WHICH I 1416 01:07:55,080 --> 01:07:56,520 UNDERSTOOD WHY. IN TERMS OF 1417 01:07:56,520 --> 01:07:59,000 COLLECTIONS WE GET FROM CENTERS 1418 01:07:59,000 --> 01:08:01,080 ACROSS THE COUNTRY IT IS 1419 01:08:01,080 --> 01:08:02,520 REMARKABLE HOW MANY RARE TUMORS 1420 01:08:02,520 --> 01:08:06,040 WE GET. THIS GIVES AN IDEA FOR 1421 01:08:06,040 --> 01:08:08,680 SARCOMAS LARGE NUMBER OF 1422 01:08:08,680 --> 01:08:10,040 SARCOMAS WITH DIFFERENT 1423 01:08:10,040 --> 01:08:14,440 HISTOLOGICAL SUB TYPES, THERE IS 1424 01:08:14,440 --> 01:08:17,880 A 30% TAKE RATE BUT SOME TUMORS 1425 01:08:17,880 --> 01:08:19,400 MUCH HIGHER SO THAT HELPED US IN 1426 01:08:19,400 --> 01:08:21,400 THE GOAL O OF DOLLING MODELS WE 1427 01:08:21,400 --> 01:08:27,680 CAN USE FOR TESTING FOR RARE 1428 01:08:27,680 --> 01:08:30,200 TUMORS. WE HAVE AMERICA CAN 1429 01:08:30,200 --> 01:08:30,840 BELIEVE CELL CANCERS LOTS OF 1430 01:08:30,840 --> 01:08:32,680 THINGS YOU DON'T SEE AND I 1431 01:08:32,680 --> 01:08:34,000 WONDER IS THAT BECAUSE NO ONE AT 1432 01:08:34,000 --> 01:08:37,120 THE CENTERS THAT ARE SENDING US 1433 01:08:37,120 --> 01:08:38,520 TISSUES STUDIES THOSE THINGS SO 1434 01:08:38,520 --> 01:08:40,280 MIGHT AS WELL SEND TO THE NCI. I 1435 01:08:40,280 --> 01:08:45,480 DON'T KNOW BUT IT IS USEFUL, WE 1436 01:08:45,480 --> 01:08:50,440 HAVE OF 6, 700 AVAILABLE MODELS 1437 01:08:50,440 --> 01:08:56,400 15, 20% ARE RARE CANCERS. THIS 1438 01:08:56,400 --> 01:08:59,200 IS A -- THE RESULT DATA SHOWING 1439 01:08:59,200 --> 01:09:03,440 HERE RESULT A SUGGESTION MADE AT 1440 01:09:03,440 --> 01:09:04,880 TIME CUPFUL O YEARS AGO WHEN I 1441 01:09:04,880 --> 01:09:06,400 MADE A PRESENTATION TO THE FNLAC 1442 01:09:06,400 --> 01:09:10,440 ADVISORY COMMITTEE, AS SOMEONE 1443 01:09:10,440 --> 01:09:11,720 RAISED HAND AND SAID ARE YOU 1444 01:09:11,720 --> 01:09:15,040 TRYING TO COLLECT MODEL RAD BY 1445 01:09:15,040 --> 01:09:17,320 AUTOPSY SPECIMENS? THAT COULD BE 1446 01:09:17,320 --> 01:09:19,880 USEFUL TO DEVELOP MODEL PRIMARY 1447 01:09:19,880 --> 01:09:21,680 AND MULTIPLE METASTATIC SITES SO 1448 01:09:21,680 --> 01:09:23,440 WE UNDERTOOK TO DO THAT AND YOU 1449 01:09:23,440 --> 01:09:24,960 WILL SEE WE HAVE ABOUT FOUR 1450 01:09:24,960 --> 01:09:27,440 MAJOR NCI DESIGNATED CANCER 1451 01:09:27,440 --> 01:09:28,760 CENTERS, TO SEND THOSE 1452 01:09:28,760 --> 01:09:30,280 SPECIMENS. THIS IS DATA FROM 1453 01:09:30,280 --> 01:09:32,600 THE FIRST 80 PATIENTS WE HAVE 1454 01:09:32,600 --> 01:09:39,840 GOTTEN MULTIPLE TAKES FROM 1455 01:09:39,840 --> 01:09:41,280 DIFFERENT TUMORS. THERE ARE 1456 01:09:41,280 --> 01:09:43,880 MAJOR PROGRAMS TO COLLECT TO 1457 01:09:43,880 --> 01:09:44,760 PANCREATIC CANCER AT SEVERAL 1458 01:09:44,760 --> 01:09:47,000 CANCER CENTERS. THAT'S BEEN A 1459 01:09:47,000 --> 01:09:48,680 SUCCESSFUL ENTERPRISE BUT WE 1460 01:09:48,680 --> 01:09:50,760 ALSO HAVE BEEN SUCCESSFUL WITH 1461 01:09:50,760 --> 01:09:53,920 MELANOMAS AND OTHER TUMORS ALSO 1462 01:09:53,920 --> 01:09:56,320 NOT A SURPRISE FOR THOSE WHO 1463 01:09:56,320 --> 01:09:57,920 WORK IN MALIGNANCIES HOW 1464 01:09:57,920 --> 01:10:00,800 DIFFICULT IT IS TO GROW PROSTATE 1465 01:10:00,800 --> 01:10:03,640 CANCER. EVEN FROM METASTATIC 1466 01:10:03,640 --> 01:10:04,800 SITES. THAT IS OUR EXPERIENCE AS 1467 01:10:04,800 --> 01:10:07,800 WELL. THIS IS A USEFUL 1468 01:10:07,800 --> 01:10:09,520 ENTERPRISE BECAUSE WE HAVE 1469 01:10:09,520 --> 01:10:11,640 NUMEROUS PATIENTS AVAILABLE 1470 01:10:11,640 --> 01:10:14,920 MODELS AVAILABLE TO PATIENTS, WE 1471 01:10:14,920 --> 01:10:17,160 HAVE PRIMARY MULTIPLE METASTATIC 1472 01:10:17,160 --> 01:10:19,800 SITES, MODEL THOSE MOLECULARLY 1473 01:10:19,800 --> 01:10:20,680 CHARACTERIZED AVAILABLE TO 1474 01:10:20,680 --> 01:10:29,400 PUBLIC FOR FURTHER EVALUATION. I 1475 01:10:29,400 --> 01:10:30,520 TALK ABOUT TRYING TO DEAL WITH 1476 01:10:30,520 --> 01:10:31,760 ISSUES WITH MODELS FROM A 1477 01:10:31,760 --> 01:10:32,720 DIVERSE POPULATION. ON THE LEFT 1478 01:10:32,720 --> 01:10:36,440 YOU CAN SEE THE PATIENT REPORTED 1479 01:10:36,440 --> 01:10:37,800 ETHNICITY, IT IS NOT A SURPRISE 1480 01:10:37,800 --> 01:10:38,920 MAJORITY OF PATIENTS REPORT 1481 01:10:38,920 --> 01:10:43,200 THEMSELVES AS EITHER BEING WHITE 1482 01:10:43,200 --> 01:10:47,160 OR UNREPORTED. ABOUT FIVE OR SIX 1483 01:10:47,160 --> 01:10:48,760 PERCENT AFRICAN AMERICAN. 1484 01:10:48,760 --> 01:10:50,480 ON THE RIGHT FROM SAME NUMBER OF 1485 01:10:50,480 --> 01:10:53,680 MODELS THE INFERRED GENETIC 1486 01:10:53,680 --> 01:10:55,480 ANCESTRY FROM THE WHOLE EXOME 1487 01:10:55,480 --> 01:10:56,600 SEQUENCING WHICH MOST OF THE 1488 01:10:56,600 --> 01:10:58,640 PATIENTS ARE EUROPEAN, ABOUT 1489 01:10:58,640 --> 01:11:00,320 FIVE OR SIX PERCENT AFRICAN 1490 01:11:00,320 --> 01:11:01,880 AMERICAN. THIS IS AN ISSUE WE 1491 01:11:01,880 --> 01:11:08,160 BECAME AWARE OF SEVERAL YEARS 1492 01:11:08,160 --> 01:11:11,360 AGO, WE HAD TWO FUNDED SITES THE 1493 01:11:11,360 --> 01:11:13,560 JOB IS TO EXPAND THE AREA OF 1494 01:11:13,560 --> 01:11:17,240 DEVELOPING MORE HISPANIC MODELS, 1495 01:11:17,240 --> 01:11:21,200 MODELS FROM PATIENTS OF WIDE 1496 01:11:21,200 --> 01:11:24,320 VARIETY OF BACKGROUNDS TO HAVE 1497 01:11:24,320 --> 01:11:27,400 THESE THINGS AVAILABLE FOR 1498 01:11:27,400 --> 01:11:29,040 SPECIFIC STUDIES APPROPRIATE FOR 1499 01:11:29,040 --> 01:11:35,120 THESE PARTICULAR BACKGROUNDS. I 1500 01:11:35,120 --> 01:11:36,560 DIDN'T SAY I HAD THE IMAGE WITH 1501 01:11:36,560 --> 01:11:38,160 UPPER RIGHT BEGINNING SLIDE, WE 1502 01:11:38,160 --> 01:11:40,160 DO SOMETHING PERHAPS THAT IS A 1503 01:11:40,160 --> 01:11:41,800 LITTLE DIFFERENT FROM MOST MAYBE 1504 01:11:41,800 --> 01:11:44,600 NOT ALL BUT MANY REPOSITORIES OF 1505 01:11:44,600 --> 01:11:46,920 THIS TYPE. WE ATTEMPT TO 1506 01:11:46,920 --> 01:11:48,200 GENERATE FROM EVERY HUMAN 1507 01:11:48,200 --> 01:11:50,280 SURGICAL OR BIOPSY SAMPLE, NOT 1508 01:11:50,280 --> 01:11:56,120 ONLY A PDX MODEL BUT AN 1509 01:11:56,120 --> 01:11:57,560 ORGANOID, TWO DIMENSIONAL MODEL 1510 01:11:57,560 --> 01:11:59,240 EARLY PASSAGE AND CANCER 1511 01:11:59,240 --> 01:12:01,240 ASSOCIATED FIBROBLASTS FROM THAT 1512 01:12:01,240 --> 01:12:07,520 BIOPSY SURGICAL SPECIMEN. OUR 1513 01:12:07,520 --> 01:12:09,400 GOAL IS TO PROVIDE ALL THESE 1514 01:12:09,400 --> 01:12:11,680 THINGS MOLECULARLY CHARACTERIZED 1515 01:12:11,680 --> 01:12:13,040 FOR INDIVIDUAL WHOSE WANT TO 1516 01:12:13,040 --> 01:12:15,960 STUDY IN 2D ORGANOIDS BUT TWO 1517 01:12:15,960 --> 01:12:19,480 MORE EXPENSIVE PDX MODEL SYSTEM 1518 01:12:19,480 --> 01:12:21,040 WHEN THEY HAVE INITIAL DATA THAT 1519 01:12:21,040 --> 01:12:23,200 WILL HELP IN DRUG DEVELOPMENT OR 1520 01:12:23,200 --> 01:12:26,440 OTHER BIOLOGICAL ISSUES. WHAT 1521 01:12:26,440 --> 01:12:31,880 YOU SEE IN THE CHECK BOARD 1522 01:12:31,880 --> 01:12:35,720 BOTTOM FROM ABOUT 169, 170 1523 01:12:35,720 --> 01:12:41,120 MODELS, WE HAVE PATIENTS, PDX 1524 01:12:41,120 --> 01:12:42,800 PDC FOR 40 PATIENTS, ALL HOSE 1525 01:12:42,800 --> 01:12:44,560 THINGS AVAILABLE, A MIX AN MATCH 1526 01:12:44,560 --> 01:12:48,200 OF VARIETY OF OTHERS SO MANY 1527 01:12:48,200 --> 01:12:49,640 MODELS TO CHOOSE FROM LOTS OF 1528 01:12:49,640 --> 01:12:51,320 HISTOLOGIES ONE CAN START IN TWO 1529 01:12:51,320 --> 01:12:52,760 DIMENSIONS AND WORK YOUR WAY UP 1530 01:12:52,760 --> 01:12:55,920 TO A THREE DIMENSIONAL MODEL AND 1531 01:12:55,920 --> 01:12:58,040 PUT IN AND EVALUATE AUTOLOGOUS 1532 01:12:58,040 --> 01:13:00,560 CANCER ASSOCIATED FIBROBLAST 1533 01:13:00,560 --> 01:13:02,440 TOGETHER FROM THE SAME PATIENT 1534 01:13:02,440 --> 01:13:03,680 WHICH IS MOLECULARLY 1535 01:13:03,680 --> 01:13:04,920 CHARACTERIZED TO UNDERSTAND THE 1536 01:13:04,920 --> 01:13:10,000 INTERACTIONS THAT ARE POSSIBLE. 1537 01:13:10,000 --> 01:13:13,960 THE REQUEST RATE LAST SEVERAL 1538 01:13:13,960 --> 01:13:15,640 MONTHS HAS GONE UP 1539 01:13:15,640 --> 01:13:21,400 SIGNIFICANTLY. NEXT SLIDE. SO 1540 01:13:21,400 --> 01:13:23,840 THIS IS A DISTRIBUTION, 1541 01:13:23,840 --> 01:13:26,480 SOMEWHERE ORDER OF 2500 MODELS 1542 01:13:26,480 --> 01:13:29,120 BUT IT IS BASICALLY EVERYTHING 1543 01:13:29,120 --> 01:13:34,720 THAT PEOPLE ASK FOR PDX 1544 01:13:34,720 --> 01:13:37,680 FRAGMENTS BUT ALSO FLASH FROZEN 1545 01:13:37,680 --> 01:13:40,120 SAMPLES FOR PROTEIN ANALYSIS. 1546 01:13:40,120 --> 01:13:43,720 DNA, RNA, AND ORGANOIDS AND 1547 01:13:43,720 --> 01:13:45,400 PBCs. ON THE RIGHT YOU CAN SEE 1548 01:13:45,400 --> 01:13:46,600 THE DISTRIBUTION OF HISTOLOGIES, 1549 01:13:46,600 --> 01:13:52,720 IT IS NOT JUST COLON CANCER BUT 1550 01:13:52,720 --> 01:13:54,960 WIDE VARIETY OF MODELS SURPRISED 1551 01:13:54,960 --> 01:13:56,760 ME, THERE ARE CERTAIN THINGS YOU 1552 01:13:56,760 --> 01:14:00,320 MIGHT OR MIGHT NOT GUESS BUT WE 1553 01:14:00,320 --> 01:14:02,400 HAVE HAD SPECIFIC REQUESTS FOR 1554 01:14:02,400 --> 01:14:05,520 RENAL CANCER MODELS THAT ARE 1555 01:14:05,520 --> 01:14:11,680 HARD TO DEVELOP FAIRLY LARGE 1556 01:14:11,680 --> 01:14:14,200 RENAL CANCER AND ORGANOIDS 1557 01:14:14,200 --> 01:14:15,680 USEFUL TO NUMEROUS INVESTIGATORS 1558 01:14:15,680 --> 01:14:20,880 ACROSS THE COUNTRY. I DIDN'T 1559 01:14:20,880 --> 01:14:23,760 WANT TO STOP WITHOUT CALLING OUT 1560 01:14:23,760 --> 01:14:25,200 SEVERAL THINGS. JUST GIVES YOU A 1561 01:14:25,200 --> 01:14:26,560 LIST OF THE SITES AND 1562 01:14:26,560 --> 01:14:29,360 INVESTIGATORS AT THOSE SITES WHO 1563 01:14:29,360 --> 01:14:32,080 REQUESTED MODELS ALMOST ALL 1564 01:14:32,080 --> 01:14:33,800 DESIGNATED CANCER CENTERS, 1565 01:14:33,800 --> 01:14:34,800 INVESTIGATORS THOSE SITES 1566 01:14:34,800 --> 01:14:39,440 REQUESTED MODELS. THERE ARE 1567 01:14:39,440 --> 01:14:40,560 MULTIPLE INVESTIGATORS WHO 1568 01:14:40,560 --> 01:14:41,880 REQUESTED MULTIPLE MODELS SO 1569 01:14:41,880 --> 01:14:47,040 THIS IS HEARTENING. USEFUL FOR 1570 01:14:47,040 --> 01:14:48,920 CENTERS THAT DON'T HAVE CAPACITY 1571 01:14:48,920 --> 01:14:50,440 TO REPOSITORY LIKE THIS OR DON'T 1572 01:14:50,440 --> 01:14:51,760 WANT TO INVEST MONEY PEOPLE CAN 1573 01:14:51,760 --> 01:14:53,360 REQUEST THESE MODELS FROM US AND 1574 01:14:53,360 --> 01:15:01,560 GET THEM AT LOW COST. YOU CAN 1575 01:15:01,560 --> 01:15:03,360 SEE VARIETY OF BIOTECHS ACTIVE 1576 01:15:03,360 --> 01:15:08,080 IN REQUESTING MODELS BUT ALSO 1577 01:15:08,080 --> 01:15:08,680 SOMETHING HEARTENING, ABOUT A 1578 01:15:08,680 --> 01:15:11,800 YEAR AGO WE GET A REQUEST FROM 1579 01:15:11,800 --> 01:15:17,960 GSK, THEY HAD STARTED THEIR OWN 1580 01:15:17,960 --> 01:15:19,080 REPOSITORY TESTING MANY YEARS 1581 01:15:19,080 --> 01:15:20,440 AGO AND GAVE UP ON IT AND 1582 01:15:20,440 --> 01:15:30,800 DECIDED TO GET BACK -- 1583 01:15:33,880 --> 01:15:37,200 >>WE LOST YOU. 1584 01:15:37,200 --> 01:15:46,520 >>JIM, YOU ARE MUTED. 1585 01:15:46,520 --> 01:15:47,840 >>MAYBE THAT CONSTRUCTION 1586 01:15:47,840 --> 01:15:48,960 FINALLY TOOK DOWN HIS -- 1587 01:15:48,960 --> 01:15:52,760 >>MY APOLOGIES. I WILL START 1588 01:15:52,760 --> 01:15:54,680 OVER AND TELL YOU THAT WE WERE 1589 01:15:54,680 --> 01:15:56,880 HEARTENED THAT GSK BASICALLY 1590 01:15:56,880 --> 01:16:02,440 WENT THROUGH OUR CATALOG AND 1591 01:16:02,440 --> 01:16:04,000 REDUCESSED LARGE -- REQUESTED 1592 01:16:04,000 --> 01:16:06,680 LARGE NUMBER OF MODELS USING 1593 01:16:06,680 --> 01:16:08,000 PDXs FOR DRUG SCREENING. WE 1594 01:16:08,000 --> 01:16:10,200 HAD LOTS OF REQUESTS FROM 1595 01:16:10,200 --> 01:16:11,200 INTRAMURAL INVESTIGATORS BUT 1596 01:16:11,200 --> 01:16:16,400 ALSO NCATS AND DOE. NEXT SLIDE 1597 01:16:16,400 --> 01:16:18,880 TO CLOSE OUT THIS PART OF MY 1598 01:16:18,880 --> 01:16:21,720 TALK, I WANT TO GET MY REAL 1599 01:16:21,720 --> 01:16:23,160 APPRECIATION TO LARGE NUMBER OF 1600 01:16:23,160 --> 01:16:25,480 NOT ONLY NCI DESIGNATED CANCER 1601 01:16:25,480 --> 01:16:30,680 CENTERS BUT MANY OF THE NCOR 1602 01:16:30,680 --> 01:16:32,240 SITES ACROSS THE COUNTRY ACTIVE 1603 01:16:32,240 --> 01:16:34,000 IN PARTICIPATING AND PROVIDING 1604 01:16:34,000 --> 01:16:35,520 US WITH MODELS THAT OTHERWISE WE 1605 01:16:35,520 --> 01:16:36,160 NEVER WOULD HAVE BEEN ABLE TO 1606 01:16:36,160 --> 01:16:44,400 COLLECT. SO I WILL MOVE TO A ONE 1607 01:16:44,400 --> 01:16:47,400 VIGNETTE IN TERMS OF COMPETITIVE 1608 01:16:47,400 --> 01:16:56,440 -- COMBINATION TRIAL STUDIES' 1609 01:16:56,440 --> 01:16:58,280 THAT MAYBE OF INTEREST. THIS WAS 1610 01:16:58,280 --> 01:16:59,840 A PAPER FIVE YEARS AGO MADE 1611 01:16:59,840 --> 01:17:02,240 POSSIBLE BECAUSE OF PRECISION 1612 01:17:02,240 --> 01:17:03,280 MEDICINE ACTIVITIES THAT WERE 1613 01:17:03,280 --> 01:17:04,600 SUPPORTED SOME YEARS AGO, THAT 1614 01:17:04,600 --> 01:17:09,240 ALLOWED US AD FREDERICK TO DO A 1615 01:17:09,240 --> 01:17:10,760 STUDY THAT TOOK EVERY AVAILABLE 1616 01:17:10,760 --> 01:17:13,200 FDA APPROVED THERAPEUTIC AGENT, 1617 01:17:13,200 --> 01:17:16,120 AND LOOK AT 5,000 UNIQUE ALL 1618 01:17:16,120 --> 01:17:19,320 POSSIBLE COMBINATIONS ACROSS THE 1619 01:17:19,320 --> 01:17:21,560 NCI 60 CELL LINE TO TRY TO FIND 1620 01:17:21,560 --> 01:17:23,800 UNIQUE COMBINATIONS THAT WOULD 1621 01:17:23,800 --> 01:17:25,160 NOT HAVE BEEN PREDICTIVE. 1622 01:17:25,160 --> 01:17:27,720 SO THIS IS A SYSTEMATIC STUDY 1623 01:17:27,720 --> 01:17:30,160 AND THERE WERE MANY, MANY 1624 01:17:30,160 --> 01:17:32,080 COMBINATIONS THAT WOULDN'T HAVE 1625 01:17:32,080 --> 01:17:35,600 BEEN PREDICTED. COMBINATION OF 1626 01:17:35,600 --> 01:17:37,920 MALOTNIB AND PACK LA TACK SOL. 1627 01:17:37,920 --> 01:17:41,000 EVERYTHING ABOVE THE LINE SHOWS 1628 01:17:41,000 --> 01:17:43,280 BY BLISS SCORE, MANY, MANY CELL 1629 01:17:43,280 --> 01:17:45,360 LINES, NOT JUST HEMATOPOIETIC 1630 01:17:45,360 --> 01:17:47,920 CELL LINES WHICH COMBINATION IS 1631 01:17:47,920 --> 01:17:50,000 ACTIVE. AND RIPPLE NEGATIVE 1632 01:17:50,000 --> 01:17:52,440 BREAST CANCER SHOWN LOWER LEFT 1633 01:17:52,440 --> 01:17:54,800 PRODUCES CURES. SO NEXT SLIDE. 1634 01:17:54,800 --> 01:17:57,560 WE WERE INTERESTED TO TRY TO 1635 01:17:57,560 --> 01:17:58,600 BEGIN TO UNDERSTAND WHY THAT WAS 1636 01:17:58,600 --> 01:18:02,800 THE CASE, TURNS OUT THAT LOOKING 1637 01:18:02,800 --> 01:18:03,600 CARPALIA CROSS THE CASCADE IT IS 1638 01:18:03,600 --> 01:18:05,600 CLEAR APOPTOSIS WAS NOT 1639 01:18:05,600 --> 01:18:08,880 MECHANISM OF ACTION FOR THE THIS 1640 01:18:08,880 --> 01:18:11,120 COMBINATION. IT IS KNOWN TO 1641 01:18:11,120 --> 01:18:14,200 ALTER P GLYCO PROTEIN AND DRUG 1642 01:18:14,200 --> 01:18:16,800 EFFLUX SINCE PACLA TOXOL IS A 1643 01:18:16,800 --> 01:18:17,720 SUBSTRATE, WE THOUGHT THAT WOULD 1644 01:18:17,720 --> 01:18:20,240 BE THE IS DA, IT IS NOT IN VIVO 1645 01:18:20,240 --> 01:18:22,360 LOWER LEFT. YOU CAN SEE UPTAKE 1646 01:18:22,360 --> 01:18:26,400 IN DEFLUX OF TAXOL IN THIS 468 1647 01:18:26,400 --> 01:18:29,400 BREAST CANCER IS NOT AFFECTED BY 1648 01:18:29,400 --> 01:18:32,040 NALOTNIB SO WE HAD NO CLEAR 1649 01:18:32,040 --> 01:18:33,280 UNDERSTANDING OF WHAT THE 1650 01:18:33,280 --> 01:18:35,200 MECHANISM OF ACTION WAS. SO WE 1651 01:18:35,200 --> 01:18:38,160 SAID OKAY IS THIS SOMETHING THAT 1652 01:18:38,160 --> 01:18:40,800 OCCURS IN XENOGRAPH OR PDX 1653 01:18:40,800 --> 01:18:44,520 MODEL? 1654 01:18:44,520 --> 01:18:46,560 SO THIS GIVES AN EXAMPLE, WE 1655 01:18:46,560 --> 01:18:50,240 WERE ABLE TO STUDY 9 PDX MODELS 1656 01:18:50,240 --> 01:18:51,600 AND WHAT IS REMARKABLE ABOUT 1657 01:18:51,600 --> 01:18:53,840 WHAT YOU SEE ON THE RIGHT IS A 1658 01:18:53,840 --> 01:18:56,200 LOT OF BLUE. THIS IS LOOKING AT 1659 01:18:56,200 --> 01:18:59,320 THESE MODELS BY QUALITATIVE 1660 01:18:59,320 --> 01:19:00,680 EVALUATION, COMPLETE RESPONSE, 1661 01:19:00,680 --> 01:19:05,840 PARTIAL RESPONSE, EFS, TIME 1662 01:19:05,840 --> 01:19:07,240 QUADRUPLING, IT IS AN EVENT FREE 1663 01:19:07,240 --> 01:19:10,640 SURVIVAL SO TIME TO GROWTH GIVES 1664 01:19:10,640 --> 01:19:13,640 YOU AND IN ESSENCE A PSEUDONYM 1665 01:19:13,640 --> 01:19:17,320 FOR PFS. UNDER AFC OR WHETHER 1666 01:19:17,320 --> 01:19:19,000 ACTUAL TIME PROGRESSIONS WERE 1667 01:19:19,000 --> 01:19:21,640 MEASURABLE AND THIS IS A VERY 1668 01:19:21,640 --> 01:19:23,120 ACTIVE COMBINATION ACROSS A LOT 1669 01:19:23,120 --> 01:19:25,960 OF DIFFERENT MODELS. IT IS 1670 01:19:25,960 --> 01:19:27,560 SOMETHING WE COULDN'T HAVE DONE 1671 01:19:27,560 --> 01:19:31,360 WITHOUT HAVING THIS REPOSITORY 1672 01:19:31,360 --> 01:19:33,920 AVAILABLE. SO THEN THE NEXT 1673 01:19:33,920 --> 01:19:36,880 THING IS ONE HAS TO DECONVOLUTE 1674 01:19:36,880 --> 01:19:38,600 THAT DATA THAT IS DATA FOR 1675 01:19:38,600 --> 01:19:40,400 COMBINATIONS SO THESE DATA WHICH 1676 01:19:40,400 --> 01:19:42,480 IS VERY CLEAR AND LEFT SIDE OF 1677 01:19:42,480 --> 01:19:44,120 THE SLIDE THAT THESE ARE -- THIS 1678 01:19:44,120 --> 01:19:46,480 IS A COMBINATION EFFECT. ACROSS 1679 01:19:46,480 --> 01:19:47,360 A VARIETY OF DIFFERENT TUMOR 1680 01:19:47,360 --> 01:19:50,160 TYPES. THE BLUE IS FOR 1681 01:19:50,160 --> 01:19:51,120 COMBINATION, BROWN IS 1682 01:19:51,120 --> 01:19:53,360 PROGRESSIVE DISEASE. YOU SEE 1683 01:19:53,360 --> 01:19:55,360 PARTIAL RESPONSE. SO THIS WAS 1684 01:19:55,360 --> 01:19:57,160 VERY HEARTENING. AND BECAUSE OF 1685 01:19:57,160 --> 01:20:03,200 THE WIDE RANGE OF ACTIVITY 1686 01:20:03,200 --> 01:20:05,680 COCOMBO IS NOW TAKEN UP INTO THE 1687 01:20:05,680 --> 01:20:07,160 INITIAL NINE ARMS OF THE INITIAL 1688 01:20:07,160 --> 01:20:12,320 COME BEMATCH TRIAL. HOW DOES 1689 01:20:12,320 --> 01:20:17,400 THIS WORK? WE HAVE DONE MULTIPLE 1690 01:20:17,400 --> 01:20:19,640 STUDIES INCLUDING RNA SEQ DATA. 1691 01:20:19,640 --> 01:20:21,640 WHAT YOU SEE IS COMBINATION IN 1692 01:20:21,640 --> 01:20:25,520 VIVO FOR PDX MODEL AND STANDARD 1693 01:20:25,520 --> 01:20:27,840 XENOGRAPH BOTTOM SEEMS TO BE 1694 01:20:27,840 --> 01:20:30,360 SIGNIFICANT INCREASE IN SIGHT 1695 01:20:30,360 --> 01:20:31,320 COIN PRODUCTION IN TUMORS FROM 1696 01:20:31,320 --> 01:20:35,400 THIS COMBINATION THAT IS OFTEN A 1697 01:20:35,400 --> 01:20:37,320 COMBINATION SPECIFIC EFFECT THAT 1698 01:20:37,320 --> 01:20:39,000 DOESN'T OCCUR TO THAT DEGREE ONE 1699 01:20:39,000 --> 01:20:42,000 DRUG OR ANOTHER. WE FOUND 1700 01:20:42,000 --> 01:20:44,240 FURTHER ANALYSIS OF RNA SEQ DATA 1701 01:20:44,240 --> 01:20:45,440 SHOWS THIS COMBINATION 1702 01:20:45,440 --> 01:20:47,320 DRAMATICALLY INCREASES THE 1703 01:20:47,320 --> 01:20:50,680 EXPRESSION OF THE GENES INVOLVED 1704 01:20:50,680 --> 01:20:52,200 IN RNA AND DNA SIGNALING WHICH 1705 01:20:52,200 --> 01:20:54,080 GIVES SOME REASON TO UNDERSTAND 1706 01:20:54,080 --> 01:20:57,720 AND EXPECT THAT IT IS REALLY 1707 01:20:57,720 --> 01:20:58,960 IMMUNE RESPONSE AT LEAST THE 1708 01:20:58,960 --> 01:21:01,800 ACTIVATION CYTOKINE ACTIVATION 1709 01:21:01,800 --> 01:21:06,440 SOMETHING THAT MAYBE IMPORTANT. 1710 01:21:06,440 --> 01:21:08,640 SO WE ARE ACTIVELY TRYING TO 1711 01:21:08,640 --> 01:21:09,960 UNDERSTAND WHETHER OR NOT DNA 1712 01:21:09,960 --> 01:21:14,240 SENSING IS -- SETS OFF NECROSIS 1713 01:21:14,240 --> 01:21:17,600 OR PERIOPTOTIC CASCADE TO GET A 1714 01:21:17,600 --> 01:21:19,280 BETTER UNDERSTANDING OF THIS 1715 01:21:19,280 --> 01:21:20,720 MECHANISM OF ACTION. AN EXAMPLE 1716 01:21:20,720 --> 01:21:21,960 OF POWER OF HAVING THESE MODELS 1717 01:21:21,960 --> 01:21:23,520 AVAILABLE AND DOING SCREENING 1718 01:21:23,520 --> 01:21:25,080 AND MECHANISM STUDIES THAT HE 1719 01:21:25,080 --> 01:21:28,080 ARE USEFUL AND CAN BE TAKEN INTO 1720 01:21:28,080 --> 01:21:30,840 CLINIC. NOW I WOULD LIKE TO 1721 01:21:30,840 --> 01:21:35,200 INTRODUCE MY COLLEAGUE, YVONNE 1722 01:21:35,200 --> 01:21:37,960 EVRARD WHO OVERSEE IT IS ENTIRE 1723 01:21:37,960 --> 01:21:40,840 REPOSITORY TO HELP YOU 1724 01:21:40,840 --> 01:21:42,560 UNDERSTAND VERY IMPORTANT 1725 01:21:42,560 --> 01:21:43,840 ACTIVITIES P PDMRs ARE 1726 01:21:43,840 --> 01:21:45,520 UNDERGOING WITH PDX COLLEAGUES 1727 01:21:45,520 --> 01:21:47,600 TO TRY TO STANER ADVERTISE 1728 01:21:47,600 --> 01:21:49,400 REPORTING OF PRE-CLINICAL TUMOR 1729 01:21:49,400 --> 01:21:50,760 VOLUME RESPONSES. YVONNE. 1730 01:21:50,760 --> 01:21:54,520 >>INC. THAT, JIM. SO SOME I 1731 01:21:54,520 --> 01:21:56,520 WILL GIVE YOU OVERVIEW OF ONE WE 1732 01:21:56,520 --> 01:21:59,640 ARE CURRENTLY DOING IN PDX 1733 01:21:59,640 --> 01:22:00,920 DEVELOPMENT TRIAL RESEARCH 1734 01:22:00,920 --> 01:22:03,160 NETWORK. PDX FOR SHORT AS WE 1735 01:22:03,160 --> 01:22:04,080 MENTIONED CANCER MOON SHOT 1736 01:22:04,080 --> 01:22:08,720 PROGRAM IN 2017. THIS GROUP IS 1737 01:22:08,720 --> 01:22:09,920 -- WE HAVE A DATA COMMONS 1738 01:22:09,920 --> 01:22:11,560 COORDINATING CENTER KEY TO 1739 01:22:11,560 --> 01:22:12,640 KEEPING THIS PROJECT PROGRAM 1740 01:22:12,640 --> 01:22:15,400 MOVING FORWARD. WE HAVE SIX 1741 01:22:15,400 --> 01:22:17,320 PARTICIPATING PDX DEVELOPMENT 1742 01:22:17,320 --> 01:22:18,600 AND TRIALS CENTERS, AND THESE 1743 01:22:18,600 --> 01:22:20,440 ARE GROUPS THAT DO ALL THE IN 1744 01:22:20,440 --> 01:22:21,880 VIVO TRANSLATIONAL RESEARCH AS 1745 01:22:21,880 --> 01:22:26,840 WELL AS CREATING MODELSS. A KEY 1746 01:22:26,840 --> 01:22:29,040 HERE IS PDX INVOLVED WITH 1747 01:22:29,040 --> 01:22:30,200 DIVISION OF CANCER TREATMENT AND 1748 01:22:30,200 --> 01:22:32,400 DIAGNOSIS AS WELL AS CENTER TO 1749 01:22:32,400 --> 01:22:33,760 REDUCE CANCER HEALTH DISPARITIES 1750 01:22:33,760 --> 01:22:36,840 SO TWO ARE FOCUSED ON 1751 01:22:36,840 --> 01:22:37,800 TRANSLATIONAL QUESTIONS 1752 01:22:37,800 --> 01:22:39,560 INVOLVING RACIAL ETHNIC 1753 01:22:39,560 --> 01:22:41,880 MINORITIES. AS A GROUP WE 1754 01:22:41,880 --> 01:22:42,920 UNDERGO DIFFERENT ACTIVITIES AND 1755 01:22:42,920 --> 01:22:44,000 ONE OF THOSE I WILL TALK ABOUT 1756 01:22:44,000 --> 01:22:47,000 TODAY IS INITIATIVE TO LOOK AT 1757 01:22:47,000 --> 01:22:48,560 TUMOR VOLUME RESPONSE. SO GO TO 1758 01:22:48,560 --> 01:22:54,600 THE NEXT SLIDE, THIS EFFORT WAS 1759 01:22:54,600 --> 01:22:58,440 SPEARHEADED BY MD ANDERSON AND 1760 01:22:58,440 --> 01:23:00,040 DR. JEFF MOSCOW AT NCI FOR THIS 1761 01:23:00,040 --> 01:23:00,800 EFFORT. 1762 01:23:00,800 --> 01:23:04,800 THE GOAL HERE WAS TO ASSESS WITH 1763 01:23:04,800 --> 01:23:06,240 THE CURRENT NEWS BY THE 1764 01:23:06,240 --> 01:23:07,880 COMMUNITY IN PUBLICATIONS AS 1765 01:23:07,880 --> 01:23:10,480 WELL AS BY PDX INVESTIGATORS AND 1766 01:23:10,480 --> 01:23:14,080 TRY TO SEE IF WE CAN'T DO 1767 01:23:14,080 --> 01:23:15,480 SOMETHING BETTER. IT IS 1768 01:23:15,480 --> 01:23:16,520 CHALLENGES THERE IS NOT A 1769 01:23:16,520 --> 01:23:18,560 STANDARD APPROACH IN VIVO TUMOR 1770 01:23:18,560 --> 01:23:19,960 GROWTH ASSESSMENT ACROSS THE 1771 01:23:19,960 --> 01:23:24,400 DIFFERENT PUBLICATIONS. 1772 01:23:24,400 --> 01:23:25,520 RESPONSES SEEN BY DIFFERENT 1773 01:23:25,520 --> 01:23:27,040 GROUPS. WHAT HAS COME OF THIS AS 1774 01:23:27,040 --> 01:23:28,400 COLLABORATIVE EFFORT WITH 1775 01:23:28,400 --> 01:23:32,840 VARIOUS PDX NET DEVELOPMENT AND 1776 01:23:32,840 --> 01:23:35,880 CENTERS IS PDX VOLUME METRIC 1777 01:23:35,880 --> 01:23:38,880 ANALYZER. SO DR. BERNSTEIN IS 1778 01:23:38,880 --> 01:23:41,480 WORK ON MANUSCRIPT ABOUT TO BE 1779 01:23:41,480 --> 01:23:42,920 PUBLISHED IN COMBINATION WITH 1780 01:23:42,920 --> 01:23:44,600 THAT SUITE OF TOOLS AVAILABLE 1781 01:23:44,600 --> 01:23:49,200 FOR COMMUNITY USE. THE VALUE OF 1782 01:23:49,200 --> 01:23:51,440 IMAGE ON BOTTOM TO UPLOAD DATA 1783 01:23:51,440 --> 01:23:53,240 AND DO VARIETY OF DIFFERENT 1784 01:23:53,240 --> 01:23:54,400 WAYS, VISUALLY REPRESENT THE 1785 01:23:54,400 --> 01:23:56,120 DATA AS WELL AS DO STATISTICAL 1786 01:23:56,120 --> 01:24:01,280 ANALYSIS. A COUPLE OF EXAMPLES 1787 01:24:01,280 --> 01:24:05,400 OF THIS, USING PACLA TAXOL 1788 01:24:05,400 --> 01:24:06,720 STUDIES DR. DOROSHOW DISCUSSED 1789 01:24:06,720 --> 01:24:08,720 TO SHOW YOU HOW TO USE THIS 1790 01:24:08,720 --> 01:24:11,240 METRIC AND KEY RECOMMENDATIONS 1791 01:24:11,240 --> 01:24:11,880 OUT OF THIS MAN JEW CRYPT THAT 1792 01:24:11,880 --> 01:24:14,080 CAME FROM THE PDX NET COMMUNITY. 1793 01:24:14,080 --> 01:24:15,880 YOU THINK IS REALLY IMPORTANT TO 1794 01:24:15,880 --> 01:24:17,320 START MOVING TOWARDS 1795 01:24:17,320 --> 01:24:21,160 STANDARDIZATION OF REPORTING 1796 01:24:21,160 --> 01:24:24,040 ACTIVITY IN PRE-CLINICAL 1797 01:24:24,040 --> 01:24:28,080 STUDIES. THIS IS AN EXAMPLE, 1798 01:24:28,080 --> 01:24:31,600 MULTIPLE WAYS IN SUITE OF TOOLS 1799 01:24:31,600 --> 01:24:33,400 TO GRAPHICALLY REPRESENT THEIR 1800 01:24:33,400 --> 01:24:36,080 DATA AND AN EXAMPLE ON THE LEFT, 1801 01:24:36,080 --> 01:24:38,840 THOSE THAT WORK WITH PDX WHICH 1802 01:24:38,840 --> 01:24:41,920 IS PRESENT VOLUME CHANGE. IT IS 1803 01:24:41,920 --> 01:24:43,120 STANDARD WAY TO REPRESENT THE 1804 01:24:43,120 --> 01:24:50,080 DATA, MANY WAYS TO DO THIS. THE 1805 01:24:50,080 --> 01:24:56,480 STUDY IN THE PACLO TAXOL DATA 1806 01:24:56,480 --> 01:24:58,920 RESPONSIVE TO THE COMBINATION. 1807 01:24:58,920 --> 01:25:00,440 WILL IS SIMILAR ACTIVITY WITH 1808 01:25:00,440 --> 01:25:07,200 PACLA TAXOL IN BLUE, NALOTNIB IS 1809 01:25:07,200 --> 01:25:10,080 -- IN THE CONTROL, YOU CAN SEE 1810 01:25:10,080 --> 01:25:12,840 ON THE LEFT, IS SHOWING THE 1811 01:25:12,840 --> 01:25:13,840 RESPONSE ON THE LEFT. ON THE 1812 01:25:13,840 --> 01:25:16,840 RIGHT IS METRIC THAT DR. MOSCOW 1813 01:25:16,840 --> 01:25:20,200 PROPOSED TO MOVE INTO LOOKING AT 1814 01:25:20,200 --> 01:25:21,080 THESE GRAPHICAL REPRESENTATIONS 1815 01:25:21,080 --> 01:25:22,440 IN A DIFFERENT WAY. THAT IS IF 1816 01:25:22,440 --> 01:25:25,080 YOU LOOK ON THE LEFT WITH THE 1817 01:25:25,080 --> 01:25:26,400 LIMITATION THERE, THE AREA WE 1818 01:25:26,400 --> 01:25:28,080 ARE MOST INTERESTED IN IS BOTTOM 1819 01:25:28,080 --> 01:25:29,240 TEN PERCENT OF THAT GROUF. SO 1820 01:25:29,240 --> 01:25:30,920 HOW DO WE REPRESENT THAT SO WE 1821 01:25:30,920 --> 01:25:33,400 CAN SEE WHAT IS HAPPENING WHEN 1822 01:25:33,400 --> 01:25:35,520 TUMOR, WHEN AGENTS HAVE 1823 01:25:35,520 --> 01:25:39,040 ACTIVITY. SO WE HAVE CREATED THE 1824 01:25:39,040 --> 01:25:40,280 SCALED AVERAGE CHANGE 1825 01:25:40,280 --> 01:25:41,400 REPRESENTATION, OF THESE GRAPHS 1826 01:25:41,400 --> 01:25:42,880 AS A WAY OF GRAPHING THE DATA SO 1827 01:25:42,880 --> 01:25:46,440 YOU CAN SEE PLUS AND MINUS 100%. 1828 01:25:46,440 --> 01:25:49,240 OR YOU LIMIT THRESHOLD THE UPPER 1829 01:25:49,240 --> 01:25:50,920 LEVEL, TO PRE-DEFINED END POINT, 1830 01:25:50,920 --> 01:25:52,880 THOSE ARE DETERMINED WITHIN THE 1831 01:25:52,880 --> 01:25:54,640 TOOL BY THE INVESTIGATOR 1832 01:25:54,640 --> 01:25:56,320 UPLOADING YOUR DATA SO WILL IS 1833 01:25:56,320 --> 01:25:57,320 FLEXIBILITY FOR THE INVESTIGATOR 1834 01:25:57,320 --> 01:25:59,080 TO DO THIS. YOU CAN SEE VERY 1835 01:25:59,080 --> 01:26:00,200 CLEARLY NOW JUST HOW MUCH 1836 01:26:00,200 --> 01:26:01,320 REGRESSION IS SEEN IN THIS 1837 01:26:01,320 --> 01:26:04,120 MODEL. AS AN EXAMPLE. IN THE 1838 01:26:04,120 --> 01:26:06,560 UPCOMING SLIDES I WILL SHOW YOU 1839 01:26:06,560 --> 01:26:08,680 WHERE THE RED ARROWS ARE, COUPLE 1840 01:26:08,680 --> 01:26:10,560 OF EXAMPLES OF FIXED DATES WHEN 1841 01:26:10,560 --> 01:26:12,120 YOU DO ANALYSIS. YOU CAN SEE 1842 01:26:12,120 --> 01:26:14,120 HERE ANOTHER WAY THESE TOOL 1843 01:26:14,120 --> 01:26:16,440 REPRESENTS THE DATA, IN 1844 01:26:16,440 --> 01:26:19,360 GRAPHICAL WAYS IS LOOKING AT FIX 1845 01:26:19,360 --> 01:26:22,520 DATES, DAY 7, DAY 21, DAY 30 TO 1846 01:26:22,520 --> 01:26:24,680 LOOK AT VARIOUS METRICS. WE HAVE 1847 01:26:24,680 --> 01:26:26,400 GROWTH INHIBITION ON THE LEFT, 1848 01:26:26,400 --> 01:26:27,880 IN THE MIDDLE IS A WATER FALL 1849 01:26:27,880 --> 01:26:29,320 PLOT, ALL THESE ARE THE TWO 1850 01:26:29,320 --> 01:26:31,320 SINGLE AGENTS AND COMBINATION OF 1851 01:26:31,320 --> 01:26:34,320 THAT, AND ONE OF THE RIGHT IS A 1852 01:26:34,320 --> 01:26:38,160 STACKED RESPONSE USING PRC -- 1853 01:26:38,160 --> 01:26:40,280 PARTIAL REGRESSION, COMPLETE 1854 01:26:40,280 --> 01:26:42,160 REGRESSION, PROGRESSIVE DISEASE. 1855 01:26:42,160 --> 01:26:45,480 WHAT YOU CAN'T SEE HERE ONE OF 1856 01:26:45,480 --> 01:26:48,200 THE RECOMMENDATIONS IS DEPENDING 1857 01:26:48,200 --> 01:26:49,760 ON THE DATA YOU PICK YOU CAN 1858 01:26:49,760 --> 01:26:52,200 HAVE DIFFERENT OVERALL 1859 01:26:52,200 --> 01:26:54,240 INTERPRETATION. IF YOU PICK DAY 1860 01:26:54,240 --> 01:26:58,400 7 TO DO ANALYSIS PREDICT PACLA 1861 01:26:58,400 --> 01:27:00,280 TAXOL IS DRIVING THE RESPONSE 1862 01:27:00,280 --> 01:27:02,640 SEEN IN THIS COMBINATION. BY 21, 1863 01:27:02,640 --> 01:27:04,720 DAY 30 THERE IS A BENEFIT TO THE 1864 01:27:04,720 --> 01:27:06,960 COMBINATION OVER SINGLE AGE 1865 01:27:06,960 --> 01:27:09,600 PACLA TAXOL. GOING INTO A STUDY, 1866 01:27:09,600 --> 01:27:11,400 HAVING CLEAR THOUGHTS OF WHAT 1867 01:27:11,400 --> 01:27:12,960 YOU PLAN ON METRIC IS GOING TO 1868 01:27:12,960 --> 01:27:17,000 BE AT THE END, NOT TAKING SHOW 1869 01:27:17,000 --> 01:27:18,200 BEST RESPONSE IS VERY IMPORTANT 1870 01:27:18,200 --> 01:27:22,360 ASPECT TO THIS. THE NEXT SLIDE. 1871 01:27:22,360 --> 01:27:24,800 IN ADDITION TO THE GRAPHICAL 1872 01:27:24,800 --> 01:27:25,480 REPRESENTATIONS THERE ARE 1873 01:27:25,480 --> 01:27:27,240 NUMEROUS WAYS TO DO STATISTICAL 1874 01:27:27,240 --> 01:27:30,080 ANALYSIS WITHIN THIS TOOL THAT 1875 01:27:30,080 --> 01:27:34,360 WILL BE RELEASED. THE METRIC WE 1876 01:27:34,360 --> 01:27:37,360 HAVE IN THIS SUITE HAS MULTIPLE 1877 01:27:37,360 --> 01:27:39,360 OPTIONS FOR CUSTOMIZATION, SO 1878 01:27:39,360 --> 01:27:40,720 DEPENDING ON HYPOTHESIS FOR THE 1879 01:27:40,720 --> 01:27:42,120 STUDY KEY INTO THE HELP YOU 1880 01:27:42,120 --> 01:27:44,960 NEED. THIS IS A COUPLE OF 1881 01:27:44,960 --> 01:27:46,560 EXAMPLES ON THE LEFT IS 1882 01:27:46,560 --> 01:27:48,440 OBJECTIVE RESPONSE OR RHESUS CRY 1883 01:27:48,440 --> 01:27:50,160 TIERIA. YOU CAN SELECT DAY -- 1884 01:27:50,160 --> 01:27:51,800 CRITERCRITERIA. YOU CAN SELECT F 1885 01:27:51,800 --> 01:27:54,160 READ OUT TO GET A PREDICTION OF 1886 01:27:54,160 --> 01:27:55,920 OVERALL RESPONSE FOR THE AVERAGE 1887 01:27:55,920 --> 01:27:58,240 OF THE GROUPS. ON THE RIGHT IS 1888 01:27:58,240 --> 01:27:59,720 TRADITIONAL WATER FALL PLOT. 1889 01:27:59,720 --> 01:28:00,520 THERE'S DIFFERENT SELECTIONS YOU 1890 01:28:00,520 --> 01:28:03,880 CAN DO FOR TYPE OF WATER FALL 1891 01:28:03,880 --> 01:28:04,800 SHOW RESPONSE FOR THOSE. NEXT 1892 01:28:04,800 --> 01:28:09,480 SLIDE. THIS IS AN EXAMPLE OF 1893 01:28:09,480 --> 01:28:11,120 EVENT FREE SURVIVAL YOU CAN 1894 01:28:11,120 --> 01:28:14,600 THRESHOLD THIS, THIS IS SURVIVAL 1895 01:28:14,600 --> 01:28:18,320 TO TUMOR QUADRUPLING, ON THE 1896 01:28:18,320 --> 01:28:20,680 RIGHT YOU SHOWS PULL DOWN WHERE 1897 01:28:20,680 --> 01:28:22,360 THAT TUMOR HAPPENED IN EACH 1898 01:28:22,360 --> 01:28:23,560 GROUP. SO YOU CAN LOOK HOW MANY 1899 01:28:23,560 --> 01:28:25,360 DAYS TOOK FOR THAT TO GET WILL 1900 01:28:25,360 --> 01:28:28,000 TO FEEL FOR THE DELAY IN 1901 01:28:28,000 --> 01:28:29,320 RESPONSE FOR THOSE WHEN YOU HAVE 1902 01:28:29,320 --> 01:28:31,760 ACTIVITY FROM DRUG RESPONSE. 1903 01:28:31,760 --> 01:28:33,240 NEXT COUPLE OF SLIDES, I WILL 1904 01:28:33,240 --> 01:28:34,840 SHOW YOU COUPLE OF THE KEY 1905 01:28:34,840 --> 01:28:36,520 RECOMMENDATIONS THAT CAME OUT OF 1906 01:28:36,520 --> 01:28:37,760 THIS EFFORT. IT IS REALLY 1907 01:28:37,760 --> 01:28:39,440 IMPORTANT THE RECOMMENDATIONS IN 1908 01:28:39,440 --> 01:28:43,200 THE MANUSCRIPT, THE ANALYSIS 1909 01:28:43,200 --> 01:28:44,720 DONE BY DR. BERNSTEIN AND TEAM 1910 01:28:44,720 --> 01:28:46,880 IS AMAZE FOR COMPARATIVE DATA 1911 01:28:46,880 --> 01:28:48,680 AND ALL DOES THIS WITH THE TOOL 1912 01:28:48,680 --> 01:28:52,840 THAT IS RELEASED. THOSE WORK IN 1913 01:28:52,840 --> 01:28:54,480 PDX UNDERSTAND THESE 1914 01:28:54,480 --> 01:28:55,840 RECOMMENDATIONS CLEARLY, YOU GO 1915 01:28:55,840 --> 01:29:00,640 THROUGH PUBLICATIONS WE ALL SEE 1916 01:29:00,640 --> 01:29:02,640 GAPS. USING CLINICALLY RELEVANT 1917 01:29:02,640 --> 01:29:04,640 DOSES AND SCHEDULES WHEREVER 1918 01:29:04,640 --> 01:29:05,840 POSSIBLE IS IMPORTANT WHEN YOU 1919 01:29:05,840 --> 01:29:07,640 CAN TRANSLATIONAL EFFORT MAKING 1920 01:29:07,640 --> 01:29:09,840 SURE YOU MONITOR BODY WEIGHT 1921 01:29:09,840 --> 01:29:12,160 WITHIN THE TOOL WE DO WE ALLOW 1922 01:29:12,160 --> 01:29:15,240 BODY WEIGHT TO UPLOAD THE BODY 1923 01:29:15,240 --> 01:29:17,760 WAY GRAPHLY WITHIN TOOL, IF YOUR 1924 01:29:17,760 --> 01:29:20,480 SIGNALING RESPONSE IS NOT 1925 01:29:20,480 --> 01:29:24,160 SUBSTANTIAL TOXICITY FROM THE 1926 01:29:24,160 --> 01:29:26,840 DRUG IN THE ANIMAL ITSELF. TWO 1927 01:29:26,840 --> 01:29:28,760 NUANCES MAKING SURE YOU HAVE 1928 01:29:28,760 --> 01:29:30,760 CLINICALLY MEANINGFUL ANTITUMOR 1929 01:29:30,760 --> 01:29:32,960 ACTIVITY. YOU CAN SEE A 1930 01:29:32,960 --> 01:29:34,000 STATISTICAL DIFFERENCE DEPENDING 1931 01:29:34,000 --> 01:29:36,200 WHAT CUT OFF YOU USE, IF YOU 1932 01:29:36,200 --> 01:29:37,680 HAVE TWO PROGRESSIVE DISEASE 1933 01:29:37,680 --> 01:29:39,320 MODELS YOU CAN HAVE 1934 01:29:39,320 --> 01:29:40,560 STATISTICALLY DIFFERENCE AND 1935 01:29:40,560 --> 01:29:41,800 FEEL YOU HAVE IMPROVEMENT WE 1936 01:29:41,800 --> 01:29:43,960 WANT TO LOOK FOR CLINICALLY 1937 01:29:43,960 --> 01:29:44,760 MEANINGFUL ACTIVITY WHERE YOU 1938 01:29:44,760 --> 01:29:47,360 ARE SEEING TUMOR REGRESSION OR 1939 01:29:47,360 --> 01:29:48,520 PROLONGED GROWTH INHIBITION. SO 1940 01:29:48,520 --> 01:29:51,320 USING THAT AS A STRONGER METRIC, 1941 01:29:51,320 --> 01:29:53,120 WILL HELP IMPROVE AND MAKING 1942 01:29:53,120 --> 01:29:55,680 SURE TWO OR MORE METRICS, NOT 1943 01:29:55,680 --> 01:29:57,920 USING RHESUS CRITERIA, AND THANK 1944 01:29:57,920 --> 01:30:01,360 YOUER MORE GROWTH INHIBITION, 1945 01:30:01,360 --> 01:30:03,360 YOU ARE DEPTH AND DURABILITY OF 1946 01:30:03,360 --> 01:30:05,720 RESPONSE IN THAT PRE-CLINICAL 1947 01:30:05,720 --> 01:30:08,800 STUDY. NEXT. FINALLY, IN 1948 01:30:08,800 --> 01:30:11,000 COMBINATION STUDIES, MAKE SURE 1949 01:30:11,000 --> 01:30:12,480 BOTH SINGLE AGENTS ARE 1950 01:30:12,480 --> 01:30:14,400 REPRESENTED AS CONTROLS SO YOU 1951 01:30:14,400 --> 01:30:18,960 CCANSHOW THE TREATMENT ACTIVITYS 1952 01:30:18,960 --> 01:30:20,720 ENHANCEMENT OVER SINGLE AGENT 1953 01:30:20,720 --> 01:30:23,480 ALONE OR VEHICLE CONTROL. THEN 1954 01:30:23,480 --> 01:30:27,160 FINALLY, DEMONSTRATING THAT 1955 01:30:27,160 --> 01:30:28,040 DEMONSTRATING ACTIVITY AT LEAST 1956 01:30:28,040 --> 01:30:30,320 TO RELEVANT MODELS MORE IF 1957 01:30:30,320 --> 01:30:31,880 POSSIBLE, THERE'S BUDGET 1958 01:30:31,880 --> 01:30:33,240 CONSTRAINTS ON THIS BUT DON'T -- 1959 01:30:33,240 --> 01:30:35,360 WE DON'T WANT TO SEE ACTIVITY IN 1960 01:30:35,360 --> 01:30:36,680 SINGLE MODEL AT LEAST HAVE TWO 1961 01:30:36,680 --> 01:30:38,120 CLINICALLY RELEVANT TO QUESTION 1962 01:30:38,120 --> 01:30:40,440 BEING ASKED WITH AGENTS BEING 1963 01:30:40,440 --> 01:30:43,200 USED. THERE ARE MULTIPLE 1964 01:30:43,200 --> 01:30:44,920 RECOMMENDATIONS IN THIS 1965 01:30:44,920 --> 01:30:47,480 MANUSCRIPT. THAT GOES PAIRED 1966 01:30:47,480 --> 01:30:49,240 WITH THIS SUITE OF TOOLS 1967 01:30:49,240 --> 01:30:50,400 AVAILABLE THAT WILL BE COMING 1968 01:30:50,400 --> 01:30:53,480 OUT FOR THE COMMUNITY TO USE IN 1969 01:30:53,480 --> 01:30:57,720 THE NEAR FUTURE. NEXT SLIDE. TWO 1970 01:30:57,720 --> 01:30:59,720 QUICK ACKNOWLEDGMENT SLIDES, ALL 1971 01:30:59,720 --> 01:31:01,840 THIS EFFORT FROM THE PDX HAS 1972 01:31:01,840 --> 01:31:03,720 BEEN ASTOUNDING. THEY ARE A 1973 01:31:03,720 --> 01:31:04,760 COLLABORATIVE NETWORK AND 1974 01:31:04,760 --> 01:31:07,200 WONDERFUL TO WORK WITH. IN BEING 1975 01:31:07,200 --> 01:31:12,040 SPEARHEADED BY GREAT OVERSIGHT. 1976 01:31:12,040 --> 01:31:14,280 THANKS FOR ALL THE WORK ON THE 1977 01:31:14,280 --> 01:31:17,200 PDMR SIDE TO THE GROUPS THAT DO 1978 01:31:17,200 --> 01:31:18,920 ALL THIS EFFORT AS WELL AS 1979 01:31:18,920 --> 01:31:20,040 CLINICS AND PATIENTS AND 1980 01:31:20,040 --> 01:31:21,280 FAMILIES. THANK YOU, WE WILL 1981 01:31:21,280 --> 01:31:24,760 TAKE QUESTIONS. 1982 01:31:24,760 --> 01:31:28,040 >>THANKS VERY MUCH, THAT WAS A 1983 01:31:28,040 --> 01:31:29,160 GREAT PRESENTATION. TO A PERSON 1984 01:31:29,160 --> 01:31:31,160 WHO USED ANIMAL MODELS MOST OF 1985 01:31:31,160 --> 01:31:32,960 MY CAREER, I COMMEND YOU, IT IS 1986 01:31:32,960 --> 01:31:37,080 REALLY VERY NICE. SO OPEN UP 1987 01:31:37,080 --> 01:31:39,640 FOR QUESTIONS. I SEE MARY. 1988 01:31:39,640 --> 01:31:43,960 >>THANK YOU, VERY MUCH. JIM, 1989 01:31:43,960 --> 01:31:45,320 ENJOYED LISTENING TO ALL IS THE 1990 01:31:45,320 --> 01:31:47,400 WONDERFUL WORK THE PDX MODELS 1991 01:31:47,400 --> 01:31:52,600 AND I WONDERED, I HAVE TWO 1992 01:31:52,600 --> 01:31:56,680 QUESTIONS, IF THE RESEARCHERS 1993 01:31:56,680 --> 01:31:57,680 REQUEST SOME OF THE ORIGINAL 1994 01:31:57,680 --> 01:31:58,680 CLINICAL SAMPLE. THE SECOND PART 1995 01:31:58,680 --> 01:32:03,440 OF THE QUESTION IS, WITH THE 1996 01:32:03,440 --> 01:32:04,080 WONDERFUL RECOMMENDATIONS YOU 1997 01:32:04,080 --> 01:32:06,120 ARE DEVELOPING WHICH IS VERY 1998 01:32:06,120 --> 01:32:11,040 IMPORTANT, WILL YOU SHARE THAT 1999 01:32:11,040 --> 01:32:15,400 WITH NCATS GENERAL ASSAY MANUAL, 2000 01:32:15,400 --> 01:32:18,400 THEY PUT OUT GUIDELINES FOR 2001 01:32:18,400 --> 01:32:22,400 RESEARCHERS DOING ROBUST ASSAYS? 2002 01:32:22,400 --> 01:32:24,920 >>THE SECOND I'M AWARE OF, AND 2003 01:32:24,920 --> 01:32:26,040 HADN'T THOUGHT ABOUT AND IT IS A 2004 01:32:26,040 --> 01:32:30,040 GREAT IDEA. WE WILL CERTAINLY 2005 01:32:30,040 --> 01:32:32,680 DO THAT. NCATS DOESN'T DO IN 2006 01:32:32,680 --> 01:32:35,080 VIVO. THEY DO CONTRACT STUFF BUT 2007 01:32:35,080 --> 01:32:36,280 INTERNALLY THEY DON'T SO THAT 2008 01:32:36,280 --> 01:32:37,800 WOULD BE VERY USEFUL. WITH 2009 01:32:37,800 --> 01:32:40,600 RESPECT TO THE PRIMARY TUMOR. 2010 01:32:40,600 --> 01:32:43,800 LET ME SAY I WOULD LOVE TO DO 2011 01:32:43,800 --> 01:32:46,000 THAT BUT ABOUT 40% OF OUR 2012 01:32:46,000 --> 01:32:48,560 SAMPLES ARE ACTUALLY 18 GAUGE 2013 01:32:48,560 --> 01:32:50,960 NEEDLE BIOPSIES THAT ARE BAUERLY 2014 01:32:50,960 --> 01:32:54,400 ENOUGH TO EVEN GET PDX STARTED. 2015 01:32:54,400 --> 01:32:55,640 UNFORTUNATELY WE COULD NEVER -- 2016 01:32:55,640 --> 01:32:58,640 THERE IS NOTHING LEFT TO SHARE. 2017 01:32:58,640 --> 01:33:00,720 HALF, A LITTLE MORE, SURGICAL 2018 01:33:00,720 --> 01:33:03,480 SAMPLES. AND THEY ARE NOT 2019 01:33:03,480 --> 01:33:06,600 ENORMOUS. WE -- I HAVE TO SAY I 2020 01:33:06,600 --> 01:33:07,480 WOULD LOVE TO BE ABLE TO GIVE 2021 01:33:07,480 --> 01:33:09,960 THOSE AWAY BUT WE HAVE OTHER 2022 01:33:09,960 --> 01:33:13,120 MECHANISMS TO GET PEOPLE PRIMARY 2023 01:33:13,120 --> 01:33:19,360 TUMORS. CHTN AND OTHERS. WE HAVE 2024 01:33:19,360 --> 01:33:21,600 NOT OFFERED THE INITIAL BIOPSY 2025 01:33:21,600 --> 01:33:24,200 SPECIMEN OR WHICH WE DON'T 2026 01:33:24,200 --> 01:33:27,080 REALLY DON'T RETAIN. OR SURGICAL 2027 01:33:27,080 --> 01:33:31,080 SPECIMENS TO SHARE. 2028 01:33:31,080 --> 01:33:32,840 >>I HAVE ONE ADDITIONAL THING. 2029 01:33:32,840 --> 01:33:34,400 IF WE HAVE RESIDUAL PATIENT 2030 01:33:34,400 --> 01:33:36,080 TISSUE WE ARE TRYING TO CREATE 2031 01:33:36,080 --> 01:33:37,760 DIFFERENT MODEL TYPES WE DO HAVE 2032 01:33:37,760 --> 01:33:39,800 WHOLE EXOME RNA SEQ DATA ON THE 2033 01:33:39,800 --> 01:33:41,160 DATABASE FOR THAT ORIGINAL 2034 01:33:41,160 --> 01:33:42,480 PATIENT MATERIAL. SO WE HAVE 2035 01:33:42,480 --> 01:33:43,920 THAT DATA WHEN WE HAVE 2036 01:33:43,920 --> 01:33:45,160 SUFFICIENT TUMOR MATERIAL LEFT 2037 01:33:45,160 --> 01:33:49,600 OVER TO DO THAT. 2038 01:33:49,600 --> 01:33:54,040 >>ALISON O. 2039 01:33:54,040 --> 01:33:56,120 >>I'M COMING ABOUT THIS FROM A 2040 01:33:56,120 --> 01:33:57,200 SLIGHTLY DIFFERENT PERSPECTIVE 2041 01:33:57,200 --> 01:33:59,200 BECAUSE I WORK IN BIOBANKING. AS 2042 01:33:59,200 --> 01:34:02,440 WELL. WHAT YOU HAVE DESCRIBED 2043 01:34:02,440 --> 01:34:07,040 HERE IS A VERY FASCINATING 2044 01:34:07,040 --> 01:34:10,960 APPROACH TO REALLY LEVERAGING 2045 01:34:10,960 --> 01:34:12,280 EVER PRECIOUS TUMOR SAMPLE YOU 2046 01:34:12,280 --> 01:34:20,240 GET. THIS IS ON TESTIMONY OF 2047 01:34:20,240 --> 01:34:22,360 ISSUES OF GETTING OUT THE WORD. 2048 01:34:22,360 --> 01:34:24,000 IF REPRESENTATIVE THIS PATIENT 2049 01:34:24,000 --> 01:34:25,680 DERIVED MODELS REPOSITORY WOULD 2050 01:34:25,680 --> 01:34:28,200 BE INTERESTED IN GIVING A 2051 01:34:28,200 --> 01:34:30,640 WEBINAR TO BOTH ISBR AND SOCIETY 2052 01:34:30,640 --> 01:34:39,240 FOR CRYOBIOLOGY ABOUT THIS 2053 01:34:39,240 --> 01:34:41,240 INITIATIVE FROM PERSPECTIVE OF 2054 01:34:41,240 --> 01:34:42,640 BIOBANKING. EVERYTHING, 2055 01:34:42,640 --> 01:34:46,080 ORGANOIDS, PDX, CANCER 2056 01:34:46,080 --> 01:34:48,080 ASSOCIATED FIBROBLAST, THIS IS A 2057 01:34:48,080 --> 01:34:49,440 FASCINATING APPROACH AND OUR 2058 01:34:49,440 --> 01:34:50,320 COMMUNITY NEEDS TO LEARN MORE 2059 01:34:50,320 --> 01:34:53,320 ABOUT IT. IF YOU ARE AMENABLE, 2060 01:34:53,320 --> 01:34:56,160 REACH OUT VIA EMAIL OR CONNECT 2061 01:34:56,160 --> 01:34:57,320 ME WITH WHOM EVER IS APPROPRIATE 2062 01:34:57,320 --> 01:34:58,680 AND WE WOULD LOVE TO EXTEND 2063 01:34:58,680 --> 01:34:59,720 INVITATION. 2064 01:34:59,720 --> 01:35:03,680 >>WE WOULD BE DELIGHTED, WE 2065 01:35:03,680 --> 01:35:10,920 HAVE DONE HATE TO SAY IT BUT 2066 01:35:10,920 --> 01:35:12,240 WHEN I GIVE THIS PRESENTATION, 2067 01:35:12,240 --> 01:35:13,400 WE THINK AS AN ADVERTISEMENT 2068 01:35:13,400 --> 01:35:17,800 BECAUSE WE ARE INTERESTED IN 2069 01:35:17,800 --> 01:35:18,600 DISTRIBUTING, IT IS A HUGE 2070 01:35:18,600 --> 01:35:20,680 AMOUNT OF WORK AND WE WANT AS 2071 01:35:20,680 --> 01:35:22,240 MANY RESEARCHERS AS POSSIBLE TO 2072 01:35:22,240 --> 01:35:24,600 TAKE ADVANTAGE OF THE FACILITY. 2073 01:35:24,600 --> 01:35:26,080 >>IN PARTICULAR WHEN YOU TALK 2074 01:35:26,080 --> 01:35:28,880 ABOUT YOU GET THESE FIND NEEDLE 2075 01:35:28,880 --> 01:35:30,360 ASPIRATES AND YOU ARE OKAYING 2076 01:35:30,360 --> 01:35:32,400 OUT EVERY PRECIOUS CELL YOU CAN 2077 01:35:32,400 --> 01:35:35,560 FROM THEM, THAT WISDOM, THAT 2078 01:35:35,560 --> 01:35:37,120 WORK FLOW IS TREMENDOUSLY 2079 01:35:37,120 --> 01:35:41,200 VALUABLE TO THE COMMUNITY. I 2080 01:35:41,200 --> 01:35:42,440 VIEW THIS AS AN IMPORTANT 2081 01:35:42,440 --> 01:35:44,640 OPPORTUNITY NOT JUST TO EXPOSE 2082 01:35:44,640 --> 01:35:47,840 THAT HIDDEN DIAMOND BUT ALSO 2083 01:35:47,840 --> 01:35:49,760 PROPAGATE WISDOM AMONG 2084 01:35:49,760 --> 01:35:52,000 PRACTICING COMMUNITY. 2085 01:35:52,000 --> 01:36:00,720 >>AGREE. RODNEY. 2086 01:36:00,720 --> 01:36:04,120 >>THANK YOU, JIM AND YVONNE. 2087 01:36:04,120 --> 01:36:07,880 THE IS A VERY GOOD DEMONSTRATION 2088 01:36:07,880 --> 01:36:12,280 OF THE DRUG COMBINATIONS 2089 01:36:12,280 --> 01:36:14,440 LEARNING ABOUT PHARMACOLOGY AS 2090 01:36:14,440 --> 01:36:17,880 WELL AS IMMUNOPHARMACOLOGY IT IS 2091 01:36:17,880 --> 01:36:21,440 NOT JUST MOLECULAR MECHANISMS 2092 01:36:21,440 --> 01:36:24,880 THAT WE USE TO BE FAMILIARIZED 2093 01:36:24,880 --> 01:36:27,560 AND GUIDE DRUG DEVELOPMENT 2094 01:36:27,560 --> 01:36:32,360 PROGRAM. SO NALOTNIB IS KINASE 2095 01:36:32,360 --> 01:36:35,560 INHIBITORS FOR THE LEUKEMIA, 2096 01:36:35,560 --> 01:36:40,760 KINASE INHIBITORS THAT AS THE 2097 01:36:40,760 --> 01:36:41,840 TRANSPORTER ACTIVITIES AND WE 2098 01:36:41,840 --> 01:36:45,120 INITIALLY THOUGHT THAT WE HAVE A 2099 01:36:45,120 --> 01:36:46,560 SLAM DUNK, WHICH WE DON'T. SO 2100 01:36:46,560 --> 01:36:50,640 REALLY IS A VERY COMPLEX 2101 01:36:50,640 --> 01:36:52,960 CYTOKINE THAT REQUIRE IN VIVO 2102 01:36:52,960 --> 01:36:55,440 INTERACTIONS THAT REQUIRE 2103 01:36:55,440 --> 01:37:00,480 VALIDATION. NOT ONLY IN THE PDX 2104 01:37:00,480 --> 01:37:04,080 MODEL BUT ALSO EVENTUALLY 2105 01:37:04,080 --> 01:37:05,760 HOPEFULLY LEARN FROM THIS AND BE 2106 01:37:05,760 --> 01:37:10,120 ABLE TO BUILD CYTOKINE 2107 01:37:10,120 --> 01:37:14,600 COMBINATIONS OR CELL 2108 01:37:14,600 --> 01:37:16,400 THERAPEUTICS. FIRST LESSON. HOW 2109 01:37:16,400 --> 01:37:20,040 DO WE DO THIS. IN THE SMALL 2110 01:37:20,040 --> 01:37:26,040 SCALE TO LARGE SCALE. YOU 2111 01:37:26,040 --> 01:37:26,840 DEMONSTRATED LARGE CLASS 2112 01:37:26,840 --> 01:37:30,240 RESOURCES. THAT IS HOW WE SCALE 2113 01:37:30,240 --> 01:37:34,360 IT INTO END OF INVESTIGATOR 2114 01:37:34,360 --> 01:37:35,880 PROGRAM AND CANCER CENTER, SO 2115 01:37:35,880 --> 01:37:38,240 FORTH SO THAT IS REALLY MY 2116 01:37:38,240 --> 01:37:42,120 QUESTION. ABOUT HOW WE 2117 01:37:42,120 --> 01:37:43,400 DISSIMILARNATE PLATFORM, -- 2118 01:37:43,400 --> 01:37:44,520 DISSEMINATE PLATFORM. SECOND IS 2119 01:37:44,520 --> 01:37:49,960 HOW CAN WE USE THE DATA 2120 01:37:49,960 --> 01:37:59,320 GENERATED CELL THERAPY 2121 01:37:59,320 --> 01:38:00,240 STANDARDS, THE GUIDANCE OF WHAT 2122 01:38:00,240 --> 01:38:02,760 PEOPLE WILL SAY, YOU KNOW, DRUG 2123 01:38:02,760 --> 01:38:05,160 COMPANIES, I WANT TO TAKE ON. IF 2124 01:38:05,160 --> 01:38:13,080 YOU HAVE X Y Z DATA FOR PROJECT 2125 01:38:13,080 --> 01:38:14,280 THAT WE SUPPORT DEVELOPMENT 2126 01:38:14,280 --> 01:38:16,160 PROGRAM. THAT IS WHAT I WANT TO 2127 01:38:16,160 --> 01:38:17,800 THROW BACK TO THE COMMITTEE 2128 01:38:17,800 --> 01:38:24,960 THINK HOW WE CAN GUIDE OVERALL 2129 01:38:24,960 --> 01:38:26,000 DIRECTION AND MONICA YOU MAY 2130 01:38:26,000 --> 01:38:27,520 HAVE THOUGHTS AS WELL. IT IS 2131 01:38:27,520 --> 01:38:30,600 REALLY FASCINATING, IT COMES 2132 01:38:30,600 --> 01:38:35,040 TOGETHER CENTERPIECE OF 2133 01:38:35,040 --> 01:38:36,080 TRANSLATION THE BASIC ENGINE SO 2134 01:38:36,080 --> 01:38:36,400 TO SPEAK. 2135 01:38:36,400 --> 01:38:39,880 >>IF I CAN RESPOND, AT LEAST I 2136 01:38:39,880 --> 01:38:41,240 CAN REMEMBER QUESTIONS 1 AND 3 I 2137 01:38:41,240 --> 01:38:44,840 CAN RESPOND TO. FROM I HOPE 2138 01:38:44,840 --> 01:38:46,600 WITHIN A YEAR, MAYBE A YEAR FROM 2139 01:38:46,600 --> 01:38:47,880 NOW OR NOT TOO LONG THEREAFTER 2140 01:38:47,880 --> 01:38:48,480 WE WILL. 2141 01:38:48,480 --> 01:38:51,480 COBACK AND MAKE A PRESENTATION 2142 01:38:51,480 --> 01:38:52,920 ABOUT SOMETHING NOT YET READY 2143 01:38:52,920 --> 01:38:54,280 FOR PRESENTATION BUT HAS BEEN 2144 01:38:54,280 --> 01:38:55,040 SOMETHING WE HAVE BEEN WORKING 2145 01:38:55,040 --> 01:38:59,920 ON FOR NOW OVER TWO YEARS. TO 2146 01:38:59,920 --> 01:39:01,800 DEVELOP -- TAKE ALL THOSE 2147 01:39:01,800 --> 01:39:03,800 ORGANOIDS AND TO DO TRUE HIGH 2148 01:39:03,800 --> 01:39:09,440 THROUGH PUT SCREENING SYSTEM FOR 2149 01:39:09,440 --> 01:39:11,720 ORGANOIDS. THERE ARE LOTS OF 2150 01:39:11,720 --> 01:39:13,680 PAPERS BUT FEW ARE REALLY TRUE 2151 01:39:13,680 --> 01:39:18,280 HIGH LIEU PUT SCREENS. NOT ONLY 2152 01:39:18,280 --> 01:39:21,520 DO WE HAVE OVER 500 INVALIDATED 2153 01:39:21,520 --> 01:39:23,280 ORGANOIDS AND MORE EVERY DAY BUT 2154 01:39:23,280 --> 01:39:27,200 WE ALSO HAVE AT FREDERICK A 2155 01:39:27,200 --> 01:39:29,960 REPOSITORY FOR SEVERAL THOUSAND 2156 01:39:29,960 --> 01:39:30,880 INVESTIGATIONAL COMPOUNDS WE 2157 01:39:30,880 --> 01:39:32,000 PURCHASE OFFER MADE OURSELVES 2158 01:39:32,000 --> 01:39:33,600 THAT REALLY CONSTITUTE ALL OF 2159 01:39:33,600 --> 01:39:36,280 THE INTERESTING COMPOUNDS THAT 2160 01:39:36,280 --> 01:39:38,440 -- SINCE THE GOVERNMENT PRODUCED 2161 01:39:38,440 --> 01:39:40,040 THEM, SYNTHESIZED THEM OR 2162 01:39:40,040 --> 01:39:44,720 PURCHASED THEM CAN BE USED WITH 2163 01:39:44,720 --> 01:39:46,840 FOR ANY PURPOSE OF HELP AND THE 2164 01:39:46,840 --> 01:39:51,240 GOAL OF THIS WHOLE EFFORT, THIS 2165 01:39:51,240 --> 01:39:53,040 IS WHAT I HOPE TO PRESENT TO YOU 2166 01:39:53,040 --> 01:39:57,880 IN A YEAR OR SO, IS TO SAY THE 2167 01:39:57,880 --> 01:40:02,680 NCI 60 WAS FINE IN 1990. BUT WE 2168 01:40:02,680 --> 01:40:03,600 SPECIFICALLY CHOSE NOT TO 2169 01:40:03,600 --> 01:40:05,960 DEVELOP EQUIVALENT OF NCI 600, 2170 01:40:05,960 --> 01:40:09,000 TO NOT DO THAT WITH OLD PLASTIC 2171 01:40:09,000 --> 01:40:10,800 ASSOCIATED CELL LINES. THE GOAL 2172 01:40:10,800 --> 01:40:15,240 IS ACTUALLY TO HAVE A THOUSAND 2173 01:40:15,240 --> 01:40:16,680 ORGANOIDS PLUS IN CASSETTES THAT 2174 01:40:16,680 --> 01:40:19,320 WE WILL OFFER TO THE PUBLIC. TO 2175 01:40:19,320 --> 01:40:20,680 THE EXTRAMURAL RESEARCHERS YOU 2176 01:40:20,680 --> 01:40:22,760 HAVE TO APPLY, NOT FOR MONEY, 2177 01:40:22,760 --> 01:40:24,920 BUT FOR PROJECT IT IS WAY WE DO 2178 01:40:24,920 --> 01:40:27,600 IN OTHER KINDS OF AREAS IN THE 2179 01:40:27,600 --> 01:40:28,840 NEXT PROGRAM AND HAVE EXTERNAL 2180 01:40:28,840 --> 01:40:30,920 REVIEW AND THEN IF YOU HAVE 2181 01:40:30,920 --> 01:40:33,000 PARTICULAR PROJECT OR TARGET OR 2182 01:40:33,000 --> 01:40:36,760 COMPOUND YOU WANT TO COMBINE 2183 01:40:36,760 --> 01:40:38,200 WITH ANYTHING IN OUR REPOSITORY 2184 01:40:38,200 --> 01:40:39,400 WE WILL DO IT FOR YOU AND FIEF 2185 01:40:39,400 --> 01:40:43,160 YOU THE DATA. WE MADE A LOT OF 2186 01:40:43,160 --> 01:40:45,600 PROGRESS, SO FAR WE HAVE A PANEL 2187 01:40:45,600 --> 01:40:47,560 IN COLON, PANCREAS, WE WANT TO 2188 01:40:47,560 --> 01:40:48,840 HAVE SEVERAL MORE PANELS WE CAN 2189 01:40:48,840 --> 01:40:54,200 OFFER TO PUBLIC. BUT THE GOAL IS 2190 01:40:54,200 --> 01:40:55,360 NO COST OFFER THESE THINGS AFTER 2191 01:40:55,360 --> 01:40:56,600 PEER REVIEW TO THE EXTRAMURAL 2192 01:40:56,600 --> 01:40:58,320 COMMUNITY TO DO EXACTLY WHAT WE 2193 01:40:58,320 --> 01:41:00,600 SAY, TO ADVANCE IDEAS THAT 2194 01:41:00,600 --> 01:41:02,280 PEOPLE HAVE PROVIDE PRELIMINARY 2195 01:41:02,280 --> 01:41:03,520 DATA SO THEY CAN GO BACK AND DO 2196 01:41:03,520 --> 01:41:05,080 THINGS IN THEIR LABORATORY THAT 2197 01:41:05,080 --> 01:41:06,880 WOULDN'T ORDINARILY BE EASILY 2198 01:41:06,880 --> 01:41:11,960 ACCOMPLISHABLE. 2199 01:41:11,960 --> 01:41:14,400 >>ANANT, DID YOU HAVE A 2200 01:41:14,400 --> 01:41:14,720 QUESTION? 2201 01:41:14,720 --> 01:41:16,320 >>WONDERING IF THERE IS AN 2202 01:41:16,320 --> 01:41:19,520 OPPORTUNITY WITH THE TISSUE THAT 2203 01:41:19,520 --> 01:41:22,040 IS BEING ACQUIRED, WHETHER THERE 2204 01:41:22,040 --> 01:41:24,160 IS OPPORTUNITY TO DIGITIZE THE 2205 01:41:24,160 --> 01:41:25,600 SLIDES AND TO THINK ABOUT 2206 01:41:25,600 --> 01:41:27,640 CREATING A SLIDE REPOSITORY, 2207 01:41:27,640 --> 01:41:29,360 ADDITIONAL SLIDE REPOSITORY THAT 2208 01:41:29,360 --> 01:41:31,720 CORRESPONDS TO THESE SUBSEQUENT 2209 01:41:31,720 --> 01:41:36,400 PDX MODELS AND ORGANOIDS BEING 2210 01:41:36,400 --> 01:41:36,720 CREATED. 2211 01:41:36,720 --> 01:41:38,520 >>POSSIBLE. THE HNEs ARE 2212 01:41:38,520 --> 01:41:40,720 ACTUALLY ZERO COST DOWNLOADABLE 2213 01:41:40,720 --> 01:41:44,560 FROM THE WEBSITE. SO WE HAVEN'T 2214 01:41:44,560 --> 01:41:48,800 HAD RESOURCES YET TO INVEST IN 2215 01:41:48,800 --> 01:41:49,920 DIGITIZING THEM AT LEAST -- 2216 01:41:49,920 --> 01:41:52,360 DIGITIZING THEM, AT LEAST ALL OF 2217 01:41:52,360 --> 01:41:54,400 THEM, SOME OF THE PDX MODELS I 2218 01:41:54,400 --> 01:41:56,760 DIDN'T HAVE CHANCE TO TALK ABOUT 2219 01:41:56,760 --> 01:41:59,520 IT, WE DO INTENSE SMALL ANIMAL 2220 01:41:59,520 --> 01:42:01,800 IMAGING. THOSE SMALL ANIMAL 2221 01:42:01,800 --> 01:42:07,280 IMAGING WHETHER MR OR 2222 01:42:07,280 --> 01:42:08,480 ULTRASOUND, AS WELL AS HISTOLOGY 2223 01:42:08,480 --> 01:42:14,000 IS UPLOADED TO THE TCIA. SO 2224 01:42:14,000 --> 01:42:15,160 ABOUT 50 MODELS QUITE 2225 01:42:15,160 --> 01:42:18,760 COMPREHENSIVE ANALYSIS OF ALL OF 2226 01:42:18,760 --> 01:42:22,240 THAT DATA FROM THE MODELS SO THE 2227 01:42:22,240 --> 01:42:24,120 GENETIC DATA IS AVAILABLE. THE 2228 01:42:24,120 --> 01:42:25,560 IMAGING DATA IS AVAILABLE AS 2229 01:42:25,560 --> 01:42:31,760 PART AND PARCEL OF THE TCIA. 2230 01:42:31,760 --> 01:42:33,640 >>BEFORE I GO TO JOHN FOR THE 2231 01:42:33,640 --> 01:42:35,200 LAST QUESTION, DOUG DID YOU HAVE 2232 01:42:35,200 --> 01:42:37,880 A COMMENT PERTINENT? 2233 01:42:37,880 --> 01:42:41,240 >>YES. THIS IS UNSOLICITED 2234 01:42:41,240 --> 01:42:43,320 ENDORSEMENT AS AN END USER OF 2235 01:42:43,320 --> 01:42:49,080 THE PDMR BUT A DIFFERENT AREA, 2236 01:42:49,080 --> 01:42:51,160 JIM AND YVONNE TALKED ABOUT THE 2237 01:42:51,160 --> 01:42:59,280 CRITICALLY IMPORTANT AREA OF 2238 01:42:59,280 --> 01:43:00,440 CANCER TREATMENT FOR EVALUATION 2239 01:43:00,440 --> 01:43:02,120 BUT IN MY LAB WE ARE ESPECIALLY 2240 01:43:02,120 --> 01:43:03,880 INTERESTED IN MUTANTS. BECAUSE 2241 01:43:03,880 --> 01:43:08,960 THE DATABASE HAS BEEN SUBJECT TO 2242 01:43:08,960 --> 01:43:10,080 GENOMIC SEQUENCE ANALYSIS, THE 2243 01:43:10,080 --> 01:43:13,520 TWO THINGS I WILL TELL YOU ARE 2244 01:43:13,520 --> 01:43:18,400 FIRST, KRAS G 12C MUTATIONS ARE 2245 01:43:18,400 --> 01:43:22,160 UNCOMMON IN PANCREATIC CANCER 2246 01:43:22,160 --> 01:43:24,560 BUT THERE ARE SEVERAL PANCREATIC 2247 01:43:24,560 --> 01:43:27,160 CANCERS WITH G 12C MUTATIONS SO 2248 01:43:27,160 --> 01:43:30,320 THAT IF YOU WANTED TO LOOK AT 2249 01:43:30,320 --> 01:43:35,320 THAT IN THE CONTEXT OF A PDX, IT 2250 01:43:35,320 --> 01:43:38,400 IS VERY EASY TOE DO SO. THEN WE 2251 01:43:38,400 --> 01:43:42,480 ARE STUDYING AN UNUSUAL BUT 2252 01:43:42,480 --> 01:43:48,520 RECURRENT MUTATION INVOLVING ROW 2253 01:43:48,520 --> 01:43:50,960 GTPASES, IT TOOK YVONNE LESS 2254 01:43:50,960 --> 01:43:53,360 THAN 30 SECONDS TO SAY THAT IN 2255 01:43:53,360 --> 01:43:57,960 THE DATABASE THERE IS A CANCER 2256 01:43:57,960 --> 01:44:02,160 WITH THIS UNUSUAL RECURRENT 2257 01:44:02,160 --> 01:44:03,800 MUTATION. WHICH THEREFORE WE ARE 2258 01:44:03,800 --> 01:44:08,800 ABLE TO STUDY. 2259 01:44:08,800 --> 01:44:10,120 >>THANK YOU FOR THE COMMENT. 2260 01:44:10,120 --> 01:44:10,720 LAST QUESTION FROM JOHN. 2261 01:44:10,720 --> 01:44:13,200 >>THIS IS A FANTASTIC RESOURCE. 2262 01:44:13,200 --> 01:44:14,920 I WANT TO ASK, I THINK ONE OF 2263 01:44:14,920 --> 01:44:18,600 THE REALMS WHERE THIS COULD HAVE 2264 01:44:18,600 --> 01:44:20,480 EXTRAORDINARY IMPACT IS IN AS 2265 01:44:20,480 --> 01:44:23,080 YOU HIGHLIGHT WITH THE SARCOMAS, 2266 01:44:23,080 --> 01:44:24,520 MORE RARE CANCER WHERE IT IS 2267 01:44:24,520 --> 01:44:26,720 MUCH HARDER TO FIND THESE 2268 01:44:26,720 --> 01:44:28,960 SAMPLES AND FIND MODELS TO WORK 2269 01:44:28,960 --> 01:44:32,200 WITH. IS THERE A FOCUS ON THAT 2270 01:44:32,200 --> 01:44:33,280 IN PARTICULAR? 2271 01:44:33,280 --> 01:44:36,400 >>ABSOLUTELY. WE HAVE 2272 01:44:36,400 --> 01:44:39,160 ENCOURAGED AS I IMPLIED IT WAS 2273 01:44:39,160 --> 01:44:43,040 EASIER TO GET THOSE SAMPLES FROM 2274 01:44:43,040 --> 01:44:44,720 ACADEMIC CENTERS MANY TIMES THAN 2275 01:44:44,720 --> 01:44:46,600 GET STAMPED AND GET STANDARD 2276 01:44:46,600 --> 01:44:48,600 BREAST CANCER BECAUSE NOT EVERY 2277 01:44:48,600 --> 01:44:50,480 CENTER HAS INVESTIGATOR WHO IS 2278 01:44:50,480 --> 01:44:52,800 INVOLVED IN STUDYING SYNOVIAL 2279 01:44:52,800 --> 01:44:54,280 SARCOMA FOR EXAMPLE SO THEY ARE 2280 01:44:54,280 --> 01:44:56,240 WILLING TO SEND US THOSE MODELS. 2281 01:44:56,240 --> 01:44:58,120 WE CAN THEN MAKE THEM AVAILABLE 2282 01:44:58,120 --> 01:44:58,920 TO THE COMMUNITY. 2283 01:44:58,920 --> 01:45:01,920 >>THAT IS GREAT. 2284 01:45:01,920 --> 01:45:04,040 >>WE DO STILL HAVE -- WE HAVE A 2285 01:45:04,040 --> 01:45:05,400 LITTLE BIT MORE TIME BEFORE WE 2286 01:45:05,400 --> 01:45:09,800 GO ON A BREAK. ANYBODY HAVE A 2287 01:45:09,800 --> 01:45:14,000 LAST MINUTE QUESTION OR COMMENT 2288 01:45:14,000 --> 01:45:15,840 LINDA. 2289 01:45:15,840 --> 01:45:20,840 >>CURIOUS WHETHER YOU HAD 2290 01:45:20,840 --> 01:45:24,000 RELATIONSHIP OR WHETHER YOU CAN 2291 01:45:24,000 --> 01:45:25,800 INCORPORATE SOME OF THE OTHER 2292 01:45:25,800 --> 01:45:29,120 MAJOR DATA CENTERS, FOR INSTANCE 2293 01:45:29,120 --> 01:45:29,920 SAINT JUDES WITH CHILDREN'S 2294 01:45:29,920 --> 01:45:33,480 TUMORS IN A PARTICULAR BRAIN 2295 01:45:33,480 --> 01:45:34,480 TUMORS, THEY HAVE QUITE A 2296 01:45:34,480 --> 01:45:36,120 COLLECTION THEMSELVES AND 2297 01:45:36,120 --> 01:45:37,160 WONDERING WHETHER SOME OF THOSE 2298 01:45:37,160 --> 01:45:39,480 COULD BE BROUGHT INTO SHARED 2299 01:45:39,480 --> 01:45:41,480 DATABASES. 2300 01:45:41,480 --> 01:45:43,040 >>ONE OF THE THINGS WE HAVE 2301 01:45:43,040 --> 01:45:44,400 DONE, THE ANSWER IS YES, WE HAVE 2302 01:45:44,400 --> 01:45:47,640 A MECHANISM TO DO THAT. NOT ONLY 2303 01:45:47,640 --> 01:45:51,680 HAVE WE PRODUCED LOTS OF MODELS 2304 01:45:51,680 --> 01:45:54,280 OURSELVES, EACH PDX NET 2305 01:45:54,280 --> 01:45:57,120 COLLABORATORS IS ALSO PROVIDED 2306 01:45:57,120 --> 01:45:59,120 US WITH WE HAVE SEVERAL HUNDRED 2307 01:45:59,120 --> 01:46:01,200 MORE MODELS THAT ARE IN FREEZERS 2308 01:46:01,200 --> 01:46:04,520 BECAUSE IT IS A MATTER OF KRAS 2309 01:46:04,520 --> 01:46:06,080 SPACE AND GROWING THESE UP AND 2310 01:46:06,080 --> 01:46:07,640 REANALYZING THEM TO PUT INTO THE 2311 01:46:07,640 --> 01:46:10,720 REPOSITORY. SO THAT AS LONG AS 2312 01:46:10,720 --> 01:46:12,960 THE PATIENTS HAVE -- IF THEIR 2313 01:46:12,960 --> 01:46:15,400 TISSUE WAS COLLECTED IN 2314 01:46:15,400 --> 01:46:17,360 ACCORDANCE WITH THE APPROPRIATE 2315 01:46:17,360 --> 01:46:19,880 CONSENTING TO ALLOW SHARING 2316 01:46:19,880 --> 01:46:21,480 GENETIC ANONYMIZED GENETIC 2317 01:46:21,480 --> 01:46:22,960 INFORMATION WE HAVE GOTTEN -- WE 2318 01:46:22,960 --> 01:46:27,520 WERE RECENTLY GOT A COLLECTION 2319 01:46:27,520 --> 01:46:29,960 OF CLANGIAL CARCINOMAS FROM NGH 2320 01:46:29,960 --> 01:46:31,280 AND THE INVESTIGATOR WAS HAPPY 2321 01:46:31,280 --> 01:46:32,440 TO SHARE THEM BECAUSE HE HAD NO 2322 01:46:32,440 --> 01:46:36,920 WAY OF LONG TERM STORAGE FOR 2323 01:46:36,920 --> 01:46:40,480 THOSE. HE USES THOSE FOR THOSE 2324 01:46:40,480 --> 01:46:41,120 OWN INVESTIGATIONS BUT THEY WILL 2325 01:46:41,120 --> 01:46:42,760 BE AVAILABLE TO THE GREATER 2326 01:46:42,760 --> 01:46:46,840 COMMUNITY. THEY ARE TAKING ON 2327 01:46:46,840 --> 01:46:47,760 COLLECTIONS THAT OTHER 2328 01:46:47,760 --> 01:46:48,640 INVESTIGATORS MIGHT HAVE HELP 2329 01:46:48,640 --> 01:46:53,080 WITH IN TERMS OF DISTRIBUTION. 2330 01:46:53,080 --> 01:46:58,080 >>GREAT. REMARKABLE. OKAY. SO 2331 01:46:58,080 --> 01:47:01,480 WE ARE NOW TAKING A BREAK. WE 2332 01:47:01,480 --> 01:47:03,840 WILL HAVE ADMINISTRATIVE SESSION 2333 01:47:03,840 --> 01:47:07,560 SO THOSE OF US THAT ARE ON THE 2334 01:47:07,560 --> 01:47:09,320 VIRTUAL WEBEX SHOULD NOT 2335 01:47:09,320 --> 01:47:10,680 DISCONNECT. EVERYONE ELSE SHOULD 2336 01:47:10,680 --> 01:47:13,000 TAKE A 30 MINUTE BREAK. THE 2337 01:47:13,000 --> 01:47:16,840 MEETING WILL RESUME PROMPTLY AT 1:20 2338 01:47:16,840 --> 01:47:18,480 >>WE HAVE THE FREDERICK 2339 01:47:18,480 --> 01:47:20,080 TECHNOLOGY SHOWCASE THAT'S GOING 2340 01:47:20,080 --> 01:47:24,240 TO BE PRESENTED TO US, BY DR.S 2341 01:47:24,240 --> 01:47:29,120 SALGALLER AND POPOV. I DON'T 2342 01:47:29,120 --> 01:47:37,040 KNOW WHO IS GOING FIRST. 2343 01:47:37,040 --> 01:47:40,000 >>HELLO. MICHAEL YOU ARE 2344 01:47:40,000 --> 01:47:40,840 PULLING UP THE SLIDES, RIGHT? 2345 01:47:40,840 --> 01:47:41,360 >>I. 2346 01:47:41,360 --> 01:47:51,680 A. -- I AM. 2347 01:47:58,000 --> 01:47:58,800 >>GOOD AFTERNOON, EVERYONE. 2348 01:47:58,800 --> 01:48:01,960 THANK YOU FOR THE OPPORTUNITY TO 2349 01:48:01,960 --> 01:48:03,560 PRESENT ON THAT SHOWCASE. MY 2350 01:48:03,560 --> 01:48:08,320 NAME IS VLADMIR POPOV, CHIEF 2351 01:48:08,320 --> 01:48:09,000 OFFICER FOR CANCER RESEARCH. I 2352 01:48:09,000 --> 01:48:10,880 HAVE BEEN WITH THE LAB SEVEN 2353 01:48:10,880 --> 01:48:12,600 YEARS, HELD SEVERAL ROLES. BUT 2354 01:48:12,600 --> 01:48:15,040 ALWAYS FOCUSING ON COLLABORATION 2355 01:48:15,040 --> 01:48:16,240 AND PARTNERSHIP DEVELOPMENT 2356 01:48:16,240 --> 01:48:18,440 OUTREACH AND PROGRAM SUPPORT. 2357 01:48:18,440 --> 01:48:20,720 I'M PLEASED TO BE HOAR TODAY AND 2358 01:48:20,720 --> 01:48:21,880 LOOKING FORWARD TO PRESENTING 2359 01:48:21,880 --> 01:48:22,880 TECHNOLOGY SHOWCASING TO WITH 2360 01:48:22,880 --> 01:48:25,080 MICHAEL. I WILL NOW LET MICHAEL 2361 01:48:25,080 --> 01:48:27,080 INTRODUCE HIMSELF. 2362 01:48:27,080 --> 01:48:28,520 >>THANK YOU VERY MUCH FOR 2363 01:48:28,520 --> 01:48:31,080 HAVING US PRESENT. I'M MICHAEL 2364 01:48:31,080 --> 01:48:32,720 SALGALLER, I ACTUALLY PART 2365 01:48:32,720 --> 01:48:37,360 STARTED MY CAREER AT THE NCI 2366 01:48:37,360 --> 01:48:38,560 POST-DOCKING WITH DR. JOE 2367 01:48:38,560 --> 01:48:40,160 SCHROENN IN THE LABORATORY OF 2368 01:48:40,160 --> 01:48:42,880 TUMOR IMMUNOLOGY AND BIOLOGY AND 2369 01:48:42,880 --> 01:48:45,000 WENT ON TO WORK FOR SEVERAL 2370 01:48:45,000 --> 01:48:48,240 YEARS WITH DR. STEVE ROSENBURG. 2371 01:48:48,240 --> 01:48:52,240 LEFT TO LEAD SEVERAL LIFE 2372 01:48:52,240 --> 01:48:54,120 SCIENCE COMPANY, WORK IN VENTURE 2373 01:48:54,120 --> 01:48:55,360 CAPITAL TO HELP OTHERS START 2374 01:48:55,360 --> 01:48:59,320 COMPANIES AND CAME BACK TO HEAD 2375 01:48:59,320 --> 01:49:01,000 THE TECHNOLOGY ANALYSIS 2376 01:49:01,000 --> 01:49:01,920 MARKETING UNIT ABOUT SIX YEARS 2377 01:49:01,920 --> 01:49:07,800 AGO. IT ALL STARTED WHEN VLAD 2378 01:49:07,800 --> 01:49:10,360 AND TEAM AND MY TEAM MET WITH 2379 01:49:10,360 --> 01:49:12,080 REPRESENTATIVES FROM FREDERICK 2380 01:49:12,080 --> 01:49:14,600 COUNTY AND CITY LATE 2016, THEY 2381 01:49:14,600 --> 01:49:16,280 WERE INTERESTED IN CREATING 2382 01:49:16,280 --> 01:49:18,200 BETTER UNDERSTANDING AND 2383 01:49:18,200 --> 01:49:20,800 AWARENESS OF THE EXCITING CANCER 2384 01:49:20,800 --> 01:49:22,360 RESEARCH BEING DONE AT THE 2385 01:49:22,360 --> 01:49:24,320 FREDERICK NATIONAL LAB AND SO 2386 01:49:24,320 --> 01:49:26,600 ONE OF US INNOCENTLY SAID WE 2387 01:49:26,600 --> 01:49:28,680 COULD ALWAYS PUT ON A MEETING. 2388 01:49:28,680 --> 01:49:31,080 IT IS SORT OF IN A GOOD WAY 2389 01:49:31,080 --> 01:49:32,960 STEAM ROLLED FROM THERE. OUR 2390 01:49:32,960 --> 01:49:36,000 INAUGURAL YEAR WAS A HALF DAVID 2391 01:49:36,000 --> 01:49:40,000 IN 2017. IN 2018 WE EXPANDED TO 2392 01:49:40,000 --> 01:49:41,880 A FULL DAY AND ADDED KEY NOTES, 2393 01:49:41,880 --> 01:49:44,280 WE ADDED THE TECH TRANSFER 2394 01:49:44,280 --> 01:49:45,760 AMBASSADORS PROGRAM WHICH VLAD 2395 01:49:45,760 --> 01:49:48,080 WILL DESCRIBE IN A FEW MINUTES. 2396 01:49:48,080 --> 01:49:50,600 ALSO POSTER PITCHES POSTERS THAT 2397 01:49:50,600 --> 01:49:52,080 TALKED ABOUT NOT JUST AS THE 2398 01:49:52,080 --> 01:49:57,080 SCIENCE BUT THE PARTNERING 2399 01:49:57,080 --> 01:50:00,200 OPPORTUNITY P. THEN IN 2019 2400 01:50:00,200 --> 01:50:02,680 BASED ON FEEDBACK WE RETURNED TO 2401 01:50:02,680 --> 01:50:05,560 HALF DAY FORMAT. AND INCLUDE 2402 01:50:05,560 --> 01:50:07,840 PANELS ON VARIOUS TOPICS THAT 2403 01:50:07,840 --> 01:50:12,480 VLAD WILL SUMMARIZE. IN 2020 WE 2404 01:50:12,480 --> 01:50:13,920 PIVOTED TO A VIRTUAL 2405 01:50:13,920 --> 01:50:16,600 OPPORTUNITY, WE EXPANDED OUR 2406 01:50:16,600 --> 01:50:19,400 OUTREACH OUTSIDE OF THE DMV AND 2407 01:50:19,400 --> 01:50:25,320 HAD SIX COUNTRIES AND 13 STATES 2408 01:50:25,320 --> 01:50:26,600 PARTICIPATE AND WERE FORTUNATE 2409 01:50:26,600 --> 01:50:29,800 ENOUGH TO WIN THE NCI DIRECTORS 2410 01:50:29,800 --> 01:50:33,080 AWARD THAT YEAR. IN 2021, WE 2411 01:50:33,080 --> 01:50:36,880 ADDED THE VOICE OF THE PATIENT, 2412 01:50:36,880 --> 01:50:39,960 HAD A FULLY VIRTUAL EVENT AGAIN, 2413 01:50:39,960 --> 01:50:42,520 WE ARE FORTUNATE ENOUGH TO WIN 2414 01:50:42,520 --> 01:50:45,640 THE FEDERAL LAB CONSORTIUM 2415 01:50:45,640 --> 01:50:48,280 AWARD, FOR SATE AND WILLCAL 2416 01:50:48,280 --> 01:50:50,600 ECONOMIC DEVELOPMENT. THIS PAST 2417 01:50:50,600 --> 01:50:53,160 YEAR WE DID OUR FIRST HYBRID 2418 01:50:53,160 --> 01:50:59,320 EVENT, VIRTUAL AND IN PERSON, WE 2419 01:50:59,320 --> 01:51:00,280 INCLUDED PROGRAMMATIC 2420 01:51:00,280 --> 01:51:01,520 PRESENTATIONS THAT GAVE OVERVIEW 2421 01:51:01,520 --> 01:51:03,000 OF RESEARCH PROGRAMS AND 2422 01:51:03,000 --> 01:51:04,360 BRANCHES RATHER THAN INDIVIDUAL 2423 01:51:04,360 --> 01:51:08,120 TECHNOLOGIES. AND HAD NEARLY 300 2424 01:51:08,120 --> 01:51:12,640 ATTENDEES. 2425 01:51:12,640 --> 01:51:13,920 >>THANK YOU, MICHAEL. YOU WILL 2426 01:51:13,920 --> 01:51:16,280 HEAR US CALLING THIS EVENT 2427 01:51:16,280 --> 01:51:17,160 UNIQUE THROUGHOUT THE 2428 01:51:17,160 --> 01:51:19,680 PRESENTATION. AND IT TRULY IS A 2429 01:51:19,680 --> 01:51:21,760 UNIQUE AND JUST A FEW REASONS WE 2430 01:51:21,760 --> 01:51:25,320 SEE IT AS SUCH. IT IS FIRST THE 2431 01:51:25,320 --> 01:51:26,960 ONLY NIH CONFERENCE WITH 2432 01:51:26,960 --> 01:51:29,000 POTENTIAL LICENSEES AND 2433 01:51:29,000 --> 01:51:30,680 COLLABORATORS AT PRIMARY 2434 01:51:30,680 --> 01:51:33,680 AUDIENCE WITH AGENDA THAT 2435 01:51:33,680 --> 01:51:34,920 ADR.sS INTEREST AND WE DO 2436 01:51:34,920 --> 01:51:36,400 TECHNOLOGY PITCHES WITH A 2437 01:51:36,400 --> 01:51:38,280 BUSINESS CASE RATHER THAN 2438 01:51:38,280 --> 01:51:39,840 SCIENTIFIC PRESENTATIONS WE 2439 01:51:39,840 --> 01:51:41,960 KEYNOTE ADDRESS, VOICE PATIENTS 2440 01:51:41,960 --> 01:51:43,720 SUCCESS STORIES INDUSTRY FOCUSED 2441 01:51:43,720 --> 01:51:46,720 PANELS AND NETWORKING. ALL WHICH 2442 01:51:46,720 --> 01:51:50,160 WILL COVER MORE DETAIL. WE HAVE 2443 01:51:50,160 --> 01:51:51,320 CO-SPONSORSHIP AGREEMENT WITH 2444 01:51:51,320 --> 01:51:55,160 ECONOMIC DEVELOPMENT OFFICES OF 2445 01:51:55,160 --> 01:51:57,160 FREDERICK COUNTY AND CITY AND 2446 01:51:57,160 --> 01:52:00,640 ALSO TECHNOLOGY DEVELOPMENT 2447 01:52:00,640 --> 01:52:01,360 CORPORATION, SPECIFIC TO 2448 01:52:01,360 --> 01:52:02,920 MARYLAND FUNDING AND THIS IS TO 2449 01:52:02,920 --> 01:52:04,480 LEVERAGE RESOURCES RELATIONSHIPS 2450 01:52:04,480 --> 01:52:08,000 AND EXPERTISE. THIS IS ONE OF 2451 01:52:08,000 --> 01:52:10,080 THE EVENTS THAT GIVES PI 2452 01:52:10,080 --> 01:52:11,880 OPPORTUNITY TO DEVELOP BUSINESS 2453 01:52:11,880 --> 01:52:13,320 CASE PRESENTATION, WE WILL COVER 2454 01:52:13,320 --> 01:52:15,960 THIS IN MORE DETAIL WHERE WE 2455 01:52:15,960 --> 01:52:18,200 WILL SHOW WHAT PRESENTATION WE 2456 01:52:18,200 --> 01:52:20,280 EXPECT PIs TO GET. THIS IS 2457 01:52:20,280 --> 01:52:22,720 MENTORED BY TECH ANALYSIS IN THE 2458 01:52:22,720 --> 01:52:24,640 MARKETING UNIT FROM NCI SIDE AND 2459 01:52:24,640 --> 01:52:27,280 PARTNERSHIP DEVELOPMENT OFFICE 2460 01:52:27,280 --> 01:52:29,080 OUTSIDE. FINALLY WE HAVE A 2461 01:52:29,080 --> 01:52:32,040 TECHNOLOGY TRANSFER AMBASSADORS 2462 01:52:32,040 --> 01:52:35,400 PROGRAM. THIS ALLOWS AMBASSADORS 2463 01:52:35,400 --> 01:52:36,400 TO PRESENT QUICK INVENTION 2464 01:52:36,400 --> 01:52:38,280 PITCHES AND POSTERS FOR 2465 01:52:38,280 --> 01:52:39,760 POTENTIAL COMMERCIAL PRODUCT 2466 01:52:39,760 --> 01:52:47,240 PERSPECTIVE. WITH OUR MISSION 2467 01:52:47,240 --> 01:52:49,000 AND OUR NCI FOCUSING ON CANCER 2468 01:52:49,000 --> 01:52:50,720 RESEARCH AND ADVANCE SCIENTIFIC 2469 01:52:50,720 --> 01:52:52,600 NEW YORK FOR BENEFITS OF PUBLIC 2470 01:52:52,600 --> 01:52:54,720 HEALTH WE DESIGNED A SHOWCASE TO 2471 01:52:54,720 --> 01:52:56,920 ADDRESS THE GAP ACTIVITIES FOUND 2472 01:52:56,920 --> 01:52:58,720 IN FEDERAL LABS AND TECHNOLOGY 2473 01:52:58,720 --> 01:53:00,840 SHOWCASE PROVIDES A MENU FOR NCI 2474 01:53:00,840 --> 01:53:04,280 AND FNL TO SHOWCASE THEIR UNIQUE 2475 01:53:04,280 --> 01:53:05,840 CAPABILITIES EXPERTISE AND 2476 01:53:05,840 --> 01:53:07,640 PROMOTE INTELLECTUAL PROPERTY 2477 01:53:07,640 --> 01:53:10,160 DEVELOPED IN OUR LAB. 2478 01:53:10,160 --> 01:53:10,960 COMMERCIALIZATION AND FURTHER 2479 01:53:10,960 --> 01:53:12,760 DEVELOPMENT OF THESE 2480 01:53:12,760 --> 01:53:13,600 TECHNOLOGIES IS CRUCIAL FOR 2481 01:53:13,600 --> 01:53:15,520 MOVING THE NEEDLE FORWARD AND 2482 01:53:15,520 --> 01:53:16,840 ADVANCING CURRENT APPROACHES IN 2483 01:53:16,840 --> 01:53:19,120 CANCER RESEARCH AND TREATMENT. 2484 01:53:19,120 --> 01:53:21,120 IT IS TO RAISING THE AWARENESS 2485 01:53:21,120 --> 01:53:23,720 OF IMPORTANT RESEARCH AND 2486 01:53:23,720 --> 01:53:25,480 CAPABILITIES AT NCI AS WELL AS 2487 01:53:25,480 --> 01:53:27,600 THROUGH BRINGING TOGETHER KEY 2488 01:53:27,600 --> 01:53:29,640 PLAYERS CRUCIAL FOR THIS 2489 01:53:29,640 --> 01:53:31,360 ECOSYSTEM, THE SHOWCASE 2490 01:53:31,360 --> 01:53:33,720 ACCOMPLISHES A FEW THINGS, THESE 2491 01:53:33,720 --> 01:53:36,240 ARE IT PRESENTS THE BEST IDEAS 2492 01:53:36,240 --> 01:53:38,600 AVAILABLE FOR COLLABORATION AND 2493 01:53:38,600 --> 01:53:42,480 LICENSING. IT ATTRACTS R&D 2494 01:53:42,480 --> 01:53:44,040 RESOURCES AND COLLABORATORS AND 2495 01:53:44,040 --> 01:53:46,280 REPRESENTS THE RETURN ON PUBLIC 2496 01:53:46,280 --> 01:53:47,800 INVESTMENT. IT ALSO STIMULATES 2497 01:53:47,800 --> 01:53:50,480 AN STRENGTHENING THE DEVELOPMENT 2498 01:53:50,480 --> 01:53:52,040 AND ULTIMATELY BENEFITS THE 2499 01:53:52,040 --> 01:53:58,440 PUBLIC HEALTH. IT IS A GREAT FIT 2500 01:53:58,440 --> 01:54:01,680 WITHIN MARYLAND AND WHY DO WE 2501 01:54:01,680 --> 01:54:03,720 SAY THAT? FIRST WE ARE IN 2502 01:54:03,720 --> 01:54:05,960 MARYLAND. I GUESS WILL IS THAT 2503 01:54:05,960 --> 01:54:08,160 SLIGHT INFLUENCE. MARYLAND IS 2504 01:54:08,160 --> 01:54:09,360 ALSO A STATE WITH LARGE 2505 01:54:09,360 --> 01:54:10,960 CONCENTRATION OF MAJOR 2506 01:54:10,960 --> 01:54:12,360 GOVERNMENT FUNDED RESEARCH. IT 2507 01:54:12,360 --> 01:54:15,880 IS NUMBER ONE IN NIH R&D 2508 01:54:15,880 --> 01:54:17,800 CONTRACT AWARDS, NUMBER ONE 2509 01:54:17,800 --> 01:54:19,320 STATE SCIENCE TECHNOLOGY WORK 2510 01:54:19,320 --> 01:54:21,800 FORCE AS WELL AS PLOYED DOCTORAL 2511 01:54:21,800 --> 01:54:24,920 SCIENTISTS. MARYLAND HAS 2512 01:54:24,920 --> 01:54:26,160 CLIMBED UP THE LADDER IN LIFE 2513 01:54:26,160 --> 01:54:29,280 SCIENCES AND BIOTECH. THERE ARE 2514 01:54:29,280 --> 01:54:29,840 ABOUT 3400 LIFE SCIENCE 2515 01:54:29,840 --> 01:54:32,400 BUSINESSES IN MARYLAND. FINALLY 2516 01:54:32,400 --> 01:54:34,360 SINCE THE SHOWCASE IS NOT ONLY 2517 01:54:34,360 --> 01:54:37,840 LOCAL STATE AND REGIONAL EVENT, 2518 01:54:37,840 --> 01:54:41,600 MARYLAND VIRGINIA AND DC TRIO IS 2519 01:54:41,600 --> 01:54:43,360 NUMBER FOUR BIOHEALTH CAPITAL IN 2520 01:54:43,360 --> 01:54:45,080 THE UNITED STATES YOU CAN ASSUME 2521 01:54:45,080 --> 01:54:48,400 THAT THE BAY AREA, BOSTON NEW 2522 01:54:48,400 --> 01:54:50,840 YORK IN FRONT OF US BUT EVERYONE 2523 01:54:50,840 --> 01:54:56,360 ELSE IS BEHIND. SO TALKING ABOUT 2524 01:54:56,360 --> 01:54:58,840 -- I WANT TO ADDRESS WHY IS THIS 2525 01:54:58,840 --> 01:55:00,480 A GOOD FIT WITHIN FREDERICK 2526 01:55:00,480 --> 01:55:02,480 COUNTCOUNTY. THIS IS WHERE FREDK 2527 01:55:02,480 --> 01:55:04,320 NATIONAL LAB IS LOCATED. 2528 01:55:04,320 --> 01:55:07,880 FREDERICK NATIONAL LAB IS TOP 2529 01:55:07,880 --> 01:55:09,760 EMPLOYER FREDERICK. PREED RICK 2530 01:55:09,760 --> 01:55:11,440 COUNTY HAS HIGH CONCENTRATION OF 2531 01:55:11,440 --> 01:55:14,200 GOVERNMENT FUNDED RESEARCH, WE 2532 01:55:14,200 --> 01:55:15,760 HAVE NATIONAL LAB, NATIONAL 2533 01:55:15,760 --> 01:55:17,920 CANCER INSTITUTE, ARMY AND MANY 2534 01:55:17,920 --> 01:55:25,800 MORE PRESENT AT FORT DETREICH. 2535 01:55:25,800 --> 01:55:27,200 ELONZA, KITE AND MANY OR SETTING 2536 01:55:27,200 --> 01:55:30,040 UP R&D AND MANUFACTURING 2537 01:55:30,040 --> 01:55:32,160 HEADQUARTERS HERE. THERE IS OVER 2538 01:55:32,160 --> 01:55:33,600 100 LIFE SCIENCE COMPANIES IN 2539 01:55:33,600 --> 01:55:35,480 FREDERICK, THIS IS GROWING 2540 01:55:35,480 --> 01:55:38,280 RAPIDLY WITH THE COUNTY NUMBER 2541 01:55:38,280 --> 01:55:40,720 ONE STRATEGIC GOAL BEING LIFE 2542 01:55:40,720 --> 01:55:42,920 SCIENCE RESEARCH. THIS IS 2543 01:55:42,920 --> 01:55:44,840 PRESENTED MARYLAND AND FREDERICK 2544 01:55:44,840 --> 01:55:46,600 COUNTY ARE REASONS WHY WE 2545 01:55:46,600 --> 01:55:49,680 SUCCESSFULLY PARTNERED WITH 2546 01:55:49,680 --> 01:55:51,240 FREDERICK ECONOMIC DEVELOPMENT, 2547 01:55:51,240 --> 01:55:52,960 COUNTY, CITY AS WELL AS IF ED 2548 01:55:52,960 --> 01:55:59,800 RAIL LAB CONSORTIUM. THIS IS TO 2549 01:55:59,800 --> 01:56:03,320 SHOW IT TRULY TAKES A VILLAGE TO 2550 01:56:03,320 --> 01:56:05,640 PUT SOMETHING TOGETHER SUCH AS 2551 01:56:05,640 --> 01:56:07,640 SHOWCASE AND MAKE IT SUCCESSFUL 2552 01:56:07,640 --> 01:56:10,280 BUT PARTNERING WITH ECONOMIC 2553 01:56:10,280 --> 01:56:12,520 DEVELOPMENT THE CITY LABS AND -- 2554 01:56:12,520 --> 01:56:14,200 WE FURTHER BUILT AND STRENGTHENS 2555 01:56:14,200 --> 01:56:16,640 THOSE RELATIONSHIPS AND ABLE TO 2556 01:56:16,640 --> 01:56:18,160 LEVERAGE THEM. WE WERE ABLE TO 2557 01:56:18,160 --> 01:56:19,880 DIRECTLY REACH BIOTECH PHARMA 2558 01:56:19,880 --> 01:56:21,680 AND STARTUPS ON BOTH LOCAL AN 2559 01:56:21,680 --> 01:56:27,240 REGIONAL LEVEL. WE HAVE NETWORKS 2560 01:56:27,240 --> 01:56:30,440 BUT BY PARTNERING WE WERE ABLE 2561 01:56:30,440 --> 01:56:32,800 TO QUADRUPLE OUR CAPABILITIES 2562 01:56:32,800 --> 01:56:33,800 AND POSITION OURSELVES AS LEAD 2563 01:56:33,800 --> 01:56:37,280 FOR FEDERAL WORLD. WE E AND AND 2564 01:56:37,280 --> 01:56:39,040 STRENGTHENED OUR RELATIONSHIP 2565 01:56:39,040 --> 01:56:40,080 WITH FERAL LABS AND ACADEMIC 2566 01:56:40,080 --> 01:56:43,000 INSTITUTIONS, PROVIDING OTHER 2567 01:56:43,000 --> 01:56:44,880 BENEFITS TO NCI SUCH AS BEST 2568 01:56:44,880 --> 01:56:46,680 PRACTICES FROM OTHER FEDERAL 2569 01:56:46,680 --> 01:56:48,080 LABS, EDUCATIONAL OPPORTUNITIES 2570 01:56:48,080 --> 01:56:49,240 THROUGH PARTNERSHIP WITH 2571 01:56:49,240 --> 01:56:51,120 ACADEMIA AS WELL AS WORK FORCE 2572 01:56:51,120 --> 01:56:55,880 DEVELOPMENT. 2573 01:56:55,880 --> 01:57:00,160 >>WE WERE ABLE TO GET A WIDE 2574 01:57:00,160 --> 01:57:02,240 SWATH OF REPRESENTATION FROM THE 2575 01:57:02,240 --> 01:57:04,400 OUTSIDE COMMUNITY BY EXPANDING 2576 01:57:04,400 --> 01:57:07,560 OUR TARGET AUDIENCE. SO BY USUAL 2577 01:57:07,560 --> 01:57:11,040 SUSPECTS WHO DO WE TYPICALLY 2578 01:57:11,040 --> 01:57:14,040 PARTNER WITH AND LICENSE TO? WE 2579 01:57:14,040 --> 01:57:15,280 DO A LOT WITH PEOPLE WORKING 2580 01:57:15,280 --> 01:57:17,760 WITH US, WE CERTAINLY GET A LOT 2581 01:57:17,760 --> 01:57:20,720 OF VISITS THROUGH OUR WEBSITE 2582 01:57:20,720 --> 01:57:22,920 AND CERTAINLY OUR FACULTY IS A 2583 01:57:22,920 --> 01:57:25,240 MAJOR SOURCE OF POTENTIAL 2584 01:57:25,240 --> 01:57:27,320 LICENSEES AND PARTNERS. . WHAT 2585 01:57:27,320 --> 01:57:31,160 WE HAVE DONE IS EXPANDED TO 2586 01:57:31,160 --> 01:57:32,560 OTHER PLACES THAT WOULD BE 2587 01:57:32,560 --> 01:57:35,320 RELEVANT FOR US. THAT INCLUDES 2588 01:57:35,320 --> 01:57:36,800 NATIONAL AND INTERNATIONAL 2589 01:57:36,800 --> 01:57:38,480 COMPANIES OF ALL STAGES FROM 2590 01:57:38,480 --> 01:57:39,600 EARLY STAGE ALL WAY THROUGH 2591 01:57:39,600 --> 01:57:43,680 PUBLIC. WE LIAISON WITH 2592 01:57:43,680 --> 01:57:45,160 INVESTORS WHO BRING IN 2593 01:57:45,160 --> 01:57:47,280 TECHNOLOGIES TO START NEW 2594 01:57:47,280 --> 01:57:49,880 COMPANIES AS WELL AS THE 2595 01:57:49,880 --> 01:57:51,240 ENTREPRENEURS WHO START THOSE 2596 01:57:51,240 --> 01:57:54,120 COMPANIES WITH THE INVESTORS. WE 2597 01:57:54,120 --> 01:57:57,800 WORK WITH TECH SCOUTS, TYPICALLY 2598 01:57:57,800 --> 01:57:58,440 SMALL BOUTIQUE FIRMS THAT HUNT 2599 01:57:58,440 --> 01:58:00,720 FOR EXCITING TECHNOLOGIES, HALF 2600 01:58:00,720 --> 01:58:03,200 OF USUALLY LARGE FAR MASS OR 2601 01:58:03,200 --> 01:58:05,960 BIOPHARMAS. THEY ARE DIRECT 2602 01:58:05,960 --> 01:58:07,400 POTENTIAL PARTNERS AFTER WE 2603 01:58:07,400 --> 01:58:09,080 CREATE AWARENESS. WE HAVE GONE 2604 01:58:09,080 --> 01:58:11,200 BEYOND THAT TO WORK WITH TRADE 2605 01:58:11,200 --> 01:58:12,440 ASSOCIATIONS, ECONOMIC 2606 01:58:12,440 --> 01:58:14,000 DEVELOPMENT ENTITIES, 2607 01:58:14,000 --> 01:58:15,760 FOUNDATIONS AND PHILANTHROPIES 2608 01:58:15,760 --> 01:58:17,840 AND SERVICE PROVIDERS, LAW FIRMS 2609 01:58:17,840 --> 01:58:20,400 CONSULTING FIRMS, REGULATORY 2610 01:58:20,400 --> 01:58:22,840 FIRMS. THEY CAN PROVIDE 2611 01:58:22,840 --> 01:58:24,080 REFERRALS TO COMPANIES THAT WE 2612 01:58:24,080 --> 01:58:27,040 MIGHT BE ABLE TO WORK WITH. ONCE 2613 01:58:27,040 --> 01:58:31,200 WE CREATE THAT AWARENESS. SO 2614 01:58:31,200 --> 01:58:34,160 BASED ON 2022 THIS GIVES A 2615 01:58:34,160 --> 01:58:37,360 LITTLE BREAK DOWN WHO ATTENDED. 2616 01:58:37,360 --> 01:58:40,480 ABOUT HALF WERE FROM NIH AND 2617 01:58:40,480 --> 01:58:43,320 THAT IS IN SOME PART BECAUSE WE 2618 01:58:43,320 --> 01:58:46,240 HAVE SO MANY PARTICIPANTS ON 2619 01:58:46,240 --> 01:58:48,360 ACTIVITIES, PIs, THE TECH 2620 01:58:48,360 --> 01:58:49,840 TRANSFER AMBASSADORS ET CETERA 2621 01:58:49,840 --> 01:58:52,680 SO THAT MAKES UP A GOOD COHORT. 2622 01:58:52,680 --> 01:58:56,880 WE HAVE HAD 26% COMPANIES, I 2623 01:58:56,880 --> 01:58:58,480 WOULD ADD MOUSES 10% AND OTHER 2624 01:58:58,480 --> 01:59:01,680 CATEGORY BECAUSE MOST OF THESE 2625 01:59:01,680 --> 01:59:03,320 WERE INDIVIDUALS WHO REGISTERED 2626 01:59:03,320 --> 01:59:05,240 USING THEIR PERSONAL ADDRESS AND 2627 01:59:05,240 --> 01:59:06,680 WE FIND THAT THE VAST MAJORITY 2628 01:59:06,680 --> 01:59:09,760 OF THEM ACTUALLY REPRESENT 2629 01:59:09,760 --> 01:59:11,640 COMPANIES THAT ARE IN STEALTH 2630 01:59:11,640 --> 01:59:12,640 MODE AND DON'T WANT TO REVEAL 2631 01:59:12,640 --> 01:59:19,800 WHO THEY ARE. SO THE NUMBER IS 2632 01:59:19,800 --> 01:59:22,040 CLOSER TO 30 TO 35%. WE HAVE 2633 01:59:22,040 --> 01:59:23,240 UNIVERSITIES ATTEND ESPECIALLY 2634 01:59:23,240 --> 01:59:25,440 TO THE FREDERICK REGIONFUL WE 2635 01:59:25,440 --> 01:59:26,320 GET ECONOMIC DEVELOPMENT 2636 01:59:26,320 --> 01:59:28,120 ENTITIES AS WELL AS FOUNDATIONS 2637 01:59:28,120 --> 01:59:29,400 ACCELERATORS AS WELL AS 2638 01:59:29,400 --> 01:59:35,320 INVESTORS. TO DO THAT, WE 2639 01:59:35,320 --> 01:59:39,560 CREATED A INTERNATIONAL NETWORK. 2640 01:59:39,560 --> 01:59:40,920 THIS MAP REPRESENTS NOT JUST 2641 01:59:40,920 --> 01:59:43,560 FOLKS WE HAD RANDOM PHONE CALL 2642 01:59:43,560 --> 01:59:45,520 WITH, THEY REPRESENT FOLKS THAT 2643 01:59:45,520 --> 01:59:50,640 ACTIVELY HELPED US MARKET THE 2644 01:59:50,640 --> 01:59:59,520 EVENT GET OUT SO WE HAVE -- WE 2645 01:59:59,520 --> 02:00:00,840 LIAISON WITH THESE INSTITUTIONS 2646 02:00:00,840 --> 02:00:05,880 AND INTI FEWS TO INDICATE THE 2647 02:00:05,880 --> 02:00:07,080 OPPORTUNITIES TO PRESENT GLOBAL 2648 02:00:07,080 --> 02:00:09,960 HEALTH AROUND THE WORL WORLD. TS 2649 02:00:09,960 --> 02:00:13,960 EVENT ALSO HAPPENS TO SERVE AN 2650 02:00:13,960 --> 02:00:15,640 IMPORTANT PURPOSE ABOUT 2651 02:00:15,640 --> 02:00:16,280 ADDRESSING SOME OF THE COMMON 2652 02:00:16,280 --> 02:00:17,160 MYTHS ABOUT THE NATIONAL 2653 02:00:17,160 --> 02:00:20,120 INSTITUTES OF HEALTH. MY TENURE 2654 02:00:20,120 --> 02:00:22,880 AT NCI HAD 20 YEARS IN BETWEEN 2655 02:00:22,880 --> 02:00:26,400 MY TWO STOPS. AND LEARNING FROM 2656 02:00:26,400 --> 02:00:27,400 THE OUTSIDE WORLD ABOUT WHAT 2657 02:00:27,400 --> 02:00:30,280 PEOPLE DO AND DO NOT UNDERSTAND 2658 02:00:30,280 --> 02:00:33,640 ABOUT THE NIH. UNFORTUNATELY, 2659 02:00:33,640 --> 02:00:35,640 AND SOMETHING THAT VLAD AND TEAM 2660 02:00:35,640 --> 02:00:37,640 ARE ADDRESSING IS COMMON THOUGHT 2661 02:00:37,640 --> 02:00:40,400 ON THE PART OF POTENTIAL 2662 02:00:40,400 --> 02:00:41,960 LICENSEES AND PARTNERS WE ONLY 2663 02:00:41,960 --> 02:00:43,120 DO BASIC RESEARCH. CERTAINLY 2664 02:00:43,120 --> 02:00:45,760 THAT IS A MAJOR FOCUS ON OURS, 2665 02:00:45,760 --> 02:00:48,440 HOWEVER, WE DO TRANSLATIONAL AND 2666 02:00:48,440 --> 02:00:53,520 CLINICAL WORK AS WELL. THERE IS 2667 02:00:53,520 --> 02:00:55,160 A WIDE MISUNDERSTANDING WE 2668 02:00:55,160 --> 02:00:57,520 SOLELY WORK WITH ACADEMIA AND 2669 02:00:57,520 --> 02:00:59,200 PROVIDE ACADEMIC FUNDING. SO WE 2670 02:00:59,200 --> 02:01:01,880 TELL THEM URN CURRENTLY WE HAVE 2671 02:01:01,880 --> 02:01:03,560 HUNDREDS OF LICENSING AND 2672 02:01:03,560 --> 02:01:04,800 PARTNERSHIPS WITH SRI AND WE 2673 02:01:04,800 --> 02:01:06,360 WOULD LOVE TO TALK WITH THEM 2674 02:01:06,360 --> 02:01:09,320 ABOUT JOINING THAT GROUP. WE 2675 02:01:09,320 --> 02:01:11,000 DON'T JUST WORK IN THE U.S., 2676 02:01:11,000 --> 02:01:13,880 YES, WE ARE FOCUSED ON 2677 02:01:13,880 --> 02:01:15,200 FACILITATING ECONOMIC 2678 02:01:15,200 --> 02:01:17,480 DEVELOPMENT IN THE U.S. BUT WE 2679 02:01:17,480 --> 02:01:18,920 CAN MARINER INTERNATIONALLY TO 2680 02:01:18,920 --> 02:01:22,360 ADDRESS GLOBAL HEALTH CONCERNS. 2681 02:01:22,360 --> 02:01:24,440 SPARSE OUR IP DOCKET IS 2682 02:01:24,440 --> 02:01:26,960 CONCERNED, YES, MAJORITY ARE 2683 02:01:26,960 --> 02:01:28,160 UNDER THE CATEGORY OF 2684 02:01:28,160 --> 02:01:30,920 THERAPEUTICS. BUT WE ALSO HAVE 2685 02:01:30,920 --> 02:01:33,280 DEVICE, DIAGNOSTICS, BIOMARKERS 2686 02:01:33,280 --> 02:01:35,640 AND MORE AND WE ALSO DO RESEARCH 2687 02:01:35,640 --> 02:01:37,640 IN PREVENTION CONTROL AND CAUSES 2688 02:01:37,640 --> 02:01:46,600 OF DISEASES AN DISORDERS. THINGS 2689 02:01:46,600 --> 02:01:48,800 BROUGHT THE TO MARKET AND 2690 02:01:48,800 --> 02:01:50,160 PATIENT DON'T SOLELY GO TO NCI 2691 02:01:50,160 --> 02:01:52,360 AND FNL. COMPANIES BRING IDEAS 2692 02:01:52,360 --> 02:01:54,240 TO US AND WE CAN CO-DEVELOP 2693 02:01:54,240 --> 02:01:57,960 TOGETHER. VLAD. 2694 02:01:57,960 --> 02:01:58,960 >>THANK YOU, SO SWITCHING A 2695 02:01:58,960 --> 02:02:01,760 LITTLE BIT TO AGENDA AND 2696 02:02:01,760 --> 02:02:02,480 FEATURES OF THE ACTUAL TECH 2697 02:02:02,480 --> 02:02:06,600 SHOWCASE WHAT IS A TYPICAL 2698 02:02:06,600 --> 02:02:08,840 AGENDA AT A TECH SHOW LOOK LIKE 2699 02:02:08,840 --> 02:02:11,920 WE START OFF WITH A KEYNOTE BUT 2700 02:02:11,920 --> 02:02:13,440 NOT ANY KEYNOTE. WE HAVE BEEN 2701 02:02:13,440 --> 02:02:15,040 TRULY FORTUNATE TO HAVE 2702 02:02:15,040 --> 02:02:17,120 REMARKABLE AND INFLUENTIAL KEY 2703 02:02:17,120 --> 02:02:18,280 NOTES AT EVERY EVENT SINCE 2704 02:02:18,280 --> 02:02:20,720 INCEPTION. JUST NAME A FEW WE 2705 02:02:20,720 --> 02:02:23,480 HAD NCI DIRECTOR DR. LOWY AND 2706 02:02:23,480 --> 02:02:26,560 DR. SHARPLESS, WE HAD PHARMA 2707 02:02:26,560 --> 02:02:28,480 EXECUTIVES DR. JIM CHERRY FROM 2708 02:02:28,480 --> 02:02:30,160 NCI, MD MARYLAND COMMERCE 2709 02:02:30,160 --> 02:02:32,000 SECRETARY KELLY SCHULTZ AND VIA 2710 02:02:32,000 --> 02:02:35,760 HEALTH INNOVATIONS RICH MAENADES 2711 02:02:35,760 --> 02:02:37,400 AND OTHERS AS WELL. THOUGH 2712 02:02:37,400 --> 02:02:39,280 THECAL BAR OF KEYNOTE COULD BE 2713 02:02:39,280 --> 02:02:40,800 EVENT ITSELF BUT WE ADDED MORE 2714 02:02:40,800 --> 02:02:42,720 THAT THAT, WE ORGANIZED PANELS, 2715 02:02:42,720 --> 02:02:44,040 THESE ARE PANELS THAT ADDRESS 2716 02:02:44,040 --> 02:02:49,080 SOME OF THE KEY QUESTIONS, HOW 2717 02:02:49,080 --> 02:02:51,760 TO WORK WITH FNL AND NCI, WHAT 2718 02:02:51,760 --> 02:02:54,080 ARE DIFFERENCES BETWEEN 2719 02:02:54,080 --> 02:02:56,600 GOVERNMENT AND NON-FUNDING, AND 2720 02:02:56,600 --> 02:02:57,720 RESOURCES FOR START YOU WERES, 2721 02:02:57,720 --> 02:03:01,280 SO ON. WE HAVE PE PRESENTATIONS, 2722 02:03:01,280 --> 02:03:02,560 THIS IS SHOWCASE PART OF THE 2723 02:03:02,560 --> 02:03:05,840 TECH SHOWCASE. WE PRESENT AND 2724 02:03:05,840 --> 02:03:07,080 WE ADVERTISE THESE TECHNOLOGIES 2725 02:03:07,080 --> 02:03:10,320 THAT ARE AVAILABLE FOR LICENSING 2726 02:03:10,320 --> 02:03:12,120 OR FOR COMMERCIALIZATION OR 2727 02:03:12,120 --> 02:03:15,640 COLLABORATION. WE WILL COVER 2728 02:03:15,640 --> 02:03:16,960 MORE SEPARATE SLIDE AS FAR AS 2729 02:03:16,960 --> 02:03:18,560 WHAT WE EXPECT FROM PIs WHEN 2730 02:03:18,560 --> 02:03:22,280 THEY PRESENT. IS WE HAVE 2731 02:03:22,280 --> 02:03:23,920 PROGRAMMATIC PRESENTATIONS. WE 2732 02:03:23,920 --> 02:03:27,040 HAVE VOICE OF PATIENT, NCI 2733 02:03:27,040 --> 02:03:29,040 PROGRAM WE MENTIONED, TALKS 2734 02:03:29,040 --> 02:03:30,920 ABOUT AND DEALS WITH NEXT 2735 02:03:30,920 --> 02:03:31,920 GENERATION TRAINING AND 2736 02:03:31,920 --> 02:03:38,920 NETWORKING. SOME OF THE BENEFITS 2737 02:03:38,920 --> 02:03:41,000 THAT ARE SPECIFIC FOR NATIONAL 2738 02:03:41,000 --> 02:03:42,080 LAB COME THROUGH AN OPPORTUNITY 2739 02:03:42,080 --> 02:03:44,560 TO COMMUNICATE TO SPECIFIC 2740 02:03:44,560 --> 02:03:46,000 RELEVANT AUDIENCE. ON THINGS 2741 02:03:46,000 --> 02:03:47,920 LIKE HOW TO WORK WITH THE 2742 02:03:47,920 --> 02:03:49,720 NATIONAL LAB. WHAT IS NATIONAL 2743 02:03:49,720 --> 02:03:51,120 LAB MEAN? WHAT KIND OF 2744 02:03:51,120 --> 02:03:52,400 PARTNERSHIPS AND COLLABORATIONS 2745 02:03:52,400 --> 02:03:54,440 ARE AVAILABLE AND HOW TO 2746 02:03:54,440 --> 02:03:56,280 ESTABLISH THOSE HOW TO APPROACH 2747 02:03:56,280 --> 02:03:58,640 NATIONAL LAB. WE TALK ABOUT 2748 02:03:58,640 --> 02:04:01,800 UNIQUE PROGRAMS AN CAPABILITIES 2749 02:04:01,800 --> 02:04:04,720 AVAILABLE FOR COLLABORATION AND 2750 02:04:04,720 --> 02:04:06,160 RESEARCH SUPPORT. PROGRAMS LIKE 2751 02:04:06,160 --> 02:04:07,960 RAS PROGRAM, CHARACTERIZATION 2752 02:04:07,960 --> 02:04:11,480 LAB, CAPER 2753 02:04:11,480 --> 02:04:13,320 CRYOELECTROMICROSCOPY. FINALLY 2754 02:04:13,320 --> 02:04:14,560 WE INFORM THE RESEARCH COMMUNITY 2755 02:04:14,560 --> 02:04:18,640 OF UNIQUE SERVICES WE PROVIDE. 2756 02:04:18,640 --> 02:04:21,360 ONLY FOUND IN FNL. THESE ARE 2757 02:04:21,360 --> 02:04:23,640 SERVICES OFFERED FOR TECHNICAL 2758 02:04:23,640 --> 02:04:25,080 SERVICE AGREEMENT AND NEEDD BY 2759 02:04:25,080 --> 02:04:26,360 COMMUNITY BUT ONLY BE FOUND AT 2760 02:04:26,360 --> 02:04:31,080 NATIONAL LAB. THIS IS WHY WE 2761 02:04:31,080 --> 02:04:34,600 OFFER THEM. SO I TALKED ABOUT 2762 02:04:34,600 --> 02:04:38,040 EDUCATING FNL AND NCI SCIENTIST 2763 02:04:38,040 --> 02:04:38,640 AND (INAUDIBLE) PRESENTATIONS 2764 02:04:38,640 --> 02:04:40,760 THIS IS THE EDUCATION AND HOW TO 2765 02:04:40,760 --> 02:04:42,200 COMMUNICATE WITH INDUSTRY AND 2766 02:04:42,200 --> 02:04:46,000 MARKET THEIR INNOVATION. MOST 2767 02:04:46,000 --> 02:04:47,480 SCIENTISTS LOVE TO TALK ABOUT 2768 02:04:47,480 --> 02:04:50,440 SCIENCE AND GO MANY, MANY SLIDES 2769 02:04:50,440 --> 02:04:52,200 OF SCIENCE BUT THIS IS A 2770 02:04:52,200 --> 02:04:54,000 DIFFERENT TYPE OF PRESENTATION. 2771 02:04:54,000 --> 02:04:56,640 WE LIMIT THEM TO TEN MINUTE 2772 02:04:56,640 --> 02:04:58,960 PRESENTATION, WE PROVIDE THEM 2773 02:04:58,960 --> 02:05:00,200 WITH TEMPLATES, AND THE 2774 02:05:00,200 --> 02:05:02,480 PRESENTATIONS ARE USUALLY ABOUT 2775 02:05:02,480 --> 02:05:03,920 EIGHT TO 12 SLIDES THAT INCLUDE 2776 02:05:03,920 --> 02:05:06,360 BASE CASE. SO THE TYPICAL -- 2777 02:05:06,360 --> 02:05:08,000 BUSINESS CASE. IT WILL HAVE 2778 02:05:08,000 --> 02:05:09,600 EXECUTIVE SUMMARY, STATE WHAT 2779 02:05:09,600 --> 02:05:13,040 THE PROBLEM IS, WE TRYING TO 2780 02:05:13,040 --> 02:05:13,920 ADDRESS, WHAT ARE CURRENT 2781 02:05:13,920 --> 02:05:16,960 SOLUTIONS OUT IN THE MARKET? AND 2782 02:05:16,960 --> 02:05:18,640 HOW DOES SOLUTION THEY ARE 2783 02:05:18,640 --> 02:05:19,960 PROPOSING IS DIFFERENT HOW IS IT 2784 02:05:19,960 --> 02:05:20,840 DIFFERENT FROM P THE ONES THAT 2785 02:05:20,840 --> 02:05:24,080 ARE OUT THERE. WE TALK ABOUT 2786 02:05:24,080 --> 02:05:25,520 BACKGROUND AND WE GIVE THEM FEW 2787 02:05:25,520 --> 02:05:27,000 SLIDES TO TALK ABOUT IT, 2788 02:05:27,000 --> 02:05:29,520 TECHNOLOGY AND SCIENCE. AND THEN 2789 02:05:29,520 --> 02:05:32,840 WE ALSO HELP THEM TALK ABOUT 2790 02:05:32,840 --> 02:05:33,640 ADDRESSABLE MARKETS AND 2791 02:05:33,640 --> 02:05:34,440 OPPORTUNITIES AND COMPETITIVE 2792 02:05:34,440 --> 02:05:38,520 ANALYSIS. THEY PROVIDE SUMMARY 2793 02:05:38,520 --> 02:05:40,480 AT END WITH CLEAR INDICATION WHO 2794 02:05:40,480 --> 02:05:41,760 LICENSING AND PARTNERING POINTS 2795 02:05:41,760 --> 02:05:45,920 OF CONTACTS ARE. IS 2796 02:05:45,920 --> 02:05:48,600 >>THANK YOU, VLAD. ALSO WANT 2797 02:05:48,600 --> 02:05:50,360 TO MENTION PIG BY BACKING ON 2798 02:05:50,360 --> 02:05:53,560 COMMENT ABOUT TEN MINUTES FOR 2799 02:05:53,560 --> 02:05:55,560 SPEAKERS, BOTH VLAD AND I ARE 2800 02:05:55,560 --> 02:05:58,440 RECOVERING SCIENTISTS AND WE 2801 02:05:58,440 --> 02:05:59,920 KNOW THAT IT IS COMMON TO RUN 2802 02:05:59,920 --> 02:06:03,440 OVER IN TIME AND ONE OF THE MANY 2803 02:06:03,440 --> 02:06:05,320 COMPLIMENTS AND ONE COMMON 2804 02:06:05,320 --> 02:06:06,520 COMPLIMENT WE GET AFTER THE 2805 02:06:06,520 --> 02:06:09,520 EVENT IS PEOPLE SAYING WOW, YOU 2806 02:06:09,520 --> 02:06:12,160 FINISHED ON TIME. SO TO HAVE 2807 02:06:12,160 --> 02:06:13,520 FIVE AND A HALF HOUR EVEN WITH 2808 02:06:13,520 --> 02:06:16,160 NO FEWER THAN 20 SCIENTISTS 2809 02:06:16,160 --> 02:06:19,240 SPEAKING AND PRETTY MUCH ON TIME 2810 02:06:19,240 --> 02:06:20,960 IS A GREAT EFFORT IN IN AND OF 2811 02:06:20,960 --> 02:06:23,600 ITSELF. WHAT DOES THIS MEAN BY 2812 02:06:23,600 --> 02:06:27,000 THE BUSINESS CASE? I START OFF 2813 02:06:27,000 --> 02:06:29,400 WITH SOMETHING THAT IS SORT OF A 2814 02:06:29,400 --> 02:06:30,720 FACTOID COMMONLY GIVEN OUT AND 2815 02:06:30,720 --> 02:06:34,960 THE EXAMPLE THE CASE I WILL GIVE 2816 02:06:34,960 --> 02:06:36,760 IS ANTIBODY DRUG CONJUGATE 2817 02:06:36,760 --> 02:06:38,200 TECHNOLOGY OF BLACKS AND 2818 02:06:38,200 --> 02:06:40,720 COUNTRIES LAB AT FNL FOR NEURAL 2819 02:06:40,720 --> 02:06:44,560 BLASTOMA, TYPICALLY THAT STARTS 2820 02:06:44,560 --> 02:06:46,120 AS FAR AS MARKET BEHIND SIMPLY 2821 02:06:46,120 --> 02:06:48,480 SAYING A $10 BILLION MARKET. THE 2822 02:06:48,480 --> 02:06:50,360 AUDIENCE WHICH ARE GOING TO BE 2823 02:06:50,360 --> 02:06:52,160 INVESTORS ENTREPRENEURS AND 2824 02:06:52,160 --> 02:06:56,160 COMPANIES IN THE CANCER SPACE, 2825 02:06:56,160 --> 02:06:57,920 KNOW CANCER IS A BIG MARKET, 2826 02:06:57,920 --> 02:07:00,000 THERE IS A HUGE SIGNIFICANT 2827 02:07:00,000 --> 02:07:02,840 UNMET MEDICAL NEED. A GREAT 2828 02:07:02,840 --> 02:07:07,400 FINANCIAL OPPORTUNITY AS WELL. 2829 02:07:07,400 --> 02:07:09,400 WE GO BEYOND THAT, THIS IS AN 2830 02:07:09,400 --> 02:07:13,360 EXAMPLE FROM DR. ST. CROIX'S 2831 02:07:13,360 --> 02:07:15,120 PRESENTATION, MY UNIT AND VLAD'S 2832 02:07:15,120 --> 02:07:16,640 GROUP HELPED PI WITH BECAUSE IT 2833 02:07:16,640 --> 02:07:19,040 IS NOT THEIR STRENGTH. THIS 2834 02:07:19,040 --> 02:07:19,800 GIVES THE DRUG MARKET LANDSCAPE, 2835 02:07:19,800 --> 02:07:21,320 AN EXAMPLE OF WHAT WAS PRESENTED 2836 02:07:21,320 --> 02:07:24,120 AT THE TECH SHOWCASE. THAT SHOWS 2837 02:07:24,120 --> 02:07:26,920 THE DIFFERENT PHASES OF 2838 02:07:26,920 --> 02:07:28,160 DIFFERENT TREATMENTS FOR 2839 02:07:28,160 --> 02:07:30,920 NEUROBLASTOMA. INDICATES WHICH 2840 02:07:30,920 --> 02:07:33,680 ARE THE TOP TEN TARGETS BY DRUGS 2841 02:07:33,680 --> 02:07:38,320 AS WELL AS THE MOLECULE TYPES. 2842 02:07:38,320 --> 02:07:41,720 IN THE BOTTOM RIGHT ANTIBODIES 2843 02:07:41,720 --> 02:07:43,080 BEING QUITE HIGH THAT INDICATES 2844 02:07:43,080 --> 02:07:45,440 TO THE AUDIENCE A GREAT APPETITE 2845 02:07:45,440 --> 02:07:46,880 MANY THE MARKET AND FROM THE 2846 02:07:46,880 --> 02:07:50,520 PATIENT FOR THIS TYPE OF 2847 02:07:50,520 --> 02:07:52,720 APPROACH. INSTEAD OF RAP 2848 02:07:52,720 --> 02:07:53,560 DOCUMENT FACT HOW MUCH IT IS 2849 02:07:53,560 --> 02:07:55,560 GROWING FROM ONE YEAR TO 2850 02:07:55,560 --> 02:07:56,840 ANOTHER, WE SHOW THEM FOR 2851 02:07:56,840 --> 02:07:59,600 EXAMPLE FOR BRAIN TUMOR, WHICH 2852 02:07:59,600 --> 02:08:01,040 NEUROBLASTOMA IS A PART, THAT 2853 02:08:01,040 --> 02:08:05,440 THERE IS A GROWING SIGNIFICANT 2854 02:08:05,440 --> 02:08:09,560 UNMET MEDICAL NEED FOR THIS. WE 2855 02:08:09,560 --> 02:08:12,280 THEN GO ON, THIS IS AN ACTUAL 2856 02:08:12,280 --> 02:08:13,320 SLIDE PRESENTED FROM THE 2857 02:08:13,320 --> 02:08:15,960 ANTIBODY DRUG CONJUGATE MARKET 2858 02:08:15,960 --> 02:08:16,640 LANDSCAPE, THE MARKET 2859 02:08:16,640 --> 02:08:20,040 OPPORTUNITY IS THAT SIX ARE FDA 2860 02:08:20,040 --> 02:08:23,480 APPROVED SO THE GOOD NEWS IS 2861 02:08:23,480 --> 02:08:27,080 THAT FDA HAS SEEN THIS 2862 02:08:27,080 --> 02:08:29,280 TECHNOLOGY BEFORE, THERE IS A 2863 02:08:29,280 --> 02:08:33,560 PATH, REGULATORY PATH THAT CAN 2864 02:08:33,560 --> 02:08:35,480 BE MIMICKED OR SHADOWED BUT 2865 02:08:35,480 --> 02:08:37,440 THERE IS ONLY SIX SO LOTS OF 2866 02:08:37,440 --> 02:08:39,960 OPPORTUNITIES STILL OUT THERE. 2867 02:08:39,960 --> 02:08:41,040 MOST MANUFACTURING IS 2868 02:08:41,040 --> 02:08:42,800 OUTSOURCED. THAT IS IMPORTANT 2869 02:08:42,800 --> 02:08:45,600 BECAUSE THIS APPEARS TO BE 2870 02:08:45,600 --> 02:08:48,640 TECHNOLOGY THAT IS COMPARATIVELY 2871 02:08:48,640 --> 02:08:50,600 EASILY MANUFACTURED SEW IT IS A 2872 02:08:50,600 --> 02:08:52,840 STRONG MARKET FOR THOSE WHO HAVE 2873 02:08:52,840 --> 02:08:54,480 OVER -- WHOSE TECHNOLOGY HAS 2874 02:08:54,480 --> 02:08:55,440 OVERCOME THOSE MANUFACTURING 2875 02:08:55,440 --> 02:08:59,040 CHALLENGES. WE TALK ABOUT 2876 02:08:59,040 --> 02:09:00,680 ADVANTAGES VERSUS OTHER THINGS 2877 02:09:00,680 --> 02:09:03,680 AND PRE-CLINICAL, CLINICAL 2878 02:09:03,680 --> 02:09:06,440 DEVELOPMENT AND IN GENERAL HAVE 2879 02:09:06,440 --> 02:09:07,960 ADVANTAGES SHOWN HERE ENHANCED 2880 02:09:07,960 --> 02:09:09,560 EFFICACY, THEY ARE NOT 2881 02:09:09,560 --> 02:09:13,640 IMMUNOGENIC AND THAT THERE IS A 2882 02:09:13,640 --> 02:09:16,320 BYSTANDER KILLING. IT INDICATES 2883 02:09:16,320 --> 02:09:18,320 IT CAN ABLATE TUMOR CELLS AND 2884 02:09:18,320 --> 02:09:20,640 TUMOR ASSOCIATED STROMA. THAT 2885 02:09:20,640 --> 02:09:21,760 THE CLINICAL TRIAL THOUGH 2886 02:09:21,760 --> 02:09:24,960 INITIALLY FOR A RARE DISEASE, 2887 02:09:24,960 --> 02:09:26,640 NEUROBLASTOMA, CAN OPEN THE DOOR 2888 02:09:26,640 --> 02:09:29,680 FOR BOTH OFF LABEL USE AS WELL 2889 02:09:29,680 --> 02:09:31,640 AS USE IN OTHER SOLID TUMORS 2890 02:09:31,640 --> 02:09:32,960 THAT COMPANIES FEEL ARE LARGER 2891 02:09:32,960 --> 02:09:37,920 MARKET. THIS IS SOMETHING 2892 02:09:37,920 --> 02:09:39,400 SIMPLE, VERY KEY AND 2893 02:09:39,400 --> 02:09:41,880 UNFORTUNATELY IS NOT OFTEN DONE 2894 02:09:41,880 --> 02:09:44,400 IS TYING TECHNOLOGY PRESENTATION 2895 02:09:44,400 --> 02:09:47,800 WHETHER HERE OR ACR ASCO TO THE 2896 02:09:47,800 --> 02:09:48,720 OPPORTUNITIES SO AFTER TALKING 2897 02:09:48,720 --> 02:09:51,320 ABOUT THEIR EXCITING WORK TIMMY 2898 02:09:51,320 --> 02:09:53,840 SAY IF YOU THINK THIS WORK IS 2899 02:09:53,840 --> 02:09:55,160 COMPELLING TO YOU, YOU CAN WORK 2900 02:09:55,160 --> 02:09:58,440 WITH IT. AND WORK WITH ME. OR 2901 02:09:58,440 --> 02:10:00,320 YOU CAN LICENSE IT AND SO THAT 2902 02:10:00,320 --> 02:10:02,440 IS WHAT WE DO HERE, WE TELL THEM 2903 02:10:02,440 --> 02:10:04,400 THE PATENT STATUS OF THE 2904 02:10:04,400 --> 02:10:07,920 TECHNOLOGY, WHERE IT IS FILED, 2905 02:10:07,920 --> 02:10:10,040 WE INCLUDE THE E NUMBERS, THE 2906 02:10:10,040 --> 02:10:11,560 EMPLOYEE INVENTION REPORT 2907 02:10:11,560 --> 02:10:13,640 NUMBERS TO EASILY LOOK UP THE 2908 02:10:13,640 --> 02:10:17,160 ABSTRACT ON OUR WEBSITE. WE 2909 02:10:17,160 --> 02:10:19,080 PROVIDE DIRECT INFORMATION TO 2910 02:10:19,080 --> 02:10:20,400 CONTACT THE INVENTOR IF THEY 2911 02:10:20,400 --> 02:10:23,560 HAVE TECHNICAL QUESTIONS AND AS 2912 02:10:23,560 --> 02:10:24,280 IMPORTANTLY, DIRECT CONTACT 2913 02:10:24,280 --> 02:10:26,160 INFORMATION FOR THE TECH 2914 02:10:26,160 --> 02:10:28,520 TRANSFER MANAGER WHO IS 2915 02:10:28,520 --> 02:10:32,200 RESPONSIBLE FOR THAT INVENTER 2916 02:10:32,200 --> 02:10:37,080 AND THAT INVENGES. I ALSO WANT 2917 02:10:37,080 --> 02:10:41,280 TO MENTION IT IS A COMPLEX 2918 02:10:41,280 --> 02:10:44,600 EVENT. THE AV EVENT STAFF AT FNL 2919 02:10:44,600 --> 02:10:47,480 CALLED IT HAIR MOST COMPLEX 2920 02:10:47,480 --> 02:10:49,360 EVENT YET. BEPULL IT OFF WITH A 2921 02:10:49,360 --> 02:10:53,200 CORE GROUP OF FIVE PEOPLE, THREE 2922 02:10:53,200 --> 02:10:55,800 FROM VLAD'S TEAM, MYSELF AND 2923 02:10:55,800 --> 02:10:57,920 MICHELLE NEWTON. THERE'S 2924 02:10:57,920 --> 02:10:59,440 CERTAINLY OTHERS INVOLVED BUT AS 2925 02:10:59,440 --> 02:11:01,200 FAR AS THE CORE, THAT IS WHO IS 2926 02:11:01,200 --> 02:11:03,000 DOING A GOOD AMOUNT OF HEAVY 2927 02:11:03,000 --> 02:11:05,320 LIFTING. THAT IS FOR 45 SPEAKERS 2928 02:11:05,320 --> 02:11:08,160 NOT JUST FROM US, BUT EXTERNAL 2929 02:11:08,160 --> 02:11:11,800 ORGANIZES TO IMPLANTING 2930 02:11:11,800 --> 02:11:13,040 MEETINGS, ET CETERA, BOTH SIDES 2931 02:11:13,040 --> 02:11:14,400 CONTRIBUTE TO HAVING IT 2932 02:11:14,400 --> 02:11:16,520 ANNOUNCED FROM THEIR WEBSITE, 2933 02:11:16,520 --> 02:11:18,320 MARKETING THE EVENT AND ALSO 2934 02:11:18,320 --> 02:11:21,920 DOING SOCIAL MEDIA, POPULATING 2935 02:11:21,920 --> 02:11:23,840 AND REHEARSING THE CONCURRENT 2936 02:11:23,840 --> 02:11:26,480 PANELS THAT VLAD TOUCHED ON, WE 2937 02:11:26,480 --> 02:11:28,560 ALSO HAVE STAKEHOLDER TABLES. 2938 02:11:28,560 --> 02:11:32,760 THESE ARE NOT VENDOR TABLES. AS 2939 02:11:32,760 --> 02:11:36,600 APPEARS RESEARCH FESTIVAL. THESE 2940 02:11:36,600 --> 02:11:39,520 ARE UNIVERSITIES LIKE COLLEGE 2941 02:11:39,520 --> 02:11:42,560 MOUNT SATE MARRIES IN THE AREA, 2942 02:11:42,560 --> 02:11:45,520 ALSO -- SAINT MARY'S. FNLCR HAS 2943 02:11:45,520 --> 02:11:47,440 A TABLE. TECH TRANSFER HAS A 2944 02:11:47,440 --> 02:11:50,960 TABLE SO PEOPLE LEARN MORE ABOUT 2945 02:11:50,960 --> 02:11:52,320 WHAT GOES INTO LICENSING FROM US 2946 02:11:52,320 --> 02:11:57,520 AND PARTNERING WITH US. 2947 02:11:57,520 --> 02:11:59,040 EXECUTED WITHOUT BUDGET. THE 2948 02:11:59,040 --> 02:12:02,040 MAIN COST EVERY YEAR HAS BEEN 2949 02:12:02,040 --> 02:12:04,280 LESS THAN $500. WE CONTRIBUTE 2950 02:12:04,280 --> 02:12:05,760 OUR TIME. IT IS IMPORTANT TO 2951 02:12:05,760 --> 02:12:07,520 MENTION THAT ALL THE MARKETING 2952 02:12:07,520 --> 02:12:10,920 MATERIALS THAT ARE PREPARED AND 2953 02:12:10,920 --> 02:12:13,040 SENT OUT, IT IS NOT OUTSOURCED 2954 02:12:13,040 --> 02:12:15,600 TO A CONTRACTOR, IT IS ALL DONE 2955 02:12:15,600 --> 02:12:19,320 BY VLAD'S PDO AND THE NCI TECH 2956 02:12:19,320 --> 02:12:26,480 TRANSFER CENTE CENTER. FORTUNATO 2957 02:12:26,480 --> 02:12:29,240 WORK WITH FNL FABULOUS AV AND 2958 02:12:29,240 --> 02:12:30,720 EVENT STAFF AND GET TO USE THE 2959 02:12:30,720 --> 02:12:33,920 FACILITY AT ATRF AND CO-SPONSORS 2960 02:12:33,920 --> 02:12:35,360 KEEP PEOPLE FED AND WATERED 2961 02:12:35,360 --> 02:12:40,360 DURING THE AFTERNOON. IT IS VERY 2962 02:12:40,360 --> 02:12:41,920 INTRICATE, I SHOW ONE EXAMPLE OF 2963 02:12:41,920 --> 02:12:44,280 WHAT WE CALL DIRECTORS NOTES. 2964 02:12:44,280 --> 02:12:47,000 THIS IS SIMPLY THE END OF ONE 2965 02:12:47,000 --> 02:12:47,880 PRESENTATION AND WHAT HAPPENS 2966 02:12:47,880 --> 02:12:53,360 WHEN WE NEED TO IN PERSON AND 2967 02:12:53,360 --> 02:12:55,800 VIRTUALLY SWITCH TO OUR FIRST 2968 02:12:55,800 --> 02:12:59,720 PANEL SESSION, YOU SEE AUTO TAP 2969 02:12:59,720 --> 02:13:01,680 WITH RESOURCE ANSWER WORK WITH 2970 02:13:01,680 --> 02:13:02,840 FREDERICK NATIONAL LAB. IT IS 2971 02:13:02,840 --> 02:13:03,960 NOT JUST WHO IS PRESENTING BUT 2972 02:13:03,960 --> 02:13:05,040 THE ACTION IN THE ROOM AND 2973 02:13:05,040 --> 02:13:05,800 VIRTUALLY THAT NEEDS TO BE 2974 02:13:05,800 --> 02:13:10,440 TAKEN. NOT JUST WHO IS 2975 02:13:10,440 --> 02:13:11,920 CONTROLLING THE SLIDES BUT HOW 2976 02:13:11,920 --> 02:13:15,320 SHOWN AND ANY NOTES. THIS GOES 2977 02:13:15,320 --> 02:13:17,080 ON FOR EIGHT TO TEN PAGES AND 2978 02:13:17,080 --> 02:13:21,040 ALL FIVE AND A HALF HOURS OF THE 2979 02:13:21,040 --> 02:13:26,040 EVENT. IT HAS HAD EXCITING 2980 02:13:26,040 --> 02:13:27,920 SUCCESS. AND I WILL TURN IT BACK 2981 02:13:27,920 --> 02:13:29,560 TO VLAD THE TALK ABOUT THAT AND 2982 02:13:29,560 --> 02:13:31,960 WRAP UP. 2983 02:13:31,960 --> 02:13:34,000 >>THANK YOU, MICHAEL. MANY 2984 02:13:34,000 --> 02:13:36,440 WONDER WHAT OUR POTENTIAL 2985 02:13:36,440 --> 02:13:38,360 SUCCESSFUL OUTCOMES OF SUCH AN 2986 02:13:38,360 --> 02:13:40,560 EVENT. SUCCESS CAN BE MEASURED 2987 02:13:40,560 --> 02:13:42,520 BY MANY INDICATORS BUT WE HAVE 2988 02:13:42,520 --> 02:13:44,600 CHOSEN TO SHOW ONE. FIRST THING 2989 02:13:44,600 --> 02:13:49,680 YOU NOTICE IS TIME LINE THESE DO 2990 02:13:49,680 --> 02:13:51,920 TAKE TIME AND PANDEMIC DIDN'T 2991 02:13:51,920 --> 02:13:55,000 HELP. IT STARTED BY CEO OF 2992 02:13:55,000 --> 02:13:56,120 (INAUDIBLE) THERAPEUTICS. A 2993 02:13:56,120 --> 02:14:00,000 START UP FROM PHILADELPHIA, 2994 02:14:00,000 --> 02:14:00,880 MAURICE HAMPTON WHO CAME TO TECH 2995 02:14:00,880 --> 02:14:04,320 SHOWCASE AND THEN IN 2019. WHEN 2996 02:14:04,320 --> 02:14:06,720 I SAY REGIONAL IT REALLY IS. HE 2997 02:14:06,720 --> 02:14:08,760 CAME FROM PHILLY TO ATTEND ONE 2998 02:14:08,760 --> 02:14:12,040 OF THE FIRST WE HAD. THIS IS 2999 02:14:12,040 --> 02:14:13,280 WHERE WE GOT INTRODUCE AND 3000 02:14:13,280 --> 02:14:15,800 STARTED TALKING AND I GOT A 3001 02:14:15,800 --> 02:14:17,400 CHANCE TO TELL HIM WHO WE ARE 3002 02:14:17,400 --> 02:14:19,240 AND WHAT WE DO, HIS COMPANY WAS 3003 02:14:19,240 --> 02:14:21,920 BASED AROUND A DRUG CANDIDATE 3004 02:14:21,920 --> 02:14:22,800 AND THROUGH CONVERSATION WE 3005 02:14:22,800 --> 02:14:25,240 IDENTIFIED POTENTIAL AALIGNMENT 3006 02:14:25,240 --> 02:14:27,360 WITH CAPABILITIES AT OUR CENTER 3007 02:14:27,360 --> 02:14:29,440 FOR ADVANCE MEDICAL RESEARCH OR 3008 02:14:29,440 --> 02:14:30,880 CAPER. WE CONNECTED WITH OUR 3009 02:14:30,880 --> 02:14:32,920 SCIENTISTS AND EXECUTED 3010 02:14:32,920 --> 02:14:33,920 COOPERATIVERY SEARCH AND 3011 02:14:33,920 --> 02:14:38,520 DEVELOPMENT AGREEMENT. INITIALLY 3012 02:14:38,520 --> 02:14:39,320 SLOWED DOWN BY PANDEMIC RESEARCH 3013 02:14:39,320 --> 02:14:40,520 IS NOW GOING WELL AND LIKELY 3014 02:14:40,520 --> 02:14:44,080 ABOUT TO EXPAND HENCES THE 3015 02:14:44,080 --> 02:14:45,640 ARROWS AT END OF THE TIME LINE. 3016 02:14:45,640 --> 02:14:47,880 HOWEVER YOU CAN SEE HOW MUTUAL 3017 02:14:47,880 --> 02:14:48,960 BENEFICIAL RELATIONSHIP HAS 3018 02:14:48,960 --> 02:14:53,000 BEEN. MAURICE IS REGULAR AT 3019 02:14:53,000 --> 02:14:55,200 EVERY SHOWCASE EVER SINCE, HE 3020 02:14:55,200 --> 02:14:59,200 SERVED AS A PANELIST AND TALKED 3021 02:14:59,200 --> 02:15:00,560 ABOUT HIS EXPERIENCE WITH NCI 3022 02:15:00,560 --> 02:15:02,960 AND FNL. HE RAISED AWARENESS OF 3023 02:15:02,960 --> 02:15:04,760 EVENT IN HIS CIRCLES AND HE IS 3024 02:15:04,760 --> 02:15:07,880 CURRENTLY EXPLORING NCI 3025 02:15:07,880 --> 02:15:11,000 TECHNOLOGIES FOR HIS PIPELINE. 3026 02:15:11,000 --> 02:15:12,000 MORE IMPORTANTLY FOR THE 3027 02:15:12,000 --> 02:15:13,360 RESEARCH COLLABORATION OUTCOMES 3028 02:15:13,360 --> 02:15:15,320 THAT BENEFIT TECHNOLOGY MAURICE 3029 02:15:15,320 --> 02:15:17,400 SECURED ADDITIONAL FUNDING BASED 3030 02:15:17,400 --> 02:15:18,360 ON HIS RELATIONSHIP WITH THE 3031 02:15:18,360 --> 02:15:26,920 NATIONAL LAB. SO THIS SLIDE IS 3032 02:15:26,920 --> 02:15:29,240 SHOW A LITTLE BIGGER PICTURE 3033 02:15:29,240 --> 02:15:30,720 BROADER OUTREACH EFFORTS FOR 3034 02:15:30,720 --> 02:15:34,240 FREDERICK NATIONAL LAB. WITH THE 3035 02:15:34,240 --> 02:15:36,680 EXPANDED PARTNERSHIP TEAM AND 3036 02:15:36,680 --> 02:15:38,080 SLOW COME BACK TO IN PERSON 3037 02:15:38,080 --> 02:15:40,240 MEETINGS AND EVENTS QUITE A 3038 02:15:40,240 --> 02:15:44,400 SUCCESSFUL 2022. OUR TEAM WAS 3039 02:15:44,400 --> 02:15:47,200 PRESENT EXTERNALLY FACING EVENTS 3040 02:15:47,200 --> 02:15:48,640 AND THIS YEAR WE SERVE AS 3041 02:15:48,640 --> 02:15:50,760 KEYNOTE PANELISTS EXHIBITER OR 3042 02:15:50,760 --> 02:15:52,400 MEETING ORGANIZER. FOR EXAMPLE 3043 02:15:52,400 --> 02:15:55,480 IN BIO THIS YEAR, WHICH IS A 3044 02:15:55,480 --> 02:15:56,840 PARTNER IN CONFERENCE, WE MET 3045 02:15:56,840 --> 02:15:58,720 WITH OVER 100 BIOTECH COMPANIES, 3046 02:15:58,720 --> 02:16:00,600 ACADEMIC INSTITUTIONS, REGIONAL 3047 02:16:00,600 --> 02:16:02,400 BIOTECH CENTERS INNOVATION 3048 02:16:02,400 --> 02:16:05,440 CENTERS INCUBATORS AND SO ON. AS 3049 02:16:05,440 --> 02:16:07,640 PART OF INVOLVEMENT WITH FEDERAL 3050 02:16:07,640 --> 02:16:10,280 LAB CONSORTIUM WE MET WITH 20 3051 02:16:10,280 --> 02:16:12,080 FEDERAL AND NATIONAL LABS IN THE 3052 02:16:12,080 --> 02:16:14,280 MID ATLANTIC REGION. THERE ARE 3053 02:16:14,280 --> 02:16:16,320 OTHER NATIONAL REGIONAL AND 3054 02:16:16,320 --> 02:16:17,840 LOCAL LISTS WHICH I WILL NOT 3055 02:16:17,840 --> 02:16:21,360 READ I PROMISE BUT THAW ARE PART 3056 02:16:21,360 --> 02:16:23,360 OFFER COLLABORATION PARTNERSHIP 3057 02:16:23,360 --> 02:16:28,640 AND OUTREACH ACTIVITIES. WE 3058 02:16:28,640 --> 02:16:31,400 DON'T DO THIS IN ISOLATION. I 3059 02:16:31,400 --> 02:16:33,400 MEAN FREDERICK NATIONAL LAB. I 3060 02:16:33,400 --> 02:16:35,760 HAVE BEEN AT THE NATIONAL LAB TO 3061 02:16:35,760 --> 02:16:37,000 SEE A TRUE GROWTH AND BUILDING 3062 02:16:37,000 --> 02:16:39,800 OF THE RELATIONSHIP BETWEEN NCI 3063 02:16:39,800 --> 02:16:42,440 AND FNL. THAT IS DEFINITELY A 3064 02:16:42,440 --> 02:16:44,080 GREAT EXAM POLL OF PARTNERSHIP 3065 02:16:44,080 --> 02:16:45,680 BETWEEN FREDERICK NATIONAL LAB 3066 02:16:45,680 --> 02:16:47,080 AND CANCER INSTITUTE AS MICHAEL 3067 02:16:47,080 --> 02:16:51,000 SAID WE DO THIS BETWEEN TWO 3068 02:16:51,000 --> 02:16:57,960 TEAMS AND WE OVER THE LAST SEVER 3069 02:16:57,960 --> 02:16:59,040 YEARS WE HAD CONFERENCES AN 3070 02:16:59,040 --> 02:17:00,640 EVENTS PARTICIPATING IN 3071 02:17:00,640 --> 02:17:02,000 TOGETHER. WE REFER AND 3072 02:17:02,000 --> 02:17:03,600 INTRODUCE COLLABORATORS AND 3073 02:17:03,600 --> 02:17:05,160 PARTNERS TO EACH OTHER ALL THE 3074 02:17:05,160 --> 02:17:07,240 TIME. I GOT TWO EMAILS THIS 3075 02:17:07,240 --> 02:17:11,520 MORNING. TEAMS GROW THROUGH 3076 02:17:11,520 --> 02:17:14,720 ACTIVITIES RESULTING IN BETTER 3077 02:17:14,720 --> 02:17:17,720 OUTREACH OUTCOMES AND 3078 02:17:17,720 --> 02:17:18,640 COMPLIMENTING OF CAPABILITIES. 3079 02:17:18,640 --> 02:17:19,400 WITH THAT I WOULD LIKE TO 3080 02:17:19,400 --> 02:17:22,960 CONCLUDE OUR PRESENTATION. HAPPY 3081 02:17:22,960 --> 02:17:26,120 TO TAKE ANY QUESTIONS. 3082 02:17:26,120 --> 02:17:29,520 >>THANK YOU BOTH. SO MUCH. THAT 3083 02:17:29,520 --> 02:17:32,720 WAS A VERY DETAILED AND 3084 02:17:32,720 --> 02:17:33,680 COMPREHENSIVE PRESENTATION, VERY 3085 02:17:33,680 --> 02:17:41,640 IMPRESSIVEMENT QUESTIONS? MARY? 3086 02:17:41,640 --> 02:17:44,440 >>WE REALLY ENJOYED THE 3087 02:17:44,440 --> 02:17:48,240 PRESENTATION. I WAS WONDERING IF 3088 02:17:48,240 --> 02:17:50,000 LIDOSE HAS ANY PARTICULAR ROLE 3089 02:17:50,000 --> 02:17:55,680 IN YOUR ACTIVITIES. 3090 02:17:55,680 --> 02:17:57,520 >>NOT REALLY NOT SPECIFICALLY 3091 02:17:57,520 --> 02:18:01,920 TO TECH SHOWCASE OR ANY 3092 02:18:01,920 --> 02:18:04,360 OUTREACH. WE TRY TO KIND OF 3093 02:18:04,360 --> 02:18:07,440 SEGREGATE LIDOSE BIOMEDICAL 3094 02:18:07,440 --> 02:18:10,200 RESEARCH THAT OPERATES THE LAB, 3095 02:18:10,200 --> 02:18:12,000 SO ALL THESE ACTIVITIES OUTREACH 3096 02:18:12,000 --> 02:18:13,400 ACTIVITIES AND PARTNERSHIPS THAT 3097 02:18:13,400 --> 02:18:16,000 WE DO, ARE FOCUS ON THE NATIONAL 3098 02:18:16,000 --> 02:18:19,080 LAB. 3099 02:18:19,080 --> 02:18:20,040 >>THANK YOU. 3100 02:18:20,040 --> 02:18:24,080 >>RODNEY. 3101 02:18:24,080 --> 02:18:26,880 >>THANK YOU. THIS IS IMPRESSIVE 3102 02:18:26,880 --> 02:18:29,520 OUTREACH IN BUILDING THE 3103 02:18:29,520 --> 02:18:36,320 COMMUNITY TO TRANSLATE IP 3104 02:18:36,320 --> 02:18:37,960 GENERATED. I WONDER YOU HAVE A 3105 02:18:37,960 --> 02:18:46,520 VERY LIMITED CREW, TO DO THIS. 3106 02:18:46,520 --> 02:18:49,600 SO DO YOU HAVE A ASSESSMENT OF 3107 02:18:49,600 --> 02:18:54,800 ALL THE IP GENERATED THE COST OF 3108 02:18:54,800 --> 02:19:00,160 DEVELOPING THOSE? CALCULATE HOW 3109 02:19:00,160 --> 02:19:01,800 MANY HAVE BEEN LICENSED AND 3110 02:19:01,800 --> 02:19:04,320 RETURN ON INVESTMENT KIND OF 3111 02:19:04,320 --> 02:19:07,040 APPROACH TO LOOK AT AS OUTCOME 3112 02:19:07,040 --> 02:19:12,160 MEASURE AND HOW WOULD THAT -- 3113 02:19:12,160 --> 02:19:15,760 COULD BE IMPROVE WITH ADDITIONAL 3114 02:19:15,760 --> 02:19:19,000 INVESTMENT WITH NCI FOR EXAMPLE 3115 02:19:19,000 --> 02:19:22,400 >>MICHAEL I WILL LET YOU START 3116 02:19:22,400 --> 02:19:24,640 THIS, SINCE NCI IS HANDLING MOST 3117 02:19:24,640 --> 02:19:25,880 IP OUT OF FREDERICK NATIONAL 3118 02:19:25,880 --> 02:19:30,280 LAB. 3119 02:19:30,280 --> 02:19:32,760 >>AS FAR AS RETURN EXAMPLE OF 3120 02:19:32,760 --> 02:19:36,280 WHAT VLAD SHOWED, THAT BRINGS IN 3121 02:19:36,280 --> 02:19:40,720 CREDA FUNDING. AS FAR AS 3122 02:19:40,720 --> 02:19:41,840 EXACTLY HOW MANY AGREEMENTS AND 3123 02:19:41,840 --> 02:19:44,600 HOW MUCH BROUGHT INTO THE NCI, 3124 02:19:44,600 --> 02:19:47,680 THAT IS A LITTLE BIT DIFFICULT 3125 02:19:47,680 --> 02:19:49,480 TO CALCULATE BECAUSE THERE IS 3126 02:19:49,480 --> 02:19:53,160 NOT A -- YOU CAN SAY A SLEW FLOW 3127 02:19:53,160 --> 02:19:55,240 OF REFERRALS, ONCE WE ARE 3128 02:19:55,240 --> 02:19:57,240 INFORMED A COMPANY IS INTERESTED 3129 02:19:57,240 --> 02:19:59,240 IN A PARTICULAR TECHNOLOGY AS A 3130 02:19:59,240 --> 02:20:01,400 RESULT OF THE SHOWCASE AND WE 3131 02:20:01,400 --> 02:20:03,720 THEN TURN IT OVER TO THE TECH 3132 02:20:03,720 --> 02:20:08,800 TRANSFER PROFESSIONAL, WE CAN 3133 02:20:08,800 --> 02:20:11,760 LOSE WHERE IT GOES FROM THERE, 3134 02:20:11,760 --> 02:20:12,960 IF IT GOES FROM THERE. WITH E 3135 02:20:12,960 --> 02:20:17,280 KNOW WITH MODEST CAUSE, THAT IT 3136 02:20:17,280 --> 02:20:18,600 IS MORE THAN PAID FOR ITSELF 3137 02:20:18,600 --> 02:20:19,360 WITH NUMBER OF AGREEMENTS THAT 3138 02:20:19,360 --> 02:20:23,240 WE HAVE HAD. EVERY ALSO SEEN A 3139 02:20:23,240 --> 02:20:26,480 GREAT UPTICK IN SECONDARY 3140 02:20:26,480 --> 02:20:28,960 REFERRALS AS VLAD'S TEAM AS WELL 3141 02:20:28,960 --> 02:20:32,600 SO TIME MONTHS LATER WE WILL GET 3142 02:20:32,600 --> 02:20:34,480 A REFERRAL FROM SOMEBODY THEY 3143 02:20:34,480 --> 02:20:35,720 TALK TO WHO HAVE BEEN TO THE 3144 02:20:35,720 --> 02:20:41,560 TECH SHOWCASE. THAT SECONDARY 3145 02:20:41,560 --> 02:20:43,720 REFERRAL, AGAIN DIFFICULT TO 3146 02:20:43,720 --> 02:20:45,680 DIRECTLY TRACK THAT TO 3147 02:20:45,680 --> 02:20:51,560 PARTICULAR AGREEMENT OR LICENSE 3148 02:20:51,560 --> 02:20:54,320 AS FAR AS ADDITIONAL RESOURCES, 3149 02:20:54,320 --> 02:20:57,080 I THINK THAT WE ARE DOING ALL 3150 02:20:57,080 --> 02:21:01,640 RIGHT WITH WHAT WE HAVE. IF WE 3151 02:21:01,640 --> 02:21:03,240 ARE ABLE TO -- I WOULD SAY THAT 3152 02:21:03,240 --> 02:21:07,240 ACTUALLY IF WE COULD BETTER 3153 02:21:07,240 --> 02:21:11,840 LEVERAGE THE OUTREACH AND 3154 02:21:11,840 --> 02:21:14,840 COMMUNICATIONS ARM OF NCI 3155 02:21:14,840 --> 02:21:19,720 ITSELF, TO BETTER PROMOTE THE 3156 02:21:19,720 --> 02:21:21,280 INTRAMURAL PROGRAM, PROMOTE WITH 3157 02:21:21,280 --> 02:21:24,040 SMALL P. WE HAVE AN MAZING 3158 02:21:24,040 --> 02:21:27,160 FACULTY AND THEY WERE NOT HERLED 3159 02:21:27,160 --> 02:21:28,760 NEARLY ENOUGH. IF MORE ATTENTION 3160 02:21:28,760 --> 02:21:30,360 COULD BE PAID TO THE AMAZING 3161 02:21:30,360 --> 02:21:35,360 WORK DONE THROUGH THE INTERMURAL 3162 02:21:35,360 --> 02:21:37,840 PROGRAM THAT WOULD BE GREAT. 3163 02:21:37,840 --> 02:21:40,200 VLAD, ANYTHING TO ADD? 3164 02:21:40,200 --> 02:21:44,080 >>I WANT TO BRIEFLY ADD 3165 02:21:44,080 --> 02:21:45,960 STRAIGHT LINE THAT DOESN'T EXIST 3166 02:21:45,960 --> 02:21:48,840 SOMEONE COMING TO THE TECH 3167 02:21:48,840 --> 02:21:50,600 SHOWCASE AND NEXT SIX MONTHS 3168 02:21:50,600 --> 02:21:51,920 LICENSE WITH ROYALTIES AN 3169 02:21:51,920 --> 02:21:52,560 DEVELOPING SOMETHING INTO 3170 02:21:52,560 --> 02:21:56,160 PRODUCT. IT MIGHT HAPPEN BUT 3171 02:21:56,160 --> 02:22:00,360 THOSE ARE VERY FEW RARE CASES. I 3172 02:22:00,360 --> 02:22:02,160 TALKED OVERALL BENEFITS, TOUCH 3173 02:22:02,160 --> 02:22:04,280 ON A LOT OF THINGS, IT TOUCHES 3174 02:22:04,280 --> 02:22:08,720 ON EDUCATING YOUR NEXT GROUP OF 3175 02:22:08,720 --> 02:22:11,280 PROFESSIONALS, BUILDING THE 3176 02:22:11,280 --> 02:22:16,160 NETWORK. WE BRING IN PARTNERS 3177 02:22:16,160 --> 02:22:17,920 HERE, WORK FORCE DEVELOPMENT, 3178 02:22:17,920 --> 02:22:19,280 THEY COME REALIZE ALL THINGS WE 3179 02:22:19,280 --> 02:22:21,280 DO AND POTENTIAL TECHNOLOGIES 3180 02:22:21,280 --> 02:22:26,240 THEY WANT TO SEND A STUDENT, 3181 02:22:26,240 --> 02:22:28,520 THEY EVEN PROPOSE TO PUTTING 3182 02:22:28,520 --> 02:22:30,440 CERTIFICATES IN PLACE FOR HARD 3183 02:22:30,440 --> 02:22:32,560 TO HIRE AREAS, WITHIN THE LAB 3184 02:22:32,560 --> 02:22:34,560 AND NCI. SO THERE ARE MULTIPLE 3185 02:22:34,560 --> 02:22:36,080 BENEFITS AND LIKE I SAID, IT IS 3186 02:22:36,080 --> 02:22:39,160 NOT USUALLY A STRAIGHT LINE 3187 02:22:39,160 --> 02:22:42,120 WHERE YOU CAN CONNECT SOMETHING 3188 02:22:42,120 --> 02:22:43,800 WITHIN A YEAR. WITH THAT 3189 02:22:43,800 --> 02:22:47,240 EXAMPLE, IT DOES TAKE TIME TO 3190 02:22:47,240 --> 02:22:49,240 BUILD THESE RELATIONSHIPS. 3191 02:22:49,240 --> 02:22:50,040 >>THANK YOU. 3192 02:22:50,040 --> 02:22:55,120 >>THANK YOU. SO THERE IS A 3193 02:22:55,120 --> 02:22:57,760 NATIONAL SMALL BUSINESS PANEL 3194 02:22:57,760 --> 02:23:03,120 START UP INVESTED BY THE 3195 02:23:03,120 --> 02:23:04,160 INSTITUTE CALLED REACH AND THE 3196 02:23:04,160 --> 02:23:06,800 CANCER CENTER AS NCI PROOF OF 3197 02:23:06,800 --> 02:23:10,600 CONCEPT CENTERS. AND I WONDER 3198 02:23:10,600 --> 02:23:11,880 THAT COULD BE INTEGRATED INTO 3199 02:23:11,880 --> 02:23:17,240 YOUR THINKING. TO HELP 3200 02:23:17,240 --> 02:23:18,040 TECHNOLOGICAL TRANSLATION AS 3201 02:23:18,040 --> 02:23:21,320 WELL AS STARTUP THAT FOLLOW ON 3202 02:23:21,320 --> 02:23:22,640 COACHING THROUGH GET THE 3203 02:23:22,640 --> 02:23:26,920 TECHNOLOGY OUT INTO THE 3204 02:23:26,920 --> 02:23:27,680 COMMUNITY FOR PRODUCT 3205 02:23:27,680 --> 02:23:29,760 DEVELOPMENT. THAT IS WHAT I AM 3206 02:23:29,760 --> 02:23:31,440 THINKING HOW TO INTEGRATE THAT. 3207 02:23:31,440 --> 02:23:34,400 >>SURE. WE DEFINITELY WOULD BE 3208 02:23:34,400 --> 02:23:38,520 OPEN TO LOOKING INTO THAT. JUST 3209 02:23:38,520 --> 02:23:41,680 TO JUMP THAT LAST COMMENT. NIH 3210 02:23:41,680 --> 02:23:45,680 SEED OFFICE IS THE NEXUS OF 3211 02:23:45,680 --> 02:23:48,200 THOSE EFFORTS. I'M HAPPY TO 3212 02:23:48,200 --> 02:23:51,760 CONNECT YOU WITH MATT MCMAHAN OR 3213 02:23:51,760 --> 02:23:52,920 SOMETHING BECAUSE IT WOULD BE 3214 02:23:52,920 --> 02:23:54,840 HELPFUL TO TAKE ADVANTAGE OF 3215 02:23:54,840 --> 02:23:56,960 SOMETHING LIKE THE I CORE AT NIH 3216 02:23:56,960 --> 02:23:58,680 OR THAT KIND OF THING TO HELP 3217 02:23:58,680 --> 02:24:00,480 YOUR INVESTIGATORS DEVELOP THEIR 3218 02:24:00,480 --> 02:24:04,440 VALUE PROPOSITIONS. AND THEIR 3219 02:24:04,440 --> 02:24:04,840 BUSINESS CASE. 3220 02:24:04,840 --> 02:24:05,400 >>ABSOLUTELY. 3221 02:24:05,400 --> 02:24:07,120 >>AGREE. 3222 02:24:07,120 --> 02:24:10,160 >>I THINK THAT IS A GREAT IDEA. 3223 02:24:10,160 --> 02:24:11,920 THAT IS REALLY BUILT ON TO WHAT 3224 02:24:11,920 --> 02:24:14,240 WE ARE TRYING TO DO HERE. WE 3225 02:24:14,240 --> 02:24:18,000 LOVE WORKING WITH SMALL 3226 02:24:18,000 --> 02:24:18,760 COMPANIES MY PERSONAL PREFERENCE 3227 02:24:18,760 --> 02:24:21,520 IS THOSE COME WITH EXCITING 3228 02:24:21,520 --> 02:24:24,200 TECHNOLOGIES AND OUT OF BOX 3229 02:24:24,200 --> 02:24:26,240 THINKING. IN THE PAST WE HAD 3230 02:24:26,240 --> 02:24:28,360 ROAD SHOW WITH SBIR OFFICES AND 3231 02:24:28,360 --> 02:24:29,600 TARGETED HOSE COMPANIES AND THEN 3232 02:24:29,600 --> 02:24:32,720 WE JUST STARTED TALKING TO THEM 3233 02:24:32,720 --> 02:24:35,880 AGAIN AS WE EXIT THIS VIRTUAL 3234 02:24:35,880 --> 02:24:38,160 WORLD BACK TO MORE IN PERSON, 3235 02:24:38,160 --> 02:24:39,640 WILL DEFINITELY FOCUS ON THAT AS 3236 02:24:39,640 --> 02:24:39,920 WELL. 3237 02:24:39,920 --> 02:24:42,320 >>THIS IS TOM STACKHOUSE IF I 3238 02:24:42,320 --> 02:24:44,240 CAN OBJECT TO THAT LAST COMMENT. 3239 02:24:44,240 --> 02:24:45,640 I'M DIRECTOR OF TECH TRANSFER 3240 02:24:45,640 --> 02:24:48,160 CENTER HERE AT NCI. SO WE HAVE 3241 02:24:48,160 --> 02:24:51,800 WHAT IS CALLED AIM INTERNALLY 3242 02:24:51,800 --> 02:24:54,000 WHICH IS THE I CORE PROGRAM AT 3243 02:24:54,000 --> 02:25:00,640 NIH. WE DEVELOPED OUR NCI PI AND 3244 02:25:00,640 --> 02:25:02,640 WE HAD TWO COHORT NOW, TURNING 3245 02:25:02,640 --> 02:25:05,000 OUT QUITE SUCCESSFUL, SEEMED TO 3246 02:25:05,000 --> 02:25:08,920 LIKE IT, IT GIVES THEM A UNIQUE 3247 02:25:08,920 --> 02:25:10,880 OPPORTUNITY TO LOOK AT RESEARCH 3248 02:25:10,880 --> 02:25:12,200 DIFFERENT VENUE. SO TO THAT 3249 02:25:12,200 --> 02:25:13,640 QUESTION YES WE ARE MOVING THAT 3250 02:25:13,640 --> 02:25:14,280 DIRECTION. THANK YOU FOR THE 3251 02:25:14,280 --> 02:25:18,560 COMMENT. 3252 02:25:18,560 --> 02:25:20,920 >>COULDN'T BE HAPPIER. 3253 02:25:20,920 --> 02:25:22,160 >>LINDA, A QUESTION. 3254 02:25:22,160 --> 02:25:26,160 >>I NOTICE YOU MENTION A POST 3255 02:25:26,160 --> 02:25:28,800 DOC OPPORTUNITY. WHAT ARE THE 3256 02:25:28,800 --> 02:25:30,040 REQUIREMENTS IN ELIGIBILITY FOR 3257 02:25:30,040 --> 02:25:31,040 TRAINEES WHO MIGHT LIKE TO BE 3258 02:25:31,040 --> 02:25:33,840 PART OF THIS? 3259 02:25:33,840 --> 02:25:36,720 >>TALKING THE EVENT ITSELF? 3260 02:25:36,720 --> 02:25:41,800 >>YEAH, ANY PAR PART OF IT. 3261 02:25:41,800 --> 02:25:43,560 THIS IS AS FAR AS NIH MISSION 3262 02:25:43,560 --> 02:25:45,160 FOR TRAINING,ING THIS SOMETHING 3263 02:25:45,160 --> 02:25:47,520 A LOT OF OUR ACADEMIC RESEARCH 3264 02:25:47,520 --> 02:25:51,040 TRAININGS ARE INTERESTED IN. AS 3265 02:25:51,040 --> 02:25:52,160 UNIVERSITIES WE TEND TO BE 3266 02:25:52,160 --> 02:25:54,440 LACKING. 3267 02:25:54,440 --> 02:25:58,760 >>THIS IS TOM, INKED ADD THE 3268 02:25:58,760 --> 02:26:02,720 AMBASSADOR PROGRAM, THE WORK 3269 02:26:02,720 --> 02:26:03,840 MICHAEL WAS REFERRING TO WITH 3270 02:26:03,840 --> 02:26:05,800 THE SHOWCASE, HAS AN APPLICATION 3271 02:26:05,800 --> 02:26:08,640 PROCESS, ANNOUNCED ACROSS NIH, 3272 02:26:08,640 --> 02:26:10,120 WE TRY TO REACH OUT AS MUCH AS 3273 02:26:10,120 --> 02:26:13,760 POSSIBLE TO THE VARIOUS TRAINING 3274 02:26:13,760 --> 02:26:16,200 PROGRAMS AT NIH TO GET 3275 02:26:16,200 --> 02:26:18,400 INVOLVEMENT AND EVERY YEAR WE 3276 02:26:18,400 --> 02:26:20,520 HAVE ANYWHERE FROM 5 TO 15 FOLKS 3277 02:26:20,520 --> 02:26:24,720 WHO JOIN THAT. AND THERE IS A 3278 02:26:24,720 --> 02:26:26,280 WHOLE CURRICULUM ACROSS A YEAR 3279 02:26:26,280 --> 02:26:27,400 THEY GO THROUGH TO LEARN ABOUT 3280 02:26:27,400 --> 02:26:31,400 TECH TRANSFER, ET CETERA. THAT 3281 02:26:31,400 --> 02:26:33,040 IS SOMETHING THAT IS NIH -- IT 3282 02:26:33,040 --> 02:26:35,600 IS OPENED UP TO NIH TWO YEARS 3283 02:26:35,600 --> 02:26:37,160 AGO, WE STARTED HERE AT NIH AND 3284 02:26:37,160 --> 02:26:38,640 OPENED UP TO ALL OF NIH TWO 3285 02:26:38,640 --> 02:26:43,560 YEARS AGO. 3286 02:26:43,560 --> 02:26:45,440 >>ANYTHING ELSE? WE STILL HAVE 3287 02:26:45,440 --> 02:26:47,080 A MINUTE OR TWO LEFT. 3288 02:26:47,080 --> 02:26:48,280 >>CAN I ASK A QUESTION? 3289 02:26:48,280 --> 02:26:50,800 >>YES. PLEASE. 3290 02:26:50,800 --> 02:26:57,080 >>SO WANT TO COMMEND PRESENTERS 3291 02:26:57,080 --> 02:26:57,960 FOR OUTSTANDING PRESENTATION. 3292 02:26:57,960 --> 02:26:59,400 HAVING BEEN AT A FEW 3293 02:26:59,400 --> 02:27:00,520 UNIVERSITIES AND WORKING WITH 3294 02:27:00,520 --> 02:27:02,200 DIFFERENT TECH TRANSFER OFFICES 3295 02:27:02,200 --> 02:27:04,440 I WE SHALL THEY COULD TAKE A 3296 02:27:04,440 --> 02:27:05,800 PAGE OUT OF YOUR PLAY BOOK. IT 3297 02:27:05,800 --> 02:27:07,800 IS A WONDERFUL WHAT Y'ALL HAVE 3298 02:27:07,800 --> 02:27:13,320 DONE. WITH THAT BLONDING ARE IF 3299 02:27:13,320 --> 02:27:14,720 I CAN ASK COUPLE OF QUESTIONS, 3300 02:27:14,720 --> 02:27:22,680 ONE ABOUT PROCESS. IN GENERAL I 3301 02:27:22,680 --> 02:27:24,920 KNOW FACULTY PIs ARE SOMETIMES 3302 02:27:24,920 --> 02:27:27,080 UNAWARE OF PUBLIC AT THIS 3303 02:27:27,080 --> 02:27:28,720 CLOSURE, VIS-A-VIS -- 3304 02:27:28,720 --> 02:27:29,640 DISCLOSURE, VIS-A-VIS PATENT 3305 02:27:29,640 --> 02:27:31,080 FILING APPLICATION, NOT ALWAYS 3306 02:27:31,080 --> 02:27:33,560 CLEAR FOR INVESTIGATORS IS TO WE 3307 02:27:33,560 --> 02:27:36,680 ARE HAPPY TO TALK SCIENCE AND 3308 02:27:36,680 --> 02:27:39,040 RESEARCH AND ONE OF THE THINGS 3309 02:27:39,040 --> 02:27:42,760 WITH IP IS OBVIOUSLY EDUCATION 3310 02:27:42,760 --> 02:27:44,560 FOR INVESTIGATORS TO UNDERSTAND 3311 02:27:44,560 --> 02:27:46,440 THAT YES YOU ARE EXCITED ABOUT 3312 02:27:46,440 --> 02:27:47,840 TECHNOLOGY BUT MAYBE DON'T WANT 3313 02:27:47,840 --> 02:27:50,560 TO GO AND PUBLICLY DISCLOSE IT 3314 02:27:50,560 --> 02:27:54,680 BEFORE YOU FILE FOR IP. SO 3315 02:27:54,680 --> 02:27:56,120 WONDERING WHETHER YOU CAN SPEAK 3316 02:27:56,120 --> 02:27:59,160 TO EDUCATIONAL ASPECT FOR PIs. 3317 02:27:59,160 --> 02:28:00,280 THEN I THOUGHT IT WAS 3318 02:28:00,280 --> 02:28:02,960 INTERESTING THE WAY YOUR 3319 02:28:02,960 --> 02:28:07,960 PRESENTING THE IP WITH LINKS TO 3320 02:28:07,960 --> 02:28:12,600 SPECIFIC PATENTS. MAYBE IT IS 3321 02:28:12,600 --> 02:28:13,720 DIFFERENT IN THERAPEUTICS FOR 3322 02:28:13,720 --> 02:28:17,720 THE ONE I LIVE IN WHICH IS MORE 3323 02:28:17,720 --> 02:28:21,040 DIAGNOSTIC SPACE. THERE IS THIS 3324 02:28:21,040 --> 02:28:22,920 IDEA PULLING TOGETHER PORTFOLIO 3325 02:28:22,920 --> 02:28:24,960 OF TECHNOLOGIES AND TRYING TO 3326 02:28:24,960 --> 02:28:26,480 MARKET PORTFOLIO VERSUS SINGLE 3327 02:28:26,480 --> 02:28:28,280 PATENT OR SINGLE MOLECULE. 3328 02:28:28,280 --> 02:28:30,360 AGAIN, COMING FROM A DIAGNOSTICS 3329 02:28:30,360 --> 02:28:32,240 PERSPECTIVE. SO WONDERING 3330 02:28:32,240 --> 02:28:33,720 WHETHER YOU CAN SPEAK TO THAT 3331 02:28:33,720 --> 02:28:37,800 AND HOW YOU GO ABOUT 3332 02:28:37,800 --> 02:28:41,120 >>SURE. FIRST ON PI EDUCATION 3333 02:28:41,120 --> 02:28:42,920 WE TELL THEM KEEP IT TO PUBLICLY 3334 02:28:42,920 --> 02:28:44,960 DISCLOSED INFORMATION. THIS IS 3335 02:28:44,960 --> 02:28:46,000 NOT THE AMERICAN ACADEMY OF FILL 3336 02:28:46,000 --> 02:28:50,680 IN THE BLANK. YOU ARE SHOWING 3337 02:28:50,680 --> 02:28:58,600 SLIDES AND SAY UNPUBLISHED. IT 3338 02:28:58,600 --> 02:29:00,040 NEEDS TO BE CENTERED ON 3339 02:29:00,040 --> 02:29:03,160 TECHNOLOGY ALREADY FILED. THIS 3340 02:29:03,160 --> 02:29:05,200 IS AN OPPORTUNITY FOR AUDIENCE 3341 02:29:05,200 --> 02:29:06,560 TO PARTNER WITH AND LICENSE 3342 02:29:06,560 --> 02:29:08,240 FROM, SO IT HAS TO BE THAT FAR 3343 02:29:08,240 --> 02:29:11,160 ENOUGH IN THE PROCESS AND TECH 3344 02:29:11,160 --> 02:29:12,360 TRANSFER MANAGERS IN GENERAL DO 3345 02:29:12,360 --> 02:29:16,640 A NICE JOB OF WORKING WITH THE 3346 02:29:16,640 --> 02:29:18,320 INVESTIGATORS IN DOCKET TO 3347 02:29:18,320 --> 02:29:20,200 DETERMINE IF TECHNOLOGY IS FAR 3348 02:29:20,200 --> 02:29:23,840 ENOUGH ALONG TO NEED FOR 3349 02:29:23,840 --> 02:29:27,600 EXAMPLE, A STEP OF FILING 3350 02:29:27,600 --> 02:29:30,880 DISCLOSURE. WE MACK IT CLEAR 3351 02:29:30,880 --> 02:29:31,880 EVERYTHING HAS TO BE PUBLIC 3352 02:29:31,880 --> 02:29:33,560 INFORMATION AND WE TELL THE 3353 02:29:33,560 --> 02:29:36,120 AUDIENCE THAT THE TECH TRANSFER 3354 02:29:36,120 --> 02:29:38,640 MANAGER WOULD BE GLAD TO EXECUTE 3355 02:29:38,640 --> 02:29:40,720 A CONFIDENTIALITY AGREEMENT IF 3356 02:29:40,720 --> 02:29:44,160 ANY WOULD LIKE THE TALK ABOUT 3357 02:29:44,160 --> 02:29:46,920 UNPUBLISHED WORK THE 3358 02:29:46,920 --> 02:29:49,800 INVESTIGATOR HAS DONE SINCE THE 3359 02:29:49,800 --> 02:30:00,640 FILINFILING. (OVERLAPPING SPEAK) 3360 02:30:04,960 --> 02:30:07,200 >>GREAT POINT. OUR GROUP PUT 3361 02:30:07,200 --> 02:30:08,440 TOGETHER TECHNOLOGY SHEETS. AND 3362 02:30:08,440 --> 02:30:10,000 THEY ARE IN VARIOUS CATEGORIES 3363 02:30:10,000 --> 02:30:12,320 SO WE HAVE ONE FOR DIAGNOSTICS 3364 02:30:12,320 --> 02:30:15,360 AND SO WE AGREE THAT DIAGNOSTICS 3365 02:30:15,360 --> 02:30:16,040 TEND TO BE MORE PLATFORM 3366 02:30:16,040 --> 02:30:19,880 SOLUTION. NOT ALWAYS OF COURSE 3367 02:30:19,880 --> 02:30:23,960 BUT IF YOU CAN DETECT SOMETHING 3368 02:30:23,960 --> 02:30:34,440 ABNORMAL IN DIAGNOSTICS, CELL 3369 02:30:42,960 --> 02:30:43,920 THERAPY OR GENE THERAPY, ET 3370 02:30:43,920 --> 02:30:44,120 CETERA. 3371 02:30:44,120 --> 02:30:51,120 >>OKAY. THANK YOU. DOUG, DID 3372 02:30:51,120 --> 02:30:51,720 YOU HAVE A COMMENT? 3373 02:30:51,720 --> 02:30:55,680 >>I SIMPLY WANT TO SAY THAT AS 3374 02:30:55,680 --> 02:31:00,560 MICHAEL POINTS OUT, IN RESPONSE 3375 02:31:00,560 --> 02:31:01,880 TO ALLEN'S QUESTION, THIS IS 3376 02:31:01,880 --> 02:31:03,160 RELATIVELY FAR DOWN THE LINE 3377 02:31:03,160 --> 02:31:07,840 WHEN IT COMES TO THE ISSUE OF IP 3378 02:31:07,840 --> 02:31:10,520 DISCLOSURES, ET CETERA, IN THE 3379 02:31:10,520 --> 02:31:12,680 INTRAMURAL PROGRAM WE -- TOM 3380 02:31:12,680 --> 02:31:14,440 STACKHOUSE AND TOM MAY WANT TO 3381 02:31:14,440 --> 02:31:17,080 COMMENT ON THIS, REALLY THE TECH 3382 02:31:17,080 --> 02:31:22,240 TRANSFER CENTER HAS AN ENTIRE 3383 02:31:22,240 --> 02:31:23,960 PROCESS IF P AN EMPLOYEE OR 3384 02:31:23,960 --> 02:31:28,160 STAFF MEMBER THINKS THAT THERE'S 3385 02:31:28,160 --> 02:31:31,360 SOMETHING PATENTABLE WE FILE AN 3386 02:31:31,360 --> 02:31:32,760 EMPLOYEE INVENTION REPORT THEN 3387 02:31:32,760 --> 02:31:35,400 WILL IS A STANDING COMMITTEE, 3388 02:31:35,400 --> 02:31:38,000 TECHNOLOGY REVIEW GROUP, THAT 3389 02:31:38,000 --> 02:31:41,720 REVIEWS THESE APPLICATIONS ON 3390 02:31:41,720 --> 02:31:43,080 MONTHLY BASIS AND MAKES 3391 02:31:43,080 --> 02:31:45,640 RECOMMENDATIONS. 3392 02:31:45,640 --> 02:31:48,400 >>YEAH. SO THIS IS TOM. I THINK 3393 02:31:48,400 --> 02:31:54,880 THAT SPEAKS TO PART OF WHAT 3394 02:31:54,880 --> 02:31:56,920 ANAND WAS ASKING. THIS SHOWCASE 3395 02:31:56,920 --> 02:31:58,960 IS FURTHER DOWN THE LINE, SO 3396 02:31:58,960 --> 02:31:59,960 THERE'S PROTECTION AROUND IT BUT 3397 02:31:59,960 --> 02:32:03,160 RELATED TO THE EIR, OUR 3398 02:32:03,160 --> 02:32:04,480 INVENTION REPORTS YOU WERE 3399 02:32:04,480 --> 02:32:07,600 ASKING HOW DO WE ENGAGE THE 3400 02:32:07,600 --> 02:32:10,480 EMPLOYEES, AWAR OF WHAT NEEDS TO 3401 02:32:10,480 --> 02:32:12,600 BE DONE TO OBTAIN A PATENT. IS 3402 02:32:12,600 --> 02:32:17,480 THAT WHAT YOU WERE ASKING? 3403 02:32:17,480 --> 02:32:21,440 >>IN TERMS OF PROCESS. I AM 3404 02:32:21,440 --> 02:32:23,000 WORKING ON SOMETHING COOL, IT 3405 02:32:23,000 --> 02:32:25,520 MIGHT BE PATENTABLE, 3406 02:32:25,520 --> 02:32:26,640 COMMERCIALIZABLE AND 3407 02:32:26,640 --> 02:32:28,440 TRANSLATABLE SO EXCITED TO TALK 3408 02:32:28,440 --> 02:32:31,360 ABOUT IT, I BLAST ON TWITTER NOW 3409 02:32:31,360 --> 02:32:33,240 PUBLIC DISCLOSURE. SO WE HAVE 3410 02:32:33,240 --> 02:32:34,640 TECH TRANSFER MANAGER AND THOSE 3411 02:32:34,640 --> 02:32:35,760 MANAGERS ARE ASSIGNED A 3412 02:32:35,760 --> 02:32:37,360 PORTFOLIO OF LABORATORIES. AND 3413 02:32:37,360 --> 02:32:38,480 THEY ARE IN CONSTANT 3414 02:32:38,480 --> 02:32:40,160 COMMUNICATION WITH THOSE PIs, 3415 02:32:40,160 --> 02:32:41,600 THEY GIVE PRESENTATIONS FROM 3416 02:32:41,600 --> 02:32:43,280 TIME TO TIME TO TALK ABOUT WHAT 3417 02:32:43,280 --> 02:32:45,200 IS AN INVENTION, WHAT IS A 3418 02:32:45,200 --> 02:32:46,440 COOPERATIVE RESEARCH DEVELOPMENT 3419 02:32:46,440 --> 02:32:49,240 AGREEMENT, ALL THOSE THINGS. 3420 02:32:49,240 --> 02:32:50,680 THEY ARE PRETTY WELL EDUCATED 3421 02:32:50,680 --> 02:32:54,720 THAT WAY ABOUT THAT. ONCE IN A 3422 02:32:54,720 --> 02:32:56,280 WHILE WE GET SOMETHING THAT 3423 02:32:56,280 --> 02:32:58,520 HAPPENS UNEXPECTEDLY, WE HAVE 3424 02:32:58,520 --> 02:33:00,440 PROCESSES IN PLACE IF WE NEED TO 3425 02:33:00,440 --> 02:33:02,440 USE THEM TO GET SOMETHING FILED 3426 02:33:02,440 --> 02:33:04,680 IF DISCLOSURE IS COMING. WE DO A 3427 02:33:04,680 --> 02:33:07,760 GOOD JOB OF KEEPING THEM 3428 02:33:07,760 --> 02:33:10,320 EDUCATED BECAUSE OF ONE ON ONE 3429 02:33:10,320 --> 02:33:11,880 TECH TRANSFER STAFF AND 3430 02:33:11,880 --> 02:33:13,240 LABORATORIES IS HUGE WAY THAT WE 3431 02:33:13,240 --> 02:33:17,880 ARE ABLE TO COMMUNICATE AND KEEP 3432 02:33:17,880 --> 02:33:18,240 UP TO DATE. 3433 02:33:18,240 --> 02:33:20,720 >>WE WILL MOVE FORWARD NOW. THE 3434 02:33:20,720 --> 02:33:27,440 NEXT PRESENTATION IS DR. DAVE 3435 02:33:27,440 --> 02:33:28,880 TUVESON WITH THE RAS WORKING 3436 02:33:28,880 --> 02:33:37,120 GROUP REPORT. 3437 02:33:37,120 --> 02:33:37,960 >>GOOD AFTERNOON, THANK YOU FOR 3438 02:33:37,960 --> 02:33:41,160 HAVING ME. I HAVE THE HONOR 3439 02:33:41,160 --> 02:33:43,280 SERVING AS THE EXTERNAL CHAIR OF 3440 02:33:43,280 --> 02:33:45,800 THE AD HOC COMMITTEE ADVISING 3441 02:33:45,800 --> 02:33:49,680 THE RAS PROGRAM AT FEDERAL 3442 02:33:49,680 --> 02:33:55,800 NATIONAL RESEARCH LABORATORY AND 3443 02:33:55,800 --> 02:34:02,760 NCI. RAS IS MOST COMMON CANCER 3444 02:34:02,760 --> 02:34:06,000 IN HUMAN CANCER AS MOST COMMON 3445 02:34:06,000 --> 02:34:07,880 ONCOGENE IN HUMAN CANCER AS YOU 3446 02:34:07,880 --> 02:34:10,280 KNOW, IT WAS DEEMED UNDRUGOR 3447 02:34:10,280 --> 02:34:12,840 DRUGGABLE BY OUR COMMUNITY AFTER 3448 02:34:12,840 --> 02:34:14,280 THE FAILURE OF TRANSFERASE 3449 02:34:14,280 --> 02:34:16,160 INHIBITORS AND HER ROWIC 3450 02:34:16,160 --> 02:34:18,880 EXPERIMENTS DONE BY MAJOR PHARMA 3451 02:34:18,880 --> 02:34:20,480 AND ACADEMIA. SO THOUGH NOT A 3452 02:34:20,480 --> 02:34:21,480 TRANSCRIPTION FACTOR PEOPLE 3453 02:34:21,480 --> 02:34:27,720 STAYED AWAY FROM IT. WHEN 3454 02:34:27,720 --> 02:34:29,480 HAROLD WAS NCI DIRECTOR THE 3455 02:34:29,480 --> 02:34:33,560 ADVISORS SUGGESTED IT MIGHT BE 3456 02:34:33,560 --> 02:34:35,000 TRACTABLE TO ORGANIZE OURSELVES 3457 02:34:35,000 --> 02:34:36,320 DIFFERENTLY SO WHICH LED TO THE 3458 02:34:36,320 --> 02:34:40,160 RAS INITIATIVE. IT STARTED IN 3459 02:34:40,160 --> 02:34:43,720 2013. THE GOAL TO MOBILIZE IN 3460 02:34:43,720 --> 02:34:45,840 ACADEMIC SECTOR PRIVATE SECTOR 3461 02:34:45,840 --> 02:34:46,720 GOVERNMENTAL SECTOR TO THINK 3462 02:34:46,720 --> 02:34:47,760 ABOUT THIS PROBLEM AND WORK 3463 02:34:47,760 --> 02:34:52,680 TOGETHER ON IT. TO DEVELOP WAYS 3464 02:34:52,680 --> 02:34:53,600 TO UNDERSTAND AND TARGET THESE 3465 02:34:53,600 --> 02:34:56,000 CANCERS AND HAVE RAS AS DRIVER 3466 02:34:56,000 --> 02:34:59,440 IN A DIFFERENT WAY. OPEN 3467 02:34:59,440 --> 02:35:02,960 RESEARCH MODEL COLLABORATIVE WAY 3468 02:35:02,960 --> 02:35:04,680 BETWEEN SECTORS KEEPING IN MIND 3469 02:35:04,680 --> 02:35:06,440 IP ISSUE YOU GUYS HAVE BEEN 3470 02:35:06,440 --> 02:35:10,400 DISCUSSING ELOQUENTLY AS I WAS 3471 02:35:10,400 --> 02:35:11,960 ARRIVING. THE IDEA WAS AT 3472 02:35:11,960 --> 02:35:15,120 FREDERICK YOU ARE ADVISORS AND 3473 02:35:15,120 --> 02:35:16,600 WHICH IS A STATE OF ART 3474 02:35:16,600 --> 02:35:20,480 FACILITY. THIS IS SERVED AS OUR 3475 02:35:20,480 --> 02:35:22,040 HOME FOR THIS INITIATIVE THE 3476 02:35:22,040 --> 02:35:23,400 PAST NINE YEARS. THE 3477 02:35:23,400 --> 02:35:28,360 COLLABORATING LABS. THE INITIAL 3478 02:35:28,360 --> 02:35:30,120 FUNDING CYCLE WAS A QUINTENIAL, 3479 02:35:30,120 --> 02:35:32,760 A FIVE YEAR APPLICATION, LEVI 3480 02:35:32,760 --> 02:35:35,960 WAS CHAIR FOR THE FIRST FIVE 3481 02:35:35,960 --> 02:35:39,720 YEARS. IT WAS REVIEW. IN 2017 IT 3482 02:35:39,720 --> 02:35:43,080 WAS RECOMMENDED TO GO FOR THE 3483 02:35:43,080 --> 02:35:44,440 SECOND COMPENDIUM OF FUNDING 3484 02:35:44,440 --> 02:35:47,000 WITH INCREASE FOCUS ON COUPLE OF 3485 02:35:47,000 --> 02:35:49,200 TANGIBLE TARGETS. FIRST FIVE 3486 02:35:49,200 --> 02:35:51,680 YEARS DERISKED IT, 3487 02:35:51,680 --> 02:35:52,920 PHILOSOPHICALLY AND EMOTIONALLY 3488 02:35:52,920 --> 02:35:57,560 THE LAST FIVE YEARS HAVE SHOWN 3489 02:35:57,560 --> 02:35:59,400 THAT WITH SERIOUS CONCENTRATED 3490 02:35:59,400 --> 02:36:03,240 ATTENTION THE ASPIRATIONAL GOALS 3491 02:36:03,240 --> 02:36:05,560 AND -- BECAME ACCOMPLISHMENTS. 3492 02:36:05,560 --> 02:36:11,240 THAT WAS A COMBINATION OF GREAT 3493 02:36:11,240 --> 02:36:13,240 STRUCTURAL BIOLOGY, BIOCHEMISTRY 3494 02:36:13,240 --> 02:36:15,360 BIOPHYSIC AND MEDICINAL 3495 02:36:15,360 --> 02:36:17,120 CHEMISTRY OF VARIOUS KINDS YOU 3496 02:36:17,120 --> 02:36:18,320 WILL HEAR ABOUT TODAY. SO IT 3497 02:36:18,320 --> 02:36:20,800 WAS RENEWED IN 2017 TO PUSH 3498 02:36:20,800 --> 02:36:26,440 AHEAD HARDER AND HERE WE ARE THE 3499 02:36:26,440 --> 02:36:31,800 NEXT FOUR YEARS. MY JOB IS 3500 02:36:31,800 --> 02:36:33,960 OUTSIDE ADVISOR TO JUST HAVE A 3501 02:36:33,960 --> 02:36:35,520 COMMITTEE OF APPROXIMATELY 12 3502 02:36:35,520 --> 02:36:39,640 PEOPLE THAT ADVISE MCCORMICK AND 3503 02:36:39,640 --> 02:36:42,840 NISSLEY AND COLLEAGUES, ANYTHING 3504 02:36:42,840 --> 02:36:44,040 FROM STRATEGIC STANDPOINT, COULD 3505 02:36:44,040 --> 02:36:46,600 BE TECHNICAL ADVICE, SCIENTIFIC 3506 02:36:46,600 --> 02:36:48,080 ADVICE, ANYTHING THAT STRETCHES 3507 02:36:48,080 --> 02:36:49,640 THEM AND MAKES THE WHOLE 3508 02:36:49,640 --> 02:36:58,600 INITIATIVE WORK MORE CLEARLY, 3509 02:36:58,600 --> 02:37:00,320 NEEDED TO ACCOMPLISH GOALS SO MY 3510 02:37:00,320 --> 02:37:01,680 JOB WAS TO SHOW UP TODAY AND 3511 02:37:01,680 --> 02:37:02,640 PRESENT THE RESULTS OF THE LAST 3512 02:37:02,640 --> 02:37:05,320 FOUR YEARS. THE OVERALL GOALS 3513 02:37:05,320 --> 02:37:08,960 FROM MY GROUP IS OVERSIGHT TO 3514 02:37:08,960 --> 02:37:09,680 FRANK AND DWIGHT AND TO BE 3515 02:37:09,680 --> 02:37:13,840 CANDID WITH THEM. ABOUT THINGS. 3516 02:37:13,840 --> 02:37:17,920 TO ENSURE THIS EFFORT WE HAVE 3517 02:37:17,920 --> 02:37:20,600 SPECIAL OPERATION EXISTING AT 3518 02:37:20,600 --> 02:37:22,400 FREDERICK IS MEETING SCIENTIFIC 3519 02:37:22,400 --> 02:37:23,680 OBJECTIVES INTERNALLY BUT ALSO 3520 02:37:23,680 --> 02:37:27,120 SOMETHING THAT RAISES THE BOATS 3521 02:37:27,120 --> 02:37:28,600 EXTERNALLY, ACADEMIC AND PRIVATE 3522 02:37:28,600 --> 02:37:32,040 SECTOR. WE HAD NINE MEETINGS 3523 02:37:32,040 --> 02:37:33,600 SINCE SEPTEMBER OF 18 UNTIL NOW. 3524 02:37:33,600 --> 02:37:38,880 SOME VIRTUAL, SOME IN PERSON. 3525 02:37:38,880 --> 02:37:40,240 HERE WE ARE LOOKING AT WHAT WE 3526 02:37:40,240 --> 02:37:41,680 ACCOMPLISHED OVER THE LAST FOUR 3527 02:37:41,680 --> 02:37:43,840 YEARS, MY JOB IS TO SUMMARIZE 3528 02:37:43,840 --> 02:37:52,200 THAT SUCCINCTLY. WE HAVE SEVERAL 3529 02:37:52,200 --> 02:37:54,440 THEMES FIRST TO LOOK AT RAS AS 3530 02:37:54,440 --> 02:37:56,080 SOMETHING THAT INFLUENCES CANCER 3531 02:37:56,080 --> 02:37:58,520 CELL BIOLOGY AND TO ASK FOR 3532 02:37:58,520 --> 02:38:00,280 THINGS ABOUT CANCER CELL BIOLOGY 3533 02:38:00,280 --> 02:38:02,600 TO INFORM WAYS TO COME UP WITH 3534 02:38:02,600 --> 02:38:04,640 NEW THERAPEUTIC WAYS TO GO AFTER 3535 02:38:04,640 --> 02:38:06,920 RAS. WHAT FRANK AND CO-WORKERS 3536 02:38:06,920 --> 02:38:09,480 WERE ABLE TO DO IS LOOK AT 3537 02:38:09,480 --> 02:38:13,240 PANELS OF CELL LINES. IN OUR 3538 02:38:13,240 --> 02:38:14,800 OWN LABORATORIES OR 3539 02:38:14,800 --> 02:38:16,000 COLLABORATORS, TO COME TO A 3540 02:38:16,000 --> 02:38:18,040 SENSE ON WHAT THE DIFFERENT RAS 3541 02:38:18,040 --> 02:38:19,440 MUTATIONS HAD IN TERMS OF 3542 02:38:19,440 --> 02:38:20,640 PROPERTIES AND PHENOTYPES AND 3543 02:38:20,640 --> 02:38:23,600 CELLS SO THEY HAD 66 PAPERS OVER 3544 02:38:23,600 --> 02:38:25,120 THESE LAST FOUR YEARS, SOME YOU 3545 02:38:25,120 --> 02:38:26,680 WILL HEAR ABOUT TODAY. THEY 3546 02:38:26,680 --> 02:38:28,280 CONFIRM METABOLISM WAS ALTERED 3547 02:38:28,280 --> 02:38:29,720 IN THE CELL LINES THAT EXPRESS 3548 02:38:29,720 --> 02:38:32,080 MUTANT RAS, VERSUS THOSE THAT 3549 02:38:32,080 --> 02:38:35,520 DID NOT, PARTICULARLY GLUTAMINE 3550 02:38:35,520 --> 02:38:38,160 METABOLISM AND REDOX METABOLISM, 3551 02:38:38,160 --> 02:38:39,520 THIS IS CORRELATE WITH 3552 02:38:39,520 --> 02:38:40,640 RESISTANCE ONCOLOGISTS USE IN 3553 02:38:40,640 --> 02:38:44,360 CLINIC. THEY WERE ABLE TO 3554 02:38:44,360 --> 02:38:48,080 CATALOG THE RAS MUTANT CELL 3555 02:38:48,080 --> 02:38:49,200 LINES IN SUCH A FASHION TO 3556 02:38:49,200 --> 02:38:51,000 BECOME A USEFUL INFORMATION 3557 02:38:51,000 --> 02:38:52,560 SOURCE FOR MULTIPLE RESEARCHERS 3558 02:38:52,560 --> 02:38:54,360 LIKE CURT HARRIS FOR P53 AND 3559 02:38:54,360 --> 02:38:56,640 CANCER RESEARCH IN 1994. THEY 3560 02:38:56,640 --> 02:38:59,880 FOUND SOME R ACTIONS MUTANTS NOT 3561 02:38:59,880 --> 02:39:02,320 CODON 12 MUTATIONS BUT OTHER 3562 02:39:02,320 --> 02:39:06,200 CODONS, AND INCREASE GTPASE I 3563 02:39:06,200 --> 02:39:08,640 WAS COMPARED TO G 12D PROTEIN. I 3564 02:39:08,640 --> 02:39:10,040 ASSUME Y'ALL ARE GREAT 3565 02:39:10,040 --> 02:39:11,720 BIOCHEMISTS SO I WILL GIVE YOU A 3566 02:39:11,720 --> 02:39:13,400 PRIMER. WHEN YOU HAVE A MUTATION 3567 02:39:13,400 --> 02:39:16,560 IN CODON 12, THE MOST COMMON MY 3568 02:39:16,560 --> 02:39:17,800 TUITIONNA R AXS HUMAN CANCER IT 3569 02:39:17,800 --> 02:39:20,200 SLOWS DOWN THE ENZYME, YOU HAVE 3570 02:39:20,200 --> 02:39:22,080 A HYPO ACTIVE PROTEIN. THE 3571 02:39:22,080 --> 02:39:23,720 THINKING IS THAT PROTEIN CAUSES 3572 02:39:23,720 --> 02:39:29,320 CHANGES IN CELL THAT CREATED 3573 02:39:29,320 --> 02:39:31,120 TRANSFORMING PROPERTY IS A DRUG 3574 02:39:31,120 --> 02:39:33,480 WOULD SPEED UP THAT PROTEIN OR 3575 02:39:33,480 --> 02:39:36,040 REMOVE PROTEIN FROM CELL. WE 3576 02:39:36,040 --> 02:39:39,440 FOUND SOME RAS ONCOGENES HAD 3577 02:39:39,440 --> 02:39:43,080 FASTER GTPASE ACTIVITY THAN WILD 3578 02:39:43,080 --> 02:39:44,680 FACTOR. SO SUGGESTING WE NEED A 3579 02:39:44,680 --> 02:39:45,560 DIFFERENCE TYPE OF DRUG FOR THAT 3580 02:39:45,560 --> 02:39:47,440 ALLELE. THAT IS UNCOMMON ALLELE 3581 02:39:47,440 --> 02:39:50,120 BUT ONE OF THEIR FINDINGS. WE 3582 02:39:50,120 --> 02:39:51,880 HAVE DONE COOL BIOPHYSICS AND 3583 02:39:51,880 --> 02:39:53,600 ONE IS TOP DOWN MASS 3584 02:39:53,600 --> 02:39:55,040 SPECTROMETRY. Y'ALL KNOW WHAT 3585 02:39:55,040 --> 02:39:56,520 MASS SPEC IS, YOU IDENTIFY 3586 02:39:56,520 --> 02:39:58,080 THINGS IN A MIX, USUALLY A 3587 02:39:58,080 --> 02:39:59,520 PEPTIDE OR SMALL MOLECULE. YOU 3588 02:39:59,520 --> 02:40:02,200 CAN ACTUALLY NOT FRAGMENT THE 3589 02:40:02,200 --> 02:40:03,800 MOLECULES FIRST AND DO -- INDUCE 3590 02:40:03,800 --> 02:40:04,600 A DIFFERENT FORM OF MASS SPEC 3591 02:40:04,600 --> 02:40:06,600 THAT I ALLOWS YOU TO SEE 3592 02:40:06,600 --> 02:40:08,400 ISOFORMS OF PROTEINS THAT MORE 3593 02:40:08,400 --> 02:40:10,880 OR LESS DIFFER DUE TO POST 3594 02:40:10,880 --> 02:40:11,760 TRANSLATIONAL MODIFICATION. THAT 3595 02:40:11,760 --> 02:40:13,520 IS APPLIED HERE AT FREDERICK AND 3596 02:40:13,520 --> 02:40:15,560 THEY HAVE EXCITING DATA ABOUT 3597 02:40:15,560 --> 02:40:18,120 DIFFERENT POPULATIONS OF RAS YOU 3598 02:40:18,120 --> 02:40:18,880 FIND IN DIFFERENT CANCER CELLS, 3599 02:40:18,880 --> 02:40:20,560 THIS TELLS US ABOUT POST 3600 02:40:20,560 --> 02:40:21,680 TRANSLATIONAL MODIFICATION AND 3601 02:40:21,680 --> 02:40:24,800 ENZYMES WHICH MAY CAUSE THAT. 3602 02:40:24,800 --> 02:40:26,400 LAST THING THEY DEVELOPED 3603 02:40:26,400 --> 02:40:28,120 SYNTHETIC MEMBRANES IN THEIR 3604 02:40:28,120 --> 02:40:32,240 SHOP AT FREDERICK TO TELL US 3605 02:40:32,240 --> 02:40:33,880 THINGS WHAT ARE THE LIPID 3606 02:40:33,880 --> 02:40:35,160 CONSTITUENTS NEEDED TO ASSEMBLE 3607 02:40:35,160 --> 02:40:38,560 THE RAS SIGNALING COMPLEX. 3608 02:40:38,560 --> 02:40:40,000 PRESENT RATESSED GOES TO 3609 02:40:40,000 --> 02:40:41,160 SURFACE. OTHER PROTEINS ARE 3610 02:40:41,160 --> 02:40:44,040 INVOLVED IN THAT. THAT'S SEEN BY 3611 02:40:44,040 --> 02:40:45,160 EFFECTOR PROTEINS HOW THAT 3612 02:40:45,160 --> 02:40:46,960 HAPPENED CHANGE HOW WE CREATE 3613 02:40:46,960 --> 02:40:49,040 POTENTIAL DRUGS. THAT LAST WAS 3614 02:40:49,040 --> 02:40:56,520 PUBLISHED NICELY RECENTLY. THE 3615 02:40:56,520 --> 02:40:58,280 MODERN WAY TO MAKE MEDICINE WITH 3616 02:40:58,280 --> 02:40:59,840 GREAT STRUCTURAL BIOLOGY. HIGH 3617 02:40:59,840 --> 02:41:01,640 THROUGH PUT CRYSTALLOGRAPHY IS 3618 02:41:01,640 --> 02:41:02,880 HOW PHARMACEUTICAL COMPANIES ARE 3619 02:41:02,880 --> 02:41:06,880 RELIANT THESE DAYS. YOU CAN DO 3620 02:41:06,880 --> 02:41:08,840 NMR BASED ET CETERA BUT HIGH 3621 02:41:08,840 --> 02:41:10,240 THROUGH PUT CRYSTALLOGRAPHY IS 3622 02:41:10,240 --> 02:41:11,760 GREAT. THIS GROUP IS PROBABLY 3623 02:41:11,760 --> 02:41:16,040 WORLD LEADING IN STRUCTURAL 3624 02:41:16,040 --> 02:41:17,480 DETERMINATION WILD TYPE MUTANT 3625 02:41:17,480 --> 02:41:19,160 RAS. I SAY THAT WITH CONFIDENCE, 3626 02:41:19,160 --> 02:41:20,520 THEY ARE PROBABLY THE BEST ON 3627 02:41:20,520 --> 02:41:23,320 THE PLANET. SO THEY HAVE GREAT 3628 02:41:23,320 --> 02:41:25,120 CRYSTALLOGRAPHY AND NOW CRYOEM 3629 02:41:25,120 --> 02:41:27,200 AS WAY TO LOOK AT VAGUE ISSUES 3630 02:41:27,200 --> 02:41:32,520 HOW MANY PROTEINS BUT NOT THE 3631 02:41:32,520 --> 02:41:33,800 TONIC RESOLUTION. THEY HAVE 3632 02:41:33,800 --> 02:41:35,600 TONIC RESOLUTION FOR WHY WOULD 3633 02:41:35,600 --> 02:41:37,360 TYPE AND RAS. THEY HAVE DONE 3634 02:41:37,360 --> 02:41:39,400 THAT FOR MANY HITS MADE 3635 02:41:39,400 --> 02:41:41,080 CHEMICALLY. AND THAT IS I THINK 3636 02:41:41,080 --> 02:41:44,880 ALSO ELEVATED THE IMPORTANCE AND 3637 02:41:44,880 --> 02:41:45,800 PROMINENCE OF PROGRAM SO THE 3638 02:41:45,800 --> 02:41:48,360 FIRST TO GET A STRUCTURE OF THE 3639 02:41:48,360 --> 02:41:51,800 RAS BINDING DOMAIN, CRAF IS THE 3640 02:41:51,800 --> 02:41:53,120 EFFECT TORR DOWNSTREAM OF MUTANT 3641 02:41:53,120 --> 02:41:55,280 RAS AND CRD, ANOTHER PROTEIN 3642 02:41:55,280 --> 02:41:57,320 DOMAIN ON RAF. BOUND TO WILD 3643 02:41:57,320 --> 02:41:58,440 TYPE AND MUTANT AND THEY 3644 02:41:58,440 --> 02:42:01,160 PUBLISPUBLISPUBLISHED IN NAY CO. 3645 02:42:01,160 --> 02:42:02,400 THAT CHANGED THE WAY PEOPLE 3646 02:42:02,400 --> 02:42:05,480 THOUGHT ABOUT SURFACE CONTACT 3647 02:42:05,480 --> 02:42:08,480 BETWEEN RAP AND RAS WITH GTP 3648 02:42:08,480 --> 02:42:10,480 THAT INFORMS CHEMISTS HOW TO 3649 02:42:10,480 --> 02:42:11,840 UNITE SMALL MOLECULES WHICH MAY 3650 02:42:11,840 --> 02:42:13,440 FIT TO BLOCK THAT INTERACTION OR 3651 02:42:13,440 --> 02:42:16,600 DO THE OPPOSITE TO BRING IT MORE 3652 02:42:16,600 --> 02:42:19,760 STRONGLY TO SO CALLED GLUE THEM. 3653 02:42:19,760 --> 02:42:21,880 USING THE GLUE VERSUS BREAK 3654 02:42:21,880 --> 02:42:24,080 METHOD THE .3 HERE THEY DEVELOP 3655 02:42:24,080 --> 02:42:26,160 FIRST IN CLASS BLOCKERS TO PI 3 3656 02:42:26,160 --> 02:42:30,320 KINASE ALPHA AND MASS GTP. PI 3 3657 02:42:30,320 --> 02:42:32,200 KINASE IS ESSENTIAL PATHWAY IN 3658 02:42:32,200 --> 02:42:36,320 ALL CELLS AND MET SOW WANTS WAN 3659 02:42:36,320 --> 02:42:37,240 SOMETIMES MY TAINTED IN CANCER 3660 02:42:37,240 --> 02:42:40,800 AND RAS MUTANT CELLS DRIVE IT IS 3661 02:42:40,800 --> 02:42:41,920 PATHWAY DIFFERENT THAN THE 3662 02:42:41,920 --> 02:42:45,040 KINASE CASCADE BUT PI 3 KINASE 3663 02:42:45,040 --> 02:42:46,600 IN GENERAL IS HARD FOR MEDICAL 3664 02:42:46,600 --> 02:42:48,040 ONCOLOGISTS TO DEVELOP BECAUSE 3665 02:42:48,040 --> 02:42:49,720 IT CAUSE HYPERGLYCEMIA AND OTHER 3666 02:42:49,720 --> 02:42:52,280 THINGS. THESE FOLKS BECAUSE THEY 3667 02:42:52,280 --> 02:42:54,680 CAN CRYSTALLIZE WITH RAS GTP 3668 02:42:54,680 --> 02:42:56,480 FIGURE A SMALL MOLECULE THAT 3669 02:42:56,480 --> 02:42:59,080 GLUEING TO AND CHEMIST USE THEIR 3670 02:42:59,080 --> 02:43:01,120 AX TO BREAK IT INDO A BLOCKER 3671 02:43:01,120 --> 02:43:03,640 COMPOUND THAT BINDS PI 3 KINASE 3672 02:43:03,640 --> 02:43:05,960 ALPHA PREVENTING FROM RAS GTP. 3673 02:43:05,960 --> 02:43:09,600 FIRST IN CLASS FIRST DESCRIBED, 3674 02:43:09,600 --> 02:43:10,720 COMPOUND. THEY HAVE TONS OF 3675 02:43:10,720 --> 02:43:12,400 CRYSTAL STRUCTURE, LOOKING AT 3676 02:43:12,400 --> 02:43:15,200 THAT COMPOUND AND BIOLOGY. LAST 3677 02:43:15,200 --> 02:43:17,000 IS NEUROFIBROMINUTE. THIS IS THE 3678 02:43:17,000 --> 02:43:19,760 GENE RESPONSIBLE WHEN MUTATED 3679 02:43:19,760 --> 02:43:23,200 FOR NEUROFIBROMATOSITOSIS. INHED 3680 02:43:23,200 --> 02:43:25,120 CANCER PRE-DISPOSITION SYNDROME 3681 02:43:25,120 --> 02:43:27,080 BECAUSE BECAUSE THEY ARE GREAT 3682 02:43:27,080 --> 02:43:28,480 AT CRYSTALLOGRAPHY, THEY WERE 3683 02:43:28,480 --> 02:43:29,800 THE FIRST THE PUBLISH THIS WORKS 3684 02:43:29,800 --> 02:43:34,000 AS A DIMER. THIS IS ESSENTIAL IF 3685 02:43:34,000 --> 02:43:36,560 THINKING ABOUT DRUGS THAT TETHER 3686 02:43:36,560 --> 02:43:39,000 NF 1 TO MUTANT RAS, ONE OF THE 3687 02:43:39,000 --> 02:43:39,760 NEXT IDEAS THEY HAVE. NEXT 3688 02:43:39,760 --> 02:43:43,840 SLIDE. SO THEY HAVE LOOKED A T 3689 02:43:43,840 --> 02:43:45,880 RAS CELL LINES, RAS CRYSTAL 3690 02:43:45,880 --> 02:43:46,680 STRUCTURE, THEY HAVE DONE 3691 02:43:46,680 --> 02:43:49,680 SOMETHING MORE SOPHISTICATED 3692 02:43:49,680 --> 02:43:51,240 FROM MOLECULAR STANDPOINT BY 3693 02:43:51,240 --> 02:43:54,800 LOOKING HOW RAS WORKS IN THE 3694 02:43:54,800 --> 02:43:56,840 MEMBRANE USING FANCY MICROSCOPES 3695 02:43:56,840 --> 02:43:58,760 BUT ALSO SUPER COMPUTERS AND 3696 02:43:58,760 --> 02:44:02,920 MACHINE LEARNING. ARTIFICIAL 3697 02:44:02,920 --> 02:44:05,600 INTELLIGENCE METHODS. BY USE 3698 02:44:05,600 --> 02:44:07,360 EMPIRIC METHODS THEY WERE ABLE 3699 02:44:07,360 --> 02:44:09,160 TO SHOW THREE STRUCTURE THAT RAS 3700 02:44:09,160 --> 02:44:11,400 HAD ON THE MEMBRANE WHEN BOUND 3701 02:44:11,400 --> 02:44:13,080 -- WHEN PRESENT AND WHEN BOUND 3702 02:44:13,080 --> 02:44:14,680 TO GTP THAT CHANGES THE 3703 02:44:14,680 --> 02:44:18,000 POPULATION STATES OF THE THREE. 3704 02:44:18,000 --> 02:44:20,400 ONE OR TWO ARE NEXT TO MEMBRANE. 3705 02:44:20,400 --> 02:44:22,400 THESE ARE LATENT STRUCTURE AND 3706 02:44:22,400 --> 02:44:24,840 CAN'T BIND TO MAP KINASE CASCADE 3707 02:44:24,840 --> 02:44:26,880 LIKE RAF. ONLY IN CYTOPLASM 3708 02:44:26,880 --> 02:44:28,560 THAT ALLOWS ACCESS TO THE RAF 3709 02:44:28,560 --> 02:44:30,320 MOLECULE. THE REASON THOSE 3710 02:44:30,320 --> 02:44:34,000 DETAILS ARE RELEVANT IS IF 3711 02:44:34,000 --> 02:44:36,280 CREATING A COMPOUND THAT BLOCKS 3712 02:44:36,280 --> 02:44:37,680 RA,F YOU DON'T WANT TO CREATE 3713 02:44:37,680 --> 02:44:38,800 ONE THAT NEVER BINDS TO PART 3714 02:44:38,800 --> 02:44:41,400 THAT IS IRRELEVANT FOR RAF SO 3715 02:44:41,400 --> 02:44:45,160 THEY KNOW EXACTLY THE PART OF 3716 02:44:45,160 --> 02:44:47,400 RAS GTP THAT STICKS IN THE 3717 02:44:47,400 --> 02:44:48,560 CYTOPLASM, THAT IS WHERE THEY 3718 02:44:48,560 --> 02:44:50,560 ARE FOCUSED. SECOND THEY USE 3719 02:44:50,560 --> 02:44:51,680 MOLECULAR DYNAMIC STIMULATION AS 3720 02:44:51,680 --> 02:44:54,800 WELL AS DIRECT MEASUREMENTS, 3721 02:44:54,800 --> 02:44:58,080 PLASMA RESONANCE TO PREDICT HOW 3722 02:44:58,080 --> 02:45:00,000 THESE THREE CONFIRMATIONS OF RAS 3723 02:45:00,000 --> 02:45:02,760 GO BACK AND FORTH AND WHICH 3724 02:45:02,760 --> 02:45:06,000 COMPLEXES, WHICH FORM OF RAS IS 3725 02:45:06,000 --> 02:45:06,640 RELEVANT IN CANCER CELLS VERSUS 3726 02:45:06,640 --> 02:45:11,960 NORMAL CELLS. UNDERSTANDING WHAT 3727 02:45:11,960 --> 02:45:13,760 IS IN THE DETAILS OF PLASMA 3728 02:45:13,760 --> 02:45:15,520 MEMBRANE IS ESSENTIAL. LAST 3729 02:45:15,520 --> 02:45:16,920 THING, THEY HAVE THIS ALCOHOL 3730 02:45:16,920 --> 02:45:18,400 PROJECT WORKING WITH ANOTHER 3731 02:45:18,400 --> 02:45:20,360 GOVERNMENTAL AGENCY. THE 3732 02:45:20,360 --> 02:45:24,720 DEPARTMENT OF ENERG ENERGY. WHEE 3733 02:45:24,720 --> 02:45:25,400 LAWRENCE LIVERPOOL NATIONAL LAB 3734 02:45:25,400 --> 02:45:27,320 HAS A SUPER COMPUTER AND THIS 3735 02:45:27,320 --> 02:45:29,440 MACHINE LEARNING BASED APPROACH 3736 02:45:29,440 --> 02:45:33,040 WHERE THEY FEED IN SIMULATIONS 3737 02:45:33,040 --> 02:45:34,240 OF DATA FROM PROJECTS ONE AND 3738 02:45:34,240 --> 02:45:38,360 TWO AND COME UP WITH ESSENTIALLY 3739 02:45:38,360 --> 02:45:40,680 A DYNAMIC ASSESSMENT HOW RAS 3740 02:45:40,680 --> 02:45:44,600 MOVES BACK AND FORTH TO ENGAGE 3741 02:45:44,600 --> 02:45:46,680 EFFECTORS AS YOU ALER 3742 02:45:46,680 --> 02:45:47,920 CONSTITUENTS MANY THE PLASMA 3743 02:45:47,920 --> 02:45:48,920 MEMBRANE. WITH THIS SUPER 3744 02:45:48,920 --> 02:45:53,000 COMPUTER APPROACH THEY ARE 3745 02:45:53,000 --> 02:45:55,240 HYPOTHESIZING ADDITIONAL 3746 02:45:55,240 --> 02:45:56,760 CONFIRMATIONS TO THINK ABOUT 3747 02:45:56,760 --> 02:45:57,880 FROM DRUG DISCOVERY STANDPOINT. 3748 02:45:57,880 --> 02:46:00,600 THIS IS THE FIRST TIME LNL HAS 3749 02:46:00,600 --> 02:46:01,800 WORKED WITH THE FREDERICK 3750 02:46:01,800 --> 02:46:03,080 NATIONAL CANCER RESEARCH 3751 02:46:03,080 --> 02:46:05,440 LABORATORY TO DO ANYTHING ON 3752 02:46:05,440 --> 02:46:06,840 THIS SCALE, USUAL WILL I LOOKING 3753 02:46:06,840 --> 02:46:08,040 AT STARS IN THE SKY AND OTHER 3754 02:46:08,040 --> 02:46:13,120 THINGS RELEVANT TO DEFENSE. SO 3755 02:46:13,120 --> 02:46:15,960 WITH THIS IS THE BACKGROUND, 3756 02:46:15,960 --> 02:46:18,320 WHICH I HAVE CHEMISTRY, GOOD 3757 02:46:18,320 --> 02:46:19,840 CHEMISTRY. I HAVE THE GOOD 3758 02:46:19,840 --> 02:46:21,400 FORTUNE OF WORKING IN ENGLAND 3759 02:46:21,400 --> 02:46:23,040 SIX YEARS, GOT TO SEE HOW THE 3760 02:46:23,040 --> 02:46:24,960 ICR WAS SET UP SOUTH OF LONDON, 3761 02:46:24,960 --> 02:46:27,720 THEY HAVE INTERNAL CHEMISTRY 3762 02:46:27,720 --> 02:46:30,760 PROGRAM. 25 TO 30 CHEMISTS THEY 3763 02:46:30,760 --> 02:46:35,120 INVENTED DRUGS LIKE TAMAZOLAMIDE 3764 02:46:35,120 --> 02:46:37,120 AND THEY HAD A GOOD INVESTMENT 3765 02:46:37,120 --> 02:46:39,640 MODEL FOR FINANCIAL SO A THIRD 3766 02:46:39,640 --> 02:46:41,400 OF BUDGET CAME FROM PATENTS. SO 3767 02:46:41,400 --> 02:46:44,680 THESE NOW HAVE A CHANCE AT THAT 3768 02:46:44,680 --> 02:46:47,080 TOO BECAUSE THEY HAVE A LEAD G 3769 02:46:47,080 --> 02:46:50,280 12C INHIBITOR, BETTER THAN AMJEN 3770 02:46:50,280 --> 02:46:52,520 AND COMPOUND FDA APPROVED TO 3771 02:46:52,520 --> 02:46:54,080 TREAT LUNG CANCER BECAUSE IT 3772 02:46:54,080 --> 02:46:55,680 HITS BOTH RAS ON AND THE RAS OFF 3773 02:46:55,680 --> 02:47:00,000 STATE. SEEMS BETTER IN VITRO 3774 02:47:00,000 --> 02:47:01,680 AND MUCH BETTER IN VIVO BY 3775 02:47:01,680 --> 02:47:03,560 ASSESSMENTS TAKEN. YOU CAN SAY 3776 02:47:03,560 --> 02:47:06,680 DO WE REALLY NEED ANOTHER G 12C 3777 02:47:06,680 --> 02:47:08,320 INHIBITOR? READ THE PAPERS IN 3778 02:47:08,320 --> 02:47:10,400 NEW ENGLAND JOURNAL AND 3779 02:47:10,400 --> 02:47:12,560 ELSEWHERE. PATIENTS ARE 3780 02:47:12,560 --> 02:47:13,120 RESPONDINGTANT SUBSEQUENTLY, 3781 02:47:13,120 --> 02:47:13,840 COME BACK WITH RHESUS TAN 3782 02:47:13,840 --> 02:47:15,200 DISEASE. IF THEY HAVE A BETTER 3783 02:47:15,200 --> 02:47:17,640 DRUG WHICH WILL HAVE MORE 3784 02:47:17,640 --> 02:47:20,040 DURABILITY, IN THE PATIENT THAN 3785 02:47:20,040 --> 02:47:21,480 THIS COULD BE BIG DEAL. OF 3786 02:47:21,480 --> 02:47:23,920 COURSE G 12C IS A RARE ALLELE 3787 02:47:23,920 --> 02:47:25,480 WHEN YOU THINK OF PANCREAS 3788 02:47:25,480 --> 02:47:27,520 CANCER AND COLON CANCER. FOR 3789 02:47:27,520 --> 02:47:29,400 THAT THEY HAVE A WHOLE PIPELINE 3790 02:47:29,400 --> 02:47:31,400 OF MOLECULES THEY THINK WILL 3791 02:47:31,400 --> 02:47:36,000 WORK IN ASPARTAT MUTANT AND 3792 02:47:36,000 --> 02:47:36,760 AVAILING MUTANT NOT READY FOR 3793 02:47:36,760 --> 02:47:38,200 CLINIC. SO THEY HAVE A COMPOUND 3794 02:47:38,200 --> 02:47:39,400 THEY CREATED WITH PARTNERSHIPS 3795 02:47:39,400 --> 02:47:42,360 WITH PHARMA. AS I SAID BEFORE 3796 02:47:42,360 --> 02:47:43,600 SEEMS BEAR THAN ANYTHING OUT 3797 02:47:43,600 --> 02:47:45,080 THERE. THINK IT WILL GO CLINIC 3798 02:47:45,080 --> 02:47:47,040 FIRST QUARTER OF THIS NEXT YEAR 3799 02:47:47,040 --> 02:47:48,200 SECOND POINT HERE THEY HAVE THE 3800 02:47:48,200 --> 02:47:51,640 FIRST PI 3 KINASE ALPHA BLOCKER 3801 02:47:51,640 --> 02:47:53,120 MOLECULE, FIRST I HAVE HEARD OF, 3802 02:47:53,120 --> 02:47:54,480 NOTHING IN THE THE LITERATURE IF 3803 02:47:54,480 --> 02:47:56,240 YOU PUBMED AND LOOKS LIKE THIS 3804 02:47:56,240 --> 02:47:58,320 COULD BE A SMART WAY TO BLOCK A 3805 02:47:58,320 --> 02:48:00,360 PATHWAY IN RAS MUTANT CELLS. 3806 02:48:00,360 --> 02:48:02,160 WILL THIS TURN OUT REALLY 3807 02:48:02,160 --> 02:48:04,000 IMPORTANT CLINICALLY? BEHAVE TO 3808 02:48:04,000 --> 02:48:06,520 SEE BUT THIS IS IMPORTANT FROM A 3809 02:48:06,520 --> 02:48:07,120 SCIENTIFIC STAND POINT WHETHER 3810 02:48:07,120 --> 02:48:09,160 IT IS IMPORTANT FROM CLINICAL OR 3811 02:48:09,160 --> 02:48:10,040 FINANCIAL STANDPOINT I WOULD SAY 3812 02:48:10,040 --> 02:48:12,200 STILL HAVE TO BE FIGURED OUT. 3813 02:48:12,200 --> 02:48:14,120 THEY HAVE THOSE OTHER MUTANT 3814 02:48:14,120 --> 02:48:16,000 ALLELES THAT I HAVE TALKED 3815 02:48:16,000 --> 02:48:19,800 ABOUT, SPARTATE ALLEL ALLELE. TY 3816 02:48:19,800 --> 02:48:21,160 HAVE WAYS OF NOT JUST GOING 3817 02:48:21,160 --> 02:48:22,720 AFTER CYSTEINE BUT OTHER AMINO 3818 02:48:22,720 --> 02:48:26,480 ACIDS WHICH EXIST IN RAS. THEY 3819 02:48:26,480 --> 02:48:31,640 HAVE ONE METHOD MAKES A GOOD 3820 02:48:31,640 --> 02:48:36,680 PROTAC. A METHOD INVENTED BY 3821 02:48:36,680 --> 02:48:38,240 CRAIG CRUISE AT YALE WHICH SMALL 3822 02:48:38,240 --> 02:48:39,920 MOLECULE UBIQUITIN LIGASE THAT 3823 02:48:39,920 --> 02:48:42,000 GOES TO PROTOSEWSOME SO THEY 3824 02:48:42,000 --> 02:48:45,160 HAVE A COUPLE THAT GOES THROUGH 3825 02:48:45,160 --> 02:48:51,000 PROTAC. AND THEY HAVE -- NEXT 3826 02:48:51,000 --> 02:48:55,480 SLIDE PLEASE. WHAT ABOUT 3827 02:48:55,480 --> 02:48:58,160 SCIENTIFIC COMMUNITY? WHEN THIS 3828 02:48:58,160 --> 02:48:58,800 STARTED, TECH YEARS AGO, MORE 3829 02:48:58,800 --> 02:49:03,560 THAN THAT, WHEN THE IDEA TO TRY 3830 02:49:03,560 --> 02:49:06,520 THIS I REMEMBER SHOULD WE GO 3831 02:49:06,520 --> 02:49:08,400 AFTER? NO. DUMB IDEA, PAPER IN 3832 02:49:08,400 --> 02:49:11,480 NATURE HE COULD DO IT FROM USCF 3833 02:49:11,480 --> 02:49:13,280 STAND POINT, A TOOL COMPOUND 3834 02:49:13,280 --> 02:49:16,320 METHOD BUT WE HAD DECIDED BEFORE 3835 02:49:16,320 --> 02:49:19,280 THEN I THINK THAT COULD BE 3836 02:49:19,280 --> 02:49:20,360 CORRECTED HOLD BY DOUG WHO HAS 3837 02:49:20,360 --> 02:49:21,800 BACK STORY BUT COMMUNITY THOUGHT 3838 02:49:21,800 --> 02:49:24,240 IT WAS NOT A SMART THING, 3839 02:49:24,240 --> 02:49:24,960 UNDRUGGABLE TARGET SO BRINGING 3840 02:49:24,960 --> 02:49:26,800 THE COMMUNITY ALONG IS A -- HAS 3841 02:49:26,800 --> 02:49:30,960 BEEN A GOAL AND THEY HAVE DONE A 3842 02:49:30,960 --> 02:49:32,080 GREAT JOB EMBRACING THE 3843 02:49:32,080 --> 02:49:33,160 IMMUNITY, VERY OPEN WITH ALL THE 3844 02:49:33,160 --> 02:49:37,680 THINGS THEY INVENTED. BEST 3845 02:49:37,680 --> 02:49:40,920 PLACE TO CRYSTALLIZE RAS THEY 3846 02:49:40,920 --> 02:49:43,680 HAD TO CREATE THE PROTEIN, DO IT 3847 02:49:43,680 --> 02:49:44,240 WITH APRESENT RATION ON IT. 3848 02:49:44,240 --> 02:49:45,600 DEVELOP ALL THE TOOLS AND 3849 02:49:45,600 --> 02:49:48,880 PLASMIDS TO CLONE THE GENES ALL 3850 02:49:48,880 --> 02:49:52,800 THE CELLS, MICROBIAL OR EUKAR 3851 02:49:52,800 --> 02:49:55,440 EUKARYOTIC TO PRODUCE PROTEIN 3852 02:49:55,440 --> 02:49:58,960 PURIFY PROTEIN CRYSTALLIZE, ALL 3853 02:49:58,960 --> 02:50:00,560 THAT, THEY INVITED THE COMMUNITY 3854 02:50:00,560 --> 02:50:03,440 TO COME TO SHOP TO LEARN THIS 3855 02:50:03,440 --> 02:50:06,600 STUFF. MULTIPLE TIMES. THE DEAL 3856 02:50:06,600 --> 02:50:07,840 WITH PHARMA IS DIFFERENT, THEY 3857 02:50:07,840 --> 02:50:10,080 HAD THE ENCOURAGE PHARMA TO GET 3858 02:50:10,080 --> 02:50:12,280 INTO SPACE. PHARMA IS NOR THAN 3859 02:50:12,280 --> 02:50:15,560 IN THE SPACE NOW. THE LAST FOUR 3860 02:50:15,560 --> 02:50:17,760 YEARS PUBLISHED 66 PAPERS AND IT 3861 02:50:17,760 --> 02:50:19,160 IS TOTALLY DERISKED AT THIS 3862 02:50:19,160 --> 02:50:20,360 POINT. EVERYONE BELIEVES 3863 02:50:20,360 --> 02:50:22,280 DRUGGABLE. THE QUESTION IS WILL 3864 02:50:22,280 --> 02:50:25,800 IT MATTER. THAT'S COMING TO THE 3865 02:50:25,800 --> 02:50:26,800 WHY THE PROGRAM IS IMPORTANT FOR 3866 02:50:26,800 --> 02:50:31,000 YOU TO CONSIDER KEEP IT GOING. 3867 02:50:31,000 --> 02:50:34,280 I ALREADY SAID, THEY HAVE GIVEN 3868 02:50:34,280 --> 02:50:35,600 1,200,000 PLASMIDS ALL THESE 3869 02:50:35,600 --> 02:50:37,200 PROTEINS AND CELL LINES DOING 3870 02:50:37,200 --> 02:50:40,880 BETTER THAN ADD GENE OR ATCC. 3871 02:50:40,880 --> 02:50:42,160 THEY RANK WITH OTHER TWO SOURCES 3872 02:50:42,160 --> 02:50:45,320 FOR THINGS. THEY SPONSORED 3873 02:50:45,320 --> 02:50:47,000 MULTIPLE INTELLECTUAL ENCOUNTERS 3874 02:50:47,000 --> 02:50:49,120 FOR PEOPLE, THEY HOST SYMPOSIA 3875 02:50:49,120 --> 02:50:52,200 IN FREDERICK. DONE IT EVERY 3876 02:50:52,200 --> 02:50:53,560 YEAR, EVERY OTHER YEAR AND THEY 3877 02:50:53,560 --> 02:50:55,560 HAVE BEEN TERRIFIC. MANY OF YOU 3878 02:50:55,560 --> 02:50:57,160 HAVE COME TO THEM AND THERE IS 3879 02:50:57,160 --> 02:50:59,440 ONE MANY A FEW WEEKS, OR NEXT 3880 02:50:59,440 --> 02:51:02,800 WEEK, I HOPE SOME ARE GOING TO 3881 02:51:02,800 --> 02:51:03,920 THAT. THEY HAVE DONE THE SOCIAL 3882 02:51:03,920 --> 02:51:05,840 MEDIA THING. WE HAVE A WEBSITE, 3883 02:51:05,840 --> 02:51:07,440 PEOPLE PUT THEIR TESTIMONIAL UP 3884 02:51:07,440 --> 02:51:08,560 ABOUT NEW STUFF THEY ARE 3885 02:51:08,560 --> 02:51:10,840 DISCOVERING AND IT'S BECOME LIKE 3886 02:51:10,840 --> 02:51:12,480 I DON'T KNOW LIKE INFORMATION 3887 02:51:12,480 --> 02:51:14,000 STREAM. EVERYONE THINKS ABOUT 3888 02:51:14,000 --> 02:51:16,000 RAS AS SOMETHING THAT CAN BE 3889 02:51:16,000 --> 02:51:17,680 DONE AND THEREFORE THEY ARE LESS 3890 02:51:17,680 --> 02:51:19,160 SCARED ABOUT OTHER TARGETS TOO. 3891 02:51:19,160 --> 02:51:21,040 RAS HAS BROKEN THE GLASS 3892 02:51:21,040 --> 02:51:25,320 CEILING. NEXT SLIDE PLEASE. 3893 02:51:25,320 --> 02:51:28,280 WHICH WOULD BE/THIS MUST BE THE 3894 02:51:28,280 --> 02:51:30,200 LAST SLIDE. FROM MY STANDPOINT 3895 02:51:30,200 --> 02:51:32,600 IS THE UNPAID ACADEMIC 3896 02:51:32,600 --> 02:51:34,440 INTERESTED ADVISOR BECAUSE I 3897 02:51:34,440 --> 02:51:36,840 STUDY PANCREAS CANCER. I THINK 3898 02:51:36,840 --> 02:51:38,120 THEY HAVE -- THEY HAVE BEEN 3899 02:51:38,120 --> 02:51:39,600 AMAZING. THEY HAVE GONE PAST 3900 02:51:39,600 --> 02:51:41,560 THEIR OBJECTIVES THEY HAD TEN 3901 02:51:41,560 --> 02:51:43,240 YEARS AGO DESPITE THE PANDEMIC 3902 02:51:43,240 --> 02:51:46,520 WE HAVE DEALT WITH. THEY HAVE 3903 02:51:46,520 --> 02:51:48,720 TWO MOLECULES HEADED TOWARDS 3904 02:51:48,720 --> 02:51:50,880 IND. ONE HITS BOTH ON AND OFF 3905 02:51:50,880 --> 02:51:53,120 STATE. I HOPE IT BLOWS THE TWO 3906 02:51:53,120 --> 02:51:54,120 FDA APPROVED OUT OF THE WATER, 3907 02:51:54,120 --> 02:51:56,680 WE HAVE I'LL HAVE TO SEE. THEY 3908 02:51:56,680 --> 02:51:58,520 HAVE THIS COMPLEX BREAKER WHICH 3909 02:51:58,520 --> 02:52:00,440 IS FIRST IN CLASS AND GOING TO 3910 02:52:00,440 --> 02:52:02,160 ENCOURAGE PHARMA TO MAKE THESE 3911 02:52:02,160 --> 02:52:03,280 TWO, FOR DIFFERENT APPROXIMATE 3912 02:52:03,280 --> 02:52:04,840 MR. AQUATIONS. THEY PROBABLY 3913 02:52:04,840 --> 02:52:06,280 HAVE AGAIN THE BEST PLACE TO 3914 02:52:06,280 --> 02:52:08,360 STUDY RAS FROM THE STANDPOINT OF 3915 02:52:08,360 --> 02:52:09,880 I HAVE A MUTATION WHAT IS 3916 02:52:09,880 --> 02:52:13,400 PROTEIN LOOK LIKE, WHAT IS THE 3917 02:52:13,400 --> 02:52:16,640 STRUCTURE, WHAT DOES IT DO 3918 02:52:16,640 --> 02:52:21,520 BIOCHEMICALLY. THEY BROADEN TO 3919 02:52:21,520 --> 02:52:23,560 EFFECTOR BE THEY NEGATIVE OR 3920 02:52:23,560 --> 02:52:25,120 POSITIVE REGULATORS OF R ASHS. 3921 02:52:25,120 --> 02:52:27,440 THEY PUBLISH PAPERS ON 3922 02:52:27,440 --> 02:52:28,920 BIOCHEMISTRY AND REGULATION. 3923 02:52:28,920 --> 02:52:30,920 THAT IS A REALLY IMPORTANT 3924 02:52:30,920 --> 02:52:32,840 FINDING. THEY HAVE THIS 3925 02:52:32,840 --> 02:52:36,000 BIOPHYSICS ARM TO THEM AND 3926 02:52:36,000 --> 02:52:37,800 MACHINE LEARNING COMPUTATIONAL 3927 02:52:37,800 --> 02:52:39,080 ARM WHICH TELLS SOMETHING HOW 3928 02:52:39,080 --> 02:52:41,200 THESE MOLECULES EXIST ON CELLS 3929 02:52:41,200 --> 02:52:44,800 WHICH ARE REQUIRED FOR LIFE, 3930 02:52:44,800 --> 02:52:47,280 CIRCUMVENTED BY CANCER TO MODIFY 3931 02:52:47,280 --> 02:52:48,880 SIGNALING PATHWAYS DOWNSTREAM. 3932 02:52:48,880 --> 02:52:52,760 THAT MIGHT BE MY LAST SLIDE. 3933 02:52:52,760 --> 02:52:56,280 CLICK IT TO TELL ME. SO I HAVE 3934 02:52:56,280 --> 02:52:56,680 RECOMMENDATIONS. MY 3935 02:52:56,680 --> 02:52:57,560 RECOMMENDATION AFTER THINKING 3936 02:52:57,560 --> 02:53:00,880 ABOUT AND TALKING TO THEM AND TO 3937 02:53:00,880 --> 02:53:02,520 MY GROUP, WE ARE FOUGHT QUITE 3938 02:53:02,520 --> 02:53:06,760 DONE. WHEN I THOUGHT SIX, 12 3939 02:53:06,760 --> 02:53:10,520 MONTHS AGO, I SAID PROBABLY THE 3940 02:53:10,520 --> 02:53:13,200 PROOF IS DONE MAYBE PHARMA WILL 3941 02:53:13,200 --> 02:53:14,320 DO THE RESTFUL DOUBT THAT IS THE 3942 02:53:14,320 --> 02:53:17,440 CASE. PHARMA IS WAY TOO 3943 02:53:17,440 --> 02:53:18,440 SHORTSIGHTED, THEY PROVED THAT 3944 02:53:18,440 --> 02:53:20,600 OVER AND OVER. I THINK HAVING A 3945 02:53:20,600 --> 02:53:22,160 SPECIAL OPS PROGRAM LIKE THIS IN 3946 02:53:22,160 --> 02:53:23,840 INSIDE MEANS WE THINK, IT MEANS 3947 02:53:23,840 --> 02:53:26,520 WE ARE NOT A REFLEX, WE HAVE A 3948 02:53:26,520 --> 02:53:27,560 BRAIN. SO IT IS IMPORTANT FOR US 3949 02:53:27,560 --> 02:53:31,440 TO KEEP GOING FOR VARIETY OF 3950 02:53:31,440 --> 02:53:33,240 REASONS. I THINK THIS INHIBITOR 3951 02:53:33,240 --> 02:53:34,680 THEY HAVE VERY EXCITED ABOUT THE 3952 02:53:34,680 --> 02:53:36,480 COMPOUND IS TOTALLY UNIQUE SO IT 3953 02:53:36,480 --> 02:53:40,880 SHOULD GET PROTECTED BY LAWYERS 3954 02:53:40,880 --> 02:53:42,040 AND GET INTO CLINIC. ONCE 3955 02:53:42,040 --> 02:53:44,600 THROUGH THE VARIOUS SMALL AND 3956 02:53:44,600 --> 02:53:46,280 MEDIUM SIZE ANIMALS. IT WILL 3957 02:53:46,280 --> 02:53:47,400 TURN OUT TO BE GREAT MAYBE AND 3958 02:53:47,400 --> 02:53:48,440 HAVE RETURN ON INVESTMENT. IF 3959 02:53:48,440 --> 02:53:49,800 YOU SET UP THE RIGHT WAY. FOR 3960 02:53:49,800 --> 02:53:57,600 THE PROGRAM. RESISTANCE TO RAS 3961 02:53:57,600 --> 02:53:59,600 INHIBITORS. THE G 12 INHIBITORS 3962 02:53:59,600 --> 02:54:00,720 ARE GREAT, SIX MONTHS LATER 3963 02:54:00,720 --> 02:54:06,520 DON'T. SO GLEVAC WITH -- DOESN'T 3964 02:54:06,520 --> 02:54:08,640 WORK. IT WORKS GREAT IN EARLY 3965 02:54:08,640 --> 02:54:10,720 CML, THAT IS TRUE OF A LOT OF 3966 02:54:10,720 --> 02:54:16,720 THINGS. SO I THINK THESE ARE 3967 02:54:16,720 --> 02:54:17,960 ABOUT RESISTANCE BECAUSE WE TELL 3968 02:54:17,960 --> 02:54:19,680 THEM, IT IS IMPORTANT THEY DO SO 3969 02:54:19,680 --> 02:54:20,800 BECAUSE SOME IS ON TARGET 3970 02:54:20,800 --> 02:54:21,680 RESISTANCE WHICH THEY ARE GREAT 3971 02:54:21,680 --> 02:54:24,680 AT. SOME IS OFF TARGET 3972 02:54:24,680 --> 02:54:25,600 RESISTANCE THEY HAVE TO KEEP 3973 02:54:25,600 --> 02:54:30,480 THAT COORDINATED ENVIRONMENT 3974 02:54:30,480 --> 02:54:31,040 COMMUNITY GOING THEY HAVE 3975 02:54:31,040 --> 02:54:33,200 BECAUSE THAT IS NEW TARGETS TO 3976 02:54:33,200 --> 02:54:35,880 TAKE ON BOARD. ONE RESISTANCE 3977 02:54:35,880 --> 02:54:40,280 PATHWAY IS MIC. THEY MIGHT HAVE 3978 02:54:40,280 --> 02:54:42,840 TO BECAUSE IT IS LIKELY ONE OF 3979 02:54:42,840 --> 02:54:44,200 THE MOST IMPORTANT RESISTANCE 3980 02:54:44,200 --> 02:54:46,240 PATHWAYS IN RAS MUTANT CANCER 3981 02:54:46,240 --> 02:54:47,760 AND YOU CAN SAY MIC IS IMPORTANT 3982 02:54:47,760 --> 02:54:51,360 FOR OTHER CANCERS TOO. I DON'T 3983 02:54:51,360 --> 02:54:52,840 KNOW THE BANDWIDTH TO DO IT WITH 3984 02:54:52,840 --> 02:54:54,840 PEOPLE NOW BUT THAT IS SOMETHING 3985 02:54:54,840 --> 02:54:55,840 AS COMMUNITY AS THINK TANK WE 3986 02:54:55,840 --> 02:54:59,640 SHOULD CONSIDER. SECOND BULLET 3987 02:54:59,640 --> 02:55:01,840 POINT. THEIR OTHER TARGETS PI 3 3988 02:55:01,840 --> 02:55:04,520 KINASE ALPHA COMPLEX COULD BE 3989 02:55:04,520 --> 02:55:06,760 TERRIFIC AND THAT MAY WORK IN 3990 02:55:06,760 --> 02:55:09,800 NON-RAS CANCERS TOO. NON-RAS 3991 02:55:09,800 --> 02:55:14,920 MUTANT CANCER. THIRD POINT, 3992 02:55:14,920 --> 02:55:17,760 THERE IS THE RENAISSANCE, OTHER 3993 02:55:17,760 --> 02:55:18,800 PEOPLE, HAVE BEEN RESPONSIBLE 3994 02:55:18,800 --> 02:55:22,360 FOR SHEPHERDING THE RENAISSANCE 3995 02:55:22,360 --> 02:55:23,720 THANKS TO DOUG FOR STAYING 3996 02:55:23,720 --> 02:55:25,320 PATIENT WITH THE PROGRAM, 3997 02:55:25,320 --> 02:55:26,880 HOPEFULLY MONICA AND NEW JOB 3998 02:55:26,880 --> 02:55:29,160 ISN'T TRYING TO CUT CORNERS WITH 3999 02:55:29,160 --> 02:55:33,040 THE BAD COMMITTEE. BECAUSE WE 4000 02:55:33,040 --> 02:55:35,840 ARE IN A GOOD SPOT OUR PATIENTS 4001 02:55:35,840 --> 02:55:36,720 NEED BETTER MEDICINE. THIS 4002 02:55:36,720 --> 02:55:39,800 PROGRAM IS GIVING US PART OF 4003 02:55:39,800 --> 02:55:44,720 THAT FIRST TIME REAL MEDICINE 4004 02:55:44,720 --> 02:55:45,600 FOR CANCER THAT ARE TOTALLY 4005 02:55:45,600 --> 02:55:47,560 TREATABLE. WE HAVE A COMMUNITY 4006 02:55:47,560 --> 02:55:49,320 OF PRIVATE AND PUBLIC AN 4007 02:55:49,320 --> 02:55:49,920 GOVERNMENT, YOU HAVE TO BRING 4008 02:55:49,920 --> 02:55:51,960 THE FDA BECAUSE YOU HAVE TO FILE 4009 02:55:51,960 --> 02:55:55,400 INDs AND THAT STUFF. I THINK 4010 02:55:55,400 --> 02:55:56,760 YOU DON'T WANT TO DISRUPT THE 4011 02:55:56,760 --> 02:56:00,600 BAND NOW BECAUSE OF METHOD FOR 4012 02:56:00,600 --> 02:56:01,760 BIOPHYSIC AND -- THAT'S 4013 02:56:01,760 --> 02:56:03,160 IMPORTANT AS WE FIGURE HOW TO 4014 02:56:03,160 --> 02:56:09,760 TREAT PATIENTS. THEY SHOULD BE 4015 02:56:09,760 --> 02:56:11,120 ALLOWED TO GO AFTER ADDITIONAL 4016 02:56:11,120 --> 02:56:14,360 RAS FAMILY MEMBERS AROUND IF WE 4017 02:56:14,360 --> 02:56:16,240 ASK HEM TO WORK ON RESISTANCE 4018 02:56:16,240 --> 02:56:18,920 THEY NEED MORE RESOURCES MAYBE 4019 02:56:18,920 --> 02:56:20,280 THAT IS NOT WHAT YOU WANT TO 4020 02:56:20,280 --> 02:56:21,920 HEAR, MAYBE YOU WANT TO HEAR 4021 02:56:21,920 --> 02:56:24,680 MORE FROM LESS, AS FROM THE 4022 02:56:24,680 --> 02:56:26,040 OUTSIDE THESE PEOPLE HAVE DONE 4023 02:56:26,040 --> 02:56:27,600 BETTER WORK THAN ANY THAT I KNOW 4024 02:56:27,600 --> 02:56:29,600 IN THE CANCER SPACE, AS A 4025 02:56:29,600 --> 02:56:31,200 COLLECTIVE COMMUNITY OPPOSED TO 4026 02:56:31,200 --> 02:56:32,720 THE INDIVIDUAL DISCOVERIES THAT 4027 02:56:32,720 --> 02:56:34,200 MADE THESE BREAKTHROUGHS FLOUT 4028 02:56:34,200 --> 02:56:35,120 THROUGHOUT. THERE'S NO WAY THEY 4029 02:56:35,120 --> 02:56:36,400 COULD HAVE DONE THIS WITHOUT 4030 02:56:36,400 --> 02:56:38,360 VILLAGE TYPE APPROACH. I'M DONE 4031 02:56:38,360 --> 02:56:40,400 WITH MY SOAP BOX. I SUCKED UP A 4032 02:56:40,400 --> 02:56:41,960 LOT OF OXYGEN GIVING YOU ONLY 4033 02:56:41,960 --> 02:56:44,240 SIX MINUTES FOR QUESTIONS. IF 4034 02:56:44,240 --> 02:56:45,960 YOU WANT TO, GO AHEAD. 4035 02:56:45,960 --> 02:56:47,800 >>GREAT REPORT. YOUR ENTHUSIASM 4036 02:56:47,800 --> 02:56:54,720 IS INFECTIOUS. COMMEND ON YOUR 4037 02:56:54,720 --> 02:56:58,440 REPORT. 4038 02:56:58,440 --> 02:57:00,360 >>I GOT ONE. THANK YOU SO UP 4039 02:57:00,360 --> 02:57:06,880 MANY DAVID, GOOD TO SEE YOU. IF 4040 02:57:06,880 --> 02:57:09,640 YOU WERE ME WHAT IS THE BIGGEST 4041 02:57:09,640 --> 02:57:12,000 WORRY? BESIDES FINDING THE MONEY 4042 02:57:12,000 --> 02:57:13,440 BUT WHAT IS YOUR BIGGEST CONCERN 4043 02:57:13,440 --> 02:57:14,720 IF YOU WERE SITTING IN MY CHAIR? 4044 02:57:14,720 --> 02:57:19,080 >>MY BIGGEST CONCERN RIGHT NOW, 4045 02:57:19,080 --> 02:57:20,400 IF I WERE ABLE TO SLIGHTLY DO 4046 02:57:20,400 --> 02:57:23,600 WHAT YOU ARE ASKING, WOULD BE TO 4047 02:57:23,600 --> 02:57:25,960 SAY BEST IN CLASS. AS OF RIGHT 4048 02:57:25,960 --> 02:57:28,600 NOW COMPARED TO TEN YEARS AGO 4049 02:57:28,600 --> 02:57:30,720 INVESTMENT IN RAS FROM BIOPHARMA 4050 02:57:30,720 --> 02:57:32,160 HAS TO BE THOUSAND TIMES BIGGER 4051 02:57:32,160 --> 02:57:36,360 THAN THEN. YOU HAVE TWO 4052 02:57:36,360 --> 02:57:38,160 BLOCKBUSTER DRUGS AND SO THERE 4053 02:57:38,160 --> 02:57:40,520 ARE INDEED BUDGET FOR RAS STUFF 4054 02:57:40,520 --> 02:57:43,000 HAS TO BE WHATEVER AND EVERYBODY 4055 02:57:43,000 --> 02:57:46,440 ELSE HAS RAS PROGRAM. THE 4056 02:57:46,440 --> 02:57:48,200 INVESTMENT BY THE PRIVATE 4057 02:57:48,200 --> 02:57:49,240 EXTRAMURAL COMMUNITY IS HUGE SO 4058 02:57:49,240 --> 02:57:51,240 YOU HAVE TO ASK WHAT THEY HAVE 4059 02:57:51,240 --> 02:57:53,440 RIGHT NOW THAT I DESCRIBE AS 4060 02:57:53,440 --> 02:57:56,560 BEST IN CLASS, IS IT REALLY BEST 4061 02:57:56,560 --> 02:57:59,680 IN CLASS? I WOULD THINK THAT YOU 4062 02:57:59,680 --> 02:58:01,920 RECALL APPROACH TO FIGURING OUT 4063 02:58:01,920 --> 02:58:03,200 IN CLEVER THEY HAVE IS POSSIBLY 4064 02:58:03,200 --> 02:58:04,920 BEST IN CLASS BUT THAT IS WHERE 4065 02:58:04,920 --> 02:58:10,760 YOU ASSEMBLE GROUP OF PEOPLE 4066 02:58:10,760 --> 02:58:11,320 PRIEST AND OUTSIDE AND THAT 4067 02:58:11,320 --> 02:58:13,600 SHOULD BE THE TASK ARE THEY BEST 4068 02:58:13,600 --> 02:58:17,120 IN CLASS, IF SO HOW TO PROTECT 4069 02:58:17,120 --> 02:58:18,480 SO COMPANY DOESN'T BUY HEM IN 4070 02:58:18,480 --> 02:58:20,040 LOT AND THEY LEAVE. SO I DON'T 4071 02:58:20,040 --> 02:58:21,240 KNOW THE ANSWER TO THAT EITHER. 4072 02:58:21,240 --> 02:58:26,760 I HAVEN'T REALLY TOTAL YOU, I 4073 02:58:26,760 --> 02:58:31,480 MEAN I RETENTION IS A HUGE ISSUE 4074 02:58:31,480 --> 02:58:35,120 IF THEY ARE BEST THAT CLASS. THE 4075 02:58:35,120 --> 02:58:37,480 MAIN WAY TO MAINTAIN THEM IS 4076 02:58:37,480 --> 02:58:40,560 MAKING SURE EGOS ARE MASSAGED. 4077 02:58:40,560 --> 02:58:44,440 YOU HAVE TO DO MIC 2, THEY CAN 4078 02:58:44,440 --> 02:58:45,640 DO BLOODY EVERYTHING THAT ANYONE 4079 02:58:45,640 --> 02:58:47,240 SHOULD HAVE TO DO IF THEY ARE 4080 02:58:47,240 --> 02:58:50,320 GOING AFTER INTRACTABLE DRUG 4081 02:58:50,320 --> 02:58:50,560 TARGET. 4082 02:58:50,560 --> 02:58:52,440 >>SO WE HAVE COUPLE OF 4083 02:58:52,440 --> 02:58:53,720 QUESTIONS. FIRST MARY. THEN 4084 02:58:53,720 --> 02:58:56,880 RODNEY. 4085 02:58:56,880 --> 02:58:59,280 >>THANK YOU, WE LEARNED A LOT. 4086 02:58:59,280 --> 02:59:00,280 GREAT PROGRESS. WONDERING WHEN 4087 02:59:00,280 --> 02:59:05,920 YOU THINK OF THE UNIQUENESS OF 4088 02:59:05,920 --> 02:59:07,800 NCI FREDERICK LABSES AND WE 4089 02:59:07,800 --> 02:59:10,120 HEARD THOSE INCREDIBLE PDX 4090 02:59:10,120 --> 02:59:13,520 MODELS, IS THERE ANY INTEREST IN 4091 02:59:13,520 --> 02:59:17,680 CREATING SPECIFIC RAS PDX MODELS 4092 02:59:17,680 --> 02:59:22,880 NO ONE ELSE HAS? 4093 02:59:22,880 --> 02:59:25,000 >>GOOD QUESTI QUESTION. THAT CD 4094 02:59:25,000 --> 02:59:27,440 EASILY BE DONE. I DON'T KNOW YOU 4095 02:59:27,440 --> 02:59:30,200 CAN DO IT AS A PDX OR AS A 4096 02:59:30,200 --> 02:59:34,040 GENETICALLY ENGINEERED MOUSE. IT 4097 02:59:34,040 --> 02:59:37,240 SEEMS THE IMMUNE RESPONSE IS 4098 02:59:37,240 --> 02:59:39,360 RELEVANT IN HUMAN AND MOUSE 4099 02:59:39,360 --> 02:59:42,360 RESPONSE TO ON TARGET THERAPIES 4100 02:59:42,360 --> 02:59:45,040 IF YOU DO PDX IN GENERAL YOU 4101 02:59:45,040 --> 02:59:49,960 DONE HAVE NK CELLS EITHER. I 4102 02:59:49,960 --> 02:59:51,960 KNOW PDXs DO EXIST TODAY AND 4103 02:59:51,960 --> 02:59:59,880 TESTING THEM ON THEM. THAT IS 4104 02:59:59,880 --> 03:00:02,760 NOT HARD. IF THEY DON'T HAVE, MY 4105 03:00:02,760 --> 03:00:04,520 LAB CAN GIVE WHATEVER THEY NEED 4106 03:00:04,520 --> 03:00:07,280 TO SET UP DIFFERENCE ALLELES AS 4107 03:00:07,280 --> 03:00:10,880 COULD HANDFUL OF MY COLLEAGUES. 4108 03:00:10,880 --> 03:00:14,520 THAT IS WHAT JIM PUT TOGETHER. 4109 03:00:14,520 --> 03:00:15,840 ME HAS GREAT COLLECTIONS AND 4110 03:00:15,840 --> 03:00:18,000 DOES HAVE MOST ALLELES IN PDX 4111 03:00:18,000 --> 03:00:19,320 FORM OR ORGANOID FORM AND YOU 4112 03:00:19,320 --> 03:00:23,680 CAN MAKE A PDX FROM ORGANOID 4113 03:00:23,680 --> 03:00:28,280 TRIVIALLY. ED FROM 4114 03:00:28,280 --> 03:00:31,920 >>THIS IS VERY INFECTIOUS. 4115 03:00:31,920 --> 03:00:36,000 CLEARLY YOU HAVE TO TAKE THIS IF 4116 03:00:36,000 --> 03:00:37,240 POSSIBLE WHAT IS POSSIBLE WITH 4117 03:00:37,240 --> 03:00:39,040 THE GROWTH OF TESTIFY TECHNOLOGY 4118 03:00:39,040 --> 03:00:46,080 OVER TIME. AND TOOLS INTEGRATING 4119 03:00:46,080 --> 03:00:50,320 EVERYTHING. THAT WE CAN USE TO 4120 03:00:50,320 --> 03:00:56,360 BUILD PROGRAM. SECOND THING, 4121 03:00:56,360 --> 03:01:00,400 THE TAGGABLE 2 COMPOUNDS GOING 4122 03:01:00,400 --> 03:01:04,880 -- THEY ARE RESISTANT. IT WOULD 4123 03:01:04,880 --> 03:01:06,160 BE IMPORTANT TO THINK ABOUT LONG 4124 03:01:06,160 --> 03:01:15,240 TERM IF YOU WANT TO COMPETE. 4125 03:01:15,240 --> 03:01:17,360 FIRST IN CLASS, DRUG 4126 03:01:17,360 --> 03:01:19,560 COMBINATIONS IF IT IS ORAL IT IS 4127 03:01:19,560 --> 03:01:20,720 LONG TERM TREATMENT, THAT IS 4128 03:01:20,720 --> 03:01:24,120 WHAT WE ARE THINKING CONSTANTLY 4129 03:01:24,120 --> 03:01:27,760 ABOUT. TARGETING. COMBINATIONS 4130 03:01:27,760 --> 03:01:30,240 TO PROVIDE THOROUGH RESPONSE. SO 4131 03:01:30,240 --> 03:01:34,040 YOU CANNOT COMPETE WITH THE 4132 03:01:34,040 --> 03:01:36,960 LARGE COMPANY, GOB TO POUR MONEY 4133 03:01:36,960 --> 03:01:37,600 IN THE CLINICAL PROGRAM SO WE 4134 03:01:37,600 --> 03:01:39,480 ARE GOING TO BE WAY BEHIND ALL 4135 03:01:39,480 --> 03:01:45,360 THE TIME. SO WHAT WE CAN COMPETE 4136 03:01:45,360 --> 03:01:46,840 IS TO DEMONSTRATE PRINCIPLE. 4137 03:01:46,840 --> 03:01:53,520 EVERYONE IS GOING AFTER DRUG 4138 03:01:53,520 --> 03:01:56,880 COMBINATIONS. SO QUESTION IS 4139 03:01:56,880 --> 03:01:59,520 THAT WHEN SHOULD FREDERICK BE 4140 03:01:59,520 --> 03:02:00,600 INVESTING AHEAD OF THE GAME 4141 03:02:00,600 --> 03:02:02,680 WHERE WE ARE GOOD AT 4142 03:02:02,680 --> 03:02:04,720 INTELLECTUAL THINKING, WAY AHEAD 4143 03:02:04,720 --> 03:02:04,960 OF TIME. 4144 03:02:04,960 --> 03:02:06,280 >>THIS IS A REALLY O -- 4145 03:02:06,280 --> 03:02:08,240 >>THAT IS WHAT I WOULD -- 4146 03:02:08,240 --> 03:02:11,800 >>THANK YOU. GREAT QUESTION. SO 4147 03:02:11,800 --> 03:02:14,480 WHEN THE FIRST AKT PLUS MEC 4148 03:02:14,480 --> 03:02:15,680 COMBINATION WAS DEVELOPED, AND 4149 03:02:15,680 --> 03:02:17,400 PUT INTO PATIENTS, THE HOPE WAS 4150 03:02:17,400 --> 03:02:20,560 IT WOULD HANDLE THE RAS CANCER. 4151 03:02:20,560 --> 03:02:22,000 I HOPE YOU KNOW THE SORRY WHAT 4152 03:02:22,000 --> 03:02:24,880 HAPPENED. PATIENTS WERE SICK. 4153 03:02:24,880 --> 03:02:26,720 BECAUSE THOSE TWO COMPOUNDS IN 4154 03:02:26,720 --> 03:02:28,360 HUMAN, CAUSES SKIN TOXICITY 4155 03:02:28,360 --> 03:02:30,320 WHICH PREVENTED DOCTORS FROM 4156 03:02:30,320 --> 03:02:31,760 DOSING MEDICINE SO YOU CAN HIT 4157 03:02:31,760 --> 03:02:36,440 THE CANCER. THEY NOW HAVE PI 3 4158 03:02:36,440 --> 03:02:38,360 KINASE ALPHA BLOCKER SO THEY DO 4159 03:02:38,360 --> 03:02:39,680 HAVE A COMPETITIVE ADVANTAGE AS 4160 03:02:39,680 --> 03:02:44,400 FAR AS I KNOW NOBODY HAS. IF 4161 03:02:44,400 --> 03:02:47,680 THEY ARE RIGHT THE PI 3 KINASE 4162 03:02:47,680 --> 03:02:49,400 ALPHA DRUG COOPERATE WITH MAP 4163 03:02:49,400 --> 03:02:53,760 KINASE INHIBITORS, THAT COULD BE 4164 03:02:53,760 --> 03:02:55,800 SOMEBODY'S ERK INHIBITOR THEY 4165 03:02:55,800 --> 03:02:56,920 HAVE A COMPETITIVE ADVANTAGE 4166 03:02:56,920 --> 03:02:59,600 ALREAALREADY. THIS IS SOMETHINGO 4167 03:02:59,600 --> 03:03:01,800 MONICA, YOU SHOULD USE YOUR 4168 03:03:01,800 --> 03:03:04,520 CLINIC AT THE NCI TO TEST THESE 4169 03:03:04,520 --> 03:03:05,880 PHASE 1 COMBINATION, DO IT 4170 03:03:05,880 --> 03:03:08,600 YOURSELF. DO THE FIRST STUDY AT 4171 03:03:08,600 --> 03:03:12,880 THE NCI. TEST THE PI 3 KINASE 4172 03:03:12,880 --> 03:03:15,440 ALPHA WITH MEK INHIBITOR AND 4173 03:03:15,440 --> 03:03:16,600 BECAUSE RODNEY IS RIGHT. IN THE 4174 03:03:16,600 --> 03:03:18,400 END OF THE DAY THE LAST THING IS 4175 03:03:18,400 --> 03:03:20,600 A ME TOO OPERATION, YOU ARE 4176 03:03:20,600 --> 03:03:23,640 PUTTING 50 MILLION BUCKS INTO 4177 03:03:23,640 --> 03:03:25,080 BECAUSE YOU COULD FUND I DON'T 4178 03:03:25,080 --> 03:03:32,680 KNOW HOW MANY RO1s. A LOT SO I 4179 03:03:32,680 --> 03:03:37,920 HI THIS QUESTION IF COMPETITIVE 4180 03:03:37,920 --> 03:03:39,920 LANDSCAPE ARE THEY STILL AFTER 4181 03:03:39,920 --> 03:03:41,560 INTRACTABLE PROBLEM OR JUST 4182 03:03:41,560 --> 03:03:42,760 COLOR NOW THAT IT IS NOT 4183 03:03:42,760 --> 03:03:48,200 INTRACTABLE? I THINK THEY HAVE 4184 03:03:48,200 --> 03:03:53,400 INFRASTRUCTURE AND THIS GROUP 4185 03:03:53,400 --> 03:03:54,640 ABLE TO SOLVE PROBLEMS BETTER 4186 03:03:54,640 --> 03:03:57,600 THAN INDUSTRY RIGHT NOW SO 4187 03:03:57,600 --> 03:04:02,200 PRINCIPLE THEY CAN GENERATE NEW 4188 03:04:02,200 --> 03:04:04,320 MOLECULES NEW IP. HOOK IT UP TO 4189 03:04:04,320 --> 03:04:06,200 CLINIC. THAT'S WHAT COMPANIES 4190 03:04:06,200 --> 03:04:12,440 DON'T HAVE. USE YOUR CLINI CLIN. 4191 03:04:12,440 --> 03:04:13,720 (OVERLAPPING SPEAKERS) 4192 03:04:13,720 --> 03:04:16,320 >>WE NEED TO MOVE ON. IN THE 4193 03:04:16,320 --> 03:04:19,600 INTEREST OF TIME. WE NEED A 4194 03:04:19,600 --> 03:04:23,600 MOTION TO APPROVE THE WORKING 4195 03:04:23,600 --> 03:04:25,640 GROUP PLAN. WORKING GROUP 4196 03:04:25,640 --> 03:04:31,480 REPORT. DO I HAVE A MOTION? 4197 03:04:31,480 --> 03:04:36,200 LISA. SECOND, JOHN. ALL THOSE IN 4198 03:04:36,200 --> 03:04:40,640 FAVOR. ANY OPPOSED? ANY OTHER 4199 03:04:40,640 --> 03:04:43,080 DISCUSSION? GREAT. THANK YOU, 4200 03:04:43,080 --> 03:04:49,160 DAVE. GREAT JOB. SO WE ARE NOW 4201 03:04:49,160 --> 03:04:51,240 MOVING TO ONGOING AND NEW 4202 03:04:51,240 --> 03:04:53,680 BUSINEBUSINESS. DR. CANE WILL GA 4203 03:04:53,680 --> 03:04:54,480 BRIEF PRESENTATION ON THE 4204 03:04:54,480 --> 03:04:57,160 ESTABLISHMENT OF A NEW FNLAC 4205 03:04:57,160 --> 03:04:58,760 WORKING GROUP TO EVALUATE THE 4206 03:04:58,760 --> 03:05:03,080 RAS PROGRAM. THE NEW PROPOSED 4207 03:05:03,080 --> 03:05:05,640 NAME IS NCI RAS INITIATIVE 4208 03:05:05,640 --> 03:05:06,880 EVALUATION TEAM AD HOC WORKING 4209 03:05:06,880 --> 03:05:09,200 GROUP. AFTER THIS PRESENTATION 4210 03:05:09,200 --> 03:05:10,880 WE NEED A MOTION TO APPROVE 4211 03:05:10,880 --> 03:05:14,840 THIS. SO PLEASE. DR. CANE. -- 4212 03:05:14,840 --> 03:05:15,880 DR. KANE. 4213 03:05:15,880 --> 03:05:17,080 >>THANK YOU, GOOD AFTERNOON, 4214 03:05:17,080 --> 03:05:18,360 THANK YOU FOR THE INVITATION TO 4215 03:05:18,360 --> 03:05:21,400 JOIN YOU TODAY. IN WAY OF 4216 03:05:21,400 --> 03:05:22,880 INTRODUCTION MY NAME IS CHRIS 4217 03:05:22,880 --> 03:05:24,400 KANE, PROGRAM OFFICER IN THE 4218 03:05:24,400 --> 03:05:26,840 OFFICE OF SCIENTIFIC OPERATIONS 4219 03:05:26,840 --> 03:05:28,640 WITH THE NCI FREDERICK. I'M ALSO 4220 03:05:28,640 --> 03:05:30,920 THE CONTRACTING OFFICER 4221 03:05:30,920 --> 03:05:32,200 REPRESENTATIVE FOR THE NCI RAS 4222 03:05:32,200 --> 03:05:34,920 INITIATIVE. IT IS MY PLEASURE TO 4223 03:05:34,920 --> 03:05:36,720 PRESENT THIS BRIEF PRESENTATION 4224 03:05:36,720 --> 03:05:37,960 ENTITLED ESTABLISHMENT OF 4225 03:05:37,960 --> 03:05:41,280 WORKING GROUP TO EVALUATE NCI 4226 03:05:41,280 --> 03:05:43,160 RAS INITIATIVE. I WOULD LIKE TO 4227 03:05:43,160 --> 03:05:45,720 BEGIN TOUCHING VISION AND 4228 03:05:45,720 --> 03:05:50,120 HISTORY OF THE RAS INITIATIVE. 4229 03:05:50,120 --> 03:05:52,520 AS DR. TUVESON ELOQUENTLY STATED 4230 03:05:52,520 --> 03:05:54,400 THE VISION AND OVERARCHING GOAL 4231 03:05:54,400 --> 03:05:56,480 IS MOBILIZE THE ENTIRE CANCER 4232 03:05:56,480 --> 03:05:57,920 RESEARCH COMMUNITY TO DEVELOP 4233 03:05:57,920 --> 03:05:59,400 WAYS TO UNDERSTAND TARGET CANCER 4234 03:05:59,400 --> 03:06:01,480 DRIVEN BY MUTANT KRAS. USING 4235 03:06:01,480 --> 03:06:04,440 THIS UNIQUE OPEN RESEARCH MODEL 4236 03:06:04,440 --> 03:06:05,920 WITH COLLABORATION ACROSS 4237 03:06:05,920 --> 03:06:07,520 GOVERNMENT, ACADEMIA, AND 4238 03:06:07,520 --> 03:06:14,560 INDUSTRY. SO THE RAS INITIATIVE 4239 03:06:14,560 --> 03:06:16,040 DEVELOPED AND ESTABLISHD IN 2013 4240 03:06:16,040 --> 03:06:17,680 AND ADDRESSED CRITICAL KNOWLEDGE 4241 03:06:17,680 --> 03:06:20,280 GAPS THAT IMPEDED RAS AS DRUG 4242 03:06:20,280 --> 03:06:22,920 TARGET FOR DECADES. THEY WERE 4243 03:06:22,920 --> 03:06:24,280 SUCCESSFUL AND PROVIDING GREATER 4244 03:06:24,280 --> 03:06:28,120 INSIGHT TO RAS BIOLOGY SOLVING 4245 03:06:28,120 --> 03:06:29,400 MULTIPLE PROTEIN STRUCTURE AND 4246 03:06:29,400 --> 03:06:30,960 PROVIDING IMPRESSIVE AMOUNT OF 4247 03:06:30,960 --> 03:06:32,560 REAGENTS TO THE OVERALL RAS 4248 03:06:32,560 --> 03:06:36,080 RESEARCH COMMUNITY. IN 2017, 4249 03:06:36,080 --> 03:06:38,160 THE RAS INITIATIVE WAS REVIEWED 4250 03:06:38,160 --> 03:06:40,640 AND RENEWED FOR ANOTHER PERIOD 4251 03:06:40,640 --> 03:06:41,720 OF PERFORMANCE WITH INCREASE 4252 03:06:41,720 --> 03:06:43,720 FOCUS ON ADVANCING RAS 4253 03:06:43,720 --> 03:06:45,040 THERAPEUTIC COMPOUNDS AND 4254 03:06:45,040 --> 03:06:47,040 PROVIDING INCREASINGLY 4255 03:06:47,040 --> 03:06:48,440 SOPHISTICATED BIOPHYSICAL MODEL 4256 03:06:48,440 --> 03:06:50,840 FOR RAS ACTIVATION SIGNALING. 4257 03:06:50,840 --> 03:06:54,040 WHICH BRINGS US TO TODAY. NCI 4258 03:06:54,040 --> 03:06:55,600 RAS INITIATIVE RESEARCH TEAM IS 4259 03:06:55,600 --> 03:06:58,560 SEEKING ADDITIONAL FIVE YEAR 4260 03:06:58,560 --> 03:07:00,920 PERIOD OF RENEWAL. WITH THE 4261 03:07:00,920 --> 03:07:01,720 EXPRESS GOALS OF PUSHING 4262 03:07:01,720 --> 03:07:03,440 VALUABLE NEW PRE-CLINICAL AND 4263 03:07:03,440 --> 03:07:06,600 CLINICAL DRUG CANDIDATES INTO 4264 03:07:06,600 --> 03:07:07,800 CLINICAL EVALUATION AND 4265 03:07:07,800 --> 03:07:10,600 BROADENING THE RAS DIRECTED 4266 03:07:10,600 --> 03:07:13,600 THERAPEUTICS TO ADDITIONAL 4267 03:07:13,600 --> 03:07:16,120 ALLELESK EFFECTOR PROTEINS AND 4268 03:07:16,120 --> 03:07:17,280 OTHER INNOVATIVE STRATEGIES SO 4269 03:07:17,280 --> 03:07:19,480 THE RENEWAL PROCESS REQUIRES 4270 03:07:19,480 --> 03:07:22,680 ESTABLISHMENT OF A U WORKING 4271 03:07:22,680 --> 03:07:29,400 GROUP. IN ORDER THE JUDGE 4272 03:07:29,400 --> 03:07:30,640 SCIENTIFIC MERIT PRODUCTIVITY 4273 03:07:30,640 --> 03:07:32,720 INNOVATION OF THE RAS 4274 03:07:32,720 --> 03:07:34,720 INITIATIVE, THE FNLAC WILL 4275 03:07:34,720 --> 03:07:37,720 CONVENE A NEW INDEPENDENT AD HOC 4276 03:07:37,720 --> 03:07:39,280 RAS INITIATIVE EVALUATION TEAM 4277 03:07:39,280 --> 03:07:41,160 WORKING GROUP TO CONDUCT REVIEW 4278 03:07:41,160 --> 03:07:45,000 OF RENEWAL PACKAGE. 4279 03:07:45,000 --> 03:07:47,560 THAT WILL CONSIST OF COMPONENTS, 4280 03:07:47,560 --> 03:07:49,240 FIRST IS REPORT AND 4281 03:07:49,240 --> 03:07:51,160 RECOMMENDATIONS OF THE EXISTING 4282 03:07:51,160 --> 03:07:53,560 FNL RAS AD HOC WORKING GROUP 4283 03:07:53,560 --> 03:07:58,400 JUST ENDORSED. ALSO INCLUDE A 4284 03:07:58,400 --> 03:08:00,680 FULL WRITTEN PROPOSAL BY THE 4285 03:08:00,680 --> 03:08:02,000 RESEARCH TEAM AND AS WELL AS IN 4286 03:08:02,000 --> 03:08:04,680 PERSON SESSION TO EXPLAIN 4287 03:08:04,680 --> 03:08:06,800 PROPOSAL IN GREATER DETAIL. . 4288 03:08:06,800 --> 03:08:08,920 WHICH THEY WERE HIGHLIGHT 4289 03:08:08,920 --> 03:08:10,360 PROGRESS TEAM MADE DURING THE 4290 03:08:10,360 --> 03:08:12,920 CURRENT PERIOD OF PERFORMANCE TO 4291 03:08:12,920 --> 03:08:14,480 DESCRIBE ENGAGEMENT WITH 4292 03:08:14,480 --> 03:08:16,920 EXTRAMURAL RAS COMMUNITY. AND 4293 03:08:16,920 --> 03:08:18,480 PROPOSEDDED FEATURE RESEARCH AND 4294 03:08:18,480 --> 03:08:20,880 DEVELOPMENT PLANS. SO THE REMAKE 4295 03:08:20,880 --> 03:08:22,360 OF THE WORKING GROUP IS ON THE 4296 03:08:22,360 --> 03:08:27,640 NEXT SLIDE. SO THE REMET WILL 4297 03:08:27,640 --> 03:08:31,640 BE TO ADVISE THIS ADVISORY 4298 03:08:31,640 --> 03:08:35,120 COMMITTEE AS WELL AS DIRECTOR OF 4299 03:08:35,120 --> 03:08:35,920 NCI CONDUCT A TECHNICAL REVIEW 4300 03:08:35,920 --> 03:08:39,680 OF RAS RENEWAL PACKAGE. TO 4301 03:08:39,680 --> 03:08:42,320 ENSURE APPROPRIATENESS OF THE 4302 03:08:42,320 --> 03:08:45,760 PROPOSED RESEARCH TO OPTIMIZE 4303 03:08:45,760 --> 03:08:48,520 AND BALANCE PARTNERSHIPS BETWEEN 4304 03:08:48,520 --> 03:08:50,520 EXTRAMURAL RAS COMMUNITY AND 4305 03:08:50,520 --> 03:08:51,960 PROVIDE THEIR OVERALL 4306 03:08:51,960 --> 03:08:53,840 INDEPENDENT ASSESSMENT OF THE 4307 03:08:53,840 --> 03:08:55,440 RAS INITIATIVE RENEWAL AND 4308 03:08:55,440 --> 03:08:56,640 PROPOSED PLANS FOR FUTURE 4309 03:08:56,640 --> 03:08:57,920 RESEARCH AND THERAPEUTIC 4310 03:08:57,920 --> 03:09:01,280 DEVELOPMENT. SO WORK PRODUCT 4311 03:09:01,280 --> 03:09:02,680 WORKING GROUP IS WRITTEN 4312 03:09:02,680 --> 03:09:05,120 TECHNICAL REPORT AND 4313 03:09:05,120 --> 03:09:06,520 RECOMMENDATION TO BE PRESENTED 4314 03:09:06,520 --> 03:09:08,920 AT THE NEXT FNLAC MEETING 4315 03:09:08,920 --> 03:09:11,400 FEBRUARY OF 2023. UPON THIS 4316 03:09:11,400 --> 03:09:13,360 ADVISORY COMMITTEE ACCEPTANCE, 4317 03:09:13,360 --> 03:09:14,000 THIS REPORT RECOMMENDATION WILL 4318 03:09:14,000 --> 03:09:17,480 PROVIDE TO THE NCI DIRECTOR. 4319 03:09:17,480 --> 03:09:19,080 FINALLY I WOULD LIKE TO DESCRIBE 4320 03:09:19,080 --> 03:09:21,000 THE PROPOSED MAKE UP OF THIS NEW 4321 03:09:21,000 --> 03:09:26,240 WORKING GROUP. SO THE PROPOSED 4322 03:09:26,240 --> 03:09:27,600 COMPOSITION WOULD BE MADE OF 4323 03:09:27,600 --> 03:09:29,680 HIGHLY REGARDED SIGNISTS 4324 03:09:29,680 --> 03:09:31,280 RECRUITED FROM BOTH ACADEMIC 4325 03:09:31,280 --> 03:09:32,640 RESEARCH COMMUNITY AS WELL AS 4326 03:09:32,640 --> 03:09:36,760 PRIVATE SECTOR. SCIENTIFIC 4327 03:09:36,760 --> 03:09:38,040 EXCELLENCE AND DOMAIN EXPERTISE 4328 03:09:38,040 --> 03:09:39,480 IS DRAWN FROM A VARIETY OF 4329 03:09:39,480 --> 03:09:42,120 ACADEMIC RAS AND CANCER BIOLOGY 4330 03:09:42,120 --> 03:09:44,320 RESEARCHERS, STRUCTURAL 4331 03:09:44,320 --> 03:09:47,560 BIOLOGIST, AND BIOPHARMACEUTICAL 4332 03:09:47,560 --> 03:09:48,880 AND RESEARCH INSTITUTE EXPERTS 4333 03:09:48,880 --> 03:09:50,960 WITH PERTINENT RELEVANT DRUG 4334 03:09:50,960 --> 03:09:51,760 DISCOVERY DEVELOPMENT 4335 03:09:51,760 --> 03:09:54,160 EXPERIENCE. THIS WORKING GROUP 4336 03:09:54,160 --> 03:09:55,720 WILL BE DEMOGRAPHICALLY BALANCED 4337 03:09:55,720 --> 03:09:57,520 IN LINE WITH NCI BEST PRACTICES 4338 03:09:57,520 --> 03:10:01,800 AND CURRENT INITIATIVES. SO 4339 03:10:01,800 --> 03:10:04,240 THIS CONCLUDES MY BRIEF 4340 03:10:04,240 --> 03:10:05,960 PRESENTATION. HAPPY TO ADDRESS 4341 03:10:05,960 --> 03:10:07,040 QUESTIONS THE ADVISORY COMMITTEE 4342 03:10:07,040 --> 03:10:08,280 MAY HAVE. THANK YOU FOR YOUR 4343 03:10:08,280 --> 03:10:11,360 ATTENTION. 4344 03:10:11,360 --> 03:10:13,920 >>THANK YOU, DR. KANEE. WE HAVE 4345 03:10:13,920 --> 03:10:16,600 TIME FOR BRIEF QUESTIONS. THEN 4346 03:10:16,600 --> 03:10:17,960 DISCUSS AND THEN TAKE VOTE. 4347 03:10:17,960 --> 03:10:19,600 THERE IS ANOTHER ITEM ON AGENDA 4348 03:10:19,600 --> 03:10:20,840 THAT IS NOT LISTED THAT WE HAVE 4349 03:10:20,840 --> 03:10:24,360 TO APPROVE SO ANY QUESTIONS FOR 4350 03:10:24,360 --> 03:10:28,080 DR. KANE? PRETTY STRAIGHT 4351 03:10:28,080 --> 03:10:30,720 FORWARD INITIATIVE THAT WILL 4352 03:10:30,720 --> 03:10:32,280 COME BACK TO IN FEBRUARY. IF 4353 03:10:32,280 --> 03:10:35,880 NOT, CAN I HAVE A MOTION TO 4354 03:10:35,880 --> 03:10:41,760 APPROVE? FIRST FOR APPROVAL? 4355 03:10:41,760 --> 03:10:42,320 >>SECOND. 4356 03:10:42,320 --> 03:10:48,280 >>ALL THOSE IN FAVOR. ANY 4357 03:10:48,280 --> 03:10:50,320 OPPOSED OR ABSTAINED. THANK YOU 4358 03:10:50,320 --> 03:10:52,880 VERY MUCH. 4359 03:10:52,880 --> 03:10:54,040 >>THANK YOU. 4360 03:10:54,040 --> 03:10:57,200 >>THANK YOU, DR. KANEE. NOT ON 4361 03:10:57,200 --> 03:10:59,240 THE AYEN DA WAS A LATE ITEM AND 4362 03:10:59,240 --> 03:11:02,680 I THINK THE DOCUMENTS WERE SENT 4363 03:11:02,680 --> 03:11:05,120 TO EVERYBODY, THEY ARE UPDATED 4364 03:11:05,120 --> 03:11:10,480 VISION STATEMENTS FOR AD HOC 4365 03:11:10,480 --> 03:11:12,280 CRYOELECTRON MICROSCOPE 4366 03:11:12,280 --> 03:11:13,200 OVERSIGHT COMMITTEE AND 4367 03:11:13,200 --> 03:11:15,400 OVERSIGHT WORKING GROUP FROM 4368 03:11:15,400 --> 03:11:20,720 CRYOELECTRON MICROSCOPY PROGRAM 4369 03:11:20,720 --> 03:11:24,640 ANYONE HAVE ANY QUESTIONS? 4370 03:11:24,640 --> 03:11:28,080 EVERYONE RECEIVE THOSE? BECAUSE 4371 03:11:28,080 --> 03:11:30,280 I NEED MOTION TO APPROVE BOTH 4372 03:11:30,280 --> 03:11:31,760 THESE MISSION STATEMENTS UNLESS 4373 03:11:31,760 --> 03:11:32,960 THERE'S SOME FURTHER DISCUSSION 4374 03:11:32,960 --> 03:11:39,480 ON THEM. ALL GOOD? OKAY. MOTION 4375 03:11:39,480 --> 03:11:44,640 TO APPROVE. THANKS,LY VIRGINIA 4376 03:11:44,640 --> 03:11:45,880 SECOND, ALL THOSE IN FAVOR, ANY 4377 03:11:45,880 --> 03:11:53,720 FURTHER DISCUSSION? OKAY. SO 4378 03:11:53,720 --> 03:11:55,120 LODUC, ANY THING ELSE WE NEED TO 4379 03:11:55,120 --> 03:11:57,840 DO TODAY? 4380 03:11:57,840 --> 03:12:02,360 >>I DON'T HAVE ANYTHING TO ADD. 4381 03:12:02,360 --> 03:12:03,560 THANK YOU FOR YOUR SERVING. 4382 03:12:03,560 --> 03:12:05,560 I WANT TO THANK YOU VERY MUCH 4383 03:12:05,560 --> 03:12:08,000 FOR YOUR PARTICIPATION. 4384 03:12:08,000 --> 03:12:11,040 >>THANKS, EVERYBODY. THIS WAS A 4385 03:12:11,040 --> 03:12:13,760 GREAT GROUP, MONICA, WE WELCOME 4386 03:12:13,760 --> 03:12:15,640 YOU, IT IS GOING TO -- THIS IS A 4387 03:12:15,640 --> 03:12:17,840 FUN GROUP AND WE WILL HAVE MORE 4388 03:12:17,840 --> 03:12:19,720 FUN IN PERSON. LOOK FORWARD TO 4389 03:12:19,720 --> 03:12:24,760 THAT. IF I HAVE NO OTHER 4390 03:12:24,760 --> 03:12:28,200 COMMENTS OR CONCERNS, I WILL 4391 03:12:28,200 --> 03:12:29,240 ADJOURN THE MEETING. THANK YOU 4392 03:12:29,240 --> 03:12:29,600 SO MUCH. 4393 03:12:29,600 --> 00:00:00,000 >>THANK YOU SO MUCH EVERYONE.